{
    "Halodrol-50 [FAST FACTS]": {
        "sections": {
            "Overview": "Halodrol-50 meets the definition of an anabolic androgenic steroid, as determined by the United States Designer Anabolic Steroid Control Act (DASCA) (8639, 103909). It is unlawful for anabolic steroids to be added to dietary supplements. Anabolic steroids are also prohibited by the World Anti-Doping Agency (WADA) (102469).\n\nNOTE: This is a Fast Facts monograph, intended to give subscribers quick information on newly emerging ingredients in products claiming to be supplements. The Natural Medicines editors will continue to monitor the literature about this topic and update it as more evidence becomes available.",
            "Safety": "POSSIBLY UNSAFE when used orally or parenterally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, gynecomastia (in males), hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094). Avoid using.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. Although there is interest in using halodrol-50 for athletic performance, there is insufficient reliable information about the clinical effects of halodrol-50 for this purpose.\nErectile dysfunction (ED). Although there is interest in using halodrol-50 for ED, there is insufficient reliable information about the clinical effects of halodrol-50 for this condition.\nExercise-induced muscle damage. Although there is interest in using halodrol-50 for muscle recovery after exercise, there is insufficient reliable information about the clinical effects of halodrol-50 for this purpose.\nMuscle strength. Although there is interest in using halodrol-50 to improve muscle strength, there is insufficient reliable information about the clinical effects of halodrol-50 for this purpose.\nObesity. Although there is interest in using halodrol-50 for weight loss, there is insufficient reliable information about the clinical effects of halodrol-50 for this purpose.\nMore evidence is needed to rate halodrol-50 for these uses.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known."
        }
    },
    "Haronga": {
        "sections": {
            "Overview": "Haronga is a small evergreen tree that grows throughout tropical areas of Africa (18, 108297). Traditionally, the leaves and bark of haronga have been used for dyspepsia, loss of appetite, and pancreatic, liver, and gallbladder complaints.",
            "Safety": "There is insufficient reliable information available about the safety of haronga when used orally.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.\nDermatologic\nOrally, photosensitivity is possible with the use of haronga due to the presence of hypericin and pseudohypericin. However, the small quantities found in haronga are unlikely to cause photosensitivity (2, 18).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of haronga.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nTraditionally, haronga extracts and tinctures have been standardized to contain 0.1% or 0.01% chrysophanic acid derivatives, respectively (18).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBOWEL OBSTRUCTION\nHaronga is thought to stimulate the secretion of gastric fluids (2, 18). Until more is known, avoid haronga in patients with obstruction of the bowels.\nless\nGALLBLADDER DISEASE\nHaronga is thought to have gallbladder stimulating effects (2, 18). Until more is known, avoid haronga in patients with gallstones, gallbladder empyema, or biliary obstruction.\nless\nPANCREATITIS\nHaronga is thought to have pancreas stimulating effects (2, 18). Until more is known, avoid haronga in patients with acute or chronic pancreatitis.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with haronga.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of haronga.",
            "Mechanism of Action": "General\nThe applicable parts of haronga are the bark and leaf (2, 18).\nAntimicrobial effects\nHaronga has demonstrated antibacterial and anti-amoebic effects (18, 1519). In vitro, the bark, leaf, and root extracts of haronga have antibacterial effects against various gram-positive and gram-negative bacteria. Type of extract or extraction method and time of harvest seem to alter the potency of these effects, with the greatest effects seen with the methanolic extract of bark that was harvested in the evening (108297).\nDigestive system effects\nHaronga can have gallbladder stimulating (2), pancreas stimulating, and gastric juice secretion stimulating effects (18)."
        }
    },
    "Hartstongue": {
        "sections": {
            "Overview": "Hartstongue is a fern that is native to most of Europe, North America, northern Africa, and eastern Asia. The frond has traditionally been used as medicine for its purported diuretic and mild laxative effects (18).",
            "Safety": "There is insufficient reliable information available about the safety of hartstongue.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNone reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDyspepsia. Although there has been interest in using oral hartstongue for dyspepsia, there is insufficient reliable information about the clinical effects of hartstongue for this purpose.\nUrinary tract infections (UTIs). Although there has been interest in using oral hartstongue for UTIs, there is insufficient reliable information about the clinical effects of hartstongue for this purpose.\nMore evidence is needed to rate hartstongue for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hartstongue.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hartstongue.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of hartstongue.",
            "Mechanism of Action": "General\nThe applicable parts of hartstongue are the above ground parts. Hartstongue contains tannins, mucilage, flavonoids (kaempferol-7-rhamnoside-3 coffeoyl-7-diglucoside), thiaminase, and sugars (sucrose and invert sugar) (18)."
        }
    },
    "Hawaiian baby woodrose": {
        "sections": {
            "Overview": "Hawaiian baby woodrose is a plant related to the morning glory. It grows in Florida, California, and Hawaii (17, 103858). The seeds of Hawaiian baby woodrose contain a compound called lysergic acid amide. Plants containing this compound have been traditionally used in shamanistic rituals in South America (103857, 103861). Traditionally, the seeds have been used for purported analgesic, diaphoretic, and hallucinogenic effects.",
            "Warnings": "Hawaiian baby woodrose seeds are touted as a \"natural LSD\" in internet advertising. Despite serious safety concerns, the seeds of the plant are legal and easily purchased from internet sources (5301, 97867, 103857, 103861).",
            "Safety": "LIKELY UNSAFE when used orally (17, 5301). The seeds of Hawaiian baby woodrose have effects similar to the hallucinogen lysergic acid diethylamide (LSD), including flashbacks and hallucinations. In one case, severe agitation led to death due to jumping from a high point (5301, 97867, 103857, 103858, 103860).\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally (17, 5301); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nHawaiian baby woodrose is generally regarded as unsafe for use. Any benefits of therapy may not outweigh the risk of toxicity. The number of seeds needed to produce adverse effects differs for each individual.\nMost Common Adverse Effects\nOrally: Dizziness, fatigue, hallucinations, hypertension, mydriasis, paranoia, sweating, tachycardia.\nCardiovascular\nOrally, approximately four homogenized Hawaiian baby woodrose seeds have been reported to cause temporary blood pressure elevation (103857). In one 18-year-old male, consuming 15 Hawaiian baby woodrose seeds resulted in tachycardia and hypertension. The patient also used cannabis, but symptoms were thought to be related to Hawaiian baby woodrose (103858). The number of seeds needed to produce adverse effects differs for each individual. Additionally, the alkaloid and lysergic acid amide contents vary from batch to batch (103857).\nless\nDermatologic\nOrally, Hawaiian baby woodrose seeds can cause sweating (5301).\nless\nGastrointestinal\nOrally, four homogenized Hawaiian baby woodrose seeds have been reported to cause nausea and vomiting (103857). The number of seeds needed to produce adverse effects differs for each individual. Additionally, the alkaloid and lysergic acid amide contents vary from batch to batch (103857).\nless\nNeurologic/CNS\nOrally, four homogenized Hawaiian baby woodrose seeds have been reported to cause fatigue lasting for 2 hours and tremor of the hands lasting for about 9 hours in one person (103857). Weakness, vertigo, and heaviness in the legs have also been reported (103857). The seeds have also been reported to cause auditory hallucinations and altered visual perception (5301, 103857, 103860). The number of seeds needed to produce adverse effects differs for each individual. Additionally, the alkaloid and lysergic acid amide contents vary from batch to batch (103857). Lysergic acid amide 2-5 mg is enough to cause hallucinations, with effects lasting 4-8 hours (5301, 5304, 97867).\nless\nOcular/Otic\nOrally, Hawaiian baby woodrose seeds can cause blurred vision, dilated pupils, and involuntary, rapid, rhythmic movement of eyeballs (5301, 103857).\nless\nPsychiatric\nOrally, four homogenized Hawaiian baby woodrose seeds has been reported to cause difficulty expressing thoughts, fits of laughter, and paranoia in one person (103857). The seed has also been reported to cause mood elevation and anxiety (103857, 103860). In an 18-year-old male, ingestion of 15 seeds resulted in erratic and bizarre behavior accompanying suicidal and homicidal ideation and depression. The patient also used cannabis, but symptoms were thought to be related to Hawaiian baby woodrose (103858). In one case report of a 29-year-old male, consuming an unknown quantity of soaked Hawaiian baby woodrose seeds and smoking cannabis resulted in severe agitation leading to a jump from a fourth-floor window and death (97867). In a 17-year-old female, ingestion of 6 seeds initially resulted in a euphoric and energetic mood, with increased socializing and school performance. The patient then developed problems with concentration, thinking, and sleep, with nightmares, anxiety, suspiciousness, and crying, resulting in hospital admission and treatment for psychosis with aripiprazole 10 mg daily and lorazepam as needed. Most symptoms resolved within 7 weeks; however, problems with concentration continued for several more weeks. Aripiprazole was discontinued 22 weeks after discharge (109536).\n\nThe number of seeds needed to produce adverse effects differs for each individual. Additionally, the alkaloid and lysergic acid amide contents vary from batch to batch (103857). Lysergic acid amide 2-5 mg is enough to cause hallucinations (97867).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of Hawaiian baby woodrose.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Hawaiian baby woodrose. Hawaiian baby woodrose seeds are eaten whole, crushed, or soaked in water (97867, 103860).",
            "Interactions with Drugs": "SEROTONERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use may increase the risk for serotonergic adverse effects.\nHawaiian baby woodrose contains chemicals which might increase serotonin levels. Combining serotonergic drugs with Hawaiian baby woodrose might increase the risk of serotonergic side effects including serotonin syndrome and cerebral vasoconstrictive disorders (8056).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH SEROTONERGIC PROPERTIES\nTheoretically, Hawaiian baby woodrose might increase serotonin levels.\nHawaiian baby woodrose contains chemicals which might increase serotonin levels. Combining Hawaiian baby woodrose with other serotonergic substances might increase the risk of serotonergic side effects including serotonin syndrome and cerebral vasoconstrictive disorders (8056). See other substances with serotonergic effects here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nPERIOPERATIVE\nHawaiian baby woodrose might affect serotonin levels. Theoretically, Hawaiian baby woodrose might interfere with surgical procedures due to serotonergic central nervous system effects or serotonergic effects on the vascular system. Tell patients to discontinue Hawaiian baby woodrose at least 2 weeks before elective surgical procedures.\nless\nPSYCHOSIS\nTheoretically, because Hawaiian baby woodrose has effects similar to LSD, individuals with psychotic tendencies might experience prolonged psychotic reactions (17).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Hawaiian baby woodrose.",
            "Pharmacokinetics": "Absorption\nFollowing ingestion of Hawaiian baby woodrose seeds, lysergic acid amide, isolysergic acid amide, ergonovine, and D-lysergic acid alpha-hydroxyethylamide were found in blood (97867, 103861). Lysergic acid amide was found in the serum 30-40 minutes after ingestion of the seeds. In at least one person, lysergic acid amide levels continued to increase approximately 90 minutes after intake (103861).\nMetabolism\nFollowing ingestion of Hawaiian baby woodrose seeds, 2-oxo 3-hydroxy metabolites of lysergamide and ergonovine were found in the blood and urine (97867).\nExcretion\nFollowing ingestion of Hawaiian baby woodrose seeds, lysergic acid amide, ergonovine, and D-lysergic acid alpha-hydroxyethylamide were found in urine (97867, 103861). The time to detection of these compounds in the urine is variable. Lysergic acid amide was detectable within one hour in one person and after 7.25 hours in another (103861). Levels are no longer detectable by 48 hours (103861).",
            "Mechanism of Action": "General\nThe applicable part of Hawaiian baby woodrose is the seed. The seeds of Hawaiian baby woodrose contain lysergic acid amide (ergine), ergonovine, and isoergine (isolysergic acid amide) (5301, 5304, 103860). Other constituents include lysergol, elymoclavine, setoclavine, and chanoclavine (103860). Lysergic acid amide and its isomers are the dominant constituents at approximately 83%, followed by ergonovine at 10% to 17% (103860). Lysergic acid amide is considered to be the most active constituent (103860). However, isolysergic acid and lysergol are also active (103857). The total ergot alkaloids in seeds can vary by at least 8.6-fold and the content of lysergic acid amide can range from trace amounts up to16 mcg per mg of seeds (103857, 103860, 109536).\nPsychiatric effects\nThe lysergic acid amide constituent of Hawaiian baby woodrose seeds affects the dopamine D2 receptor. It also seems to be a partial agonist or antagonist of adrenergic and serotonergic receptors (103737, 103860). The lysergic acid amide in Hawaiian baby woodrose is thought to have similar hallucinogenic effects to lysergic acid diethylamide (LSD) due to its activity at the 5-HT2 receptor. Drugs that are 5-HT2 receptor antagonists, such as cyproheptadine and atypical antipsychotics, might block the effects of Hawaiian baby woodrose (17, 103737, 103860)."
        }
    },
    "Hawthorn": {
        "sections": {
            "Overview": "Hawthorn is a flowering shrub of the rose family grown throughout North and South American, Europe, and Asia (113113). Multiple species are commonly found in Hawthorn preparations, including: C. laevigata, C. oxyacantha, C. monogyna and C. mexicana (54659, 54662, 54665, 113112, 113113). Traditionally, hawthorn has been used orally to improve digestion and blood circulation, and for asthma, diarrhea, parasitic infections, and kidney and bladder disorders. Topically, hawthorn has traditionally been used as a poultice or wash for boils, sores, ulcers, itching, and frost bite.",
            "Warnings": "In January 2024, the FDA issued a warning to the public to avoid some hawthorn root extract supplements derived from Mexican Hawthorn root, also known as tejocote (Crataegus mexicana), because they may be contaminated or adulterated with toxic yellow oleander which can lead to gastrointestinal, neurological, and cardiovascular adverse effects that may be severe, or even fatal. The FDA further advises anyone who has taken the tejocote Hawthorn root extract products listed in their warning letter to contact their health care provider immediately for health evaluation (113114).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. Hawthorn preparations in doses of up to 1800 mg daily seem to be safe when used for up to 16 weeks. Although hawthorn might be safe for long-term use, current studies have not evaluated safety past 16 weeks (8279, 8280, 8281, 10144, 17203, 104689).\nThere is insufficient reliable information available about the safety of hawthorn when used topically.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, hawthorn seems to be well tolerated when used appropriately. Topically, no adverse effects have been reported, although a thorough evaluation of safety outcomes has not been conducted.\nSerious Adverse Effects (Rare)\nOrally: Multiorgan hypersensitivity reactions resulting in acute renal failure have been reported rarely.\nCardiovascular\nOrally, tachycardia (with facial pains) of uncertain relationship to hawthorn was reported in a multicenter clinical trial (54640). Palpitations (19244) were reported in three patients in a large surveillance trial of 3,664 patients with cardiac failure (54692) and in 11 patients with congestive heart failure (CHF) in a literature review of 5,577 patients (19247). Circulation failure has been reported in two patients with CHF in a literature review of 5,577 patients (19247). Incidences of hospitalization, hospitalization due to CHF, worsening of CHF, angina, and atrial fibrillation have also been reported with the use of hawthorn extract WS 1442 (Crataegutt forte), although it is unclear if these events are related to hawthorn supplementation or existing CHF (19222). In clinical trials, chest pain (8281), short-term increases in blood pressure (19240), and other non-specific heart problems (17203) have also been reported following the use of various hawthorn preparations (e.g. WS 1442, Korodin).\n\nOrally, severe bradycardia, bradypnea, and Mobitz type 1 second degree heart block have been reported in a 16-year-old female who consumed Hawthorn root extract. Blood tests indicated plasma digoxin levels in the therapeutic range, despite no history of digoxin use. Medical treatment for digoxin cardiotoxicity did not improve symptoms. Symptoms gradually normalized over 3 days after discontinuation of the product (113112). Similarly, a 40-year-old female presented with bradycardia and elevated plasma digoxin levels after taking hawthorn root extract 196 mg daily for 2 days with no history of digoxin use. Symptoms resolved within 24 hours (113113).\nless\nDermatologic\nOrally, erythematous rash has been reported in patients with CHF in a literature review of 5,577 patients (19247). Non-specific rashes and itching (19222, 19243) as well as toxiderma from the fruits of hawthorn (54670) have also been reported.\nless\nGastrointestinal\nOrally, rare abdominal discomfort of uncertain relationship to hawthorn has been reported in a large clinical trial, surveillance study, case reports, and a literature review (19247, 54640, 54692, 113112). Digestive intolerance (19241), diarrhea (19243, 113112), flatulence (8281), gastroenteritis (8281), increased bowel movements (19243), obstipation (8281), mild and rare nausea (10144, 19247, 19244), vomiting (113112), nutritional and metabolic problems (17203), and other non-specific gastrointestinal effects (19222), have also been reported. Furthermore, gastrointestinal hemorrhage has been reported in two patients with CHF in a literature review of 5,577 patients (19247).\nless\nMusculoskeletal\nIn clinical trials, arthritis (8281), back pain (8281), weakness (19243), and other non-specific musculoskeletal effects (19222) have been reported following the use of various hawthorn preparations (e.g. WS 1442, CKBM-A01). Additionally, in a case report, myalgia has been reported following use of hawthorn root extract (113113).\nless\nNeurologic/CNS\nOrally, headache and dizziness/vertigo were reported in 2 patients in a large surveillance trial of 3,664 patients with cardiac failure (54692), in 15 patients with CHF as reported in a literature review of 5,577 patients (19247), in a varying number of clinical trial participants (8281, 19222, 19244), and in case reports (113112, 113113). Incidences of fainting (19222), fever (17203), and infrequent, mild and transient sleepiness have also been reported (19221, 54692).\nless\nPsychiatric\nOrally, agitation was reported in a large surveillance trial of 3,664 patients with cardiac failure (54692).\nless\nPulmonary/Respiratory\nOrally, bronchitis has been reported following the use of hawthorn extract WS 1442 (8281), and bradypnea has been reported following the use of hawthorn root extract (113112).\nless\nRenal\nA case of multiorgan hypersensitivity reaction and acute renal failure following the consumption of C. orientalis has been reported (54654).\nless\nOther\nFlu-like syndrome (8281) and other non-specific infections have been reported following the use of the hawthorn extract WS 1442 (17203, 19222). Hawthorn has also been reported to cause nosebleeds (8281, 10144).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAngina. It is unclear if oral hawthorn is beneficial in patients with angina.\nPreliminary clinical research in patients with angina taking chronic beta-adrenergic receptor blockers or ACE inhibitor therapy shows that taking a hawthorn (Crataegus pinnatifada) extract 100 mg orally three times daily for four weeks improves angina and electrocardiogram (ECG) findings and reduces nitroglycerin intake when compared with placebo (19242). Other preliminary clinical research in patients with unstable angina shows that taking hawthorn 10 grams and hu zang 15 grams orally daily for 4 weeks does not reduce the frequency of angina pectoris attacks when compared with control. However, taking hawthorn and hu zang improved some subjective symptom scores and quality of life scores (109610).\nless\nAnxiety. Oral hawthorn has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA clinical study in adults with mild to moderate generalized anxiety shows that taking a specific product (Sympathyl, not available in the US) containing hawthorn, magnesium, and California poppy for 90 days modestly improves anxiety scores when compared with placebo (12583). Also, a clinical study in adults with adjustment disorder and anxious mood shows that hawthorn, in combination with black horehound, passion flower, valerian, kola nut, and guarana, modestly improves anxiety scores when compared with placebo (6250). It is unclear if these effects are due to hawthorn, other ingredients, or the combination. Another small clinical study in healthy adults shows that taking a combination of herbal extracts containing hawthorn, passionflower, ballota, and valerian root daily for 14 days reduces subjective anxiety and objective sympathetic and autonomic nervous system activation in response to a psychosocial stressor when compared with placebo (111222). It is unclear if these effects are due to hawthorn, other ingredients, or the combination.\nless\nArrhythmia. Although there has been interest in using oral hawthorn for arrhythmia, there is insufficient reliable information about the clinical effects of arrhythmia for this condition.\nAtherosclerosis. Although there has been interest in using oral hawthorn for atherosclerosis, there is insufficient reliable information about the clinical effects of arrhythmia for this condition.\nCardiovascular disease (CVD). Although there has been interest in using oral hawthorn for CVD, there is insufficient reliable information about the clinical effects of arrhythmia for this condition.\nCognitive function. Oral hawthorn has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nIn a preliminary clinical trial, a single dose of 25 drops of a combination product of D-camphor and hawthorn berry extract (Korodin) was superior to placebo for increasing cognitive performance in elderly female patients as measured by visuomotor speed and information processing capacity. The active treatment group showed an improvement in attentional and mental performance (19240, 91504).\nless\nCongestive heart failure (CHF). The evidence on the effects of oral hawthorn in patients with CHF is conflicting. Although some older research suggests it may be beneficial, more recent, larger studies suggest it may actually increase the risk for complications.\nThere is contradictory evidence about the effects of hawthorn extract in heart failure patients. Several clinical studies show that taking specific hawthorn leaf and flower extracts (LI 132, Faros 300, Lichtwer Pharma; WS 1442, Crataegutt forte, Dr. Willmar Schwabe Pharmaceuticals; or HeartCare, Nature's Way) 240-600 mg daily improves ejection fraction and exercise tolerance, reduces subjective symptoms, and decreases the risk of death in patients with New York Heart Association (NYHA) stage II heart failure. In these studies, the maximum effect was usually seen after 6-12 weeks of treatment (8279, 8280, 11449, 19221, 19223, 19225, 19226, 19227, 19228). Another clinical trial shows that hawthorn extract (WS 1442, Crataegutt forte, Dr. Willmar Schwabe Pharmaceuticals or HeartCare, Nature's Way) 1800 mg daily, combined with diuretic therapy, improves exercise tolerance and reduces subjective symptoms in NYHA stage III heart failure. In this study, maximum effect was usually seen after 16 weeks of treatment (8281). In another trial, patients with NYHA II heart failure taking either hawthorn (LI 132, Faros) 300 mg three times daily or captopril 12.5 mg three times daily experienced similar improvements in cardiac performance and symptoms (19230).\n\nHowever, other clinical research suggests no benefit and possible harm with hawthorn. A large-scale clinical trial (SPICE) in patients with NYHA stage II or III heart failure shows that taking specific hawthorn extracts (WS 1442, Crataegutt forte, Dr. Willmar Schwabe Pharmaceuticals; HeartCare, Nature's Way) 900 mg daily for 24 months, in combination with conventional treatment, does not decrease hospitalization due to progressive heart failure, non-fatal myocardial infarction, or cardiac death (17203). Another clinical trial in patients with NYHA stage II or III heart failure shows that taking these same specific hawthorn extracts at the same dose for up to 6 months does not slow the progression of heart failure when compared with placebo (19222). In a retrospective analysis of this study, it was shown that heart failure progression was significantly increased in patients taking hawthorn when compared with placebo. The rate of death was also increased by 1.7% over placebo, and heart failure-related hospitalizations increased by 8% over placebo in patients treated with hawthorn (16824).\nless\nHyperlipidemia. Although there has been interest in using oral hawthorn for hyperlipidemia, there is insufficient reliable information about the clinical effects of arrhythmia for this condition.\nHypertension. It is unclear if oral hawthorn is beneficial for lowering blood pressure.\nOne preliminary clinical trial showed that taking hawthorn standardized extract 1,000-2,500 mg daily for three days does not significantly reduce blood pressure in hypertensive or prehypertensive patients when compared with placebo (19244). However, another study in patients with diabetes and hypertension shows that taking a specific hawthorn extract (LI 132) 1,200mg daily for 16 weeks significantly decreased diastolic, but not systolic, blood pressure when compared with placebo (19245).\nless\nObesity. Oral hawthorn has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA clinical study in adults who are overweight shows that taking a mixture of extracts of hawthorn leaves and satsuma mandarin orange peels, 840-1200 mg daily for 12 weeks, slightly reduces body weight, body mass index, and fat percentage, but not waist or hip circumferences, when compared with placebo (115342). It is unclear if these effects are due to hawthorn, other ingredients, or the combination.\nless\nOrthostatic hypotension. Oral hawthorn has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in older adults with orthostatic hypotension shows that taking a specific combination product containing hawthorn and camphor (Korodin Herz-Kreislauf-Tropfen) 25 drops orally three times daily for 7 days attenuates the blood pressure reduction upon standing when compared with placebo. Signs and symptoms of orthostatic hypotension such as dizziness, blurry vision, and falls also seem to be reduced when compared with baseline (39614, 39617). A meta-analysis of 4 studies shows that giving single doses of 20-25 drops of the same combination product increases systolic and diastolic blood pressure when compared with placebo (103620). However, the studies have methodologic problems and, while 2 were conducted in females with orthostatic hypotension, the others involved health young adults or normotensive elderly subjects. The effect of hawthorn alone for treatment of orthostatic hypotension has not been determined. The combination product used in these studies is not available in the US.\nless\nMore evidence is needed to rate hawthorn for these uses.",
            "Dosing & Administration": "Adult\nOral:\nHawthorn extract has most often been used as 160-1200 mg daily in divided doses. See Effectiveness section for condition-specific information.\n\nHawthorn extract used in clinical trials has commonly been standardized to a range of 17.3% to 20.1% oligomeric procyanidins (17203, 19226, 8280, 8281, 104689).\nChildren\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nHawthorn extract WS 1442 (Crataegutt forte) has been standardized to a range of 17.3% to 20.1% oligomeric procyanidins (17203, 19226, 104689), while some studies have reported specific standardization to 18.75% (8280, 8281) or 84.3 mg oligomeric procyanidins (16824). The U.S. brand HeartCare (Nature's'Way) is also standardized in this fashion.\n\nHawthorn extract LI 132 (Faros 600) has been standardized to 2.2% flavonoids (19245). Crataesor has been standardized to 5% procyanidins and 2% flavonoids (19241). Hawthorn Supreme System Support liquid phyto-caps (250 mg) has been standardized to 50 mg oligomeric procyanidins (19244). Korodin has been standardized to contain 97.3 gram fluid extract from fresh hawthorn berries, 2.5 grams natural D-camphor, and 0.2 grams menthol as an aromatic ingredient per 100 grams (91504).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, hawthorn may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.\nIn vitro and animal research shows that hawthorn can inhibit platelet aggregation (95528, 95529, 95530, 95531). However, its effect in humans is unclear. One observational study shows that patients taking hawthorn shortly before undergoing coronary artery bypass graft (CABG) surgery or valve replacement surgery have a 10% incidence of postoperative bleeding, compared with 1% in those who never consumed hawthorn extract (95527). However, clinical research shows that taking a specific preparation of dried hawthorn leaves and flowers (Crataesor, Soria Natural Lab) 800 mg three times daily for 15 days does not affect platelet aggregation or levels of thromboxane B2, the metabolite of thromboxane A2, in healthy humans (54664).\nless\nBETA-BLOCKERS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might cause additive effects on blood pressure and heart rate.\nSome evidence shows that hawthorn might lower blood pressure and heart rate (12595, 19245, 113112, 113113).\nless\nCALCIUM CHANNEL BLOCKERS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might cause additive coronary vasodilation and hypotensive effects.\nSome evidence shows that hawthorn might lower blood pressure due to vasodilatory effects (12595, 19245).\nless\nDIGOXIN (Lanoxin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, hawthorn might potentiate the effects and adverse effects of digoxin.\nHawthorn appears to improve cardiac output (12595); however, hawthorn does not appear to affect digoxin pharmacokinetics (19249). Case reports suggest that at least one species of hawthorn root extract (Crataegus mexicana) may produce adverse effects similar to digoxin and can cross-react with digoxin assays, leading to falsely elevated plasma digoxin levels (113112, 113113).\nless\nNITRATES\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might cause additive coronary vasodilatory effects.\nSome evidence shows that hawthorn might lower blood pressure due to vasodilatory effects (12595, 19245).\nless\nPHOSPHODIESTERASE-5 INHIBITORS\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use might result in additive vasodilation and hypotension.\nHawthorn might inhibit PDE-5 and cause vasodilation (12595).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, hawthorn may have antiplatelet effects in some people.\nHawthorn might inhibit platelet aggregation (95527, 95528, 95529, 95530, 95531). Concomitant use of hawthorn with other herbs and supplements that affect platelet aggregation could theoretically increase the risk of bleeding. See other products with antiplatelet activity here. See products with anticoagulant activity here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nHawthorn might have hypotensive effects (12595). Theoretically, concomitant use of hawthorn with other herbs and supplements that decrease blood pressure might increase the risk of hypotension.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nHEART FAILURE\nHawthorn might interact with many prescription drugs used to treat heart disease. Avoid use until more is known. A specific extract of hawthorn (WS 1442, Crataegutt forte, Dr. Willmar Schwabe Pharmaceuticals or HeartCare, Nature's'Way) has been shown to increase death and hospitalization due to heart failure. A retrospective safety analysis, from a clinical trial in patients with New York Heart Association stages II or III heart failure, shows that taking 450 mg twice daily for up to 6 months increases the risk of death associated with heart failure by 1.7% and hospitalization by 8% (16824).\nless\nPERIOPERATIVE\nHawthorn might inhibit platelet aggregation and increase the risk of postoperative bleeding when used prior to surgery (95527, 95528, 95529, 95530, 95531). Tell patients to discontinue hawthorn at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "DIGOXIN ASSAY\nAt least one species of hawthorn root extract (Crataegus Mexicana) may cross-react with certain commercial digoxin assays and result in falsely elevated plasma digoxin levels (113112, 113113).\nless",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hawthorn.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of hawthorn.",
            "Mechanism of Action": "General\nThe applicable parts of hawthorn are the leaves, berries, flowers, and roots. Major pharmacologically active components are believed to be flavonoids, particularly the oligomeric proanthocyanidins (OPCs) such as procyanidin B2, procyanidin clusters (DP 4, 5, 6), catechin, and epicatechin (54659, 54662, 54665). Other known constituents include caffeic acid, chlorogenic acid, hesperidin, hyperoside, myricitrin, oleanolic acid, O-methyoxyphenethylamine, phenylethylamine, quercitrin, rutin, tocopherols, tyramine, ursolic avid, vitamin C, isovitexin, vitexin, vitexin-2-O-rhamnoside, and vitexin rhamnoside (19241, 54657, 54662).\nAntineoplastic effects\nHawthorn may exhibit antineoplastic activity and collagen stabilizing actions. Two triterpenes, uvaol and ursolic acid, were isolated from hawthorn and suggested to be responsible for cytotoxicity against human and murine cancer cell lines (54641). Triterpene-enriched fractions of hawthorn extract have demonstrated almost complete inhibition of cultured larynx cancer cell growth and stronger in vitro activity than 6-mercaptopurine solution(54695). The exact mechanism of action is not well understood.\nAntioxidant effects\nFree radical properties have been demonstrated in vivo (54682, 54699), and may depend on the phenol (54681) or flavonoid content of the extract.\nAntiplatelet effects\nIn vitro and animal research shows that hawthorn extract can inhibit ADP- and epinephrine-induced platelet aggregation and prolong bleeding time (95528, 95529, 95530, 95531). The extracts inhibit synthesis of thromboxane A2, a stimulator of platelet aggregation. The active constituents are thought to include flavonoids and sesquiterpenes (95529, 95531). However, the effect of hawthorn on platelet aggregation in humans is conflicting. One observational study shows that taking hawthorn shortly before undergoing cardiovascular surgery is associated with a 9% higher incidence of postoperative bleeding compared with never consuming hawthorn (95527). However, clinical research shows that taking a specific preparation of dried hawthorn leaves and flowers (Crataesor, Soria Natural Lab) 800 mg three times daily for 15 days does not affect platelet aggregation or levels of thromboxane B2, the metabolite of thromboxane A2, in healthy humans (54664). These conflicting results may be due to the use of different hawthorn species, extracts, and doses.\nCardiovascular effects\nHawthorn preparations have been traditionally used for cardiovascular conditions (98380). Hawthorn acts on the myocardium by increasing force of contraction and lengthening the refractory period, increasing coronary blood flow and cardiac output, and reducing oxygen consumption (10144, 11450, 12595). Hawthorn's cardiotrophic properties are attributed to increased membrane permeability for calcium (11450), and phosphodiesterase inhibition, which increases intracellular cAMP. Increased cAMP leads to increased coronary blood flow, vasodilation, and positive inotropic effects (11450, 12595). Hawthorn seems to have hypotensive and vasodilatory activity. In a human study, hawthorn extract had beneficial effects on endothelial function (104689). In animals, it seems to cause peripheral vasodilation and to induce endothelium-dependent arterial relaxation. The proantocyanidin constituents seem to be responsible for this effect (12595).\n\nThere is also interest in using hawthorn for reducing arrhythmic events (12595). One theory is that hawthorn might reduce arrhythmias by reducing adrenergic stimulation. In vitro, hawthorn leaf extract had a dose-dependent negative chronotropic effect on cardiac muscle cells. This effect is thought to be due to beta-adrenergic receptor blockade similar to propranolol (98380). However, this effect has not been confirmed in humans. Another theory is that hawthorn might block potassium channels, prolong action potential repolarization, and prolong the QT interval similarly to class III antiarrhythmic agents. Preliminary studies in animal models support this theory. However, a small clinical trial in healthy adults shows that a single dose of hawthorn 160 mg orally has no effect on electrocardiographic measures such as QT, PR and QRS intervals (98381).\n\nFinally, some preliminary research in humans and animals suggests hawthorn might lower serum cholesterol, low-density lipoprotein (LDL) cholesterol, and/or triglycerides (12595, 104689). In an animal model, hawthorn seems to lower accumulation of lipids in the liver and aorta. The fruit extract may lower cholesterol by increasing bile acid excretion, reducing cholesterol synthesis by the liver, and enhancing LDL-receptor activity. Hawthorn also seems to have antioxidant activity (12595).\nDermatologic effects\nSkin aging is caused by exposure to ultraviolet (UV) A and B rays from sunlight. There is interest in using polyphenols from hawthorn to protect from UVB radiation damage to slow skin aging. Preliminary research in human skin cell lines and in animal models shows that hawthorn polyphenol extract increases activity of antioxidant enzymes and reverses oxidative stress caused by UVB irradiation. Hawthorn extract also seems to reduce epidermal thickening and increase collagen production, which might help to reduce wrinkles and skin damage from UVB radiation (98379)."
        }
    },
    "Hazelnut": {
        "sections": {
            "Overview": "Hazelnut is the nut from the hazel tree. It is rich in monounsaturated fatty acids (102034). The nut is commonly consumed as a food.",
            "Warnings": "The Food Allergen Labeling and Consumer Protection Act (FALCPA) of 2004 recognizes tree nuts as a major food allergen in the United States and requires that tree nuts, including hazelnut, be labeled on packaged food and supplement products (105410).",
            "Safety": "LIKELY SAFE when used in amounts commonly found in foods. Hazelnuts have been safely consumed as part of the diet in a quantity of 29-60 grams (18-40 nuts) per day (102033, 102034, 102331).\nPREGNANCY AND LACTATION: LIKELY SAFE when used in amounts commonly found in foods.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, hazelnut is well tolerated.\nSerious Adverse Effects (Rare)\nAll routes of administration: Allergic reactions, including oral allergy syndrome and anaphylaxis.\nDermatologic\nOrally, hazelnut can cause atopic dermatitis in patients with a hazelnut allergy. In one case, hazelnut essence in hydroxyzine syrup was determined to be the likely cause of atopic dermatitis in a toddler (102031).\nless\nImmunologic\nOrally, hazelnut can cause an allergic reaction in sensitive individuals, with severity ranging from oral allergy syndrome to anaphylaxis (5991, 5998, 102029, 102030, 102031, 102032). The prevalence of hazelnut sensitization varies by geographic location, with hazelnut allergy reported more often in areas with greater birch tree pollen exposure. Hazelnut allergy is more common in adults than children, but children are more likely to develop severe reactions (102032).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY INEFFECTIVE\nObesity. Most clinical research shows that consuming hazelnuts or hazelnut oil does not improve weight loss.\nMost clinical research in overweight and obese adults shows that consuming 29-69 grams of hazelnuts daily or taking hazelnut oil 25 grams daily for 4-12 weeks does not decrease body weight, body mass index (BMI), or other measures of body composition when compared with placebo (102033, 102034).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nCoronary heart disease (CHD). It is unclear if consuming hazelnuts as part of the diet reduces the risk for CHD.\nEpidemiological research has found that people who increase dietary consumption of nuts, including hazelnuts, might have a lower risk of CHD and death due to coronary events. However, there is no available evidence showing that eating hazelnut, specifically, reduces the risk of CHD (8478, 13299). In 2003, the US Food and Drug Administration (FDA) determined that it would allow a qualified health claim stating that consuming 1.5 ounces of nuts, such as hazelnuts, per day, as part of a diet low in saturated fat and cholesterol, may reduce the risk of CHD. The FDA has concluded that this claim is based on supporting, rather than conclusive, evidence (102331).\nless\nDementia. Although there is interest in using oral hazelnut to prevent dementia, there is insufficient reliable information about the clinical effects of hazelnut for this purpose.\nHyperlipidemia. It is unclear if consuming hazelnuts as part of the diet can lower lipid levels.\nOne meta-analysis of three preliminary clinical trials shows that consuming 29-60 grams of hazelnut daily as part of the diet for 8-12 weeks reduces low-density lipoprotein (LDL) cholesterol by around 6 mg/dL, but does not significantly improve total cholesterol, high-density lipoprotein (HDL) cholesterol, or triglycerides, when compared with a control diet (102034). The effects of hazelnut on lipid levels in patients with hyperlipidemia are unclear, as the studies analyzed in the meta-analysis included patients with and without elevated lipid levels.\nless\nMore evidence is needed to rate the effectiveness of hazelnut for these uses.",
            "Dosing & Administration": "Adult\nOral:\nHazelnuts are typically consumed in moderation as part of the diet. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hazelnut.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "CROSS-ALLERGENICITY\nHazelnut is believed to be cross reactive with peanut (5991), walnut (102032), cashew nut (102032), mugwort pollen (5993), brazil nut (5994), birch pollen (5996), and macadamia nut (5997) in some patients. Adults tend to have a greater incidence of cross-allergenicity between birch pollen and hazelnut when compared with children (102030). Some research suggests that the mechanisms of allergenicity between hazelnut and peanut are different and not related to IgE cross-reactivity. In one study, 68% of hazelnut-sensitized patients also showed sensitivity to peanut, although cross-reactivity to specific nut proteins was less common (102029). Other research suggests hazelnut-peanut cross-sensitivity is due to some degree of IgE involvement (102032).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the treatment or presentation of overdose with hazelnut.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of hazelnut.",
            "Mechanism of Action": "General\nThe applicable part of hazelnut is the kernel, or nut. The skin of the kernel may also be consumed (103810). Hazelnuts contain 54.6% to 63.2% oil, 14.3 to 18.2% protein, and 9.8% to 13.2% fiber (5995). Hazelnuts are rich in monounsaturated fatty acids (102034).\nCardiovascular effects\nOxidized low-density lipoprotein (LDL) is thought to increase atherosclerosis. Laboratory research indicates that hazelnut extract, containing phenolic acid antioxidants, inhibits oxidation of LDL and, therefore, may theoretically reduce atherosclerosis (103810).\nNeuroprotective effects\nHazelnut appears to reduce beta-amyloid peptide-induced neuron apoptosis. Animal research shows that hazelnut supplementation reduces markers of neuron apoptosis in rats that were administered exogenous beta-amyloid peptide. It is unclear which constituent of hazelnut reduces markers of neuron apoptosis (103809).\nWeight loss effects\nThe beta-3 adrenergic receptor (ADRB3) is thought to play a role in the regulations of lipolysis and body weight. Some research shows that hazelnut oil decreases methylation of the ADRB3 gene (102033). The mechanism and clinical outcomes of this effect are unclear."
        }
    },
    "Heart's Ease": {
        "sections": {
            "Overview": "Heart's ease is a type of plant. It is native to or naturalized in large parts of Europe, the Middle East, and Central Asia. It is traditionally used as medicine (54705, 100059).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately (12). ...when used topically and appropriately (12). A lotion containing 5% heart's ease extract has been safely used in a study lasting up to 4 weeks (67372).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, heart's ease seems to be generally well tolerated (12). It has caused hemolysis in a nine-month-old infant with glucose-6-phosphate-dehydrogenase (G6PD) deficiency (11324).\nHematologic\nOrally, heart's ease boiled extract has caused hemolysis in a nine-month-old infant with glucose-6-phosphate-dehydrogenase (G6PD) deficiency. The methyl ester of salicylic acid, a constituent of heart's ease, is hypothesized to be responsible for this effect (11324).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAtopic dermatitis (eczema). Preliminary clinical research shows that applying an ointment containing 5% each of the extracts of heart's ease, gotu kola, and Oregon grape twice daily for 4 weeks does not improve eczema when compared with a base cream. However, patients with eczema on skin exposed to cold weather might experience some improvement (67372).\nChronic obstructive pulmonary disease (COPD). Preliminary clinical research in men aged 40-70 years with a history of smoking and stage 2 COPD shows that taking a combination of heart's ease 165 mg, calendula flowers 165 mg, and elderberry 165 mg (Inflaminat, INAT-Farma), 3 capsules daily for 6 months, modestly improves the score on the 5-point breathlessness, cough, and sputum scale (BCSS) and the mean forced expiratory volume in 1 second (FEV1), compared with no changes in the placebo group. However, the number of COPD exacerbations per month does not seem to be affected (103629). It is unclear if these effects are due to heart's ease, other ingredients, or the combination.\nMore evidence is needed to rate heart's ease for these uses.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Traditionally, heart's ease has been consumed as one cup of tea three times per day. The tea is prepared by steeping 1.5 grams of the above ground parts in 150 mL boiling water for 5-10 minutes and then straining (18).\n\nChronic obstructive pulmonary disease (COPD): A combination of heart's ease 165 mg, calendula flowers 165 mg, and elderberry 165 mg (Inflaminat, INAT-Farma), 3 capsules daily for 6 months, has been used (103629).\nTopical:\nGeneral: Traditionally, heart's ease is applied externally three times per day as a poultice or prepared tea (18).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of heart's ease.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "GLUCOSE-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY\nThere is one case report of hemolysis in an infant with G6PD deficiency who consumed heart's ease boiled extract. It is hypothesized that the methyl ester of salicylic acid, a constituent of heart's ease, was responsible for this effect (11324). Until more known, patients with G6PD deficiency should avoid heart's ease.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of heart's ease.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of heart's ease.",
            "Mechanism of Action": "General\nThe applicable parts of heart's ease are the above ground parts (18). Constituents in heart's ease include flavonoids, phenylcarbonic acids, coumarins, salicylic acid derivatives, and macrocyclic peptides known as cyclotides (54707, 100059).\nAnti-inflammatory effects\nHeart's ease is traditionally used for inflammatory lung and skin conditions. In vitro, heart's ease extract inhibited the secretion of various inflammatory cytokines, resulting in inhibition of the proliferation of activated lymphocytes. The bioactive constituents appeared to be the cyclotides (100059).\nCardiovascular effects\nThere is interest in using heart's ease as a cardioprotective agent. In vitro and animal research shows that heart's ease extracts have vasorelaxant and hypotensive effects, although the precise mechanism of action is unclear (104155).\nImmunologic effects\nIn vitro, heart's ease extract inhibits the secretion of various inflammatory cytokines. This results in inhibition of the proliferation of activated lymphocytes, although it does not affect their activation. The bioactive constituents appear to be the cyclotides (100059)."
        }
    },
    "Heather": {
        "sections": {
            "Overview": "Heather is an evergreen shrub native to Europe and North Africa. It is also cultivated in the U.S., Canada, and Australia (100600, 100601).",
            "Safety": "POSSIBLY SAFE when used orally or topically and appropriately (12).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally and topically, heather seems to be well tolerated (18). No adverse effects have been reported; however, a high quality assessment of safety has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of heather.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Traditionally, one cup of tea made with 1.5 grams of heather flower, leaf, and plant top parts three times daily between meals has been used (18).\nTopical:\nGeneral: Traditionally as a bath, 500 grams of heather flower, leaf, and plant top parts has been added to a few liters of water, strained, and then added to a full bath (18).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of heather.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of heather.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of heather.",
            "Mechanism of Action": "General\nThe applicable parts of heather are the flower, leaf, and plant top. Constituents of heather include phenolic compounds such as proanthocyanidins and anthocyanins; triterpenes such as ursolic acid and oleanolic acid; flavonoids such as quercetin, myricetin, and kaempferol; tocopherols; fatty acids such as linolenic acid, palmitic acid, and linoleic acid; amino acids such as glutamic acid and aspartic acid; and other organic acids such as ascorbic acid (100600, 100602, 100603).\nAnti-inflammatory effects\nIn vitro research shows that heather extracts have anti-inflammatory effects (100600).\nAnticancer effects\nIn vitro research shows that heather extracts have cytotoxic effects against breast, cervical, gastric, liver, and lung cancer cell lines. Researchers suggest that the triterpene constituents are responsible for the cytotoxic effects of heather (100600).\nAntimicrobial effects\nHeather extracts appear to have antimicrobial effects, with the greatest activity against Gram-positive bacteria (100600). In vitro research shows that heather extracts can inhibit the growth of Enterococcus faecalis, Escherichia coli, Gardenerella vaginalis, Klebsiella pneumoniae, Listeria monocytogenes, methicillin-resistant Staphylococcus aureus (MRSA), Morganella morganii, Neisseria gonorrhoeae, Proteus mirabilis, Proteus vulgaris, and Pseudomonas aeruginosa, although the antimicrobial effects appear to be weaker when compared with positive controls such as amoxicillin, ampicillin, imipenem, and vancomycin (100600, 100601).\nAntioxidant effects\nIn vitro research shows that heather extracts have antioxidant effects through scavenging of reactive oxygen species (100600).\nAntiviral effects\nIn vitro research shows that heather extracts have antiviral activity against hepatitis C virus (HCV). Heather extracts with higher concentrations of ursolic acid and oleanolic acid appear to have greater anti-HCV activity. It is thought that these constituents interfere with viral entry and impair HCV replication through inhibition of NS5B polymerase activity (100604).\nPhotoprotective effects\nAnimal and in vitro research shows that heather extract seems to protect against skin inflammation, sunburn, and damage to DNA caused by ultraviolet B rays, likely due to its antioxidant effects (100602, 100603)."
        }
    },
    "Hedge Mustard": {
        "sections": {
            "Overview": "Hedge mustard is a plant found in Europe, Asia, and northern Africa. The above ground parts are traditionally used in medicine (18, 103592). Traditional and historical uses of hedge mustard include sore throat and cough, laryngitis, bronchitis, asthma, mastitis, urinary tract diseases, orchitis, gallbladder problems, and cancer.",
            "Safety": "POSSIBLY UNSAFE when the fresh flowering parts are used orally due to the presence of cardioactive glycosides (18).\nThere is insufficient reliable information available about the safety of hedge mustard when used topically.\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally (18); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, hedge mustard might be unsafe due to its cardiac glycoside constituents. Topically, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted for either route of administration.\nSerious Adverse Effects (Rare)\nOrally: Theoretically, digitalis-like effects including cardiac rhythm disorders, diarrhea, headache, and vomiting.\nCardiovascular\nOrally, hedge mustard may theoretically cause digitalis-like effects such as cardiac rhythm disorders (18).\nless\nGastrointestinal\nOrally, hedge mustard may theoretically cause digitalis-like effects such as vomiting and diarrhea (18).\nless\nNeurologic/CNS\nOrally, hedge mustard may theoretically cause digitalis-like effects such as headache (18).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of hedge mustard.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hedge mustard.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nDIGOXIN (Lanoxin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking hedge mustard with digoxin might increase the risk of cardiac glycoside toxicity.\nThe flowering above ground parts of hedge mustard contain cardioactive glycosides (2, 18). Theoretically, taking hedge mustard with digoxin might increase the risk of cardiac glycoside toxicity.\nless\nDIURETIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking hedge mustard with diuretic drugs might increase the risk of cardiac glycoside toxicity.\nThe flowering above ground parts of hedge mustard contain cardioactive glycosides (2, 18). Theoretically, concomitant use of potassium depleting diuretics and hedge mustard can increase the risk of cardiac glycoside toxicity due to potassium depletion (506).\nless\nMACROLIDE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking hedge mustard with macrolide antibiotics might increase the risk of cardiac glycoside toxicity.\nThe flowering above ground parts of hedge mustard contain cardioactive glycosides (2, 18). Macrolide antibiotics appear to increase the gastrointestinal absorption of oral digoxin. Theoretically, concomitant use of macrolide antibiotics might increase the absorption of the cardiac glycosides found in hedge mustard (17).\nless\nQUININE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking hedge mustard with quinine might increase the risk of cardiac glycoside toxicity.\nThe flowering above ground parts of hedge mustard contain cardioactive glycosides (2, 18). Quinine may reduce the clearance of oral digoxin. Theoretically, concomitant use of quinine with hedge mustard might reduce the clearance of cardiac glycosides found in hedge mustard (506).\nless\nSTIMULANT LAXATIVES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking hedge mustard with stimulant laxatives might increase the risk of cardiac glycoside toxicity.\nThe flowering above ground parts of hedge mustard contain cardioactive glycosides (2, 18). Theoretically, overuse or misuse of stimulant laxatives may increase the risk of cardiac glycoside toxicity due to potassium depletion (2).\nless\nTETRACYCLINE ANTIBIOTICS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking hedge mustard with tetracycline antibiotics might increase the risk of cardiac glycoside toxicity.\nThe flowering above ground parts of hedge mustard contain cardioactive glycosides (2, 18). Tetracycline antibiotics appear to increase the gastrointestinal absorption of oral digoxin. Theoretically, concomitant use of tetracycline antibiotics might increase the absorption of the cardiac glycosides found in hedge mustard (17).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nCARDIAC GLYCOSIDE-CONTAINING HERBS\nTheoretically, hedge mustard might increase the risk of cardiac glycoside toxicity when used with other cardiac glycoside-containing herbs.\nThe flowering above ground parts of hedge mustard contain cardioactive glycosides (2, 18). Concomitant use might increase the risk of cardiac glycoside toxicity (19). See other products with cardiac glycosides here.\nless\nHORSETAIL\nTheoretically, hedge mustard might increase the risk of cardiac glycoside toxicity when used with horsetail.\nThe flowering above ground parts of hedge mustard contain cardioactive glycosides (2, 18). Concomitant use of horsetail with hedge mustard might increase the risk of cardiac toxicity due to potassium depletion (19).\nless\nLICORICE\nTheoretically, hedge mustard might increase the risk of cardiac glycoside toxicity when used with licorice.\nThe flowering above ground parts of hedge mustard contain cardioactive glycosides (2, 18). Concomitant use of licorice with hedge mustard might increase the risk of cardiac toxicity due to potassium depletion (19).\nless\nSTIMULANT LAXATIVE HERBS\nTheoretically, hedge mustard might increase the risk of cardiac glycoside toxicity when used with stimulant laxative herbs.\nConcomitant use of stimulant laxatives with hedge mustard might increase the risk of cardiac toxicity due to potassium depletion (19). See other products with laxative effects here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nHEART DISEASE\nThe flowering above ground parts of hedge mustard contain cardioactive glycosides (2, 18). Theoretically, cardiac glycosides may exacerbate heart disease or interfere with existing drug therapy.\nless\nPOTASSIUM DEFICIENCY\nDo not use hedge mustard in people with potassium deficiency. Using hedge mustard in patients with potassium deficiency can precipitate cardiac glycoside toxicity (3805).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nTheoretically, digitalis-like effects including cardiac rhythm disorders, diarrhea, headache, and vomiting can occur due to the cardiac glycosides in hedge mustard (18).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with hedge mustard.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of hedge mustard.",
            "Mechanism of Action": "General\nThe applicable parts of hedge mustard are the above ground parts. The foliage contains vitamin C, 0.05% cardenolides (cardioactive glycosides), glucosinolates including sinigrin and gluconapin, terpenes, and flavonoids. Hedge mustard also contains the volatile mustard oil allyl isothiocyanate and 3-butenylisothiocyanate (18, 103592).\nAntioxidant effects\nIn vitro, hedge mustard extract has antioxidant effects (103592). These effects may play a role in the potential clinical effects of hedge mustard."
        }
    },
    "Hedge-Hyssop": {
        "sections": {
            "Overview": "Hedge-hyssop is considered unsafe for oral use; avoid using (18).",
            "Safety": "UNSAFE when used orally (18).\nPREGNANCY AND LACTATION: UNSAFE when used orally due to toxic potential (18).",
            "Adverse Effects": "General\nOrally, taken in toxic doses, hedge-hyssop may cause vomiting, bloody diarrhea, colic, and kidney irritation characterized by initial diuresis followed by anuria. When people ingest very large amounts, spasms, paralysis, and circulatory collapse occur. Death occurs rarely (18).",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of hedge-hyssop.",
            "Dosing & Administration": "Adult\nNo typical dosage.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Mechanism of Action": "The applicable parts of hedge-hyssop are the above ground parts. Hedge-hyssop contains cucurbitacin glycosides which are released in aqueous environments and are extremely irritating to mucous membranes (18)."
        }
    },
    "Hemlock": {
        "sections": {
            "Overview": "Hemlock is native to Europe and western Asia and was introduced into North America as an ornamental plant (6338, 6339, 6341). All parts of the plant are considered poisonous. It is frequently found in the US and southern Canada along fences, in modified soils, roadside ditches, abandoned construction sites, pastures, crops, riverbanks, and fields (6338, 6341, 96876). Accidental poisoning has occurred when the hemlock plant is mistaken for parsnip, parsley, wild celery, anise, or when wild birds or mammals that have consumed hemlock seeds are eaten (6338, 6340, 6344, 96876, 96877, 96878).",
            "Safety": "UNSAFE when used orally (6338). All parts of hemlock including seeds, flowers, and fruits are considered poisonous (6338, 6339). Death has resulted after ingestion of hemlock (6340, 54711). Damage to the tubule cells of the kidneys (acute tubular necrosis), rapid breakdown of muscle tissue and release of muscle tissue byproducts into the blood (rhabdomyolysis), and subsequent kidney failure, as well as respiratory arrest, have also been reported following ingestion of hemlock (54709, 54716, 54718, 54727). Prompt medical attention is advised after ingestion of hemlock (6341).\nCHILDREN: UNSAFE when used orally (6340). Acute, sometimes lethal poisoning has resulted after ingestion of leaf material (6340) or when hollow stems are used as peashooters, flutes, or whistles (6338).\nPREGNANCY AND LACTATION: UNSAFE when used orally because ingestion can be lethal (6338); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nHemlock is generally regarded as unsafe for use. Any benefits of therapy may not outweigh the risk of toxicity. Orally, hemlock can cause burning of the mouth, throat, and abdomen, nausea, vomiting, excessive urination, salivation, drowsiness, mydriasis, muscle pain, rapid muscle swelling and stiffness, rhabdomyolysis, and tachycardia followed by bradycardia. It can also cause loss of speech, paralysis, encephalopathy, unconsciousness, rapid respiration and respiratory arrest, cardiovascular collapse, renal toxicity, and death (6340, 6341, 54709, 54711, 54712, 54716, 54717, 54718, 96877, 96878).\nCardiovascular\nOrally, hemlock can cause tachycardia followed by bradycardia, cardiovascular collapse, and death (6340, 6341, 54712, 96877). In one case report, a 6-year old girl had prolonged coagulation tests after accidental ingestion of hemlock (96877). It can also cause hypertension (110410).\n\nIntravenously, hemlock resulted in a brief cardiac arrest followed by return of spontaneous circulation in one case report (96876).\nless\nGastrointestinal\nOrally, hemlock causes burning of the mouth, throat, and abdomen (6341, 96877). It can also cause nausea, vomiting, and increased salivation (54712, 96878, 110410).\nless\nGenitourinary\nOrally, hemlock can cause excessive urination (54712).\nless\nMusculoskeletal\nOrally, hemlock can cause muscle pain, rapid muscle swelling and stiffness, and rhabdomyolysis (6340, 6341, 54712, 110410). Plasma exchange effectively improved the signs of rhabdomyolysis in one case of hemlock poisoning (54727).\nless\nNeurologic/CNS\nOrally, hemlock can cause drowsiness, fatigue, lethargy, dizziness, numbness, loss of speech, tremors, paralysis, seizures, encephalopathy, unconsciousness, and death (6340, 6341, 10778, 54711, 54712, 54716, 96877, 110410). Death from hemlock toxicity is usually due to respiratory paralysis (96879, 96877).\n\nA case report describes prolonged status epilepticus in a 41-year-old, previously healthy female who mistook hemlock root for parsnip. She developed severe vomiting and drowsiness, followed by prolonged status epilepticus which was refractory to multiple drugs. Seizures and the abnormal electroencephalogram were ultimately controlled with thiopental, gradually weaning to long-term oral treatment with lacosamide and perampanel, which returned the patient to her baseline level of functioning (110411).\nless\nOcular/Otic\nOrally, hemlock can cause blurred vision and mydriasis (54712, 110410).\nless\nPulmonary/Respiratory\nOrally, hemlock can cause rapid respiration (54712) as well as acute respiratory arrest (54709, 96878). In one case report, a 45-year old woman required mechanical ventilation after accidental ingestion of hemlock (96878). Death from hemlock toxicity is usually due to respiratory paralysis (96876, 96877).\nless\nRenal\nOrally, hemlock has been reported to cause myoglobinuria, acute tubular necrosis, and acute renal failure (54716, 54717, 54718, 54728). Plasma exchange effectively improved the signs of renal failure in one case of hemlock poisoning (54727).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of hemlock.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hemlock.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "The poisonous properties of hemlock are due to the presence of piperidine alkaloids, such as gamma-coniceine, coniine, N-methyl-coniine, conhydrine, and pseudoconhydrine. These are present in the root, stem, leaf, flower, fruit, and seed of the hemlock plant (54712, 54713).",
            "Pharmacokinetics": "Absorption\nAfter oral intake, the hemlock constituents coniine and gamma-coniceine can be measured in the blood (96878).",
            "Mechanism of Action": "General\nAll parts of the hemlock plant contain toxic constituents. Coniceine and coniine are the main nicotinic or piperidine alkaloids in hemlock (6338, 6340, 6341, 54712, 54713). Other toxic alkaloids include N-methyl coniine, conhydrine, and pseudoconhydrine (96877). The quantity of poisonous alkaloids in hemlock decreases as the plant and fruit ripens and reaches maturity (6338). Hemlock is most toxic during early stages of growth in the spring (6338, 6339). Green fruit contains larger amounts of toxic alkaloids than mature fruit and seeds (6338). The constituent coniine predominates in the plant during sunny, dry weather, while coniceine predominates during early growth periods. During cloudy and rainy weather, the constituents coniine and coniceine are produced in equal amounts (6339).\nToxic effects\nThe toxic alkaloid constituents of hemlock act at the neuromuscular junction of the autonomic ganglia (6341), stimulating and then paralyzing nicotinic receptors (6340). Larger doses of the alkaloids produce narcotic-like depressant activity (6340). The early symptoms of toxicity, due to nicotinic acetylcholine receptor stimulation, include vomiting, diaphoresis, tachypnea, salivation, and urination. Later effects, caused by blocking of nicotinic receptors, include bradycardia, tremor, visual disturbance, neuromuscular blockade, paralysis, apnea, convulsions, and coma (110410)."
        }
    },
    "Hemlock Water Dropwort": {
        "sections": {
            "Overview": "Hemlock water dropwort is commonly found in ditches, watering places, and marshy areas and banks (6334, 6337). It is considered to be the most poisonous plant in the British Isles (6334). Hemlock water dropwort has been accidentally ingested after mistaking the tuber for wild parsnip, radish, sweet flag, or pignut (6334, 6337, 103905).",
            "Safety": "UNSAFE when used orally (6334). Ingestion of the root may be fatal due to its oenanthotoxin content. The fatal amount of oenanthotoxin is 10-20 mg, which is present in about 20 grams of hemlock water dropwort root. However, the concentration of oenanthotoxin in the root varies by the season and is highest during winter and spring (6335, 6337, 103905). Accidental ingestion requires prompt medical attention (6334).\nThere is insufficient reliable information available about the safety of hemlock water dropwort when used topically.\nCHILDREN: UNSAFE when used orally (6334). Poisoning has occurred after accidental ingestion of roots or tubers (6334).\nPREGNANCY AND LACTATION: UNSAFE when used orally. Ingestion can be lethal (6334).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, hemlock water dropwort root can cause nausea, dizziness, (6334), abdominal pain (6335), vomiting, sweating (6332), salivation, weakness, confusion, slurred speech, muscle spasms, tonic-clonic movements, glycosuria, hematuria, hyperventilation, cyanosis, exhaustion (6334), seizures, metabolic acidosis (6335, 103905), generalized convulsions (6332), unconsciousness (6334), dilated pupils, cardiac arrest , respiratory depression, and death (6332, 103905). There is no known antidote for hemlock water dropwort poisoning (103905).\nCardiovascular\nOrally, hemlock water dropwort root can cause cardiac arrest. In a case report, a 63-year-old male suffered cardiac arrest, grand mal seizure, and severe metabolic acidosis after mistakenly eating hemlock water dropwort roots that he thought were radishes. Supportive care was insufficient and the patient died within a day. There is no known antidote for hemlock water dropwort poisoning (103905).\nless\nGastrointestinal\nOrally, hemlock water dropwort root can cause nausea, salivation (6334), abdominal pain (6335), and vomiting (6332, 103905).\nless\nMusculoskeletal\nOrally, hemlock water dropwort root can cause weakness, paralysis, muscle spasms, tonic-clonic movements, seizures, and generalized convulsions (6332, 6334, 6335, 103905).\nless\nNeurologic/CNS\nOrally, hemlock water dropwort root can cause dizziness (6334), confusion, slurred speech, exhaustion (6334), unconsciousness, tonic-clonic movements, seizures, and generalized convulsions (6332, 6334, 6335).\nless\nOcular/Otic\nOrally, hemlock water dropwort root can cause dilated pupils (6332).\nless\nPulmonary/Respiratory\nOrally, hemlock water dropwort root can cause hyperventilation and respiratory depression (6334, 103905).\nless\nRenal\nOrally, hemlock water dropwort root can cause glycosuria, hematuria, and metabolic acidosis (6334, 6335, 103905).\nless\nOther\nOrally, hemlock water dropwort root can cause sweating (6332), cyanosis (6334), and death (6332).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of hemlock water dropwort.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hemlock water dropwort.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of hemlock water dropwort.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of hemlock water dropwort.",
            "Mechanism of Action": "General\nThe applicable parts of hemlock water dropwort are the root, flowers, and leaves. Essential oil from the flowers and roots consist of monoterpene hydrocarbons, ocimene, and sabinene (103906). Oenanthotoxin, a highly unsaturated alcohol (6334), is the active principle toxin found in hemlock water dropwort (6332). The roots of hemlock water dropwort are considered to be the most poisonous part of the plant and the toxin is found in the yellowish staining juice of the root (6334). The toxin is unstable when exposed to air and is chemically similar to cicutoxin found in water hemlock (Cicuta virosa) (6334).\nDermatologic effects\nTraditionally, the leaves and flowers of hemlock water dropwort have been used for dermatologic conditions. In vitro research shows that essential oil from the aerial parts of hemlock water dropwort has antifungal and anti-inflammatory effects (103906).\nNeurologic effects\nThe exact mechanism of action of oenanthotoxin in hemlock water dropwort is unknown, but animal studies suggest that oenanthotoxin antagonizes the effect of gamma-aminobutyric acid on nerve impulses in the brain stem (6334, 103905)."
        }
    },
    "Hemp": {
        "sections": {
            "Overview": "Hemp is a plant native to western and central Asia that has been used for food, fiber, and medicine for at least 3,000 years in China and the Middle East. It is the same species (Cannabis sativa) as the cannabis plant, but the two plants are differentiated by their delta-9-tetrahydrocannabinol (THC) content. The Agriculture Improvement Act of 2018, also known as the 2018 Farm Bill, defines hemp as containing less than 0.3% THC dry weight, whereas cannabis contains more than 0.3% THC (99608, 101124, 101141, 101142).",
            "Warnings": "The passage of the 2018 Farm Bill exempted hemp and its constituents, including cannabidiol (CBD), from the Controlled Substances Act, making it legal for sale. However, in May 2019, the FDA approved a prescription formulation of CBD (Epidiolex) for use. Since CBD is an ingredient in the drug Epidiolex, it cannot be legally included in foods or dietary supplements (99608, 101141). However, this has been disputed and enforcement has been lacking; dietary supplements and foods containing CBD are prevalent in the marketplace (89911, 99608, 106638).\n\nThe 2018 Farm Bill also permitted domestic hemp production, resulting in the establishment of the U.S. Domestic Hemp Production Program in March 2021. This program makes it legal to grow hemp in all 50 states and details requirements for licensing hemp producers, testing THC levels, disposing of plants exceeding maximum THC content, and ensuring compliance (104892).\n\nCoronavirus disease 2019 (COVID-19): Despite claims to the contrary, there is no good evidence to support using hemp for COVID-19. Recommend healthy lifestyle choices and proven prevention methods instead.",
            "Safety": "LIKELY SAFE when hemp seed, hemp protein, and hemp seed oil are used orally in food amounts. Hulled hemp seed, hemp seed protein powder, and hemp seed oil are generally recognized as safe (GRAS) in the US (100531).\nPOSSIBLY SAFE when hemp seed oil is used orally and appropriately as medicine, short-term. Hemp seed oil in doses of 2-6.3 grams daily has been safely used for 3-6 months (88183, 16791, 101145). Hemp seed oil in doses of 30 mL (27.6 grams) daily has been used safely for 2 months (101125).\nThere is insufficient reliable evidence available about the safety of hemp oil, flowers, or leaves.\nCHILDREN: There is insufficient reliable information available about the safety of hemp in children. Adverse effects have been noted in case reports, but details related to specific hemp products are limited (101153, 110287).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, hemp products are generally well tolerated in food amounts. In larger amounts, hemp seed oil seems to be well tolerated.\nSerious Adverse Effects (Rare)\nOrally: Rare cases of anaphylaxis have been reported. Long QT syndrome, torsades de pointes, and syncope have also been reported rarely.\nCardiovascular\nAcquired long QT syndrome, torsades de pointes, and syncope have been reported in a 56-year-old woman following the intake of supplements containing hemp oil. The hemp supplements provided cannabidiol (CBD), and possibly cannabigerol (CBG). Although the exact dose is unknown, up to six times the recommended dose had been used for approximately 6 weeks, in combination with a supplement containing berberine. While hospitalized, intravenous magnesium and saline were used to stabilize heart rhythm. It is unknown whether this adverse effect was related to the hemp oil, berberine, or their interaction (110104).\nless\nHepatic\nOrally, there is a case report of elevated liver enzymes and hepatitis in a two-year-old boy given hemp extract 2.5 mL, providing 125 mg phytocannabinoid, five to eight times daily for infantile spasms and refractory seizures. The total dose of phytocannabinoids was approximately 60-100 mg/kg daily (110287).\nless\nImmunologic\nOrally, there are case reports of allergy to hemp seed, although this is uncommon (101140, 101154). A 44-year-old male developed hives during a meal of hemp seed-crusted seafoods. Later, he developed facial swelling, shortness of breath, and problems speaking. Evaluation revealed allergy to a specific protein in hemp seed. He did not react to smoked cannabis (101140). In other cases, anaphylaxis, facial swelling, and worsening asthma have been reported in association with a first exposure to hemp seed, although some had smoked cannabis previously (101154).\n\nTopically, a case of patch-test confirmed allergic contact dermatitis to hemp seed oil has been reported in a 22-year-old woman. The initial rash started at the application point on her back and spread to her arms, hands, and neck (110288).\n\nAirborne exposure to hemp pollen is a relatively common cause of allergic respiratory symptoms in some locations (101155).\nless\nNeurologic/CNS\nOrally, cases of acute cannabinoid toxicity with neurological symptoms in children and adults have been associated with intake of hemp seed oil. There is a case report of decreased alertness, stupor, bloodshot eyes, and fixed gaze in a 2-year-old male probably related to the intake of one teaspoon hemp seed oil (CANAH) containing 0.06% delta-9-tetrahydrocannabinol (THC) twice daily for 3 weeks. After stopping the oil, irritability was reported over the next few days (101153).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAtopic dermatitis (eczema). It is unclear if oral hemp seed oil is beneficial in patients with eczema.\nA small preliminary clinical trial in patients with eczema shows that taking hemp seed oil 30 mL daily for 8 weeks improves skin dryness, itchiness, and use of dermal medication when compared with baseline, but not when compared with an olive oil control (101125).\nless\nConstipation. Oral hemp seed has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nClinical research in patients with functional constipation shows that taking a proprietary Chinese herbal medicine (Hemp Seed Pill) containing hemp seed, rhubarb root, peony root, apricot kernel, bitter orange fruit, and magnolia bark twice daily for 8 weeks results in a response rate to 43%, compared with 8% in those taking placebo. The response rate was defined as an increase of at least 1 complete spontaneous bowel movement per week. This combination product also improved the responder rate in the 2 weeks after treatment, as well as the overall use of rescue therapy, when compared with placebo (101127). Data from this study pooled with data from another larger study in adults with functional constipation shows that this same product increases the likelihood of complete response, defined as at least 3 complete spontaneous bowel movements per week or an increase over baseline of at least 1 weekly, by 1.43 times when compared with placebo. Complete spontaneous bowel movements per week also increased by 1 when compared with placebo (107319). It is unclear if these effects are due to hemp seed, other ingredients, or the combination.\nless\nDysmenorrhea. Although there is interest in using oral hemp for dysmenorrhea, there is insufficient reliable information about the clinical effects of oral hemp for this condition.\nFamilial hypercholesterolemia. It is unclear if oral hemp seed oil is beneficial in children with this condition.\nA small preliminary clinical trial shows that taking hemp seed oil (AlfaLife, Freia Farmaceutici Srl) 3 grams daily for 8 weeks does not improve levels of total or low-density lipoprotein (LDL) cholesterol when compared with no treatment in hyperlipidemic children aged 6-16 years who are also following a low-fat diet with high fruit and vegetable intake (101144).\nless\nHypertension. It is unclear if oral hemp seed protein is beneficial for hypertension.\nA small clinical trial in adults with hypertension shows that consuming hemp seed protein 45-50 grams, with or without bioactive peptides, daily for 6 weeks reduces 24-hour ambulatory systolic and diastolic blood pressure when compared to casein protein, with greater reduction observed with the addition of bioactive peptides (115745). The validity of these results is limited by the lack of data on patients' hypertension medications, diet, and physical activity.\nless\nJoint pain. Although there is interest in using oral hemp for joint pain, there is insufficient reliable information about the clinical effects of oral hemp for this condition.\nMultiple sclerosis (MS). Oral hemp seed has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in patients with relapsing-remitting MS shows that taking a combination of hemp seed oil 5.4-6.3 grams and evening primrose oil three times daily for 6 months seems to improve disability scores and relapse rate when compared to baseline. However, the control group in this study ingested olive oil and also experienced notable improvements in disability and relapse rates (88183). This study is limited due to high dropout rate and because there was no statistical comparison between treatment and control groups.\nless\nObesity. It is unclear if an oral cannabidiol-rich hemp oil extract helps to improve weight loss.\nA small clinical study in healthy overweight adults shows that taking a specific hemp oil extract (PlusCBD Extra Strength Hemp Extract, CV Sciences) as 60 mg, providing 15 mg cannabidiol, daily for 6 weeks, does not reduce weight or body mass index when compared with placebo (103805). The validity of this study is limited due to its exploratory nature and lack of control for voluntary dietary changes.\nless\nOsteoarthritis. It is unclear if oral hemp seed is beneficial in patients with osteoarthritis.\nA clinical study in 18 older adults with osteoarthritis undergoing in-hospital rehabilitation following knee or hip arthroplasty shows that consuming pasta enriched with hemp seed flour for 6 weeks improves pain scores by about 3 points, compared with only 1 point in those consuming a regular pasta control (107320). A small clinical study in adults with knee osteoarthritis shows that taking a hemp seed oil supplement 826 mg daily in combination with ginger extract and terpenes such as beta-caryophyllene and myrcene for 45 days reduces patient-reported pain and severity and improves functionality when compared to hemp seed oil alone (115742). However, the clinical significance of these findings is unclear; additionally, it is unclear if these results are due to hemp seed oil, the other ingredients, or the combination.\nless\nPain (chronic). It is unclear if hemp oil reduces chronic pain.\nA small clinical study in adults with chronic pain receiving chiropractic care shows that taking a combination supplement containing hemp oil standardized to 15 mg of phytocannabinoids, broccoli extract, and calamari oil daily for 12 weeks decreases pain intensity and interference of pain with general activity, walking, and sleeping when compared with a mineral oil placebo (114971). It is unclear if these effects are due to hemp oil, other ingredients, or the combination.\nless\nPsychological well-being. Although there is interest in using oral hemp for psychological well-being, there is insufficient reliable information about the clinical effects of oral hemp for this condition.\nMore evidence is needed to rate hemp for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nHemp contains delta-9-tetrahydrocannabinol (THC) levels of less than 0.3% dry weight (99608, 101124, 101141, 101142). Most clinical trials have used hemp seed oil (88183, 101125, 101144, 101145). Hemp seed oil contains no to low levels of cannabinoids, including THC and cannabidiol (101122, 101124). However, hemp oil, which is obtained from the flowers and/or leaves, contains THC and higher amounts of cannabidiol (101124).\n\nThe Cannabis sativa plant is classified as a phytoremediator, meaning that it readily absorbs contaminants from the soil. Due to this, hemp products are at high risk for contamination with these compounds, including heavy metals and pesticides. Alarming concentrations of pesticides have been found in cannabinoid-containing products, including hemp products, sold in the Netherlands, California, and Canada (102337).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nACE INHIBITORS (ACEIs)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, consuming hemp seed protein isolate with ACE inhibitors might have additive effects and increase the risk of hypotension.\nHemp seed protein hydrolysate has shown ACE inhibitor-like effects in a hypertensive animal model (101136). However, hempseed oil consumption does not seem to reduce blood pressure in humans (101144). Until more is known, monitor blood pressure and potassium levels.\nless\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hemp seed might increase the risk of bleeding when used concomitantly with anticoagulant/antiplatelet drugs.\nIn animal research, hemp seed at 5% of the diet inhibits platelet aggregation in vitro (101137). However, in human research, taking hemp seed oil 2 grams daily for 12 weeks does not inhibit the aggregation of platelets in vitro (16791).\nless\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hemp seed protein may have additive effects with antihypertensive drugs.\nIn a hypertensive animal model, hemp seed protein hydrolysate reduced systolic blood pressure by a mechanism possibly involving the inhibition of renin and angiotensin converting enzyme (ACE) activities. However, there was no effect of hemp seed protein on blood pressure in normotensive animals (101136). Furthermore, hempseed oil consumption does not seem to reduce blood pressure in humans (101144).\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hemp might decrease the levels and clinical effects of CYP1A2 substrates.\nIn vitro research shows that hemp induces CYP1A2 enzymes (111404).\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hemp might decrease the levels and clinical effects of CYP3A4 substrates.\nIn vitro research shows that hemp induces CYP3A4 enzymes (111404).\nless\nESTROGENS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hemp might interfere with hormone therapy due to its estrogenic effects.\nIn an ovariectomized animal model, a diet containing hemp seed 1%, 2%, or 10% resulted in normalized plasma levels of 17-beta-estradiol (101132). The mechanism of action for this effect is unclear.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, hemp seed or hemp seed oil might increase the risk of bleeding.\nIn animal research, hemp seed at 5% of the diet inhibits platelet aggregation in vitro (101137). However, in human research, taking hemp seed oil 2 grams daily for 12 weeks does not inhibit the aggregation of platelets in vitro (16791). Hemp seed might have additive effects when used with other anticoagulant/antiplatelet products. See other products with antiplatelet effects here\n\n. See products with anticoagulant effects here\n\n.\nless\nHERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nTheoretically, hemp seed protein might lower blood pressure.\nIn a hypertensive animal model, hemp seed protein reduced systolic blood pressure. However, there was no effect of hemp seed protein on blood pressure in normotensive animals (101136). Furthermore, hempseed oil consumption does not seem to reduce blood pressure in humans (101144). Hemp seed might have additive effects with other hypotensive products.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCANNABIS ALLERGY\nPatients who are allergic to cannabis might also be allergic to hemp (101154). Patients who are allergic to cannabis should use caution or avoid using hemp.\nless\nPERIOPERATIVE\nTheoretically, hemp seed protein hydrolysate might interfere with blood pressure control during and after surgical procedures. Hemp seed protein might reduce blood pressure (101136). Tell patients to discontinue hemp seed protein at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hemp.",
            "Pharmacokinetics": "Absorption\nIn animals and humans, most studies suggest that consuming hemp seed oil increases levels of fatty acids, such as linoleic acid, alpha-linolenic acid, and gamma-linolenic acid in the blood (101125, 101126, 101130, 101131, 101147).",
            "Mechanism of Action": "General\nThe applicable parts of hemp are the flowers, leaves and the seed, including the whole seed, the oil, and the protein (99608, 101124, 101141, 101142). Depending on the variety, hemp seed oil contains 16.0% to 23.0% alpha-linolenic acid, 47.0% to 57.3% linoleic acid, 9.0% to 19.9% oleic acid, 2.6% to 4.4% gamma-linolenic, and 2% stearidonic acid (16791, 101123, 101125, 101126, 101132, 101142, 101144, 101149, 101152). Unsaponifiable matter contains beta-sitosterol, campesterol, phytol, cycloartenol, and gamma-tocopherol (101142). The oil also contains very low levels (<5ppm) of as many as 30 cannabinoids, including cannabiripsol, cannabitriols, cannabigerols, cannabidiols, cannabielsoin, cannabinols, tetrahydrocannabinols, cannabichromenes, and cannabicitran (101122). The seeds also contain flavonoids, flavonols, and other polyphenols including lignanamides, caffeoyltyramine, and cannabisins (101121, 101149).\n\nHemp seed is a good quality source of protein with lysine as the rate-limiting amino acid (101143, 101148). Hemp seed protein is primarily edestin and albumin (101129). Selective breeding of hemp has nearly removed delta-9-tetrahydrocannabinol (THC) from the seed (101137).\n\nHemp flower and leaves, and hemp oil, contain phytocannabinoids, especially cannabidiol, as well as terpenoids (101124).\nAnti-arthritic effects\nHemp is traditionally used for arthritis and joint pain. In vitro, hemp seed oil induces the production of an anti-rheumatoid factor, as well as the apoptosis of a rheumatoid arthritis synovial cell line (101133).\nAnti-cancer effects\nHemp is traditionally used for cancer. In vitro, hemp seed oil extract induced apoptosis of cancer cell lines; however, hemp seed and hemp flour extracts did not (101149).\nAnti-hypertensive effects\nIn a hypertensive animal model, hemp seed protein hydrolysate reduced systolic blood pressure. The mechanism of action is possibly related to a suppression of renin and angiotensin converting enzyme (ACE) activities as shown. Hemp seed protein isolate itself also had antihypertensive effects but was not as effective as the hydrolysate. There was no effect of either protein isolate on blood pressure in normotensive animals (101136). These protein products also had antioxidant effects in the hypertensive model (101135).\nAnti-inflammatory effects\nHemp seed is traditionally used for its anti-inflammatory effects. In various cell lines in vitro, hemp seed extract or seed protein hydrolysate fractions decreased the production of inflammatory cytokines, prostaglandins, and/or other mediators, possibly by inhibiting specific cellular pathways (101128, 101148).\nGastrointestinal effects\nHemp seed is traditionally used for constipation. In an animal model, hemp seed increases water content of feces and increases the number of bowel movements. Hemp seed was found to increase mucosal secretion from colonic tissue in vitro in a manner involving one or more electrolyte channels or exchangers (101134).\nHepatic effects\nThere is interest in using hemp seed products for preventing fatty liver disease. Animal research shows that consumption of defatted hemp seed protein attenuates liver enzyme elevations and markers of steatosis when used instead of, or in addition to, a high-fat diet (104477).\nHypolipidemic effects\nBased on the presence of polyunsaturated omega-6 and omega-3 fatty acids in hemp seed oil, it is of interest for reducing levels of plasma cholesterol. However, human research in children with hypercholesterolemia and in healthy adults, as well as most animal research, does not support the cholesterol-lowering effects of hemp seed oil (16791, 101126, 101144, 101147, 103805, 110285). However, a small clinical trial in obese adults suggests that taking hemp oil extract 60 mg daily may produce small improvements in high density lipoprotein (HDL) cholesterol. After 6 weeks of treatment, HDL increased by approximately 3 mg/dL, compared with a decrease of approximately 2 mg/dL in the placebo group (103805). Also, there may be peptide sections of the edestin and albumin proteins that have hypolipidemic effects. In vitro, some hemp seed peptides inhibited the enzyme HMG-CoA reductase and increased the uptake of low-density lipoprotein (LDL) cholesterol into cells by increasing expression of the LDL receptors (101129).\nMetabolic effects\nAn acute feeding study in healthy patients suggests that consuming hemp protein 20-40 grams is similar to soy protein 20-40 grams for reducing postprandial glucose and insulin response when compared with a carbohydrate control (104478)."
        }
    },
    "Hemp Agrimony": {
        "sections": {
            "Overview": "Hemp agrimony is an herb, the flowers of which are sometimes used medicinally. Hemp agrimony contains hepatotoxic pyrrolizidine alkaloids (PA). PAs are most concentrated in the plant roots, but may be found in all plant parts (12841, 12860).\n\nKEY HIGHLIGHTS\nTraditionally used for liver and gallbladder disorders, skin infections, and other conditions, but there is insufficient reliable evidence to rate its effectiveness for any use.\nLikely unsafe when taken by mouth or applied topically to broken skin. Hemp agrimony contains hepatotoxic pyrrolizidine alkaloids (PAs). The safety when used on unbroken skin is unclear.",
            "Safety": "LIKELY UNSAFE when products containing hepatotoxic pyrrolizidine alkaloid (PA) constituents are used orally. Repeated exposure to low concentrations of hepatotoxic PAs can cause severe veno-occlusive disease. Hepatotoxic PAs might also be carcinogenic and mutagenic (12841, 12842). Tell patients not to use hemp agrimony preparations that are not certified and labeled as hepatotoxic PA-free. ...when products containing hepatotoxic PAs are used topically on abraded or broken skin. Absorption of hepatotoxic PAs through broken skin can lead to systemic toxicities (12841). Tell patients not to use topical hemp agrimony preparations that are not certified and labeled as hepatotoxic PA-free.\n\nThere is insufficient reliable information available about the safety of using topical PA-free hemp agrimony on unbroken skin.\nPREGNANCY: LIKELY UNSAFE when used orally. Hemp agrimony preparations, containing hepatotoxic pyrrolizidine alkaloid (PA) constituents, might be teratogenic and hepatotoxic (12841, 12842). There is insufficient reliable information available about the safety of using hemp agrimony products that do not contain hepatotoxic PAs during pregnancy.\nLACTATION: LIKELY UNSAFE when used orally. Hepatotoxic pyrrolizidine alkaloid (PA) constituents in hemp agrimony are excreted in milk (12841, 12842). There is insufficient reliable information available about the safety of using hemp agrimony products that do not contain hepatotoxic PAs during lactation.",
            "Adverse Effects": "General\nOrally, the major concern with hemp agrimony preparations is the hepatotoxic pyrrolizidine alkaloid (PA) content. These constituents are hepatotoxic, pneumotoxic, carcinogenic, and mutagenic (12841, 12842). Chronic exposure to other plants containing hepatotoxic PA constituents is associated with veno-occlusive disease (4021, 12842). Dietary supplements sold in the US are not required to disclose the amount of PAs they contain (3484); therefore, all oral preparations containing hemp agrimony should be considered potentially unsafe.\nHepatic\nOrally, the major concern with hemp agrimony preparations is the hepatotoxic pyrrolizidine alkaloid (PA) content (12841, 12842). Chronic exposure to other plants containing hepatotoxic PA constituents is associated with veno-occlusive disease (4021). Subacute veno-occlusive disease causes vague symptoms with persistent liver enlargement (4021). Symptoms of acute veno-occlusive disease include colicky epigastrium pain, vomiting and diarrhea, and ascites formation within several days. Enlargement and induration of the liver occurs within a few weeks (12842). Dietary supplements sold in the US are not required to disclose the amount of PAs they contain (3484); therefore, all oral preparations containing hemp agrimony should be considered potentially unsafe.\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of hemp agrimony.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hemp agrimony.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nCYTOCHROME P450 3A4 (CYP3A4) INDUCERS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nHemp agrimony contains hepatotoxic pyrrolizidine alkaloids (PA) which are substrates of cytochrome P450 3A4 (CYP3A4) (12841, 12860). Theoretically, drugs that induce CYP3A4 might increase the conversion of PAs to toxic metabolites. Some drugs that induce CYP3A4 include carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin), rifampin, rifabutin (Mycobutin), and others.\nHEPATOTOXIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nHemp agrimony contains hepatotoxic pyrrolizidine alkaloids (PA) (12841, 12860). Theoretically, using hemp agrimony with hepatotoxic drugs might have additive adverse effects on the liver. Some drugs that can adversely affect the liver include acetaminophen (Tylenol and others), amiodarone (Cordarone), carbamazepine (Tegretol), isoniazid (INH), methotrexate (Rheumatrex), methyldopa (Aldomet), fluconazole (Diflucan), itraconazole (Sporanox), erythromycin (Erythrocin, Ilosone, others), phenytoin (Dilantin), lovastatin (Mevacor), pravastatin (Pravachol), simvastatin (Zocor), and many others.",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS THAT INDUCE CYTOCHROME P450 3A4 (CYP3A4)\nTheoretically, herbs that induce CYP3A4 might increase the conversion of hepatotoxic PAs to toxic metabolites, enhancing toxicity (12841, 12860). Herbs that induce CYP3A4 include echinacea, garlic, licorice, St. John's wort, and schisandra.\nPYRROLIZIDINE ALKALOID (PA)-CONTAINING HERBS AND SUPPLEMENTS\nConcomitant use is contraindicated due to the risk of additive toxicity. Herbs containing hepatotoxic PAs include alkanna, boneset, borage, butterbur, coltsfoot, comfrey, forget-me-not, gravel root, hemp agrimony, and hound's tongue; and the Senecio species plants dusty miller, groundsel, golden ragwort, and tansy ragwort (12841).",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCROSS-ALLERGENICITY\nTheoretically, hemp agrimony might cause an allergic reaction in individuals sensitive to the Asteraceae/Compositae family (12842). Members of this family include ragweed, chrysanthemums, marigolds, daisies, and many other herbs.\nless\nLIVER DISEASE\nTheoretically, pyrrolizidine alkaloids (PA) might exacerbate liver disease (12841, 12842).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of hemp agrimony.",
            "Pharmacokinetics": "There is insufficient reliable information available about the standardization of hemp agrimony.",
            "Mechanism of Action": "General\nThe applicable part of hemp agrimony is the flowering herb (12841, 12860).\nHepatic effects\nHemp agrimony contains various pyrrolizidine alkaloids (PA), some of which are toxic. PAs are most concentrated in the plant roots, but may be found in all plant parts. PAs, particularly unsaturated PAs, can cause hepatotoxicity. Cyclic diesters such as retrorsine and senecionine are the most hepatotoxic. Liver toxicity may result from PA-enhanced oxidative stress, but the exact mechanism of toxicity is unknown. Single doses of 10-20 mg PAs or chronic ingestion of amounts less than 10 mcg can cause veno-occlusive disease. PAs are metabolized by cytochrome P450 3A4 (CYP3A4) to toxic dehydroalkaloids and pyrroles. Enzyme inducers such as phenobarbital seem to enhance toxicity (12841, 12860). Pyrroles are excreted as N-acetyl cysteine conjugates. Some researchers speculate that early administration of N-acetylcysteine might reduce toxicity (11988).\n\nMetabolism is also affected by pregnane X receptor induction of CYP3A4. Genetic or drug induced variation in CYP3A4 or pregnane X receptor activity can affect the degree of PA toxicity by increasing or decreasing its metabolism (12841, 12842). Hepatotoxic PAs are also toxic to the lungs. In animals, pneumotoxicity occurs as pulmonary hypertension and right ventricular hypertrophy. Hepatotoxic PAs are carcinogenic and mutagenic. There are sufficient amounts of hepatotoxic PAs in herbal products to cause toxicity (12841, 12842)."
        }
    },
    "Hempnettle": {
        "sections": {
            "Overview": "Hempnettle is a flowering herb that is native to southern and central Europe. It has traditionally been used as medicine for its purported astringent, diuretic, and expectorant effects (18).",
            "Safety": "There is insufficient reliable information available about the safety of hempnettle.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNone reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nCough. Although there has been interest in using oral hempnettle for cough, there is insufficient reliable information about the clinical effects of hempnettle for this purpose.\nRespiratory tract infections. Although there has been interest in using oral hempnettle for respiratory tract infections, there is insufficient reliable information about the clinical effects of hempnettle for this purpose.\nMore evidence is needed to rate hempnettle for these uses.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Traditionally, hempnettle tea has been prepared by steeping 2 grams of the above ground parts in 150 mL boiling water for 5-10 minutes and then straining. The tea has been consumed as 1 cup three times daily.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hempnettle.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hempnettle.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of hempnettle.",
            "Mechanism of Action": "General\nThe applicable parts of hempnettle are the above ground parts (18). There is insufficient reliable information available about the possible mechanism of action and active ingredients of hempnettle."
        }
    },
    "Henbane": {
        "sections": {
            "Overview": "Henbane is a flowering plant that grows up to 80 cm in height (18). It is native to Europe, western and northern Asia, and northern Africa, and has been introduced into North America (18).",
            "Safety": "POSSIBLY SAFE when henbane leaf is used orally and appropriately, short-term. Henbane leaf powder has been used with apparent safety in single doses of up to 1 gram, which have been standardized to contain 500-700 mg of total alkaloids. The maximum daily dosage should not exceed 3 grams, corresponding to 1500-2100 mg of total alkaloids (2, 18).\nLIKELY UNSAFE when the leaf is used orally in doses above 3 grams daily. This maximum tolerated dose contains 1500-2100 mg of total alkaloids, which include hyoscyamine and scopolamine. These alkaloids have a narrow therapeutic range; excessive doses can cause poisoning and death (2, 18).\nThere is insufficient reliable information available about the safety of henbane seed and flower.\nPREGNANCY AND LACTATION: LIKELY UNSAFE when used orally because of its risk of poisoning (18).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, henbane can cause anticholinergic effects including dry mouth, vision disturbances, tachycardia, difficult urination, constipation, and skin flushing (2, 18). At higher doses, poisoning can occur due to the hyoscyamine and scopolamine constituents of henbane. Symptoms of toxicity include hyperpyrexia and somnolence, followed by CNS stimulation with restlessness, hallucinations, delirium, memory impairment, ataxia, and manic episodes, followed by exhaustion and coma. Henbane can cause death by asphyxiation (2, 18, 100917).\nCardiovascular\nOrally, henbane can cause tachycardia, especially at higher doses (2, 18, 100917).\nless\nDermatologic\nOrally, henbane reduces sweating, resulting in flushing of the skin and hyperpyrexia (2, 18, 100917).\nless\nGastrointestinal\nOrally, henbane causes reduced muscle activity in the bowel, leading to constipation (2, 18, 100917).\nless\nGenitourinary\nOrally, henbane can cause difficulty with urination (2, 18, 100917).\nless\nNeurologic/CNS\nOrally, high doses of henbane can cause toxicity due to its hyoscyamine and scopolamine constituents. Neurologic symptoms of henbane toxicity include somnolence, followed by CNS excitation involving restlessness, hallucinations, memory impairment, delirium, and manic episodes, followed by exhaustion and coma (2, 18, 100917).\nless\nOcular/Otic\nOrally, high doses of henbane can cause toxicity due to its hyoscyamine and scopolamine constituents. Ocular symptoms of henbane toxicity include visual disturbances (2, 18, 100917).\nless\nOther\nOrally, high doses of henbane can cause toxicity due to its hyoscyamine and scopolamine constituents. Toxicity can result in coma and death by asphyxiation in some cases (2, 18, 100917). Treatment of henbane toxicity includes stomach lavage, activated charcoal, supportive therapy, and, in severe cases, the antidote physostigmine (100917).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of henbane.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: Traditionally, a typical single dose of standardized henbane leaf powder is 500 mg, which corresponds to 250-350 mg of total alkaloids. The maximum single dose of henbane is 1 gram, which corresponds to 500-700 mg of total alkaloids. The maximum daily dosage is 3 grams, which corresponds to 1500-2100 mg of total alkaloids (2, 18).\nStandardization & Formulation\nStandardized henbane leaf powder 1 gram contains 500-700 mg total alkaloids (2, 18).",
            "Interactions with Drugs": "ANTICHOLINERGIC DRUGS\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nConcomitant use of henbane can have additive anticholinergic effects and adverse effects with amantadine, antihistamines, atropine, belladonna alkaloids, hyoscyamine, phenothiazines, procainamide, scopolamine, and tricyclic antidepressants (2).",
            "Interactions with Supplements": "ANTICHOLINERGIC HERBS\nTheoretically, concomitant use of henbane with other anticholinergic alkaloid-containing herbs can have additive therapeutic and adverse effects. Anticholinergic herbs include angels trumpet, belladonna, deadly nightshade, European mandrake, jimson weed, and scopolia.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nCONGESTIVE HEART FAILURE (CHF)\nHenbane might cause tachycardia and exacerbate CHF due to its hyoscyamine (atropine) and scopolamine content (15).\nless\nCONSTIPATION\nHenbane might cause constipation due to its hyoscyamine (atropine) and scopolamine content (15).\nless\nDOWN SYNDROME\nPatients with Down syndrome might be hypersensitive to the antimuscarinic effects (mydriasis, positive chronotropic heart effects, etc.) of hyoscyamine (atropine) and scopolamine contained in henbane (15).\nless\nGASTROESOPHAGEAL REFLUX DISEASE (GERD)\nHenbane might delay gastric emptying and decrease lower esophageal pressure, promoting gastric retention and exacerbating reflux due to its hyoscyamine (atropine) and scopolamine content (15).\nless\nFEVER\nHenbane might increase the risk of hyperthermia in patients with fever due to its hyoscyamine (atropine) and scopolamine content (15).\nless\nPEPTIC ULCER\nHenbane might delay gastric emptying and exacerbate gastric ulcers due to its hyoscyamine (atropine) and scopolamine content (15).\nless\nGI INFECTIONS\nHenbane might suppress GI motility causing retention of infecting organisms or toxins due to its hyoscyamine (atropine) and scopolamine content (15).\nless\nHIATAL HERNIA\nHenbane might delay gastric emptying and decrease lower esophageal pressure, promoting gastric retention and exacerbating hiatal hernia due to its hyoscyamine (atropine) and scopolamine content (15).\nless\nNARROW-ANGLE GLAUCOMA\nHenbane might increase ocular tension in patients with narrow-angle (angle-closure) glaucoma due to its hyoscyamine (atropine) and scopolamine content (2, 15).\nless\nOBSTRUCTIVE GI TRACT DISEASE\nHenbane might exacerbate obstructive GI tract diseases (including atony, paralytic ileus, and stenosis) due to its hyoscyamine (atropine) and scopolamine content (15).\nless\nTACHYARRHYTHMIAS\nHenbane might cause tachycardia due to its hyoscyamine (atropine) and scopolamine content (2, 15).\nless\nTOXIC MEGACOLON\nHenbane might suppress intestinal motility, which might produce paralytic ileus and exacerbate toxic megacolon, due to its hyoscyamine (atropine) and scopolamine content (2, 15).\nless\nULCERATIVE COLITIS\nHenbane might suppress intestinal motility, which might produce paralytic ileus and precipitate toxic megacolon, due to its hyoscyamine (atropine) and scopolamine content (15).\nless\nURINARY RETENTION\nHenbane might increase urinary retention due to its hyoscyamine (atropine) and scopolamine content (2, 15).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of henbane.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of henbane.",
            "Mechanism of Action": "General\nThe applicable parts of henbane are the dried leaves, flowering tops, and dried seeds (18, 100916). The primary constituents of the leaves, fruits, and roots responsible for the activity of henbane are the tropane alkaloids, including hyoscyamine, hyoscine, and scopolamine (100916, 100917). With storage, hyoscyamine, which is the levorotatory isomer of atropine, converts to racemic atropine (18, 100917). There are also flavonol glycosides present in henbane, including quercetin, rutin, and kaempferol. An extract of the seeds contains cleomiscosin B, venkatasin, daturalactone-4, and balanophonin (100916).\nAnticholinergic effects\nThe tropane alkaloids, including hyoscyamine, hyoscine, and scopolamine, competitively inhibit acetylcholine, causing anticholinergic and parasympatholytic effects. The inhibition of acetylcholine occurs at muscarinic receptors but not at the nicotinic receptors on ganglia and motor endplates (2, 18). The peripheral anticholinergic effects on the autonomic nervous system result in smooth muscle relaxation, particularly in the GI tract. Henbane also has central nervous system (CNS) effects including sedation (2, 18).\nAntiparkinsonian effects\nHenbane is traditionally used for the treatment of Parkinson disease. In a mouse model of Parkinson disease, an aqueous methanol extract of henbane seeds reduces striatal dopamine loss and motor disabilities. These improvements are likely due to the anticholinergic effects of henbane. The extract also inhibits monoamine oxidase B (MAO-B) activity, reducing the breakdown of dopamine. Inhibition of the generation of hydroxyl radicals in mitochondria may also contribute to the antiparkinsonian effects of henbane (100916)."
        }
    },
    "Henna": {
        "sections": {
            "Overview": "Henna refers to the powdered leaves of the plant Lawsonia inermis, which is used in many parts of the world as a hair and skin dye. Lawsone is an ingredient in henna that is toxic when ingested (100852).\n\nHenna should not be confused with henna root (Alkanna tinctoria), also referred to as alkanna root (6).",
            "Safety": "LIKELY SAFE when applied topically for up to 2 weeks (104798, 104794, 104795, 104799). Henna is approved for topical use as a color additive in hair cosmetics in the US (11). Although contact dermatitis and hypersensitivity reactions have been reported with topical use (1370, 4146, 4148, 6144, 6145, 6146, 6147, 6148, 6149, 6150, 6151), most reported allergic reactions to henna are due to the added compound para-phenylenediamine (PPD). PPD is not a compound naturally found in henna and is added to enhance the effects of henna as a dye, especially \"black\" henna. However, allergic reactions to pure henna have been confirmed with skin patch testing in a small number of patients (100830, 100836, 100842).\nUNSAFE when used orally. Ingestion of henna has been linked to serious adverse events such as rhabdomyolysis, renal failure, hemolytic anemia, and death (12, 100852, 104797).\nCHILDREN: POSSIBLY UNSAFE when used topically, especially on infants (4147, 6144, 6149, 6150, 10381). Application of henna is associated with hemolysis in infants deficient in glucose-6-phosphate dehydrogenase (G6PD) (4147, 10381).\nCHILDREN: UNSAFE when used orally (12).\nPREGNANCY AND LACTATION: UNSAFE when used orally. Henna is believed to have abortifacient properties (12). There is insufficient reliable information available about the safety of henna when used topically; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, henna can cause an upset stomach, possibly due to tannin content (18, 104797). Henna has also been linked to rhabdomyolysis, renal injury and failure, hemolytic anemia, and mortality when taken orally (100852, 104797).\n\nTopically, henna can cause contact dermatitis, including redness, itching, burning, swelling, scaling, fissuring, papules, blisters, and scarring (1370, 4146, 6144, 6145, 6146, 6147, 6148, 6149, 6150). Although some allergic reactions to pure henna have been confirmed with skin patch testing, most reported allergic reactions to henna are due to the added compound para-phenylenediamine (PPD). PPD is not found naturally in henna. It is added to enhance the effects of henna as a dye, especially \"black\" henna (100830, 100836, 100842).\n\nIn infants and children with glucose 6-phosphate dehydrogenase (G6PD) deficiency, topical henna use has been associated with hemolysis, anemia, reticulocytosis, and indirect hyperbilirubinemia (4147, 10381, 100839, 100840).\nGastrointestinal\nOrally, henna can cause an upset stomach, possibly due to tannin content (18, 104797). Ingestion of henna might also exacerbate diseases such as ulcerative colitis, although evidence is limited. A 45-year-old female with ulcerative colitis in remission reportedly experienced 10 days of chemical colitis with symptoms of severe bloody diarrhea, abdominal pain, and fever, starting one week after ingesting one liter of diluted henna powder (100854). However, because the ingredients in the product taken by the patient were never confirmed, it is unclear if the adverse effect was due to henna, another ingredient, or a contaminant in the product.\nless\nHematologic\nTopically, henna has been associated with hemolysis, anemia, reticulocytosis, and indirect hyperbilirubinemia in infants and children with glucose 6-phosphate dehydrogenase (G6PD) deficiency (4147, 10381, 100839, 100840).\n\nOrally, henna might also have this effect in adults, particularly in those with G6PD deficiency. In one case report, a 69-year-old man accidentally ingested 2 teaspoons of henna leaves and developed severe symptoms of lawsone poisoning, including hemolysis, renal failure, and cardiac ischemia. It is likely that this man had G6PD deficiency, but this was not confirmed by testing (100852). At least one case of hemolytic anemia following oral use of an unknown quantity of henna has been reported in an adult without G6PD deficiency. After taking henna for 2 days, an 85-year-old man developed abdominal pain and severe sequelae of hemolytic anemia including jaundice, acute kidney injury, dyspnea, and cardiac arrest. The symptoms resolved after treatment with corticosteroids and hydration therapy (104797).\nless\nImmunologic\nTopically, henna can cause allergic contact dermatitis, with symptoms of redness, itching, burning, swelling, scaling, fissuring, papules, blisters, and scarring (1370, 4146, 6144, 6145, 6146, 6147, 6148, 6149, 6150, 100830, 100836, 104798). Although some allergic reactions to pure henna have been confirmed with skin patch testing, most reported allergic reactions to henna are due to the added compound para-phenylenediamine (PPD). PPD is not found naturally in henna. It is added to enhance the effects of henna as a dye, especially \"black\" henna (100830, 100836, 100842).\n\nTwo reports of occupational exposure to henna were associated with immediate-type hypersensitivity involving urticaria, rhinitis, wheezing, and bronchial asthma (4148, 6151).\nless\nRenal\nOrally, henna leaf might cause kidney injury, rhabdomyolysis, and renal failure. These adverse effects might be due to the henna constituent, lawsone, or the added ingredient phenylenediamine (PPD) (100841, 100852, 104796). In a case report, a 34-year-old male with a history of chronic drinking presented with acute kidney injury after ingesting 700 mL of boiled henna leaves daily for 3 days. The damage resolved after 7 days of supportive care (100841). It was unclear if the acute kidney injury was due to the henna itself or to a contaminant. In another report, a 73-year-old female developed rhabdomyolysis and acute kidney injury after ingesting a single dose of an unknown amount of henna powder. The complications resolved after 2 weeks of hemodialysis (104796).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nChemotherapy-induced acral erythema. Anecdotal evidence suggests that topical application of henna in cancer patients receiving capecitabine may improve acral erythema (100838).\nChemotherapy-induced peripheral neuropathy. Preliminary clinical research in adult females with chemotherapy-induced peripheral neuropathy shows that topical application of 50 grams of henna powder to hands and feet after oxaliplatin infusions reduces self-reported neuropathy severity scores when compared with no intervention (104799).\nContact dermatitis. Preliminary clinical research in patients with contact dermatitis secondary to lower limb prostheses shows that applying henna 1% ointment daily for 2 weeks reduces the severity of pain, edema, and itching when compared with placebo. However, use of henna ointment increases the severity of redness when compared with placebo (104798).\nPressure ulcers. Preliminary clinical research in adults with pressure ulcers shows that applying topical henna powder 1 gram once improves healing when compared with either daily topical olive oil or no intervention. When compared with olive oil or no intervention, patients treated with henna demonstrated a 61% and 90% smaller ulcer area, respectively, and 38% and 66% better ulcer healing scores, respectively, after 7 days (104794).\nWound healing. Preliminary clinical research in patients requiring episiotomy during childbirth shows that applying topical henna 2% ointment to the surgical incision daily for 2 weeks modestly improves redness, pain, and wound healing scores when compared with placebo or no intervention. It is unclear if these modest effects are clinically relevant. The effects of henna 2% ointment were similar to those of Persian oak 5% ointment (104795).\nMore evidence is needed to rate henna for these uses.",
            "Dosing & Administration": "Adult\nTopical:\nChemotherapy-induced acral erythema: Henna powder mixed with water has been applied to hands and feet and wrapped with a cloth. The mixture has been washed off after 5-6 hours (100838).\n\nChemotherapy-induced peripheral neuropathy: Henna powder 50 grams has been applied to the hands and feet overnight. The powder was washed off in the morning, after 8-10 hours (104799).\n\nContact dermatitis: Henna 1% ointment applied once daily for up to 2 weeks has been used (104798).\n\nPressure ulcers: Henna powder 1 gram mixed with 10 mL of water and applied directly to the ulcer has been used as a single dose. The solution was washed off after 30 minutes (104794).\n\nWound healing: Henna 2% ointment applied once daily for 2 weeks has been used (104795).br>\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of henna.",
            "Interactions with Drugs": "LITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nHenna is thought to have diuretic properties. Theoretically, due to these potential diuretic effects, henna might reduce excretion and increase levels of lithium. The dose of lithium might need to be decreased.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nGLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY\nTopically, henna has been reported to cause hemolysis in infants and children with G6PD deficiency (4147, 10381, 100839, 100840). Henna should be avoided in patients with G6PD deficiency.\nless\nHENNA HYPERSENSITIVITY\nAvoid topical exposure by individuals with henna hypersensitivity.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of henna.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of henna.",
            "Mechanism of Action": "General\nThe applicable part of henna is the leaf. Henna leaf contains lawsone, gallic acid, and 5% to 10% tannin (11).\nAnticancer effects\nStudies suggest that the henna ingredient lawsone might have antitumor effects (11).\nAntimicrobial effects\nSome evidence suggests henna might have activity against Mycobacterium tuberculosis (4150). The constituents lawsone and gallic acid, have antibacterial and antifungal properties (11).\nGastrointestinal effects\nStudies suggest that the henna ingredient lawsone might have antispasmodic effects (11).\nHematologic effects\nEvidence shows the henna ingredient lawsone might be able to decrease the formation of sickled cells in individuals with sickle cell anemia (4149).\nRenal effects\nHenna leaf is thought to have diuretic properties (18).\nReproductive effects\nIn female rats, henna leaves inhibit fertility (11)."
        }
    },
    "Herb Paris": {
        "sections": {
            "Overview": "Herb Paris is a plant native to Europe, Russia, and the Caucasus (102538).\n\nKEY HIGHLIGHTS\nTraditionally used for pain, including headache, nerve pain, and rheumatoid arthritis (RA), but there is insufficient reliable evidence to rate its effectiveness for these uses.\nLikely unsafe when used orally. Side effects may include nausea, vomiting, diarrhea, and respiratory paralysis.\nNo known major interactions.",
            "Safety": "LIKELY UNSAFE when used orally. The plant and berry are poisonous (18).\nPREGNANCY AND LACTATION: UNSAFE when used orally (18).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Herb Paris can cause nausea, vomiting, diarrhea, headache, miosis, and respiratory paralysis (18).\nGastrointestinal\nOrally, Herb Paris can cause nausea, vomiting, and diarrhea (18).\nless\nNeurologic/CNS\nOrally, Herb Paris can cause headache (18).\nless\nOcular/Otic\nOrally, Herb Paris can cause miosis. Paristyphnin, a constituent of Herb Paris, is thought to be responsible for this effect (18).\nless\nPulmonary/Respiratory\nOrally, Herb Paris can cause respiratory paralysis. Paristyphnin, a constituent of Herb Paris, is thought to be responsible for this effect (18).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of Herb Paris.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Herb Paris.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of Herb Paris.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Herb Paris.",
            "Mechanism of Action": "General\nThe applicable part of Herb Paris is the whole plant with ripe fruit. Herb Paris contains triterpene saponins (pennogenintetra glycosides), also referred to as parissaponins, which cause local irritation. This increases absorption of the toxic constituent, paristyphnin (18)."
        }
    },
    "Herb Robert": {
        "sections": {
            "Overview": "Herb Robert is an herb native to Asia, Central Europe, and the Mediterranean. It is also found in temperate areas of North and South America and North Africa. Herb Robert has been used in traditional medicine (99143, 99144, 99146). It is characterized by a strong, unpleasant smell (99144, 99146).",
            "Safety": "There is insufficient reliable information available about the safety of Herb Robert.\nPREGNANCY AND LACTATION: Insufficient reliable information is available; avoid using.",
            "Adverse Effects": "General\nThere is currently a limited amount of information on the adverse effects of Herb Robert. Topically, Herb Robert has been reported to cause allergic contact dermatitis (99144, 99146).\nImmunologic\nTopically, Herb Robert can cause contact dermatitis. There are at least two cases of known contact sensitization of elderly individuals to Herb Robert through gardening (99144, 99146). One case resulted in an erythema multiforme-like eruption requiring treatment with steroids (99146).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nOtitis media. Clinical research of an herbal mixture containing the essential oils of Herb Robert, clove, and lavender shows that placing 3 drops in the ear every 12 hours for one week improves otitis media symptoms including pain, tenderness, itching, edema, and discharge when compared with baseline. These improvements are similar to those achieved with ciprofloxacin 0.3% otic drops. Additionally, approximately 90% of patients receiving either treatment had a negative culture after 7 days (99145). It is unclear if these effects are due to Herb Robert, the other ingredients, or the combination.\nMore evidence is needed to rate Herb Robert for this use.",
            "Dosing & Administration": "Adult\nOtic:Otitis media: Three drops of an herbal mixture containing the essential oils of Herb Robert, clove, and lavender have been placed in the ear every 12 hours for one week (99145).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Herb Robert.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of Herb Robert.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Herb Robert.",
            "Mechanism of Action": "General\nThe applicable parts of Herb Robert are the above ground parts. Herb Robert contains several flavonoids including rutin, quercetin, kaempferol, ellagic acid, and other flavonoids and polyphenols (99143).\nAnti-cancer effects\nHerb Robert is traditionally used for cancer. Extracts of Herb Robert have cytotoxic effects against various cancer cells in vitro (9143).\nAntimicrobial effects\nSome evidence suggests that an ethanolic extract of Herb Robert can inhibit the growth of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Some evidence also suggests the extract has anti-fungal effects (18, 99145).\nAntiviral effects\nSome evidence indicates that the extract of fresh Herb Robert, including the root, has a mild antiviral effect against the vesicular stomatitis virus (18)."
        }
    },
    "Hercules Club": {
        "sections": {
            "Overview": "Hercules club is a tree with a spiny trunk. The bark and berry of the tree have been used as medicine. It has traditionally been used to improve circulation and for its purported anti-inflammatory, diaphoretic, and emmenagogic effects (12).",
            "Safety": "There is insufficient reliable information available about the safety of Hercules club when used orally.\nPREGNANCY: LIKELY UNSAFE when used orally (12) because it might have menstrual stimulant effects (19). There is insufficient reliable information available about the safety of the berry during pregnancy; avoid using.\nLACTATION: POSSIBLY UNSAFE when used orally because it might cause colic in nursing infants (19).",
            "Adverse Effects": "General\nNone reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of Hercules club.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of Hercules club.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTACIDS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, Hercules club may decrease the clinical effects of antacids.\nDue to reports that Hercules club increases stomach acid, Hercules club might decrease the effectiveness of antacids (19).\nless\nH2-BLOCKERS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, Hercules club may decrease the clinical effects of H2 blockers.\nDue to reports that Hercules club increases stomach acid, Hercules club might decrease the effectiveness of H2-blockers (19).\nless\nPROTON PUMP INHIBITORS (PPIs)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, Hercules club may decrease the clinical effects of PPIs.\nDue to reports that Hercules club increases stomach acid, Hercules club might decrease the effectiveness of PPIs (19).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Hercules club.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of Hercules club.",
            "Mechanism of Action": "General\nThe applicable parts of Hercules club are the bark and berry. Hercules club contains nitidine, chelerythrine, asarinin, and neoherculin (4).\nNeurologic effects\nReports of death after ingestion by cattle, chickens, and fish have been attributed to the neuromuscular blocking properties of Hercules club bark (4). However, this has not been validated in scientific research."
        }
    },
    "Hesperidin": {
        "sections": {
            "Overview": "Hesperidin is a flavanone diglycoside. It is principally found in unripe citrus fruit and is known as a citrus bioflavonoid. Hesperidin is found in both the orange fruit and orange juice (94545, 105292).",
            "Warnings": "This topic does not discuss proprietary products containing 'Micronized Purified Flavonoid Fraction' (MPFF). This fraction contains diosmin 90%, as well as small amounts of hesperidin and other flavonoids making up the remaining 10%. See Diosmin for discussion of these products.",
            "Safety": "LIKELY SAFE when used orally in amounts found in foods.\nPOSSIBLY SAFE when supplements are used orally and appropriately, short-term. Doses of up to 3 grams daily have been used with apparent safety for up to 3 months (37494, 54850, 94544, 105275, 105276).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally in amounts found in foods.\nPREGNANCY AND LACTATION: POSSIBLY SAFE when used orally in doses of up to 100 mg daily for 30 days in combination with diosmin. Some evidence suggests that taking this combination may be associated with placental insufficiency when used during the third trimester of pregnancy; however, the combination does not seem to induce fetal abnormalities, retard fetal growth, increase the risk of intrauterine death, or affect birth weight. Also, when breastfeeding, this combination does not seem to affect infant growth or feeding (54970).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, hesperidin is generally well tolerated.\nDermatologic\nA case of recurrent allergic dermatitis was reported in a 70-year-old female with no known allergies who applied topical hesperidin methyl chalchone (94538).\nless\nImmunologic\nA case of recurrent allergic dermatitis was reported in a 70-year-old female with no known allergies who applied topical hesperidin methyl chalchone (94538).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY INEFFECTIVE\nHypercholesterolemia. Oral hesperidin does not seem to reduce cholesterol levels.\nClinical studies and a meta-analysis of the available clinical research show that taking hesperidin 400-800 mg daily for 4-12 weeks does not affect total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, or triglyceride levels when compared with placebo in healthy and obese individuals with or without mild hypercholesterolemia (94539, 102315). However, some preliminary clinical research shows that taking glucosyl hesperidin, a soluble hesperidin derivative, 500 mg daily for 24 weeks modestly lowers serum levels of triglycerides and LDL cholesterol when compared with baseline in patients with both hypercholesterolemia and hypertriglyceridemia, but not in those without hypertriglyceridemia (54800). The validity of this finding is limited by the lack of a comparator group.\nless\nObesity. Oral hesperidin does not seem to be beneficial for weight loss.\nA meta-analysis of two clinical trials shows that taking hesperidin for 6-12 weeks does not affect body weight or body mass index (BMI) when compared with placebo, although it may modestly improve waist circumference (105280, 105281). The studies included in this analysis were short-term and were not designed to evaluate weight as a primary endpoint. Other clinical research conducted in Japan shows that taking glucosyl hesperidin, a soluble hesperidin derivative, 470 mg orally daily for 12 weeks does not reduce body weight, total fat area, or subcutaneous fat area when compared to baseline in modestly overweight patients (94544).\n\nHesperidin has also been evaluated in combination with green tea extract. One clinical study in overweight individuals shows that taking a combination of glucosyl hesperidin 178 mg and green tea extract, providing epigallocatechin gallate (EGCG) 146 mg, daily for 12 weeks modestly attenuates an increase in weight and BMI when compared with placebo. Sub-group analyses suggest that the greatest effects occurred in individuals less than 50 years of age (108152). It is unclear if these effects are due to hesperidin, green tea extract, or the combination.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. It is unclear if oral hesperidin is beneficial for improving athletic performance.\nSmall clinical studies in healthy male cyclists show that taking a specific form of hesperidin (Cardiose, HealthTech BioActives) has some benefit on athletic performance. One study shows that taking this form of hesperidin 500 mg once, five hours prior to exercise, improves average power, maximum speed, and total energy when compared with placebo. However, it does not improve peak power, time to peak power, or total oxygen consumption (102312). Taking this form of hesperidin 500 mg daily for 8 weeks modestly improves the highest average power output that can be maintained for one hour and the maximal power during an incremental test when compared with placebo. However, there was no effect on the aerobic or anaerobic ventilatory thresholds, oxygen use, or the times to peak power or maximum speed when compared with placebo (105277).\nless\nChronic prostatitis and chronic pelvic pain syndrome (CP/CPPS). Although there is interest in using oral hesperidin for CP/CPPS, there is insufficient reliable information about the clinical effects of hesperidin for this condition. There is research evaluating the use of micronized purified flavonoid fraction, which contains small amounts of hesperidin. See Diosmin for more information.\nChronic venous insufficiency (CVI). Oral hesperidin has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nClinical research shows that taking a specific combination product containing hesperidin methyl chalcone 150 mg, butcher's broom root extract 150 mg, and ascorbic acid 100 mg (Cyclo 3 Fort) usually for 1-3 months may decrease pain, heaviness, cramps, and paresthesia in patients with CVI (37483).\n\nThere is also research evaluating the use of micronized purified flavonoid fraction, which contains small amounts of hesperidin, for CVI. See Diosmin for more information.\nless\nCognitive function. Although there is interest in using oral hesperidin for improving cognitive function, there is insufficient reliable information about the clinical effects of hesperidin for this condition.\nCoronary artery bypass graft (CABG) surgery. Although there is interest in using oral hesperidin for patients undergoing CABG surgery, there is insufficient reliable information about the clinical effects of hesperidin for this purpose. There is research evaluating the use of micronized purified flavonoid fraction, which contains small amounts of hesperidin. See Diosmin for more information.\nDiabetes. It is unclear if oral hesperidin is beneficial for diabetes.\nClinical research in adults with diabetes shows that taking hesperidin (Swanson Health Products) 500 mg once daily for 6 weeks reduces systolic blood pressure and the mean arterial blood pressure by about 3% and 2.5%, respectively, when compared with placebo. Although this improvement is statistically significant, it is unlikely to be considered clinically significant. Also, hesperidin does not modify levels of fasting blood glucose or measures of insulin resistance (98697, 105292). A prospective observational study in patients with type 1 or type 2 diabetes has found that taking a specific product (Flebotrofine, AMNOL Chimica Biologica) containing hesperidin for 3 months is not associated with improvements in HbA1c, cholesterol, or triglyceride levels when compared with baseline. Other ingredients in this product included L-arginine, troxerutin, diosmin, black currant extract, and gotu kola extract (108151).\n\nThere is also research evaluating the use of micronized purified flavonoid fraction, which contains small amounts of hesperidin, for diabetes. See Diosmin for more information.\nless\nDiabetic neuropathy. It is unclear if oral hesperidin is beneficial for diabetic neuropathy.\nA small clinical study in adults with type 2 diabetes, peripheral neuropathy, and metabolic syndrome on oral antidiabetic therapy shows that taking hesperidin 1 gram daily improves diabetic neuropathy as measured by the Michigan Neuropathy Screening Instrument (MNSI) and a physical exam performed by a neurologist when compared with antidiabetic therapy alone. The improvements in measures of diabetic neuropathy were greater when hesperidin was taken with diosmin 1 gram daily compared with either supplement alone or antidiabetic therapy alone, suggesting a synergistic effect (112797).\nless\nDiabetic retinopathy. Although there is interest in using oral hesperidin for diabetic retinopathy, there is insufficient reliable information about the clinical effects of hesperidin for this condition.\nExercise-induced muscle soreness. It is unclear if oral hesperidin is beneficial for preventing muscle soreness due to exercise.\nA very small clinical study in sedentary young adults shows that taking hesperidin methyl chalcone 500 mg daily for 3 days prior to intense exercise improves physical performance and postural balance and relieves impaired strength and muscle soreness upon palpation but does not relieve muscle soreness during active movement when compared with placebo (112801).\nless\nHemorrhoids. Oral hesperidin has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with acute hemorrhoidal crisis shows that taking a specific supplement (Triade H, Omikron Italia Srl) containing hesperidin, diosmin, and troxerutin daily for 43 days results in significantly less pain, bleeding, anal itching, and medication use when compared with placebo (93885). This product was given as one sachet of powdered diosmin 300 mg, troxerutin 300 mg, hesperidin 300 mg, and vitamin C 12 mg mixed in water orally three times daily for 3 days, then two sachets daily for 2 days, then one sachet daily for seven days, followed by one tablet containing hesperidin 100 mg, diosmin 300 mg, and troxerutin 300 mg daily for one month (93885).\n\nThere is also research evaluating the use of micronized purified flavonoid fraction, which contains small amounts of hesperidin, for hemorrhoids. See Diosmin for more information.\nless\nHypertension. It is unclear if oral hesperidin is beneficial for hypertension.\nPreliminary clinical research in overweight males with or without hypertension shows that taking hesperidin 136 mg or drinking 250 mL of orange juice containing hesperidin 136 mg twice daily for 4 weeks lowers diastolic, but not systolic, blood pressure by around 5 mmHg when compared with placebo (94543). However, a meta-analysis of the available clinical research shows that taking hesperidin supplements 400-800 mg daily for 4-12 weeks does not reduce systolic or diastolic blood pressure when compared with placebo in healthy and obese individuals with or without hypertension (102315). Due to the mixed populations evaluated in this research, the effect of hesperidin in patients with diagnosed hypertension is unclear.\nless\nHypertriglyceridemia. It is unclear if oral hesperidin is beneficial for hypertriglyceridemia.\nPreliminary clinical research in patients with hypercholesterolemia shows that taking glucosyl hesperidin, a soluble hesperidin derivative, 500 mg daily for 6 weeks modestly lowers triglyceride levels when compared with baseline in patients who also have hypertriglyceridemia, but not in those without hypertriglyceridemia. However, glucosyl hesperidin did not lower cholesterol levels; a lower dose of 100 mg daily had no effect on either outcome (105290). Clinical research in a similar population shows that taking glucosyl hesperidin 500 mg daily for 24 weeks reduces triglyceride levels by up to 34% from baseline and modestly reduces levels of low-density lipoprotein cholesterol (54800). The validity of the findings in these studies is limited by the lack of a comparator group.\nless\nLymphedema. Oral hesperidin has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nClinical research in females with lymphedema due to breast cancer surgery shows that taking three capsules of a specific combination product (Cyclo 3 Fort), which contains hesperidin methyl chalcone 150 mg, butcher's broom root extract 150 mg, and ascorbic acid 100 mg per capsule, three times daily orally for 90 days reduces swelling in the upper arm and forearm and improves mobility and heaviness when compared with placebo (37494).\n\nThere is also research evaluating the use of micronized purified flavonoid fraction, which contains small amounts of hesperidin, for lymphedema. See Diosmin for more information.\nless\nMetabolic syndrome. It is unclear if oral hesperidin is beneficial for metabolic syndrome.\nA small clinical study in adults with metabolic syndrome shows that taking hesperidin (Shaanxi Yuantai Biological Technology Co., Ltd) 500 mg twice daily for 12 weeks increases the number of patients who no longer have defined metabolic syndrome by almost two-fold when compared with placebo. There were also modest reductions in fasting blood glucose, triglycerides, and systolic blood pressure, as well as the total number of patients with abdominal obesity, elevated blood pressure, and elevated fasting blood sugar. However, there were no differences in levels of high-density lipoprotein (HDL) cholesterol, diastolic blood pressure, or waist circumference (105288). In another preliminary clinical study using the same product, there were modest reductions in systolic blood pressure and triglyceride levels when compared with no treatment. However, there were no effects on other measures of metabolic syndrome or the overall number of patients with defined metabolic syndrome. This study also shows that when hesperidin is taken in combination with flaxseed 15 grams twice daily, serum concentrations of triglycerides and glucose, as well as systolic blood pressure, were modestly improved when compared with control. The prevalence of individuals with defined metabolic syndrome at the end of treatment was reduced by approximately 77%, which was significant when compared with the control group (105276). Another small clinical study in adults with metabolic syndrome, type 2 diabetes, and peripheral neuropathy on oral antidiabetic therapy shows that taking hesperidin 1 gram daily reduces body mass index, fasting blood glucose, triglycerides, and low-density lipoprotein cholesterol but not systolic blood pressure, diastolic blood pressure, or HDL cholesterol when compared with control. These effects are enhanced when hesperidin is combined with diosmin 1 gram daily (112797).\nless\nMinor bleeding. Although there is interest in using oral hesperidin for minor bleeding, there is insufficient reliable information about the clinical effects of hesperidin for this purpose. There is research evaluating the use of micronized purified flavonoid fraction, which contains small amounts of hesperidin. See Diosmin for more information.\nNonalcoholic fatty liver disease (NAFLD). It is unclear if oral hesperidin is beneficial for NAFLD; the available evidence is conflicting.\nA small clinical trial in adults with NAFLD shows that taking hesperidin 1 gram daily for 12 weeks along with lifestyle modification improves hepatic steatosis as measured by transient elastography when compared with placebo and lifestyle modification. Taking hesperidin also modestly improves total cholesterol, triglyceride, alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT) levels. However, there were no effects on liver fibrosis or levels of aspartate aminotransferase (AST), fasting blood glucose, insulin, low-density lipoprotein (LDL) cholesterol, or high-density lipoprotein (HDL) cholesterol (102313). Other preliminary clinical research using the same treatment protocol shows that although there were modest reductions in ALT, there was no effect on liver steatosis, liver fibrosis, or other metabolic measures. When used in combination with flaxseed 30 grams daily, levels of fasting blood glucose and a measure of insulin resistance were modestly improved (105275). These studies may have been too small to detect differences in most endpoints.\nless\nRheumatoid arthritis (RA). It is unclear if oral hesperidin is beneficial for RA.\nA small clinical study shows that drinking a 100 mL beverage containing alpha-glucosyl hesperidin 3 grams daily orally for 12 weeks might improve symptoms of RA when compared with placebo (54850).\nless\nVaricose veins. Although there is interest in using oral hesperidin for varicose veins, there is insufficient reliable information about the clinical effects of hesperidin for this condition. There is research evaluating the use of micronized purified flavonoid fraction, which contains small amounts of hesperidin, for this purpose. See Diosmin for more information.\nVenous leg ulcers. Although there is interest in using oral hesperidin for venous leg ulcers, there is insufficient reliable information about the clinical effects of hesperidin for this condition. There is research evaluating the use of micronized purified flavonoid fraction, which contains small amounts of hesperidin, for this purpose. See Diosmin for more information.\nCoronavirus disease 2019 (COVID-2019). It is unclear if oral hesperidin is beneficial for COVID-19.\nA large clinical study in unvaccinated outpatients with symptomatic COVID-19 shows that taking hesperidin 1000 mg at bedtime for 14 days after symptom onset does not reduce the proportion of subjects with the most common symptoms (e.g., fever, cough, shortness of breath, and anosmia), number of symptoms after 14 days, or duration of individual symptoms when compared with placebo (112800). However, the study was limited by significant attrition.\nless\nMore evidence is needed to rate hesperidin for these uses.",
            "Dosing & Administration": "Adult\nOral:\nHesperidin has most often been used in doses of 450-1000 mg daily for 6-12 weeks. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hesperidin.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, hesperidin may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.\nAnimal research suggests that hesperetin, a bioflavonoid aglycone derivative of hesperidin, may have antiplatelet activity (54822).\nless\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking hesperidin with antihypertensive drugs might increase the risk of hypotension.\nSome clinical and animal research shows that hesperidin can decrease blood pressure (54851, 94543, 98697, 105278). However, other clinical research shows that hesperidin does not affect blood pressure (102315).\nless\nCELIPROLOL (Celicard)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hesperidin may decrease the levels and clinical effects of celiprolol.\nAnimal research shows that concomitant use of hesperidin may reduce the plasma area under the curve of celiprolol by up to 75% (91760). This effect has not been reported in humans.\nless\nCNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concomitant use with CNS depressants may cause additive sedative effects.\nAnimal studies show that hesperidin has sedative effects, due to opioid receptor activity (54841) and can increase sedation when used with diazepam (54789). This effect has not been reported in humans.\nless\nDILTIAZEM (Cardizem, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hesperidin may increase the levels and clinical effects of diltiazem.\nAnimal research suggests that hesperidin may enhance the bioavailability of diltiazem, increasing the plasma area under the curve of diltiazem by up to 65.3% (91761). This effect has not been reported in humans.\nless\nP-GLYCOPROTEIN SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hesperidin might inhibit P-glycoprotein-mediated drug efflux and potentially increase levels of drugs that are substrates of P-glycoprotein.\nIn vitro research shows that hesperidin can inhibit P-glycoprotein efflux (54908). This effect has not been reported in humans.\nless\nVERAPAMIL (Calan, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hesperidin might increase the levels and clinical effects of verapamil.\nAnimal research suggests that hesperidin may enhance the bioavailability of verapamil, increasing the plasma area under the curve of verapamil by 96.8% (91762). This effect has not been reported in humans\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, hesperidin may have antiplatelet effects.\nAnimal research suggests that hesperetin, a bioflavonoid aglycone derivative of hesperidin, may have antiplatelet activity (54822). Theoretically, hesperidin might increase the risk of bleeding when used concomitantly with anticoagulant/antiplatelet herbs and supplements. See other products with antiplatelet activity here. See products with anticoagulant activity here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nTheoretically, hesperidin might have hypotensive effects.\nSome clinical and animal research suggests that hesperidin can decrease blood pressure (54851, 94543, 98697). However, some clinical research shows that hesperidin does not affect blood pressure (102315). Until more is known, use hesperidin with caution in patients taking herbs with hypotensive effects.\nless\nHERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nTheoretically, hesperidin might have sedative effects.\nAnimal studies show that hesperidin can have sedative effects (54841, 54789). Theoretically, concomitant use with herbs and supplements that have sedative properties might increase the risk of excessive drowsiness. See other products with sedative activity here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING DISORDERS\nTheoretically, hesperidin might increase the risk of bleeding; use with caution. Animal research suggests that hesperetin, a bioflavonoid aglycone derivative of hesperidin, may have antiplatelet activity (54822).\nless\nPERIOPERATIVE\nTheoretically, hesperidin might cause additive CNS depression when combined with anesthesia, and may also increase the risk of bleeding during surgical procedures. Tell patients to discontinue hesperidin at least 2 weeks before elective surgical procedures. Animal studies suggest that hesperidin has sedative effects (54841, 54789) and may increase the risk of bleeding (54822, 54838).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hesperidin.",
            "Pharmacokinetics": "Absorption\nSome research suggests that pure hesperidin has a bioavailability of less than 25% (53374). Micronization can increase bioavailability of hesperidin, increasing absorption by 40% compared with non-micronized hesperidin formulations. Additionally, the bioavailability of the 2S-hesperidin enantiomer is greater than a mixture of both hesperidin stereoisomers due to the greater formation of hesperidin catabolites in the 2S-enantiomer formulation (112799). In one pharmacokinetic study, the Cmax for orally administered hesperidin was 825.78 ng/mL (2731.8 nmol/L) and the mean AUC was 4846.20 ng*h/mL (54819). Following the ingestion of blood orange juice in human subjects, the Cmax for hesperidin was 43.4 ng/mL and 79.8 ng/mL after 150 mL and 300 mL intake, respectively (54825). Human and animal research suggest that the absorption of hesperidin takes place in the large intestine, with concentrations evident in the plasma within 20 minutes and with a Tmax ranging from 4-6 hours (54819, 54825, 54863, 54867).\nMetabolism\nAnimal research shows that hesperidin undergoes rapid and extensive phase II metabolism (54842). Hesperidin is hydrolyzed by gut microflora in the colon into its aglycone (hesperetin) (54976, 54867, 54888) and then conjugated mainly into glucuronides (54763, 54867, 105278). The major urinary metabolite is 3-hydroxy-4-methoxyphenyl hydracrylic acid (54772). Other hesperidin metabolites found in human plasma and urine include hesperetin-3'-sulfate, hesperetin-3'-glucuronide, hesperetin-7-sulfate, and hesperetin-7-glucuronide (54867, 105277, 105278).\nExcretion\nHesperidin is minimally excreted in urine, and research shows that people can be low, intermediate, or high urinary hesperidin excreters with the relative cumulative urinary excretion ranging from 0.6% to 8% (54819, 54867, 112799).One study shows that a micronized formulation of 2S-hesperidin has greater bioavailability, overall hesperidin metabolite and catabolite excretion in urine, and relative urinary hesperidin excretion compared with non-micronized and stereoisomeric formulations of hesperidin (112799). Some animal research shows that the urinary excretion of hesperidin metabolites was higher in rats administered glucosyl hesperidin than those receiving pure hesperidin (54806). Animal research shows that hesperidin is also excreted by non-renal routes (54842). Some clinical research suggests that elderly patients may have reduced excretion of hesperidin, whereas sex, weight and contraceptive pill use do not affect hesperidin excretion (54867). In one human study, the elimination half-life of orally administered hesperidin was around 3 hours (54819).",
            "Mechanism of Action": "General\nHesperidin is one of over 4000 flavonoids found in plants (4919, 4959, 5006). It is in a class of flavonoids primarily derived from citrus fruits and is known as a citrus bioflavonoid. It is closely related to other citrus bioflavonoids such as quercetin, rutin, and diosmin (4861, 4900, 4919, 4956).\nAnalgesic effects\nThe analgesic effect of hesperidin may be explained by peripheral rather than central mechanisms (4861, 4900, 4919, 4956) and may involve opioid receptors (54841).\nAnti-aging effects\nAnimal research suggests that hesperidin may have anti-aging effects. Hesperidin was found to suppress NF-kappaB activation through signal transduction pathways, NIK/IKK, ERK, p38, and JNK as well as suppress the translocation of Trx/Ref-1 indicating beneficial redox activity (54814).\nAnti-inflammatory effects\nAnimal and human research show that hesperidin has anti-inflammatory effects in the body, reducing levels of some inflammatory cytokines and inflammatory proteins, such as high-sensitivity C-reactive protein (hs-CRP) (98697, 105275, 112798). One meta-analysis of clinical studies in healthy adults shows that taking hesperidin 88-500 mg daily as supplements or orange juice reduces CRP, interleukin (IL)-6, and IL-4 but not tumor necrosis factor-alpha when compared with control (112798). However, another meta-analysis of 6 clinical studies shows that hesperidin does not seem to affect CRP, interleukin (IL)-6, or E-selectin levels (102314).\n\nOther research suggests that hesperidin's modest anti-inflammatory activity seems to help restore normal capillary permeability and have beneficial vascular effects. Hesperidin inhibits phosphodiesterase and increases intracellular cyclic adenosine monophosphate (cAMP), which causes decreased production of inflammatory prostaglandins E2 and F2 and thromboxane B2. Hesperidin has also reduced the generation of free radicals and inhibited tumor growth in laboratory research (4861, 4900, 4919, 4956).\nAnticancer effects\nSome in vitro research suggests that hesperidin may have anticancer effects via its ability to reduce the generation of free radicals and inhibit tumor growth (4861, 4900, 4919, 4956, 54771, 54779).\nAntidiabetic effects\nHesperidin might be helpful in diabetes. In animal research, hesperidin reduced blood glucose, in part, by increasing hepatic glycolysis and glycogen concentration or by lowering hepatic gluconeogenesis (54784, 54913).\nAntihypertensive effects\nHuman research shows that there is a linear trend between hesperidin intake and decreases in systolic blood pressure (SBP), but not diastolic blood pressure (DBP). Decreases in SBP were directly related to decreases in the expression of pentraxin-3 (PTX3) (105278). Animal research shows that glucosyl hesperidin enhances endothelium-dependent vasodilation in response to acetylcholine and reduces oxidative stress by inhibiting nicotinamide adenine dinucleotide phosphate oxidase expression in the vasculature, thereby improving hypertension in spontaneously hypertensive rats (54851).\nAntioxidant effects\nA meta-analysis of clinical studies in healthy adults shows that taking hesperidin 88-500 mg daily as a supplement or in orange juice reduces malondialdehyde but does not change total antioxidant content, glutathione, superoxide dismutase, or catalase levels when compared with control (112798).\nAntiplatelet effects\nSome in vitro research suggests that hesperidin inhibits platelet aggregation by interfering with cyclooxygenase-1 activity and PLC-gamma2 phosphorylation (54822).\nAntiviral effects\nSome in vitro research shows that glucosyl hesperidin prevents influenza a virus replication via inhibition of viral sialidase (54892).\nBone effects\nClinical research shows that taking calcium 500 mg orally with hesperidin 500 mg daily for 50 days appears to improve retention of calcium in the bones by 5.5% from baseline. However, since taking calcium alone was not a comparator for this study, the effect of hesperidin is on calcium retention is unclear (94541). Some animal research suggests that hesperidin inhibits bone loss (54818, 54843) by a mechanism similar to that of statin drugs (54818). In an animal model of postmenopausal osteoporosis, hesperidin seemed to maintain the bone mineral density and concentration of calcium in the femur (54766).\nCardiovascular effects\nHesperidin is most often used for vascular conditions such as hemorrhoids and varicose veins in combination with other citrus bioflavonoids,. These bioflavonoids seems to work by improving venous tone, reducing stasis, restoring normal capillary permeability, and improving lymphatic drainage. Hesperidin might improve venous tone and reduce stasis by improving vasculature response to adrenergic stimulation. Hesperidin's anti-inflammatory effects seem to help restore normal capillary permeability. Hesperidin inhibits phosphodiesterase and increases intracellular cyclic adenosine monophosphate (cAMP), which causes decreased production of inflammatory prostaglandins E2 and F2 and thromboxane B2 (4861, 4900, 4919, 4956).\n\nAdditionally, hesperidin seems to improve endothelial function (37478, 94545). Preliminary clinical research shows that taking hesperidin 500 mg orally daily for 3 weeks increases flow-mediated dilation which is related to improvement in endothelial function in patients with metabolic syndrome. Additionally, serum inflammatory biomarkers such as C-reactive protein were reduced (94545). In vitro research also shows that hesperidin decreases inflammation and lipid accumulation in the endothelium via modulation of gene expression on leukocytes, suggesting that it may have anti-atherogenic and cardioprotective effects (94542).\n\nSome in vitro research suggests that hesperidin inhibits platelet aggregation by interfering with cyclooxygenase-1 activity and PLC-gamma2 phosphorylation (54822).\nMusculoskeletal effects\nHesperidin is of interest for improving athletic performance. Taking hesperidin 500 mg daily for 8 weeks reduces body fat and increases muscle mass in male cyclists (105279). A clinical study in amateur cyclists shows that taking 2S-hesperidin (Cardiose, HealthTech BioActives) 500 mg daily for 8 weeks might improve athletic performance by improving acid-base status as shown by increased bicarbonate anion, actual base excess, standard bicarbonate, and decreased lactate during aerobic exercise and recovery. Additionally, 2S-hespiridin intake decreases lactate during aerobic exercise, anaerobic exercise, and recovery. This suggests that 2S-hesperidin could lead to a greater contribution of fatty acid oxidation at lower exercise intensities and improved recovery after intense exercise (112803). Furthermore, 2S-hesperidin intake by amateur cyclists during the off season prevents decreases in the partial pressure of oxygen, which could help prevent a loss of performance during subsequent high-intensity exercise following lower levels of training (112802).\nNeuroprotective effects\nIn vitro research shows that hesperidin and neohesperidin protect against hydrogen peroxide-induced neurotoxicity (54844). In an animal model, hesperidin offered a protective effect against 3-nitropropionic acid (a model to study Huntington disease) attenuating behavioral alterations, oxidative stress, and mitochondrial enzymes complex dysfunction; hesperidin may act through a nitric oxide mechanism (54903).\nRadioprotective effects\nSome animal research shows that hesperidin exerts radioprotective effects against gamma irradiation via free radical scavenging (54804, 54859)."
        }
    },
    "Hexadrone [FAST FACTS]": {
        "sections": {
            "Overview": "Hexadrone meets the definition of an anabolic androgenic steroid, as determined by the United States Designer Anabolic Steroid Control Act (DASCA) (8639, 103909). It is unlawful for anabolic steroids to be added to dietary supplements. Anabolic steroids are also prohibited by the World Anti-Doping Agency (WADA) (102469).\n\nNOTE: This is a Fast Facts monograph, intended to give subscribers quick information on newly emerging ingredients in products claiming to be supplements. The Natural Medicines editors will continue to monitor the literature about this topic and update it as more evidence becomes available.",
            "Safety": "POSSIBLY UNSAFE when used orally or parenterally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, gynecomastia (in men), hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally or parenterally. Anabolic androgenic steroids can disrupt the body's hormonal balance and cause various adverse effects including reduced fertility, hair loss, acne, and behavioral changes. Anabolic androgenic steroid use has also been associated with hepatotoxicity and increased risk for heart disease. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing anabolic steroids are dangerous (91094). Avoid using.",
            "Effectiveness": "The effectiveness of hexadrone is unknown.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known."
        }
    },
    "Hibiscus sabdariffa": {
        "sections": {
            "Overview": "Hibiscus sabdariffa is a bushy annual plant. It is found in Central and West Africa, South East Asia, India, the West Indies, and the Americas (93805, 93808, 93816). Traditionally, Hibiscus sabdariffa has many uses, including for liver health, fever, infections, and as a galactagogue.",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Hibiscus sabdariffa has Generally Recognized As Safe (GRAS) status for use in foods in the US (4912).\nPOSSIBLY SAFE when used orally and appropriately in medicinal amounts. Hibiscus sabdariffa tea has been safely consumed in amounts of up to 720 mL daily for up to 6 weeks (16894, 93805, 93814). Hibiscus sabdariffa extracts, including a specific Hibiscus sabdariffa leaf extract (Green Chem), have also been safely used in doses of up to 1000 mg daily for up to 90 days (17415, 54989, 93805, 93809, 105307).\nCHILDREN: POSSIBLY SAFE when used orally and appropriately. Hibiscus sabdariffa calyx powder has been used with apparent safety at a dose of 2 grams three times daily for 4 weeks by adolescents aged 12-18 years (93816).\nPREGNANCY: POSSIBLY UNSAFE when used orally. Hibiscus sabdariffa is thought to be a menstrual stimulant, and might have abortifacient effects (19).\nLACTATION: POSSIBLY UNSAFE when used orally in large amounts. Animal research found that administering large doses of Hibiscus sabdariffa during lactation decreases food and water intake during pregnancy and delays puberty in offspring (93810); however, this has not been assessed in humans.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, Hibiscus sabdariffa is generally well tolerated.\nGastrointestinal\nOrally, taking a specific Hibiscus sabdariffa leaf extract (Green Chem) 1 gram daily has been associated with reports of transient gastrointestinal symptoms such as abdominal distention, flatulence, and epigastric pain in one clinical trial. However, the overall rate of these adverse effects was similar to placebo (17415). Taking Hibiscus sabdariffa calyx extract 6 grams daily has been associated with single cases of nausea in one clinical trial (55000). Taking Hibiscus sabdariffa calyx powder 6 grams daily has been associated with reports of mild and transient constipation in one clinical trial (93816). Taking 0.5-1 liters of tea daily, made by steeping 10-15 grams of dried Hibiscus sabdariffa calyces, has been associated with one report of stomach pain in one clinical trial (101733).\nless\nGenitourinary\nOrally, taking Hibiscus sabdariffa calyx extract 6 grams daily has been associated with one report of dysuria in one clinical trial (55000).\nless\nNeurologic/CNS\nOrally, taking Hibiscus sabdariffa calyx extract 3 grams daily has been associated with one report of tremor and headache in one clinical trial (55000).\nless\nOcular/Otic\nOrally, taking Hibiscus sabdariffa calyx extract 3 grams daily has been associated with one report of tinnitus in one clinical trial (55000).\nless\nPulmonary/Respiratory\nTaking 0.5-1 liters of tea daily, made by steeping 10, 15, or 20 grams of dried Hibiscus sabdariffa calyces, has been associated with two reports of dyspnea in one clinical trial. A clear association with Hibiscus sabdariffa could not be made (101733).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nHypertension. Oral Hibiscus sabdariffa seems to lower blood pressure by a small amount in patients with mild to moderate hypertension.\nMost research shows that drinking Hibiscus sabdariffa tea daily can modestly lower blood pressure in patients with pre-hypertension or mild hypertension after 2-6 weeks of treatment (16894, 54985, 54995, 90159, 93817, 101730, 108867). In addition, some research shows that drinking Hibiscus sabdariffa tea daily can modestly lower blood pressure in patients with either untreated or insufficiently treated mild to moderate hypertension (54989, 93815, 101733, 108867). These studies have used tea made from 1.25-10 grams or 150 mg/kg, brewed in 150 mL to 500 mL of water and taken one to three times daily for 2-6 weeks (16894, 54985, 54989, 54995, 90159, 93815, 93817, 101730, 101733, 108867). The dose has been increased to 15 or 20 grams, brewed in 1000 mL for daily consumption for 2-3 weeks if needed (101733, 108867). In this population, research shows that drinking Hibiscus sabdariffa tea or infusions is more effective than hydrochlorothiazide 25 mg daily and as effective as captopril 25 mg twice daily for lowering systolic and diastolic blood pressure (54989, 93815). Pooled analyses of results from clinical research shows that drinking Hibiscus sabdariffa tea or taking Hibiscus sabdariffa extract lowers systolic blood pressure by 5-8 mmHg and diastolic blood pressure by about 4 mmHg in patients with or without mild hypertension (93817, 105304). The clinical relevance of these results is uncertain due to the small size and low quality of the included studies. Some researchers suggest that there is insufficient reliable evidence to determine if the effects of Hibiscus sabdariffa are clinically relevant (17114).\n\nTaking Hibiscus sabdariffa in combination with other ingredients has also showed beneficial effects on blood pressure in clinical research. In one study, a specific product containing Hibiscus sabdariffa extract in combination with olive leaf extract (NW Roselle) for 8 weeks was found to be as effective as captopril 25 mg twice daily for reducing systolic and diastolic blood pressure (105302). In another study, a specific product (MetabolAid, Monteloeder S.L.) providing Hibiscus sabdariffa and lemon verbena extracts for 12 weeks reduced systolic, but not diastolic, blood pressure. However, these effects were limited to daytime ambulatory readings (105303).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nCancer. Although there has been interest in using oral Hibiscus sabdariffa for cancer, there is insufficient reliable information about the clinical effects of Hibiscus sabdariffa for this condition.\nConstipation. Although there has been interest in using oral Hibiscus sabdariffa for constipation, there is insufficient reliable information about the clinical effects of Hibiscus sabdariffa for this purpose.\nDiabetes. It is unclear if oral Hibiscus sabdariffa is beneficial for diabetes.\nPooled analyses of results from clinical research show that taking Hibiscus sabdariffa lowers fasting blood glucose levels by approximately 4 mg/dL (105304, 105305). However, only one low-quality study included in one of these analyses examined the effects of Hibiscus sabdariffa on fasting blood glucose levels in patients with type 2 diabetes (105305). Therefore, any benefit specific to this population is unclear.\nless\nDry mouth. Topical Hibiscus sabdariffa has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with dry mouth shows that taking a specific mucoadhesive tablet (Aqualief, Helsinn Healthcare SA), containing a combination of Hibiscus sabdariffa and carnosine, 400 mg three times daily after meals for 6 days increases saliva production and improves symptoms of dry mouth when compared to baseline. While saliva production was also increased in patients taking placebo, the increase was 3-fold greater with the combination product, and significant improvements in dry mouth symptoms were lacking in the placebo group (103288). It is unclear if these findings are due to Hibiscus sabdariffa, carnosine, or the combination.\nless\nDry skin. It is unclear if oral Hibiscus sabdariffa is beneficial for dry skin.\nA crossover clinical study in healthy adults shows that drinking Hibiscus sabdariffa 100 mL twice daily for 6 months improves skin moisture but does not improve skin surface water loss or sebum secretion when compared to baseline (112426). However, it is unclear whether any improvements are clinically significant or apply to patients with dry skin.\nless\nDyslipidemia. It is unclear if oral Hibiscus sabdariffa is beneficial for dyslipidemia.\nSome preliminary clinical research shows that drinking Hibiscus sabdariffa tea or taking Hibiscus sabdariffa extract can decrease total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides, and can increase high-density lipoprotein (HDL) cholesterol, in patients with metabolic disorders (54997, 54999). These studies used Hibiscus sabdariffa 2 grams in 240 mL boiling water, steeping for 20-30 minutes, twice daily and Hibiscus sabdariffa extract 100 mg daily, each for 4 weeks (54997, 54999). Clinical research also shows that taking powdered dried Hibiscus sabdariffa 6 grams daily reduces LDL cholesterol by approximately 8% in obese adolescents with dyslipidemia (93816). Additionally, two meta-analyses shows that taking Hibiscus sabdariffa extract modestly reduces LDL cholesterol levels (105305, 105306).\n\nHowever, other preliminary clinical research shows that taking Hibiscus sabdariffa extract does not improve cholesterol or triglyceride levels in patients with hypercholesterolemia (17415, 55000). Two pooled analyses of clinical data show that Hibiscus sabdariffa does not improve total cholesterol, HDL cholesterol, LDL cholesterol, or triglycerides when compared with placebo, a change in diet, or black tea in patients with hyperlipidemia, metabolic disorders, or obesity (93805, 105304). The differing conclusions of these trials and meta-analyses are related to their inclusion and exclusion criteria with respect to age and populations of focus.\nless\nKidney stones (nephrolithiasis). Although there has been interest in using oral Hibiscus sabdariffa for kidney stones, there is insufficient reliable information about the clinical effects of Hibiscus sabdariffa for this condition.\nMetabolic syndrome. Some small clinical studies suggest that oral Hibiscus sabdariffa may be beneficial for metabolic syndrome.\nIn adults with metabolic syndrome, a small clinical trial shows that taking Hibiscus sabdariffa powder 500 mg daily for 4 weeks modestly reduces systolic blood pressure and triglyceride levels by 5% and 15%, respectively, when compared with baseline. These changes were significant when compared with placebo. However, there was no effect on diastolic blood pressure, fasting glucose or insulin levels, cholesterol levels, or body mass index (105307). Other preliminary clinical research in adults with metabolic syndrome shows that taking Hibiscus sabdariffa extract 100 mg daily for one month modestly reduces fasting glucose and low-density lipoprotein (LDL) cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels when compared with baseline. When taken in combination with recommendations to follow the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) diet, triglyceride levels and blood pressure were also modestly reduced (54999).\nless\nObesity. Oral Hibiscus sabdariffa has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nTwo small clinical trials in overweight and obese females show that taking a combination product (MetabolAid, Monteloeder SL) containing Hibiscus sabdariffa and lemon verbena extracts as 500 mg per capsule daily for 2 months modestly increases weight loss when compared with placebo (97290, 101731). This combination also reduces hunger and increases satiety, and has small to moderate beneficial effects on low-density lipoprotein (LDL) cholesterol, heart rate, and blood pressure (97290). The effects in obese individuals seem to be less than those seen in overweight individuals, with no overall change in abdominal circumference or percent body fat in obese individuals (101731). A meta-analysis of these two studies and several others in overweight or obese individuals shows that taking Hibiscus sabdariffa in combination with other ingredients daily for 6-12 weeks modestly improves body mass index, weight, and body fat percentage when compared with control (112427). However, the validity of these results is limited by the heterogeneity of the included studies. Additionally, it is unknown if these effects are due to Hibiscus sabdariffa, other ingredients, or the combination.\nless\nUrinary tract infections (UTIs). It is unclear if oral Hibiscus sabdariffa is beneficial for UTIs.\nPopulation research in patients with urinary catheters living in long-term care facilities has found that drinking Hibiscus sabdariffa tea is associated with a 36% lower risk of UTIs when compared with not drinking tea (93807).\n\nSome small clinical studies that have evaluated the use of Hibiscus sabdariffa in combination with other ingredients suggest that they might reduce the occurrence of symptomatic UTIs in females with recurrent UTIs. One study used a product containing Hibiscus sabdariffa 200 mg, D-mannose 1000 mg, and Lactobacillus plantarum Lp-115 (1 billion colony forming units) daily for 15 days each month for 6 months (101734); the other study used a specific product (Monurelle Plus, Zambon Italia) containing Hibiscus sabdariffa 100 mg, xyloglucan 100 mg, gelatin 50 mg, and propolis 100 mg twice daily for 14 days (101735). Also, a small observational study in patients with an uncomplicated UTI has found that taking two tablets of a specific combination product (Acidif plus) containing Hibiscus sabdariffa extract 100 mg, boswellia gummy dry extract 100 mg, and L-methionine 400 mg daily for 7 days is associated with reduced UTI symptoms and reduced bacteriuria when compared with taking an unreported dose of fosfomycin for two days (103783). However, due to the poor quality of these studies, the magnitude of benefit is unclear. Also, it is unknown whether these effects are due to Hibiscus sabdariffa, other ingredients, or the combination.\nless\nWound healing. Although there has been interest in using topical Hibiscus sabdariffa for wound healing, there is insufficient reliable information about the clinical effects of Hibiscus sabdariffa for this purpose.\nMore evidence is needed to rate Hibiscus sabdariffa for these uses.",
            "Dosing & Administration": "Adult\nOral:\nHibiscus sabdariffa is typically used as a powder, extract, or tea for 4-12 weeks. See Effectiveness section for condition-specific information.\n\nHibiscus sabdariffa extract is sometimes standardized to anthocyanin content. Anthocyanin content has ranged from 0.5 mg/gram in teas or powders to 3.6 mg/gram in extracts (16894, 54989, 55000, 93815, 105307).\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nHibiscus sabdariffa extract used in clinical research is mainly prepared from calyces and often standardized to anthocyanin content. One extract used in clinical research has been standardized to contain 3.6 mg anthocyanins/gram (55000). Hibiscus sabdariffa tea or powder used in clinical research has been standardized to contain 0.5-0.96 mg anthocyanins/gram or 5.63 mg cyanidin glucoside equivalents per gram (16894, 54989, 93815, 105307). A specific combination product (NW Roselle) containing Hibiscus sabdariffa and olive leaf extracts was standardized to delphinidin-3-sambubioside found in Hibiscus sabdariffa and oleuropein found in the olive leaf (105302). A specific combination product (Metabolaid, Monteloeder SL) containing lemon verbena and Hibiscus sabdariffa extracts 500 mg per capsule was standardized to contain 3.5% anthocyanins and 15% verbascoside (97290, 101731, 105303).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nACETAMINOPHEN (Tylenol, others)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nINSIGNIFICANT\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, taking Hibiscus sabdariffa with acetaminophen might decrease the clinical effects of acetaminophen.\nThere is some evidence that consuming a Hibiscus sabdariffa beverage (Zobo drink) before taking acetaminophen can decrease the elimination half-life of acetaminophen. Hibiscus sabdariffa does not seem to decrease maximum concentration or area under the curve of acetaminophen (12184). The clinical significance of this is unknown.\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking Hibiscus sabdariffa with antidiabetes drugs might increase the risk of hypoglycemia.\nMost clinical research shows that Hibiscus sabdariffa can reduce blood glucose levels (54999, 105304, 105305).\nless\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking Hibiscus sabdariffa with antihypertensive drugs might increase the risk of hypotension.\nMost clinical evidence suggests that taking Hibiscus sabdariffa reduces systolic and diastolic blood pressure (16894, 54985, 54995, 105304). In animal research, Hibiscus sabdariffa increased the hypotensive effects of single doses of losartan and amlodipine (102459, 107901).\nless\nCHLOROQUINE (Aralen)\nInteraction Rating\nMAJOR Do not take this combination.\nSeverity\nHIGH\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTaking Hibiscus sabdariffa tea along with chloroquine seems to reduce levels of chloroquine.\nWhen taken together, Hibiscus sabdariffa tea significantly reduces the bioavailability of chloroquine (55004). This may reduce its clinical effects. People taking chloroquine for the treatment or prevention of malaria should avoid Hibiscus sabdariffa tea.\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Hibiscus sabdariffa extract might reduce the metabolism of CYP1A2 substrates.\nIn vitro research shows that Hibiscus sabdariffa calyx extract inhibits CYP1A2 (93811). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 2A6 (CYP2A6) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Hibiscus sabdariffa extract might reduce the metabolism of CYP2A6 substrates.\nIn vitro research shows that Hibiscus sabdariffa calyx extract inhibits CYP2A6 (93811). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 2B6 (CYP2B6) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Hibiscus sabdariffa extract might reduce the metabolism of CYP2B6 substrates.\nIn vitro research shows that Hibiscus sabdariffa calyx extract inhibits CYP2B6 (93811). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 2C19 (CYP2C19) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Hibiscus sabdariffa extract might reduce the metabolism of CYP2C19 substrates.\nIn vitro research shows that Hibiscus sabdariffa calyx extract inhibits CYP2C19 (93811). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 2C8 (CYP2C8) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Hibiscus sabdariffa might reduce the metabolism of CYP2C8 substrates.\nIn vitro research shows that Hibiscus sabdariffa calyx extract inhibits CYP2C8 (93811). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 2C9 (CYP2C9) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Hibiscus sabdariffa extract might reduce the metabolism of CYP2C9 substrates.\nIn vitro research shows that Hibiscus sabdariffa calyx extract inhibits CYP2C9 (93811). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 2D6 (CYP2D6) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Hibiscus sabdariffa extract might reduce the metabolism of CYP2D6 substrates.\nIn vitro research shows that Hibiscus sabdariffa calyx extract inhibits CYP2D6 (93811). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 2E1 (CYP2E1) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Hibiscus sabdariffa extract might reduce the metabolism of CYP2E1 substrates.\nIn vitro research shows that Hibiscus sabdariffa calyx extract inhibits CYP2E1 (93811). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, Hibiscus sabdariffa extract might reduce the metabolism of CYP3A4 substrates.\nIn vitro research shows that Hibiscus sabdariffa calyx extract inhibits CYP3A4 (93811). This interaction has not been reported in humans.\nless\nDICLOFENAC (Voltaren, others)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTaking Hibiscus sabdariffa with diclofenac may increase the levels and adverse effects of diclofenac.\nPharmacokinetic research in humans shows that drinking a beverage made with Hibiscus sabdariffa flowers reduces the excretion of diclofenac by approximately 38% when compared with water. The clinical significance of this is unknown (101726).\nless\nLOSARTAN (Cozaar)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, Hibiscus sabdariffa might increase the levels and clinical effects of losartan.\nAnimal research in rats with laboratory-induced hypertension shows that providing Hibiscus sabdariffa for 14-17 days prior to a single administration with losartan modestly increases losartan concentrations and increases hypotensive effects when compared with a single administration of losartan alone (102459). It is not clear if Hibiscus sabdariffa alters the concentration or effects of losartan when taken continuously. Additionally, this interaction has not been shown in humans.\nless\nSIMVASTATIN (Zocor)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMILD\nOccurrence\nPROBABLE\nLevel of Evidence\nB (Case-control study)\nTaking Hibiscus sabdariffa with simvastatin might reduce the levels and clinical effects of simvastatin.\nA pharmacokinetic study in humans shows that taking a beverage prepared with dried Hibiscus sabdariffa flower 300 grams concurrently with a single dose of simvastatin 40 mg increases the clearance of simvastatin by about 45% and reduces peak levels of simvastatin by 18% (96270).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nHibiscus sabdariffa might have hypoglycemic effects.\nPreliminary clinical research shows that Hibiscus sabdariffa extract reduces blood glucose in some patients (54999). Theoretically, concomitant use of Hibiscus sabdariffa with herbs and supplements with hypoglycemic activity could increase the risk of additive adverse effects, specifically hypoglycemia. See other products with hypoglycemic activity here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nHibiscus sabdariffa might have hypotensive effects.\nMost clinical research suggests that taking Hibiscus sabdariffa can lower blood pressure in some patients (16894, 54985, 54995, 105304). Theoretically, combining Hibiscus sabdariffa with other herbs and supplements with hypotensive effects might increase the risk of hypotension.\nless",
            "Interactions with Conditions": "PERIOPERATIVE\nTheoretically, Hibiscus sabdariffa might interfere with blood glucose control during and after surgical procedures. Tell patients to discontinue Hibiscus sabdariffa at least 2 weeks before elective surgical procedures. Hibiscus sabdariffa might affect blood glucose levels (54999).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with Hibiscus sabdariffa.",
            "Pharmacokinetics": "Absorption\nIn healthy individuals, Hibiscus sabdariffa resulted in increased plasma levels of cyanidin-3-sambubioside, delphinidin-3-sambubioside, and the phenolics gallic acid, 3-O-methyl gallic acid (3OMGA), 4-O-methyl gallic acid (4OMGA), and hippuric acid. Maximum levels were obtained about 1.5 hours after ingestion (54990, 101732).\nExcretion\nIn healthy individuals, Hibiscus sabdariffa resulted in urinary excretion of cyanidin-3-sambubioside, delphinidin-3-sambubioside, and total anthocyanins with maximum excretion occurring 1.5-2 hours after ingestion (54990).",
            "Mechanism of Action": "General\nThe applicable part of Hibiscus sabdariffa is the flower, calyx or sepal, leaves, stems, and seeds (93805, 93806, 93808, 101732). Sepal extracts contain significant amounts of vitamin C, anthocyanins, and polyphenols. The sepal also contains the highest concentration of water-soluble antioxidants (15375). The seed and leaf of Hibiscus sabdariffa contain significant amounts of vitamin E; the stem and sepal contain smaller amounts (15375). The Hibiscus sabdariffa seeds contain the highest concentration of lipid soluble antioxidants (15375). The Hibiscus sabdariffa flower is rich in anthocyanins, organic acids, and flavonoids (54999, 55001, 93807, 93808, 93809, 93816). Examples of anthocyanins include delphinidin-3-sambubioside and cyanidin-3-sambubioside (93804). Hibiscus sabdariffa acid and citric acid are examples of organic acids (93809). Hibiscus sabdariffa also contains nutrients such as iron, zinc, vitamin C and B vitamins, and other nutrients. The levels of specific nutrients depend on the part of the plant (93806, 93808).\n\nHibiscus sabdariffa seed contains about 19% oil. The main fatty acids contained in the oil include about 40% linoleic acid, 29% oleic acid, and 20% palmitic acid. The seed oil also contains several sterols including beta-sitosterol, 5-avenasterol, campesterol, and others (15375).\nAnthelmintic effects\nHibiscus sabdariffa extracts seem to have anthelmintic properties (11).\nAnti-diabetic effects\nHibiscus sabdariffa is commonly used to reduce levels of blood glucose. In animal models of diabetes, Hibiscus sabdariffa reduced insulin resistance, the production of glycated end-products, and blood fats. Hibiscus sabdariffa also appears to inhibit the enzymes involved in carbohydrate breakdown (93808). In human research, drinking Hibiscus sabdariffa does not affect post-prandial glucose levels of insulin response (101732).\nAnti-inflammatory effects\nThe anti-inflammatory effects of Hibiscus sabdariffa might play a role in reduction of fever and pain. Hibiscus sabdariffa extract reduces levels of cytokines in animal models. It may also inhibit cyclooxygenase (93807, 93808). In animal and laboratory research, Hibiscus sabdariffa extract inhibited the cellular signaling that promotes inflammation in renal cells (93807). The inhibition of inflammatory processes, including gene expression, and infiltration of cells, has resulted in decreased kidney inflammation in an animal inflammatory model (93807). However, in human research, Hibiscus sabdariffa had no effect on levels of high sensitivity C-reactive protein (hs-CRP) (105307).\nAntimicrobial effects\nHibiscus sabdariffa is commonly used for urinary tract infections. Most research shows that Hibiscus sabdariffa extracts have antibacterial and antifungal activity in vitro (11, 93807, 93808). However, in other research, Hibiscus sabdariffa did not have antibacterial effects against Escherichia coli, Staphylococcus aureus, or Pseudomonas aeruginosa (93806).\nAntioxidant effects\nThe antioxidant effects of Hibiscus sabdariffa extract might play a role in its clinical effects. Hibiscus sabdariffa extracts and major constituents have shown antioxidant effects in human, animal, and in vitro research. The main antioxidants appear to be the anthocyanins and protocatechuic acid (55001, 93808, 93809). The antioxidant effects of Hibiscus sabdariffa appear to play a role in the protection of blood vessels, as well as the kidney and liver (93808, 93812). Also, the antioxidant effects of Hibiscus sabdariffa might play a role in cellular signaling to induce apoptosis and death of cancer cells (93808). Additionally, a crossover clinical study in healthy adults shows that drinking Hibiscus sabdariffa 100 mL twice daily for 6 months improves some oxidative indices (i.e., thiobarbituric acid reactive substance, Trolox equivalent antioxidant capacity) and levels of antioxidant enzymes (i.e., glucose-6 phosphate dehydrogenase, glutathione peroxidase, glutathione reductases, superoxide dismutase) when compared to baseline (112426).\nAntispasmodic effects\nHibiscus sabdariffa extracts seem to have intestinal and uterine muscle antispasmodic activity. Extracts can also relax smooth muscles of blood vessels and the bladder (11, 18, 93808).\nGastrointestinal effects\nIn vitro, Hibiscus sabdariffa increases the intestinal permeability of the hydroxocobalamin form of vitamin B12. Theoretically, Hibiscus sabdariffa might increase the oral bioavailability of vitamin B12 (96271).\nHypotensive effects\nHibiscus sabdariffa extracts has demonstrated hypotensive effects in humans, including those with and without hypertension (16894, 54985, 54995, 102459, 105304, 108869, 112428, 112429). Various mechanisms of action have been proposed to explain the potential hypotensive effects of Hibiscus sabdariffa. In animal research, Hibiscus sabdariffa extract had diuretic effects, increasing both urine production and sodium and chloride excretion, but not potassium excretion (93804). However, studies in animals and humans are mixed with respect to increased diuresis or increased excretion of electrolytes following Hibiscus sabdariffa consumption (93808, 93815). Other potential mechanisms of action include inhibition of angiotensin converting enzymes (ACE) or calcium influx, vasodilation, or histamine or acetylcholine-like mechanisms (93808, 93813, 93815, 101732). Increased flow mediated dilation has occurred in humans within 2 hours of drinking Hibiscus sabdariffa (101732). In humans, Hibiscus sabdariffa extract decreases blood levels of sodium, as well as potassium and chloride. This may also play a role (93815). Various constituents, including some anthocyanins, appear to have ACE inhibitory activity (93808).\nLactation effects\nHibiscus sabdariffa is commonly used to promote lactation. In animal research, Hibiscus sabdariffa extract increased levels of prolactin (93808).\nWeight loss effects\nIn animal research, Hibiscus sabdariffa appears to reduce adipogenesis and fat accumulation, as well as inhibit the breakdown and absorption of starch (93808). A small clinical study in healthy adults shows that drinking a Hibiscus sabdariffa calyces tea 200 mL twice daily for 30 days modestly reduces abdominal circumference, but does not impact most lipid parameters, when compared with baseline (108869). Another small clinical study shows that taking a combination product containing lemon verbena and Hibiscus sabdariffa extracts was associated with an increase in satiety and a reduction in hunger. Additionally, the combination product was associated with preventing an increase in plasma levels of ghrelin, which stimulates hunger, and increasing plasma levels of glucagon-like peptide-1 (GLP-1), which increases satiety. No changes were seen in levels of insulin, C-peptide, or fibroblast growth factor 23 (FGF-23) (97290).\nWound healing effects\nIn animal research, Hibiscus sabdariffa extract in a cream had wound healing effects. The mechanism of action is not clear although it was considered to be possibly related to antioxidant effects and unlikely related to antibacterial mechanisms (93806)."
        }
    },
    "Higenamine": {
        "sections": {
            "Overview": "Higenamine is a beta-agonist alkaloid that naturally occurs in plants such as aconite, asarum, lotus, sacred bamboo, and Lamarck's bedstraw (95550, 102052).",
            "Warnings": "Higenamine can be found in products promoted as pre-workout and weight-loss supplements. In some cases it is listed on the label, and in other cases it is undeclared (95550). The use of higenamine is prohibited in sports; it is included on the World Anti-Doping Agency (WADA) Prohibited List (102053).\n\nThe US Food & Drug Administration (FDA) considers higenamine to be a new dietary ingredient (NDI), which requires an NDI notification. However, the FDA has not received NDI notifications from manufacturers of higenamine-containing products, and it remains unapproved as an NDI (107432).",
            "Safety": "POSSIBLY UNSAFE when used orally or intravenously. While oral and intravenous higenamine have been used with apparent safety in a few small clinical studies (95552, 97577, 107431), thorough evaluations of safety outcomes have not been conducted. Additionally, laboratory research shows that higenamine may have cardiac stimulant effects due to its effect on beta2-adrenoreceptors (95552). Also, higenamine is one of the primary cardioactive constituents in aconite. Ingestion of aconite has been associated with several reports of serious cardiovascular toxicity including palpitations, tachycardia, sustained ventricular tachycardia, ventricular fibrillation, and death (559, 3490, 15499). Theoretically, ingesting purified or extracted higenamine could increase the risk of cardiac toxicity.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and intravenously, higenamine may be unsafe. Research on the use of higenamine alone is limited; however, aconite, a plant that contains higenamine, can cause serious cardiovascular toxicity. It is unclear if higenamine alone might have similar effects.\nMost Common Adverse Effects\nOrally: Headache.\n\nIntravenously: Dizziness and headache.\nSerious Adverse Effects (Rare)\nOrally: Rhabdomyolysis.\n\nIntravenously: Dyspnea and palpitations.\nCardiovascular\nOrally, the safety of higenamine has not been studied in high-quality clinical trials. However, higenamine has been shown to have cardiac stimulant effects due to its effect on beta2-adrenoreceptors. In animal models, it appears to significantly increase heart rate; however, it does not appear to increase blood pressure (18027). Higenamine is one of the primary cardioactive constituents in aconite. Aconite has been associated with several reports of serious cardiovascular toxicity including palpitations, tachycardia, sustained ventricular tachycardia, ventricular fibrillation, and death (559, 3490, 15499). Theoretically, isolated higenamine could also increase the risk of cardiac toxicity.\n\nIntravenously, higenamine may cause palpitations and chest tightness (95552, 97577).\nless\nMusculoskeletal\nOrally, higenamine might cause rhabdomyolysis. In a case report, a 22-year-old active duty male experienced paraspinal rhabdomyolysis after consuming higenamine-containing supplement (JACK3D micro) at 150% the recommended dose and performing heavy exercise shortly after consumption. Renal function returned to normal after a couple of days; however, severe muscle pain improved only after 3 months. Patient had a complete recovery 4 months after the incident (95551).\nless\nNeurologic/CNS\nOrally, higenamine may cause headache (107431).\n\nIntravenously, higenamine may cause dizziness and headache (97577).\nless\nPulmonary/Respiratory\nIntravenously, higenamine may cause dyspnea (97577).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAsthma. Although there has been interest in using oral higenamine for asthma, there is insufficient reliable information about the clinical effects of higenamine for this purpose.\nAthletic performance. It is unclear if oral higenamine is beneficial for improving athletic performance in female athletes.\nA very small clinical study in recreational female athletes shows that taking higenamine 25 mg three times daily for 3 weeks does not improve measures of cardiopulmonary function during exercise when compared with placebo (107431). However, this study may have been underpowered to detect differences between groups.\nless\nCough. Although there has been interest in using oral higenamine for cough, there is insufficient reliable information about the clinical effects of higenamine for this purpose.\nErectile dysfunction (ED). Although there has been interest in using oral higenamine for ED, there is insufficient reliable information about the clinical effects of higenamine for this purpose.\nObesity. Although there has been interest in using oral higenamine for obesity, there is insufficient reliable information about the clinical effects of higenamine for this purpose.\nOsteoarthritis. Although there has been interest in using oral higenamine for osteoarthritis, there is insufficient reliable information about the clinical effects of higenamine for this purpose.\nMore evidence is needed to rate higenamine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\n\nAvoid taking higenamine with caffeine-containing foods or beverages. Theoretically, this might increase the risk of cardiac toxicity (18019, 18021, 18024, 18027).\nStandardization & Formulation\nThere is laboratory evidence indicating that numerous higenamine formulations are labeled inaccurately. One assessment of 24 different commercial products listing higenamine on the label showed that none of the products listed an accurate amount of higenamine. The quantity of higenamine ranged from undetectable amounts to about 62 mg per serving, which was 0% to 200% of what was actually listed on the label (97577).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, higenamine might increase the risk of bleeding or bruising when taken with anticoagulant/antiplatelet drugs.\nAnimal research shows that higenamine inhibits platelet aggregation and reduces the size of thrombus formation (18026).\nless\nCYTOCHROME P450 2D6 (CYP2D6) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, higenamine might increase the levels and clinical effects of drugs metabolized by CYP2D6.\nIn vitro research shows that higenamine inhibits CYP2D6 enzymes (91878). However, this effect has not been reported in humans.\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, higenamine might increase the levels and clinical effects drugs metabolized by CYP3A4.\nIn vitro research shows that higenamine inhibits CYP3A4 enzymes by 21% (91878). However, this effect has not been reported in humans.\nless\nPROPRANOLOL (Inderal)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nINSIGNIFICANT\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, the positive inotropic effects of higenamine might be reduced by propranolol.\nAnimal research shows that higenamine has a positive inotropic effect on the heart, and administering propranolol appears to block this cardiac effect (18021). In animals, propranolol also appears to inhibit corpus cavernosum relaxation induced by higenamine (18029).\nless\nSTIMULANT DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, higenamine might increase the risk of cardiovascular toxicity when taken with stimulant drugs.\nHigenamine has stimulant effects due to agonist activity at beta2-adrenoreceptors. In cardiac muscle, higenamine appears to have a positive inotropic effect and increase heart rate (18019, 18021, 18024, 18027). However, it does not appear to increase blood pressure (18027).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT HERBS AND SUPPLEMENTS\nTheoretically, higenamine might have antiplatelet effects.\nTaking higenamine with other products that increase the risk of bleeding might have additive effects. Animal research shows that higenamine inhibits platelet aggregation and reduces the size of thrombus formation (18026). See products with anticoagulant activity here. See products with antiplatelet activity here.\nless\nHERBS AND SUPPLEMENTS WITH STIMULANT PROPERTIES\nTheoretically, higenamine might have cardiac stimulant effects.\nTaking higenamine with other products that have stimulant properties might have additive effects. In cardiac muscle, higenamine appears to have a positive inotropic effect and increase heart rate (18019, 18021, 18024, 18027). However, it does not appear to increase blood pressure (18027). See products with stimulant activity here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nPERIOPERATIVE\nHigenamine may have stimulant effects due to agonist activity at beta2-adrenoreceptors (95552), which might cause increased heart rate if used perioperatively. Tell patients to discontinue higenamine at least 2 weeks before elective surgical procedures.\nless\nTACHYARRHYTHMIAS\nTheoretically, higenamine might worsen or exacerbate tachyarrhythmias due to agonist activity at beta2-adrenoreceptors. Until more is known, avoid use in patients with tachyarrhythmias. In cardiac muscle, higenamine appears to have a positive inotropic effect and increase heart rate (18019, 18021, 18024, 18027, 95552). However, it does not appear to increase blood pressure (18027).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with higenamine.",
            "Pharmacokinetics": "Absorption\nAnimal research shows that time to peak concentration after oral consumption of higenamine was 10 minutes (95552).\nDistribution\nPharmacokinetic parameters of higenamine have been evaluated following intravenous (IV) administration in healthy Chinese adults. After administering 22.5 mcg/kg IV, peak concentrations ranged from 15-44 ng/mL. The area under the concentration-time curve (AUC) was 5.39 ng h/mL (18030, 95552).\nMetabolism\nHigenamine is partially metabolized into a sulfate conjugate prior to excretion (95550).\nExcretion\nThe estimated clearance of higenamine is 3.8 L/minute (95550, 95552). Pharmacokinetic parameters of higenamine have been evaluated following intravenous administration in healthy Chinese adults. After administering higenamine 22.5 mcg/kg IV, the half-life was about 8 minutes and 94% of higenamine was eliminated 30 minutes after administration. After 8 hours, the recovery of higenamine was 9.3% in the urine, meaning that the majority was likely eliminated by the liver (18030, 95552, 97577).",
            "Mechanism of Action": "General\nHigenamine is a benzyltetrahydroisoquinoline alkaloid. It is a constituent in several plant species including aconite, Annona squamosa, asarum, lotus, and Nandina domestica (sacred bamboo) (95550, 102052). Higenamine hydrochloride, the form of higenamine most often used in supplements, is generally synthetically manufactured rather than extracted from plants (95552).\nAnti-inflammatory effects\nHigenamine is thought to have anti-inflammatory effects. Higenamine appears to affect multiple inflammatory processes. It appears to scavenge free radicals, inhibit lipid peroxidation, and decrease glycosaminoglycan polymerization (18022). Higenamine might also reduce inflammation by inhibiting inducible nitric oxide synthase expression (18025).\nAnticoagulation effects\nHigenamine appears to have antiplatelet and antithrombotic effects. In an animal model of thrombosis, higenamine inhibited platelet aggregation and reduced the size of thrombus formation (18026).\nAntihistamine effects\nHigenamine is thought to have antihistamine effects. In an animal model, higenamine decreases swelling induced by histamine (18022). Additionally, in animal models, higenamine relaxes histamine-contracted tracheal and bronchial smooth muscle (18017, 18022, 18028).\nCardiovascular effects\nHigenamine appears to have cardiostimulant effects through agonistic activity at the beta2-adrenoreceptor (18017, 18022, 18028, 95552). It has been identified as the cardioactive constituent of aconite roots and Annona squamosa (18018, 18019, 18024). In the cardiac muscle, aconite appears to activate sodium channels leading to tachyarrhythmias (2634, 15499).\n\nIn humans and in animal tissue models, intravenous higenamine appears to have positive chronotropic and inotropic effects (18019, 18021, 18024, 18027, 95552). In animal and human models of bradycardia, higenamine increases heart rate (18020, 95552). One animal tissue study shows that higenamine increases heart rate through action on the sinoatrial node (102051). In animal models of heart failure, higenamine was also found to increase force of cardiac contraction (18024). Higenamine does not appear to significantly increase blood pressure in animal models, and in some cases, it has induced premature ventricular beats (18027).\nSexual enhancement effects\nThere is interest in using higenamine for erectile dysfunction. Due to its beta-adrenergic effects, higenamine appears to cause relaxation of animal model corpus cavernosum (18029)."
        }
    },
    "Histidine": {
        "sections": {
            "Overview": "Histidine is an essential amino acid that occurs naturally in the diet (96311, 96312).",
            "Safety": "LIKELY SAFE when used orally in the amounts found in foods.\nPOSSIBLY SAFE when used orally in larger amounts, short-term. L-histidine has been used with apparent safety in doses of up to 4 grams daily for up to 12 weeks (2347, 2353, 96311, 108621), or in doses of up to 8 grams daily for up to 4 weeks (108620).\nPREGNANCY AND LACTATION: LIKELY SAFE when used orally in the amounts found in foods. There is insufficient reliable information available about the safety of histidine when used in larger amounts during pregnancy or lactation.",
            "Adverse Effects": "General\nOrally, histidine has been used with apparent safety in clinical research; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nCholera. Oral L-histidine seems to reduce diarrhea in adults with cholera.\nA clinical study in adults with severe cholera receiving ciprofloxacin shows that drinking a rice-based oral rehydration solution (CeraLyte-90, CERA products) supplemented with L-histidine (Ajinomoto Chemical) 2.5 grams per liter as needed for 72 hours decreases the frequency of stool output at 32 hours, the weight of stool at 72 hours, the amount of intravenous fluid needed during the first 48 hours, and the duration of diarrhea by roughly 5 hours when compared with drinking the oral rehydration solution alone (96312).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAtopic dermatitis (eczema). It is unclear if oral L-histidine is beneficial in adults and children with atopic dermatitis.\nA small clinical crossover study in adults with atopic dermatitis shows that taking L-histidine 4 grams daily for 8 weeks improves clinician-reported disease severity scores by 32% to 34% when compared with baseline (108621). The lack of washout period prior to crossover and its subsequent carryover effect prevents useful statistical comparison to placebo, limiting the validity of these findings. A small clinical study in children aged 1-7 years with mild to moderate atopic dermatitis shows that taking L-histidine 0.8 grams daily for 12 weeks improves disease severity by 49% when compared with baseline (108652). The lack of statistical comparison to the placebo group limits the validity of these findings.\nless\nKidney failure. It is unclear if oral L-histidine is beneficial for anemia in patients with kidney failure.\nA small clinical study in patients with chronic uremia and patients undergoing maintenance hemodialysis shows that taking L-histidine 4 grams daily does not improve anemia when compared with placebo (2352).\nless\nMetabolic syndrome. It is unclear if oral histidine is beneficial in patients with metabolic syndrome.\nA clinical study in females with obesity and metabolic syndrome shows that taking histidine 2 grams twice daily is associated with reduced insulin resistance, body mass index, waist circumference, and fat mass at 12 weeks when compared with placebo. It is unclear if the improvement from baseline differed between groups. Other lipid parameters were not affected (96311).\nless\nRheumatoid arthritis (RA). It is unclear if oral L-histidine is beneficial in patients with RA.\nA small clinical study in patients with RA shows that taking L-histidine 4.5 grams daily for 30 weeks does not improve clinical measurements when compared with placebo (2350).\nless\nMore evidence is needed to rate histidine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nL-histidine has most often been used in doses of 4 grams daily. See Effectiveness section for condition-specific information.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of histidine. However, L-histidine is the isomer most commonly evaluated in clinical research (2347, 2353, 96311, 108621).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "FOLIC ACID DEFICIENCY\nUse of histidine in individuals with folic acid deficiency can cause accumulation of the metabolite formiminoglutamic acid (FIGLU) (2355). Avoid use in patients with folic acid deficiency.\nless",
            "Interactions with Lab Tests": "None know.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with histidine.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of histidine.",
            "Mechanism of Action": "General\nHistidine is an essential amino acid involved in a wide range of metabolic processes (2354).\nAnti-inflammatory effects\nIn SW872 adipocytes with palmitic acid induced insulin resistance and inflammation, treatment with histidine dose-dependently decreased the mRNA expression of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), as well as the protein expression of nuclear factor kappa-beta. This suggests that histidine reduces the expression of cytokines via effects on the nuclear factor kappa-beta pathway in adipocytes (96311). In obese females with metabolic syndrome, supplementation with histidine for 12 weeks increased levels of adiponectin and decreased levels of non-essential fatty acids and inflammatory markers such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) when compared with placebo. However, treatment did not affect levels of C-reactive protein (96311).\nAntibiotic effects\nIn cholera infection, mucosal secretion of water and electrolytes occur. This is due to cholera toxin stimulating levels of adenylate cyclase, cAMP, and prostaglandins. In animals, histidine decreases secretory responses through inhibition of intestinal adenylate cyclase. By reacting with prostaglandins, adenylate cyclase can be inhibited, leading to a block of cAMP formation, theoretically decreasing secretion of fluids (96312).\nAntioxidant effects\nHistidine can scavenge free radicals and chelate metal ions. In obese females with metabolic syndrome, supplementation with histidine for 12 weeks increased levels of antioxidants such as superoxide dismutase and glutathione peroxidase when compared with placebo. However, treatment did not affect levels of malondialdehyde (96311)."
        }
    },
    "Holly": {
        "sections": {
            "Overview": "Holly is a flowering evergreen tree or shrub from the genus Ilex which grows in temperate and subtropical climates and can reach up to 7 meters in height (107872). Many Ilex species are referred to as holly. English holly (Ilex aquifolium) and American holly (Ilex opaca) are used as ornamental Christmas holly (6). Yaupon (Ilex vomitoria), Appalachian tea (Ilex glabra), and cassena (Ilex cassine) may also be included in discussions of holly (6).",
            "Safety": "UNSAFE when the berries are ingested. Eating berries can be fatal (18).\nThere is insufficient reliable information available about the safety of holly leaves.\nCHILDREN: UNSAFE when the berries are ingested. Eating berries can be fatal (6).\nPREGNANCY AND LACTATION: UNSAFE when berries are ingested (6). There is insufficient reliable information available about the safety of holly leaves; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, ingestion of holly leaf can cause GI irritation, diarrhea, nausea, and vomiting (6, 18). Holly leaf spines may tear or puncture skin or mucous membranes (6). Ingestion of as few as 2 holly berries can cause vomiting and diarrhea in small children (6). Ingestion of more than 5 holly berries can cause nausea, vomiting, and diarrhea (6, 18). Ingestion of 20-30 holly berries can cause death (18).\nGastrointestinal\nOrally, ingestion of holly leaf can cause GI irritation, diarrhea, nausea, and vomiting (6, 18). Holly leaf spines may tear or puncture skin or mucous membranes (6). Ingestion of as few as 2 holly berries can cause vomiting and diarrhea in small children (6). Ingestion of more than 5 holly berries can cause nausea, vomiting, and diarrhea (6, 18).\nless\nNeurologic/CNS\nOrally, ingestion of more than 5 holly berries can cause stupor (6, 18).\nless\nOther\nOrally, ingestion of 20-30 holly berries can cause death (18).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of holly.",
            "Dosing & Administration": "Adult\nOral:\nGeneral: People typically use 3.9 grams of powdered leaves in a tea, taken to reduce the effects of intermittent fevers (5254).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of holly.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nDEHYDRATION\nIn addition to toxic effects, berry ingestion may cause or exacerbate dehydration by inducing vomiting and diarrhea (6).\nless\nELECTROLYTE IMBALANCE\nBerry ingestion may cause or exacerbate electrolyte imbalance by inducing vomiting and diarrhea (6).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation and treatment of overdose with holly.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of holly.",
            "Mechanism of Action": "General\nThe applicable parts of holly are the leaf and berry. Constituents of holly include saponins and a cyanogenic glycoside (4, 6). An aqueous extract of the leaves contains terpenoids, including amyrin, lupeol, ursolic acid, and ursolic aldehyde; sugars including sucrose, maltose, and cellobiose; and phenolic acids including caffeic acid, malic acid, quinic acid, and ferulic acid.\nGastrointestinal effects\nSaponin constituents of holly are thought to cause GI irritation and emetic effects (6).\nHypocholesterolemic effects\nIn rats fed a high-cholesterol diet, giving holly (specifically Ilex aquifolium) leaf extract attenuates increases in total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and weight when compared with the high-cholesterol diet alone. It also reduces oxidative lipid degradation and hepatic steatosis (107872)."
        }
    },
    "Hollyhock": {
        "sections": {
            "Overview": "Hollyhock is a plant that grows in temperate and tropical climates throughout the world. It is typically found growing on river banks and in salt marshes (100719).",
            "Safety": "There is insufficient reliable information available about the safety of hollyhock.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of hollyhock.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hollyhock.",
            "Interactions with Drugs": "ANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nAnimal and in vitro research shows that hollyhock flower extracts might lower blood glucose levels (100719). While the effect of hollyhock in patients with diabetes has not been studied, theoretically, hollyhock might decrease blood glucose and have additive effects in patients treated with antidiabetes drugs. Dose adjustments to diabetes medications may be necessarily. Some antidiabetes drugs include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, metformin (Glucophage), pioglitazone (Actos), rosiglitazone (Avandia), and others.",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nAnimal and in vitro research suggests that hollyhock flower extracts might lower blood glucose levels (100719). Theoretically, hollyhock may have additive effects when used with other herbs and supplements that also lower glucose levels. This might increase the risk of hypoglycemia in some patients. Some herbs and supplements with hypoglycemic effects include alpha-lipoic acid, bitter melon, chromium, devil's claw, fenugreek, garlic, guar gum, horse chestnut, Panax ginseng, psyllium, Siberian ginseng, and others.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nDIABETES\nAnimal and in vitro research suggests that hollyhock flower extracts might lower blood glucose levels (100719). Theoretically, hollyhock might decrease blood glucose and increase the risk for hypoglycemia in patients with diabetes. Tell patients with diabetes to use hollyhock cautiously and monitor blood glucose levels closely. Dose adjustments to diabetes medications might be necessary.\nless\nSURGERY\nAnimal and in vitro research suggests that hollyhock flower extracts might lower blood glucose levels (100719). Theoretically, hollyhock might interfere with blood glucose control during and after surgical procedures. Tell patients to discontinue hollyhock at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of hollyhock.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of hollyhock.",
            "Mechanism of Action": "General\nThe applicable parts of hollyhock are the seed, root, stem, leaf, and flower. Polysaccharide constituents are found in hollyhock seeds. The stems and leaves contain gibberellin glucosides and polysaccharides (100719). Hollyhock flowers contain phenolic acids and flavonoids. Specific flavonoids found in ethanolic extracts of hollyhock flowers include apigenin, astragalin, dihydrokaempferol, dihydrokaempferol glucosides, kaemperfol-3-O-rutinoside, taxifolin glucosides, and trans-tiliroside (100718, 100719).\nAnticancer effects\nIn vitro research shows that trans-tiliroside, a constituent extracted from hollyhock flower extract, has cytotoxic activity against hepatocellular carcinoma cells (100718). The mechanism of this effect is unknown.\nAntidiabetic effects\nIn a mouse model of diabetes, oral administration of hollyhock flower ethanolic extract 200-400 mg/kg for 8 weeks appears to attenuate the rise of serum glucose levels when compared with placebo. Increased expression of protein kinase B, phosphoinositide 3-kinase, insulin receptor substrate 2, and glucose transporter type 4 genes was reported in these mice, and in vitro research shows that the constituents dihydrokaempferol glucoside and taxifolin glucoside enhance the uptake of glucose in liver cells. These results suggest that the antidiabetic effects of hollyhock are due to modulation of signaling pathways involving glucose metabolism, transport, and uptake (100719).\nAntioxidant effects\nIn vitro research shows that the hollyhock flower constituents dihydrokaempferol and dihydrokaempferol glucoside have antioxidant effects, as assessed via the Trolox equivalent antioxidant capacity (TEAC) assay (100718)."
        }
    },
    "Holy Basil": {
        "sections": {
            "Overview": "Holy basil is an aromatic, perennial shrub (6). It is native to India, and is also found in Australia, West Africa, and some Middle Eastern countries. It is used in Ayurvedic medicine (55036, 91562, 91563) and is considered a sacred plant in Hinduism (91562). The Hindu name for holy basil, Tulsi, means \"the incomparable one\" (91564). Holy basil is sometimes called \"hot basil\" because of its peppery taste. It's often added to Southeast Asian dishes (91565).",
            "Safety": "POSSIBLY SAFE when used orally, short-term. Holy basil leaf extract has been used with apparent safety at a dose of 500 mg daily for 60-90 days (12242, 18107, 19575, 91571, 96944). ...when used topically in the mouth, short-term. Holy basil has been used with apparent safety as a 4% mouthwash solution for up to 30 days (91570, 103621).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used in high doses during pregnancy or when trying to conceive. Animal research suggests that relatively high doses of holy basil extract (200 mg/kg) may reduce implantation rate when used for one week, while long-term use of higher doses (2-4 grams/kg) may decrease the number of full-term pregnancies (55040, 91569). There is insufficient reliable information available regarding the safety of holy basil during lactation; avoid using.",
            "Adverse Effects": "General\nOrally and topically, holy basil extract seems to be well tolerated.\nMost Common Adverse Effects\nOrally: Loose stools and nausea.\n\nTopically: Bitter taste with oral application.\nGastrointestinal\nOrally, two out of 24 participants taking capsules containing holy basil extract in one clinical study experienced nausea or loose stools (55037).\n\nTopically, holy basil mouthwash has been reported to cause a bitter taste in clinical trials (55038).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAging. Although there has been interest in using oral holy basil for aging, there is insufficient reliable information about the clinical effects of holy basil for this purpose.\nAsthma. Although there has been interest in using oral holy basil for asthma, there is insufficient reliable information about the clinical effects of holy basil for this condition.\nDental plaque. Small clinical studies suggest that topical use of holy basil mouthwash, gel, or toothpaste may modestly reduce the severity of dental plaque.\nSmall clinical studies in patients with mild to moderate dental plaque or gingivitis shows that using 10 mL of a mouthwash containing holy basil leaf extract 4% twice daily for 30 days reduces plaque severity by about 17% to 28% when compared with baseline (91570, 103621). In one study, this effect was significant when compared with a placebo mouthwash and similar to a mouthwash containing chlorhexidine 0.12% (91570), whereas the other study did not conduct comparisons between study groups (103621). A small clinical study in patients with chronic gingivitis shows that applying holy basil extract 2% gel as a gingival massage twice daily for 30 days reduces plaque severity when compared with baseline (110030). The validity of this finding is limited by the lack of statistical comparison to the other study groups. Also, a small clinical trial in children 14-15 years of age shows that brushing with toothpaste containing holy basil leaf extract 4% twice daily for 3 weeks reduces plaque severity when compared with placebo, with similar improvements when compared with a fluorinated toothpaste (104183).\n\nHoly basil has also been evaluated in combination with other ingredients. A small study shows that rinsing with 10 mL of a solution containing tea tree oil, clove, and holy basil (0.2% to 0.3% of each), for 30 seconds twice daily for 21 days, reduces plaque formation by 64%. This reduction is similar to a 72% reduction seen in the active control group using a mouth rinse containing thymol, eucalyptol, menthol, and methyl salicylate (91446).\nless\nDiabetes. Small clinical studies suggest that oral holy basil may modestly improve glycemic control in patients with diabetes.\nOne small clinical trial in adults with type 2 diabetes shows that taking holy basil dried leaf powder 2.5 grams daily for 4 weeks decreases fasting and postprandial blood glucose by 18%, compared with a 7% reduction in those taking placebo (12242). Another small clinical study in patients with type 2 diabetes shows that taking holy basil 250 mg twice daily in combination with glyburide 5 mg daily for 3 months reduces fasting blood glucose by 16%, postprandial blood glucose by 13%, and glycated hemoglobin (HbA1c) levels by 18% when compared with glyburide alone (91571).\nless\nDyspepsia. Although there has been interest in using oral holy basil for dyspepsia, there is insufficient reliable information about the clinical effects of holy basil for this purpose.\nGeneralized anxiety disorder (GAD). It is unclear if oral holy basil is beneficial in patients with GAD.\nOne small, uncontrolled clinical study in patients with GAD shows that taking holy basil leaf extract 500 mg twice daily following meals for 60 days reduces anxiety and associated symptoms of stress and depression when compared to baseline (19575). The validity of these findings is limited by a lack of control group.\nless\nGingivitis. Small clinical studies suggest that topical use of holy basil mouthwash or toothpaste may modestly improve gingivitis.\nSmall clinical studies in patients with mild to moderate dental plaque or gingivitis shows that using 10 mL of a mouthwash containing holy basil leaf extract 4% twice daily for 30 days reduces gingivitis by about 23% to 40% when compared with baseline (91570, 103621). In one study, these effects were significant when compared with placebo mouthwash and similar to those of a mouthwash containing chlorhexidine 0.12% (91570), whereas the other study did not conduct statistical comparisons between study groups (103621). A small clinical trial in children 14-15 years of age shows that brushing with toothpaste containing holy basil leaf extract 4% twice daily for 3 weeks reduces the severity of gingivitis when compared with placebo, with similar improvements when compared with a fluorinated toothpaste (104183). However, a small clinical study in patients with chronic gingivitis shows that applying holy basil leaf extract 2% gel as a gingival massage twice daily for 30 days does not reduce gingivitis severity when compared with baseline (110030).\n\nHoly basil has also been evaluated in combination with other ingredients. A small clinical study shows that rinsing with 10 mL of a solution containing tea tree oil, clove, and holy basil (0.2% to 0.3% of each), for 30 seconds twice daily for 21 days, reduces gum inflammation by 76%. This reduction is similar to a 70% reduction seen in the active control group using a mouth rinse containing thymol, eucalyptol, menthol, and methyl salicylate (91446).\nless\nHeadache. Although there has been interest in using oral holy basil for headache, there is insufficient reliable information about the clinical effects of holy basil for this purpose.\nHepatitis. Although there has been interest in using oral holy basil for hepatitis, there is insufficient reliable information about the clinical effects of holy basil for this condition.\nHypercholesterolemia. Although there has been interest in using oral holy basil for hypercholesterolemia, there is insufficient reliable information about the clinical effects of holy basil for this purpose.\nHypertension. Although there has been interest in using oral holy basil for hypertension, there is insufficient reliable information about the clinical effects of holy basil for this purpose.\nInsect repellent. Although there has been interest in using topical holy basil as an insect repellent, there is insufficient reliable information about the clinical effects of holy basil for this purpose.\nInsomnia. It is unclear if oral holy basil is beneficial for sleep problems.\nA moderate-sized clinical study in adults with stress and sleep problems (i.e., unrefreshing sleep or difficulty falling or staying asleep) shows that taking holy basil 125 mg twice daily for 8 weeks does not improve patient-reported or wearable tracker scores related to sleep when compared with placebo (112416). However, the interpretation of these results is limited by self-reported outcomes and use of a non-validated measurement tool for sleep (i.e., Fitbit device).\nless\nObesity. It is unclear if oral holy basil is beneficial in overweight or obese patients.\nOne small clinical study in individuals with overweight or obesity shows that taking holy basil extract 250 mg twice daily for 8 weeks slightly reduces body weight and improves levels of triglycerides or low-density lipoprotein (LDL) cholesterol and certain glycemic indices when compared to baseline, but not when compared with no treatment. Holy basil extract also did not improve liver enzymes when compared to baseline or with no treatment (96944).\nless\nOral submucous fibrosis. It is unclear if topical holy basil paste is beneficial for oral submucous fibrosis.\nA moderate-sized clinical study in adults with oral submucous fibrosis conducted in India shows that applying a paste containing holy basil extract 250 mg intraorally twice daily for 1 month modestly improves mouth opening scores and patient-reported burning sensation at the 3 month follow up when compared to baseline (112424). However, the validity of these findings is limited by poor methodology and lack of a comparator group.\nless\nRespiratory tract infections. Although there has been interest in using oral holy basil for respiratory tract infections, including bronchitis, common cold, influenza, and tuberculosis, there is insufficient reliable information about the clinical effects of holy basil for these conditions.\nStress. It is unclear if oral holy basil is beneficial in patients with stress.\nOne small clinical trial in patients experiencing various symptoms of stress shows that taking a specific holy basil extract (OciBest, Natural Remedies Pvt. Ltd.) 400 mg in the morning and 800 mg at night for 6 weeks decreases self-reported symptoms of stress, including forgetfulness, sexual problems and sleep problems of recent origin, and frequency of exhaustion, when compared with placebo (18107). A moderate-sized clinical study in adults with stress and sleep problems shows that taking holy basil 125 mg twice daily for 8 weeks modestly improves stress scores but does not improve individual symptoms related to stress including anxiety, mood disturbance, physical function, depression, fatigue, or sleep disturbance when compared with placebo (112416). However, the interpretation of these findings is limited by self-reported outcome measures and unclear clinical significance.\nless\nTinea corporis. Although there has been interest in using topical holy basil for tinea corporis, there is insufficient reliable information about the clinical effects of holy basil for this purpose.\nMore evidence is needed to rate holy basil for these uses.",
            "Dosing & Administration": "Adult\nOral:\nHoly basil leaf extract has most often been used as 500 mg daily, taken in divided doses, for 1.5-3 months. See Effectiveness section for condition-specific information.\nTopical:\nHoly basil leaf extract 4% has been used as a mouthwash at a dose of 10 mL twice daily for 30 days. See Effectiveness section for condition-specific information.\nChildren\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nChemical constituents of holy basil reportedly vary with time, cultivation process, and storage. Eugenol and ursolic acid are two main active constituents to which holy basil has been standardized in clinical and laboratory research (91567).\n\nA specific product containing holy basil whole plant extract (OciBest, Natural Remedies Pvt. Ltd.) 400 mg has been standardized to contain >0.1% w/w ociglycoside-I, >0.2% w/w rosmarinic acid, and >2.5% w/w triterpene acids (oleanolic acid and ursolic acid) (18107).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, holy basil seed oil might increase the risk of bleeding when used with anticoagulant or antiplatelet drugs.\nAnimal research shows that holy basil seed oil can prolong bleeding time, possibly due to inhibition of platelet aggregation (13251). However, it is not known if this occurs in humans.\nless\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, holy basil might increase the risk of hypoglycemia when taken with antidiabetes drugs.\nSmall clinical studies show that taking holy basil can decrease fasting blood glucose and other measures of glycemic control in patients with type 2 diabetes (12242, 91571).\nless\nPENTOBARBITAL (Nembutal)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, holy basil seed oil might increase the sedative effects of pentobarbital.\nAnimal research shows that holy basil seed oil increases pentobarbitone-induced sleeping time (13056, 13251). However, it is not known if this occurs in humans or if this applies to other barbiturates or sedatives.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, holy basil might have antiplatelet effects.\nTaking holy basil with other products that increase the risk of bleeding might have additive effects. Animal research shows that holy basil seed oil can prolong bleeding time, possibly due to inhibition of platelet aggregation (13251). See products with anticoagulant activity here. See products with antiplatelet activity here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, holy basil might have hypoglycemic effects.\nTaking holy basil with other products with hypoglycemic potential might increase the risk of hypoglycemia. Small clinical studies show that holy basil may lower blood glucose levels (12242, 91571). See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nHYPOTHYROIDISM\nTheoretically, holy basil might lower thyroid hormone levels; until more is known, use with caution in patients with hypothyroidism. Animal research shows that holy basil may lower thyroxine (T4) levels (55057).\nless\nPERIOPERATIVE\nHoly basil has antiplatelet (13251) and hypotensive (13251) effects, which might cause excessive bleeding and interfere with blood pressure control if used perioperatively. Tell patients to discontinue holy basil at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with holy basil.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of holy basil.",
            "Mechanism of Action": "General\nThe applicable parts of holy basil are the leaf, stem, seed, and oil. Active constituents of the leaves and stems include saponins, flavonoids, triterpenoids, and tannins (12236). Some of these specific constituents include the flavonoids cirsilineol, cirsimaritin, isothymusin, apigenin, orientin, and vicenin; the polyphenols rosmarinic acid and isothymonin; and the triterpenoid ursoloic acid (15004, 55011, 55035, 55048). The leaves also contain an essential oil which contains eugenol, methyl eugenol, and caryophyllene (12239, 12242, 15004). Polysaccharides have also been found (55031). The seed oil of holy basil contains linoleic acid (52%), linolenic acid (17%), oleic acid (14%), palmitic acid (12%), and stearic acid (3%) (55030, 55054).\nAnalgesic effects\nHoly basil leaf extract seems to have analgesic activity in animal models (12246, 12248). It is thought to have both central and peripheral analgesic activity. The eugenol constituent is thought to be partially responsible for the analgesic activity (12248).\nAnthelmintic effects\nHoly basil leaf essential oil seems to have anthelmintic activity in vitro. This effect is thought to be due to the eugenol constituent (13252).\nAnti-inflammatory properties\nThere is preliminary evidence that the leaf extract and the seed oil of holy basil might reduce the inflammatory response in animals (12239, 12246, 55049, 55054). The linolenic acid component of the oil is thought to be responsible for the anti-inflammatory effect. It is thought to inhibit the cyclooxygenase (COX) and lipoxygenase pathways of arachidonic acid metabolism (12240, 12241, 55049). Constituents of the leaves and stems of holy basil including eugenol, cirsilineol, cirsimaritin, isothymusin, apigenin, rosmarinic acid, and isothymonin also appear to inhibit COX. Of these, eugenol appears to produce the strongest inhibition (15004). This is thought to contribute to the antipyretic effects of holy basil leaf and root extract demonstrated in animal models (12246, 12248, 91568).\nAnti-stress effects\nHoly basil is considered an anti-stress or adaptogenic remedy in Ayurvedic medicine. In clinical research, taking holy basil whole plant extract or leaf extract improves symptoms of stress and/or generalized anxiety disorder (18107, 19575, 112416).\n\nResearch in stress-induced rats suggests that holy basil fresh leaf juice may reduce anxiety-like behaviors and negative neuronal changes in the substantia nigra (112419). Another rat study attributes the anti-stress activity of holy basil to its ability to lower stress-induced increases in cholesterol, lactate dehydrogenase, and alkaline phosphatase (55016). Also, various animal models suggest that holy basil leaf extract can attenuate several measures of noise-induced stress response, including changes in plasma corticosterone levels and neurotransmitter levels in the brain (55009, 55015, 55024, 55028, 55032, 55051).\nAnti-toxin effects\nThere is preliminary evidence that an aqueous extract of holy basil leaves decreases some measures of mercury toxicity in animal models (12238).\nAnticancer effects\nThere is interest in using holy basil seed oil for cancer. Topically, holy basil fresh leaf paste or extract, applied to the buccal pouch mucosa of animals, has been shown to decrease the incidence of papillomas and squamous cell carcinomas, and increase survival rate in animal tumor models (55005). Orally, holy basil leaves have been shown to decrease the incidence of chemically-induced neoplasia, papillomas, and hepatomas in animal models (46863, 55043). Increased activity of enzymes known to detoxify carcinogens, including cytochrome P450, cytochrome b5, aryl hydrocarbon hydroxylase, and glutathione S-transferase, has been observed in animal models following oral treatment with holy basil leaf extract (55047). Also, preliminary evidence suggests that the oil can delay progression and improve survival rate in animals with experimentally induced fibrosarcoma. This effect has been attributed to antioxidant effects of the oil (13253).\nAntilipidemic properties\nHoly basil leaf appears to lower levels of total cholesterol and triglycerides in the blood, liver, heart, and kidneys in animal models (55044, 55052). Also, taking 2.5 grams of holy basil leaf powder daily for 4 weeks reduces total cholesterol levels in patients with type 2 diabetes (12242). The exact mechanism of action is unclear.\nAntimicrobial effects\nHoly basil extracts inhibit various bacterial pathogens in vitro, including Klebsiella species, Escherichia coli, Proteus species, Staphylococcus aureus, Vibrio cholera, Neisseria gonorrhoeae, and Salmonella typhi (40970, 55013, 55025). Holy basil oil inhibits Staphylococcus aureus and Pseudomonas aeruginosa in vitro (55030). The antibacterial activity of holy basil oil has been attributed to its constituent linolenic acid (55030). In vitro, holy basil extract inhibits Candida albicans (55013).\nAntioxidant effects\nConstituents of holy basil, including eugenol, have shown antioxidant activity in vitro (15004, 44398). Also, evidence from animal research shows that holy basil leaf extracts and holy basil polysaccharides can reduce lipid peroxidation induced by hypercholesterolemia, myocardial infarction, or cerebral reperfusion injury (55012, 55020, 55021, 55031).\nCardiovascular effects\nIn an animal model, holy basil seed oil prolongs bleeding time, possibly due to inhibition of platelet aggregation. Linolenic acid contained in the seed oil can be converted to eicosapentaenoic acid (EPA). EPA can inhibit thromboxane A2 (TXA2), which results in decreased platelet aggregation (13251). The seed oil of holy basil also seems to have a hypotensive effect, possibly due to a vasodilatory effect, in animal models (13251).\nDental effects\nThere is interest in using Holy basil for dental purposes, such as reducing plaque and gingivitis. Proposed mechanisms include possible activity against Streptococcus mutans, which has been demonstrated in vitro, or an increase in salivary pH (110031). Further research is needed to validate any mechanisms for this indication.\nEndocrine effects\nHoly basil has demonstrated activity on glycemic control, thyroid function, and androgen production. In animal models and in humans, there is preliminary evidence that holy basil leaf extract has hypoglycemic activity (12242, 12249, 12250, 49632, 55006, 55023, 55045, 55052). It is hypothesized the holy basil reduces blood glucose by improving beta-cell function and enhancing insulin secretion (12242). Other evidence from animal research suggests that the hypoglycemic activity of holy basil may result from its ability to correct reduced activity of enzymes involved in carbohydrate metabolism, including glucokinase, hexokinase, and phosphofructokinase (55017).\n\nA relatively high dose of holy basil leaf extract (500 mg/kg) has been shown to decrease serum thyroxine (T4) concentrations in an animal model. Serum levels of triiodothyronine (T3) or the T3/T4 ratio were unaffected (55057). Also, animal research suggests that holy basil leaves decrease sperm count, sperm motility, and possibly fertility and reproductive behavior. Sperm parameters return to normal 2 weeks after discontinuing treatment (12243, 12244, 55014, 55018).\nGastrointestinal effects\nHoly basil seed oil and holy basil extract seem to have protective effects against aspirin, indomethacin, alcohol, and stress-induced ulceration in animals. It is thought that the oil or extracts might protect against gastric ulceration by reducing gastric acid secretion, increasing mucin secretion, inhibiting lipoxygenase, and having an antihistaminic effect (13254, 55019, 55029, 55046).\nImmunomodulating effects\nSeed oil from holy basil seems to have immunomodulatory effects. There is preliminary evidence that the oil can decrease the humoral and cell-mediated immune response to stress in animal models (12247). Also, in humans, holy basil extract increases levels of interferon (IFN)-gamma, interleukin (IL)-4, and the percentages of T-helper cells and natural killer cells (55037).\nNeurologic/CNS effects\nHoly basil has a variety of central nervous system effects. It reduces the duration of convulsions in animals subjected to electroshock- or pharmacologically-induced seizures. In animal models, holy basil leaf or stem extracts in doses of 400-1000 mg/kg have anticonvulsant effects comparable to phenytoin (12236, 96945). Although holy basil extract does not have additive effects with valproate in an animal model, the combination resulted in improved neurobehavioral outcomes, such as memory (96945).\n\nHoly basil also has some stimulatory effects in animal models. It also has additive activity with bromocriptine, suggesting that it has dompamine-2 receptor agonist activity (13056). Conversely, holy basil seed oil has been shown to prolong pentobarbitone-induced sleeping time in animals. However, this may be due to inhibition of the metabolism of pentobarbitone by cytochrome P450, as opposed to an additive sedative effect (13251).\nRadioprotective effects\nVarious animal models have shown that holy basil leaf extract protects against radiation injury and increases survival following exposure to gamma radiation. The radioprotective effect has been attributed to the free radical scavenging activity of the flavonoid constituents orientin and vicenin (55007, 55008, 55050, 55053, 55055, 55058, 55059). An aqueous extract appears to be more effective and less toxic than an aqueous ethanol extract, and intraperitoneal administration appears to be more effective than intramuscular, intravenous, or oral administration (55042).\nWound healing properties\nHoly basil leaf extract has been shown to increase wound healing in an animal model by increasing the rate of epithelization and wound contraction (55033)."
        }
    },
    "Homotaurine": {
        "sections": {
            "Overview": "Homotaurine is an amino acid that is not involved in protein synthesis, but is an analog of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It is found naturally in some types of algae (101093, 101094, 112072). Although homotaurine was under development as a prescription drug for Alzheimer disease, the FDA determined in 2007 that the results of a North American phase 3 trial did not demonstrate efficacy. The manufacturer then terminated a European trial in progress and decided to market homotaurine as a nutritional supplement (17067). The Alzheimer Association issued a statement stating that they do not support use of homotaurine, and that marketing it is not in the best interests of patients with Alzheimer disease, their families, or the general public (17068).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. Homotaurine has been used with apparent safety in doses of up to 150 mg twice daily for up to 36 months (17062, 17063, 17064, 17065, 101097, 101099, 101100, 104786).\nThere is insufficient reliable information available about the safety of homotaurine when used topically.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, homotaurine seems to be generally well tolerated. The most frequent side effects reported in clinical trials are nausea, vomiting, diarrhea, dizziness, headache, and sleep disorders (17063, 17064, 17065, 101097, 101099, 104786).\nGastrointestinal\nOrally, some of the most frequent side effects of homotaurine are nausea, vomiting, and diarrhea (17063, 17064, 17065, 101097, 101099, 104786). Nausea and vomiting are dose-dependent and the incidence ranges from 5% to 30% with doses of 50-150 mg twice daily (17064). However, in some large studies, nausea and vomiting occurred at a similar rate in the placebo group (101097).\nless\nNeurologic/CNS\nOrally, some of the most frequent side effects of homotaurine are dizziness, headache, and sleep disorders (17063, 17064, 17065, 104786).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAlzheimer disease. The majority of research in individuals with Alzheimer disease shows that homotaurine does not improve cognitive function. However, homotaurine might have benefit in specific individuals with mild symptoms, especially those with homozygous APOE4/4 (17062, 17064, 17065, 17066, 17067, 101097, 101100, 101101).\nPreliminary clinical research in 58 patients over age 50 with mild to moderate Alzheimer disease has compared homotaurine 50 mg, 100 mg, or 150 mg twice daily to placebo. After 3 months, there were dose-dependent reductions in cerebrospinal fluid (CSF) levels of amyloid-beta (Abeta)42, especially in patients with mild symptoms, but no change in cognitive or clinical measures of the disease (17062, 17064, 17065). Also, clinical research shows that taking homotaurine 150 mg twice daily for 78 weeks might preserve hippocampal volume (101100). However, in a large-scale, placebo-controlled clinical trial involving 1052 patients, homotaurine was no more effective than placebo for improving cognitive function (17066, 17067, 101101). Despite this overall lack of benefit, a sub-analysis of two large clinical trials in patients with mild Alzheimer disease shows that homotaurine 150 mg twice daily for 78 weeks might stabilize cognitive function. This sub-analysis identified an improvement of 71% to 125% when compared with placebo, depending on the specific tool used to measure cognitive function. Also, the greatest effect appeared to occur in APOE4/4 homozygous patients. However, taking homotaurine 100 mg twice daily was no more effective than placebo, regardless of population (101097). Due to the exploratory nature of these sub-analyses, more research is needed to confirm benefits in patients with mild symptoms of Alzheimer disease, especially those homozygous to APOE4/4.\nless\nCognitive impairment. Preliminary clinical research in patients with amnestic mild cognitive impairment shows that taking homotaurine 50 mg twice daily for one year improves immediate short-term memory recall by about 18%, compared to a slight worsening in untreated patients. The improvement in memory with homotaurine is associated with anti-inflammatory activity, and an attenuation of hippocampal volume loss (101094, 101098, 112072).\nGlaucoma. Preliminary clinical research in adults with primary open-angle glaucoma and controlled intraocular pressure shows that taking homotaurine 50 mg, citicoline 500 mg, and vitamin E 12 mg orally once daily for 4 months, in addition to standard pressure-lowering treatment, improves visual contrast sensitivity scores and self-reported quality of life scores by about 10%, when compared with standard treatment alone (104786). Other preliminary clinical research in adults with primary open-angle glaucoma and intraocular pressure controlled with beta blocker and/or prostaglandin analog eye drops, shows that taking a specific combination of homotaurine 50 mg and citicoline 500 mg (Neuprozin) orally once daily for 4 months improves retinal cell function and neural conduction when compared with eye drop treatment alone, without altering intraocular pressure. Pattern standard deviation, which measures localized loss in the visual field is improved (112074). It is unclear if these effects are due to homotaurine, other ingredients, or the combinations, although some evidence suggests a synergistic effect between homotaurine and citicoline (112074).\nParkinson disease. Preliminary clinical research shows that taking homotaurine 50 mg twice daily for 6 months does not improve symptoms of Parkinson disease when compared with no treatment. However, it has a modest effect on daytime sleepiness when compared to baseline (101099). The validity of this finding is limited by the lack of a comparator group.\nMore evidence is needed to rate homotaurine for these uses.",
            "Dosing & Administration": "Adult\nOral:\nAlzheimer disease: Homotaurine 150 mg twice daily for 78 weeks has been used (101097).\n\nCognitive impairment: Homotaurine 50 mg daily for 2 weeks and then 100 mg daily for 50 weeks has been used (101094, 101098).\n\nGlaucoma: Homotaurine 50 mg in combination with citicoline 500 mg, and vitamin E 12 mg once daily for 4 months has been used (104786).\n\nParkinson disease: Homotaurine 50 mg twice daily for 6 months has been used (101099).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of homotaurine.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with homotaurine.",
            "Pharmacokinetics": "Absorption\nHomotaurine is bioavailable when taken orally. Peak plasma levels occur 1.5-2.5 hours after ingesting regular tablets, and 4-6 hours after ingesting enteric-coated tablets (17062, 17063, 17065). The peak level is increased 1.5-fold when homotaurine is taken with a high-fat meal, but the total amount absorbed is unchanged (17065).\nDistribution\nHomotaurine is transported across the blood-brain barrier (17064, 17065, 112072).\nExcretion\nThe plasma elimination half-life of homotaurine is 1-3 hours, but the half-life for elimination from the brain is longer (17062, 17063, 17064, 17065).",
            "Mechanism of Action": "General\nHomotaurine is an amino acid that is not used for protein synthesis, but is an analog of the inhibitory neurotransmitter, gamma aminobutyric acid (GABA) (112072). It is found in certain types of seaweed, although the homotaurine used in supplements is typically prepared synthetically (101093, 101094).\nAlcohol dependence effects\nAnimal research suggest that homotaurine can reduce ethanol craving and intake. The proposed mechanism of this effect is interference with ethanol-induced activation of the mesolimbic dopamine reward system in the brain (17053). A derivative of homotaurine, calcium acetylhomotaurinate, known as acamprosate, is FDA-approved for maintenance of abstinence in people with alcohol dependence.\nAnti-dementia effects\nThere is interest in using homotaurine for treatment of Alzheimer disease. One of the processes linked to the progression of Alzheimer disease is the deposition of extracellular amyloid plaques in the brain (17062, 17065). The primary constituent of these plaques is amyloid-beta peptides, which are formed by cleavage of amyloid precursor protein (17061, 17065). Homotaurine binds to soluble amyloid-beta peptides, interfering with the binding of sulfated glycosaminoglycans (GAGs), and therefore with the formation of amyloid-beta fibrils, aggregation of fibrils, and formation of amyloid plaques (17061, 17062, 17064, 17065). This mechanism of action suggests that homotaurine is most likely to slow progression of Alzheimer disease, and is more likely to be effective in early disease, before large amounts of amyloid plaque have been formed (17062, 17064). Cell culture and animal studies have demonstrated that homotaurine can maintain amyloid-beta in a non-fibrillar form, can decrease cell death induced by amyloid-beta42, and can inhibit amyloid deposition (17061, 17064, 17065). In animals, homotaurine reduces brain amyloid plaque load, decreases cerebral levels of soluble and insoluble amyloid-beta40 and amyloid-beta42, and reduces plasma amyloid-beta levels (17061, 17064, 17065).\n\nAmyloid-beta peptides are also involved in the pathogenesis of cerebral amyloid angiopathy. This condition occurs with aging, and involves accumulation of amyloid in cerebral blood vessels, causing vessel breakdown and hemorrhagic stroke (17063). People with certain apolipoprotein E genotypes are at increased risk for this condition. In an animal model of cerebral amyloid angiopathy, homotaurine binds soluble amyloid-beta and reduces vascular amyloid deposition (17063).\nAnti-inflammatory effects\nIn human studies, taking homotaurine 50 mg twice daily for 12 months decreases levels of the proinflammatory cytokine, interleukin (IL)-18, and increases levels of anti-inflammatory IL-10 and IL-33, when compared to baseline (112072).\nEffects in autism\nIn a valproic acid-induced animal model of autism spectrum disorder (ASD), homotaurine, 50 mg by intraperitoneal injection daily for 21 days, ameliorates behavioral deficits, including decreased sociability and spatial memory, and increased stereotypy. Possible mechanisms include decreasing oxidative stress and inflammation, as shown by lowering of malondialdehyde and proinflammatory cytokine levels, and increasing superoxide dismutase, reduced glutathione, catalase, and anti-inflammatory cytokine levels. ASD is thought to involve dysregulation of GABA-ergic signaling, and homotaurine can normalize expression of glutamic acid decarboxylase-67 which is involved in GABA synthesis. It also preserves Purkinje cell density in the cerebellum, and decreases pyknosis in the prefrontal cortex (112073).\nGamma-aminobutyric acid (GABA)-like effects\nMany of the potential clinical benefits of homotaurine may be related to its role as a GABA receptor agonist, including neuroprotective and immunomodulatory effects. Homotaurine is an agonist at GABA-A receptors (17056, 17057). Other agonists at these receptors in the central nervous system (CNS) have anticonvulsant, anxiolytic, and sedative effects. Anticonvulsant effects of homotaurine have been reported in preliminary studies. Animals pretreated with homotaurine were partially protected from seizures and pathologic brain changes caused by injection of kainic acid (17054).\n\nHomotaurine also has a small effect on presynaptic GABA-B receptors, acting as a weak agonist (17055, 17056, 17059, 101093). Both agonist and competitive antagonist effects of homotaurine at GABA-B receptors have been reported in vitro (17055, 17056, 17057). Agonists at GABA-B receptors cause opening of potassium channels, and inhibit the release of neurotransmitters such as acetylcholine (17055, 17056, 17059). Preliminary data suggest that actions at GABA-B receptors in the CNS may be responsible for analgesic effects of homotaurine (17055, 17056, 17058, 17059). These analgesic effects are potentiated by baclofen, which is a GABA-B agonist (17055, 17058). The analgesic effects of homotaurine are also potentiated by morphine and inhibited by naloxone, suggesting opioid mechanisms are involved (17058).\nImmune effects\nIn animal models, homotaurine seems to inhibit effector T cell proliferation and enhance T regulatory responses by acting as a GABA receptor agonist. This mechanism is thought to play a role in the modest reversal of newly-developed, but not severe, hyperglycemia in an animal model of early type 1 diabetes, as well as benefits in other autoimmune models of rheumatoid arthritis and multiple sclerosis (101093, 101096).\nOphthalmic effects\nThere is interest in using homotaurine to treat glaucoma. Some researchers have suggested homotaurine may prevent retinal ganglion cell death by inhibiting amyloid aggregation and/or GABA-like activity, but research evaluating these theories is lacking (104786)."
        }
    },
    "Honey": {
        "sections": {
            "Overview": "Honey is a sweet, viscous fluid produced by honey bees from the nectar of several varieties of plants. It is commonly used as a sweetener in food. Honey is also used for medicinal purposes (93071).",
            "Warnings": "Coronavirus disease 2019 (COVID-19): Despite claims to the contrary, there is no good evidence to support using honey for COVID-19. Recommend healthy lifestyle choices and proven prevention methods instead.",
            "Safety": "LIKELY SAFE when used orally and appropriately (13160, 14319). Concerns about botulism pertain only to children under 12 months of age and not to adults (13160). ...when used topically and appropriately. A specific commercially available wound dressing containing manuka honey (Medihoney) is approved as a medical device by the US Food and Drug Administration (FDA) (16353, 16355, 16357, 16362, 16369, 16371). Some evidence suggests other honey preparations can also be used safely when applied to the skin or used to rinse the mouth (395, 396, 397, 398, 399, 7847, 7849, 13133, 14317)(16358, 16372, 97704, 101034, 108530).\nPOSSIBLY SAFE when properly diluted honey is used intranasally. Manuka honey 16.5% solution has been used with apparent safety as a nasal rinse twice daily for 14 days (103969). ...when specific, medical-grade honey products are used in eye drops. A specific product (Optimel Manuka Plus Eye Drops, Melcare Biomedical Pty Ltd) has been used safely 2-3 times daily for up to 4 weeks (105231, 105234).\nLIKELY UNSAFE when honey produced from the nectar of rhododendrons is used orally. This type of honey contains grayanotoxins, which may lead to cardiovascular symptoms, such as arrhythmias, hypotension, chest pain, bradycardia, syncope, asystole, various types of heart block, and myocardial infarction (12220, 55119, 55122, 55125, 55126, 55129, 55141, 55142, 55157)(55163, 55170, 55171, 55180, 55183, 55190, 55224, 55233, 55234, 55239)(55248, 55260, 55261, 55280, 55281).\nCHILDREN: LIKELY SAFE when used orally and appropriately, short-term in children at least 12 months of age (15910, 17299, 55210, 55253, 97693).\nCHILDREN: POSSIBLY UNSAFE when used orally in children less than 12 months of age. Ingestion of raw honey contaminated with Clostridium botulinum spores can cause botulism poisoning in infants under 12 months of age (13160, 55067, 55290, 91359). This is not a danger for older children or adults. Medical-grade, sterilized honey has been used with apparent safety in the formula of premature newborns at doses of up to 15 grams daily for up to 2 weeks (97697).\nPREGNANCY AND LACTATION: LIKELY SAFE when consumed in food amounts. The concern about botulism pertains to children under 12 months of age and not to pregnant adults (13160). There is insufficient reliable information available about the safety of honey when used for medicinal purposes when pregnant or breast-feeding.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and topically, honey is generally well tolerated in those at least 1 year of age. When given intranasally or into the eyes, honey seems to be well tolerated. However, honey containing grayanotoxins, which are found in rhododendrons, is likely unsafe and should be avoided.\nMost Common Adverse Effects\nOrally: Nausea, stomach pain, and vomiting.\n\nTopically: Burning, pain, and stinging.\n\nIntranasally: Burning and nausea.\n\nOcular: Stinging.\nSerious Adverse Effects (Rare)\nOrally: Case reports of botulism in infants have occurred. Anaphylaxis has been reported in sensitive individuals. Honey from the Black Sea coast of Turkey, which is derived from the nectar of rhododendrons, has caused respiratory depression, dizziness, sweating, weakness, bradycardia, atrioventricular (AV) block, hypotension, cardiac arrhythmias, and myocardial infarction within a few minutes to several hours after consumption.\nCardiovascular\nHoney from the Black Sea coast of Turkey has been linked with a unique form of poisoning. Honey from this region sometimes contains excessive concentrations of grayanotoxins from rhododendrons, which can cause bradycardia, atrioventricular (AV) block, cardiac arrhythmias, myocardial infarction, and hypotension within a few minutes to several hours after consumption (12220, 55110, 55126, 55129, 55238, 55269, 55270, 55280). Fatalities have not been reported. Patients typically respond to fluids and reversal of cardiac conduction abnormalities with atropine.\nless\nDermatologic\nTopically, the use of honey applied to wounds can cause local pain, stinging, and burning in about 5% of patients, some of whom stop treatment as a result (16356, 16357, 16358, 16361, 91362, 97694, 96595). Theoretically, honey may cause excessive drying of wounds, which could delay healing. This can be managed by application of saline packs as needed (7850).\nless\nGastrointestinal\nOrally, honey may cause mild nausea, vomiting, and stomach ache (12220, 55119, 55190, 55294, 97693). Honey from the Black Sea coast of Turkey has been linked with a unique form of poisoning. Honey from this region sometimes contains excessive concentrations of grayanotoxins. These toxins can cause increased salivation, nausea, and vomiting within a few minutes to several hours after consumption (12220, 55119, 55190, 55294). Intranasally, honey may cause nausea (55216).\nless\nImmunologic\nOrally, honey can cause allergic reactions, including anaphylaxis (6, 11, 108531, 108532). These reactions may be due to various components of the honey, including the honey itself, pollen, or bee secretions (91370). When used topically, local allergic reactions have been reported in people with pre-existing atopy (16356, 55118). Allergic contact dermatitis related to honey enriched with propolis has been reported (91365).\nless\nNeurologic/CNS\nOrally, honey may cause nervousness, insomnia, and hyperactivity in children (91366, 97693). Honey from the Black Sea coast of Turkey has been linked with a unique form of poisoning. Honey from this region sometimes contains excessive concentrations of grayanotoxins, which can cause dizziness, sweating, and weakness within a few minutes to several hours after consumption (12220, 55110, 55119, 55296).\nless\nOcular/Otic\nWhen used in eye drops, transient stinging has been reported rarely (105231, 105234).\nless\nPulmonary/Respiratory\nWhen used intranasally, a burning sensation of the nasal passages has been reported (55216). Honey from the Black Sea coast of Turkey, which sometimes contains excessive concentrations of grayanotoxins, can cause respiratory depression within a few minutes to several hours after consumption (12220, 55110, 55119, 55296).\nless\nOther\nSome honey is contaminated with Clostridium botulinum spores, which poses a risk to infants (6, 11, 13160, 55067, 55290, 91359). Botulinum spores can proliferate in the intestines of infants and cause botulism poisoning (55112). However, this is not a concern for older children and adults.\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nBurns. Topical application of gauze containing honey seems to improve burn healing.\nHoney applied directly in gauze applications seems to improve formation of granulation tissue and speed healing time in partial thickness burns. The benefits of honey appear to be comparable to topical antibiotics, including silver sulfadiazine and moisture permeable polyurethane dressing (OpSite) (395, 396, 397, 398, 399, 14317, 55175, 55200, 55204, 55264)(91363, 97696). In these studies, honey has been used under dressings or impregnated in gauze as needed for up to 12 weeks. The duration between changing of dressings or gauze has varied (395, 396, 397, 398, 399, 55175, 55200, 55204, 55264, 91363). One small clinical study in adults with moderate burns shows that early surgical intervention with tangential excision and skin grafting appears to improve outcomes when compared with honey (7848). However, poor study design limits the reliability of these findings.\nless\nCough. Most studies show that oral honey reduces cough in children. It is unclear whether oral honey is beneficial for cough in adults.\nClinical research shows that taking honey 2.5-10 mL (0.5-2 teaspoons) at bedtime reduces nighttime cough frequency and severity and improves sleep when compared with placebo in children aged 2 years and older with upper respiratory tract infections (URTIs) (15910, 55253, 97693, 103959). Honey also appears to be at least as effective as the cough suppressant dextromethorphan in typical over-the-counter doses (15910, 17299, 97693). The effects of honey on cough duration are not known (97693). One clinical study in children 1-5 years of age with URTIs and cough for up to 7 days shows that acacia honey is similarly effective to a honey-flavored placebo, given as 3 mL one hour before bedtime for 2 consecutive nights, for reducing cough frequency and severity and improving sleep (110003). However, this study may have been inadequately powered to detect a difference between groups.\n\nA meta-analysis of the available research suggests that honey does not improve cough in adults when compared with usual care (103959). However, due to the small number of available studies, the analysis might have been inadequately powered to detect a smaller magnitude of benefit. Some research in adults has also evaluated honey in combination with other ingredients. In adults with post-infectious cough of at least 3 weeks' duration, taking 25 grams of a paste in a warm water solution providing honey 20.8 grams and coffee 2.9 grams every 8 hours for one week reduces cough frequency by about 93% when compared with baseline. Those taking prednisolone experienced a cough reduction of 20% (91367). It is unclear if this effect is due to honey, coffee paste, or the combination.\nless\nDiabetic foot ulcers. Topical honey seems to be beneficial for diabetic foot ulcers.\nA meta-analysis of mainly lower quality clinical trials including 267-616 patients with diabetic foot ulcers shows that applying dressings impregnated with honey for 1-2 weeks shortens the wound debridement and healing time and increases the rate of wound healing by moderate to large amounts when compared with other dressings (101032). Individual clinical studies also show that using dressings impregnated with manuka honey (Medihoney Tulle Dressing) or beri honey decreases healing time for diabetic foot ulcers by 11-12 days and reduces the need for antibiotics when compared with saline-soaked gauze (19739, 91364, 97701).\nless\nDry eye. Specific manuka honey eyedrops seem to be modestly beneficial for improving symptoms of dry eye.\nMost clinical research shows that specific honey products might be helpful for symptoms of dry eye (97694, 97695, 105231, 105234). Preliminary clinical research shows that applying a specific manuka honey product (Optimel Manuka Plus Dry Eye Drops, Melcare Biomedical Pty Ltd) 2-3 times daily for 14 or 28 days reduces some, but not all, measures of eye discomfort (97694, 105234). In patients with dry eye due to contact lenses, dry eye symptoms were reduced by about 18% when compared with baseline (97694). In patients with general mild dry eye symptoms, preliminary clinical research shows that symptoms were reduced by about 52% when compared with baseline (105234). These improvements were significant when compared with lubricant drops (97694, 105234).\n\nSpecific honey products also seem to be beneficial for dry eye associated with meibomian gland dysfunction. In these patients, preliminary clinical research shows that using Optimel Manuka Plus Eye Drops (Melcare, Biomedical Pty Ltd) or Optimel Antibacterial Manuka Eye Gel (Melcare Biomedical Pty Ltd) twice daily for 3 or 8 weeks along with warm compresses improves the function of the tear glands (97695, 105231). In one study, 73% to 95% of participants using the honey products required less lubricant, compared with 48% of participants using warm compresses alone. However, the honey products did not improve bacterial counts, redness, or dryness (97695). In another study, eye dryness, lid margin, conjunctival redness, and meibomian gland function were modestly improved when compared with baseline. All improvements were statistically similar to the control group receiving a lubricant. However, patients using a lubricant did not experience an improvement in eye dryness when compared to baseline (105231).\nless\nHerpes labialis (cold sores). Applying honey to cold sores may heal lesions 2-4 days faster than conventional therapies.\nA meta-analysis of three clinical trials, including one relatively large study, in patients with herpes labialis shows that applying honey to lesions 4-5 times daily reduces lesion healing time by around 2 days, although it does not improve pain when compared with acyclovir 5% cream (108526). Also, a small crossover trial in patients with recurrent cold sores shows that applying medical grade honey three times daily to lesions at the onset of symptoms or blistering reduces lesion healing time by around 4 days and improves symptoms such as pain and itching when compared with conventional treatments, which ranged from prescription antivirals to herbal remedies and wound care products (108527).\nless\nOral mucositis. Rinsing the mouth with and then slowly swallowing honey seems to be beneficial for oral mucositis prevention or treatment, although most research is lower quality.\nAlthough contradictory evidence exists (55219, 91361), most research shows that honey may have some benefit in preventing or reducing symptoms of oral mucositis (16352, 55133, 55137, 55202, 55241, 55245, 55265, 91368, 97704, 104562). A meta-analysis of eight trials shows that applying honey reduces the development of intolerable oral mucositis lesions by approximately 52%. Applying honey to lesions also appears to reduce pain associated with oral mucositis; however, the number of studies included in this latter analysis was small (101035). Another meta-analysis suggests that pure natural honey may be more effective than manuka honey or local honey for treating oral mucositis (101034). However, these analyses have significant quality issues. They included studies that did not fit inclusion criteria and omitted studies that did fit inclusion criteria (103967). The majority of these studies have had patients rinse with and then slowly swallow up to 20 mL honey three times or more daily, usually before radiation therapy, 15 minutes after radiation therapy, and 6 hours after radiation therapy or at bedtime. Some studies have used honey topically or as ice chips or lozenges (16352, 55133, 55137, 55202, 55219, 55241, 55265, 91361, 97704, 101034)(101035, 104562). Also, rinsing the mouth and swallowing a paste of honey or honey and coffee 10 mL every 3 hours for one week has been used (91368). Preliminary clinical research in patients undergoing chemoradiation and using conventional treatments shows that a combination of licorice powder 5 grams mixed in honey and applied twice daily along with oral licorice powder 500 mg twice daily for 6 weeks also seems to reduce the risk of oral mucositis and severe symptoms when compared with conventional treatments alone (104562). However, it is not clear whether any benefit in this study is due to honey, licorice, or the combination.\n\nIn pediatric intensive care patients aged 2-16 years, preliminary clinical research shows that applying a local honey, 1-1.5 grams/kg in two divided doses, with a spoon to the inside of the mouth, teeth, lips, and tongue, reduces the severity and development of oral mucositis when compared with using chlorhexidine. However, honey was not as effective as topical vitamin E (101036).\nless\nRosacea. Topical honey seems to be beneficial for rosacea.\nClinical research in adults shows that applying a 90% medical-grade kanuka honey (Honevo) with glycerin to affected areas twice daily for 8 weeks and washed off after 30-60 minutes is more effective than Cetomacrogol, an emollient, for improving symptoms of rosacea. Approximately twice as many patients responded to the honey product when compared with Cetomacrogol cream (97699).\nless\nWound healing. Topical honey seems to improve the healing of various types of wounds, although the optimal formulation and application regimen remains unclear.\nSeveral small clinical trials and case reports describe the use of honey or honey-impregnated dressings for various types of wounds, including post-surgical wounds, chronic leg ulcers, abscesses, burns, abrasions, lacerations, and skin graft donor sites. Honey seems to improve granulation and epithelialization, reduce odors and purulent exudate, help clean the wound, increase eradication of infection, reduce pain, and decrease time to healing (7847, 7849, 14317, 16354, 16355, 16357, 16358, 16360, 16362, 16369)(16372, 16374, 55109, 55130, 55144). Meta-analyses of clinical research show that applying honey reduces healing time of partial thickness burns by 4.7 days when compared with conventional dressing and about 5 days when compared with silver sulfadiazine. Honey also appears to improve healing time for postoperative wounds when compared with antiseptic washes followed by gauze (55264). In some reports, wounds healed with honey after failing previous treatments (16369, 16371).\n\nHoney applied directly to wounds appears to be comparable to hydrogels such as carboxymethylcellulose, povidone iodine, and hypochlorite solutions (16355, 16358, 16360, 16376, 55235). Honey dressings also appear to be comparable to hydrocolloid dressings, paraffin gauze, nanocrystalline silver, and saline-soaked gauze (16358, 16360, 16372, 55101). However, poor study design limits the reliability of some of these findings. Trials cannot be directly compared due to variation in wound type and severity, patient characteristics, honey type and processing, dressing techniques, treatment duration, and concomitant use of antibiotics. Adequate blinding is also difficult to achieve due to the distinctive properties and smell of honey (16360). Many of the clinical trials used manuka honey, which is derived from the nectar of Leptospermum scoparium and is gamma irradiated to inactivate bacterial spores (16355, 16357, 16362, 16369, 16371). Other trials used unprocessed honey (16358, 16372). Honey dressings are typically changed every 24-48 hours, although in some cases dressings are changed only twice weekly (16355, 16362, 16372, 16374, 55101, 55130, 55235). In children aged 2 months to 14 years, honey soaked gauze has been packed into wounds twice daily until closure (16376). When used directly, unprocessed honey or manuka honey 15-30 mL has been applied and covered with sterile gauze and bandages or a polyurethane dressing. When applied directly, honey is typically used every 12-48 hours, although in some cases it has been used only once weekly (16354, 16358, 16369, 16372, 16376, 55144).\nless\nHerpetic gingivostomatitis. Slowly swallowing honey seems to be beneficial for herpetic gingivostomatitis treatment in children.\nClinical research in children aged 2-8 years with primary herpetic gingivostomatitis shows that use of a local honey 5 mL every 4 hours with slow swallowing, in combination with acyclovir 15 mg/kg five times daily for 7 days, results in the clearing of oral lesions 3 days faster when compared with acyclovir and a placebo syrup. Drooling and difficulties eating also improved faster, and pain and the need for analgesics were reduced. Fever and extra-oral lesions were not improved (101038).\nless\nPOSSIBLY INEFFECTIVE\nAcne. Topical honey does not seem to be beneficial for acne.\nClinical research in adolescents and adults 16 years of age and older shows that applying a 90% medical-grade kanuka honey (Honevo) with glycerine to the face twice daily after using an antibacterial soap does not improve facial acne when compared with antibacterial soap alone (97700).\nless\nHyperlipidemia. Oral honey does not seem to improve lipid levels in patients with hyperlipidemia.\nA meta-analysis of 15 small clinical studies in patients with hyperlipidemia shows that taking honey 20-75 grams daily for up to 4 months does not reduce total cholesterol, low-density lipoprotein (LDL) cholesterol, or triglyceride levels when compared with control (108533).\nless\nRhinosinusitis. Intranasal honey does not seem to be beneficial for improving symptoms of chronic rhinosinusitis.\nA small clinical study in adults who have undergone maximal medical and surgical treatment for allergic fungal rhinosinusitis shows that using 2 mL of an intranasal spray containing honey 50% in saline once daily at night for 30 days does not reduce symptoms when compared with usual treatment (55216). Manuka honey nasal spray also does not seem to work better than saline spray in adults with chronic rhinosinusitis. A small clinical study shows that manuka honey 10% (Medihoney, Derma Sciences) in saline sinus irrigation twice daily for 30 days is no more effective than saline irrigation for reducing overall symptoms (97705). Additionally, a small clinical study in patients with recalcitrant chronic rhinosinusitis shows that using manuka honey 16.5% twice daily augmented with 1.3 mg/mL methylglyoxal sinonasal rinses for 14 days is no better than taking targeted oral antibiotics and performing normal saline rinses twice daily (103969). However, this study was not adequately powered to detect a difference between treatment groups. Additional research is needed to determine if honey-containing nasal sprays are beneficial in circumstances with limited access to antibiotics or nasal steroids, or in patients with high immunoglobulin E (IgE) levels (55216, 97705).\n\nIntranasal honey has also been evaluated in patients recovering from surgery for rhinosinusitis. A small clinical study in adults with chronic rhinosinusitis who have undergone endoscopic sinus surgery shows that applying 2 mL of Tualang honey to the nasal dressing, which remains in place for one week, results in similar improvements in symptoms when compared with a triamcinolone-containing dressing at 7, 14, and 28 days after surgery. However, at 3 months after surgery, triamcinolone seems to provide further improvement in rhinosinusitis symptoms and surgical recovery when compared with honey (108529).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAllergic rhinitis (hay fever). It is unclear if oral honey is beneficial for hay fever.\nPreliminary clinical research shows that consuming honey one tablespoon (20 grams) daily, in addition to standard treatment, does not improve allergy symptoms (14319). Other preliminary clinical research shows that ingesting honey 1 gram/kg daily for 4 weeks, in addition to taking loratadine 10 mg daily, may improve allergic symptoms during treatment and for up to 4 weeks following cessation of treatment. However, it's not clear if this improvement is significant when compared with loratadine alone (91360).\nless\nAlveolar osteitis. It is unclear if oral honey is beneficial for alveolar osteitis.\nA small, low-quality clinical study in patients with alveolar osteitis after dental surgery shows that applying gauze soaked in 2 mL of honey, 3 times over 10 days, improves healing, pain, and formation of granulation tissue when compared with baseline (103961).\nless\nAsthma. Oral honey has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nOne preliminary clinical study shows that taking a combination of honey and black seed modestly improves measures of lung function when compared with baseline in patients with moderate to severe asthma. However, another preliminary clinical study using this combination did not show improvement on all measures. Both studies were small and may not have been adequately powered to detect a difference in outcomes (105228). Other preliminary clinical research shows that taking a combination of honey and celery seed modestly improves some measures of lung function when compared with baseline (105228). It is unclear whether any benefit is due to honey, the other ingredient, or the combinations. Additionally, the validity of these studies is limited by the lack of a comparator group.\nless\nAthletic performance. Although there is interest in using oral honey to improve athletic performance, there is insufficient reliable information about the clinical effects of honey for this purpose.\nAtopic dermatitis (eczema). It is unclear if topical honey is beneficial for atopic dermatitis.\nIn patients with bilateral atopic dermatitis, a small preliminary clinical trial shows that topical application of manuka honey to one site overnight for 7 days improves lesions when compared to baseline (105239). The validity of this finding is limited by the lack of a placebo comparator group.\nless\nBlepharitis. It is unclear if topical honey is beneficial for blepharitis.\nA small clinical study in patients with blepharitis shows that applying MGO Manuka Honey microemulsion (Manuka Health New Zealand Ltd) eye cream to closed eyelids nightly for 3 months improves symptoms of dry eye and reduces ocular mites and bacterial load when compared with no intervention (103962). The validity of this finding is limited by the lack of a placebo comparator group.\nless\nCataracts. Although there is interest in using topical honey for cataracts, there is insufficient reliable information about the clinical effects of honey for this condition.\nCatheter-related infections. It is unclear if topical medical honey is beneficial for preventing catheter-related infections in patients on hemodialysis or in those with diabetes.\nPreliminary clinical research shows that manuka honey (Medihoney, Medihoney Pty Ltd) applied three times weekly to the exit sites of tunneled, cuffed central venous hemodialysis catheters is as effective as mupirocin ointment in reducing the incidence of catheter-associated infection and bacteremia. It may also be associated with a lower rate of bacterial resistance than mupirocin (16361). A retrospective analysis also found that use of povidone iodine for dialysis catheter site care is associated with a 58% increased cumulative incidence rate of exit-site infections or peritonitis when compared with use of medical honey. Patients were followed from catheter insertion until catheter removal, transplant, death, or end of treatment (101039). However, well-designed clinical research shows that application of antibacterial honey (Medihoney Antibacterial Wound Gel, Comvita) 10 mg at the exit site along with standard care is no more effective than standard care alone for reducing dialysis-related infections (91362).\n\nIt is unclear if honey reduces the risk of catheter-related infection in patients with diabetes. Some evidence shows that applying an antibacterial honey product approximately doubles the risk of infection and peritonitis in patients with diabetes when compared with no honey (91362). However, a large retrospective analysis found that exit-site application of honey was associated with a lower chance of peritoneal dialysis-related infection when compared with povidone iodine, even in patients with diabetes (101039).\nless\nChemotherapy-related fatigue. Oral honey has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with breast cancer and chemotherapy-related fatigue shows that taking a specific product (Jollab tonic beverage) containing honey, saffron, and rose water, as 20 mL three times daily for 4 weeks, reduces scores on a cancer fatigue scale when compared with placebo. Scores on a visual analog fatigue scale and on a fatigue severity scale were only improved when compared with baseline, not placebo (110001).\nless\nCorneal opacity. Although there is interest in using topical honey for corneal opacity, there is insufficient reliable information about the clinical effects of honey for this purpose.\nCorneal ulceration. It is unclear if honey-containing ophthalmic drops are beneficial for corneal ulceration.\nA small clinical study in patients with foreign body-induced corneal ulceration shows that applying ophthalmic drops containing honey into the affected eye every 6 hours for 14 days might speed up healing of corneal epithelial defect, but does not improve corneal infiltration, when compared with using ciprofloxacin eye drops. The honey in these drops was produced from the nectar of various ziziphus species (103968). The validity of this study is limited by its small size and short duration.\nless\nDiabetes. It is unclear if oral honey is beneficial for diabetes.\nIn patients with type 2 diabetes, small clinical trials show that taking honey 50 grams or 1-2.5 grams/kg daily for 8 weeks increases glycated hemoglobin (HbA1c) levels by a small amount (55182, 105235). However, lower doses of 5-25 grams daily for 16 weeks or 0.5 grams/kg daily for 12 weeks seem to have no effect on HbA1c and may modestly reduce levels when compared to baseline or no treatment (105230, 105236). Also, although some research disagrees, taking honey does not seem to affect fasting levels of insulin or glucose, or measures of insulin resistance (105230, 105235, 105236).\n\nThere is conflicting evidence regarding the effects of honey on lipid levels in patients with diabetes. Some preliminary clinical research shows that consuming honey 0.5-2.5 grams/kg daily modestly decreases total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides, and modestly increases high-density lipoprotein (HDL) cholesterol (55182, 105230), while other research does not show any effect on plasma lipids (105236). In patients with type 1 diabetes, one clinical study shows that taking honey 0.5 mL/kg daily for 12 weeks decreases fasting blood glucose, total cholesterol, triglycerides, and LDL cholesterol when compared with control (55263).\nless\nDiabetic neuropathy. It is unclear if oral honey is beneficial for diabetic neuropathy.\nIn patients with mild to moderate diabetic neuropathy who are taking antidiabetes medications and gabapentin, preliminary clinical research shows that taking honey 0.5 gram/kg daily in water for 3 months modestly reduces nerve pain and improves quality of life when compared with baseline. Nerve conduction was generally not affected (105230). The validity of this study is limited by the lack of an appropriate control group.\nless\nDiarrhea. Small clinical studies suggest that oral honey is beneficial in children and infants with diarrhea.\nOne small clinical study in children and infants with gastroenteritis shows that adding honey to oral rehydration solution (ORS) at a concentration of 50 mL per liter ORS decreases the frequency of vomiting and diarrhea, and reduces recovery time when compared with ORS alone (55194). Other clinical research shows that adding honey to ORS at the same concentration reduces the duration of diarrhea by about 1.4 days when compared with standard ORS in infants and children with bacterial gastroenteritis, but not when all types of gastroenteritis are considered (55273). Another small clinical study in children hospitalized with acute diarrhea shows that taking 1.5-2 mL of honey every 6 hours for 5 days plus 5 mL of zinc gluconate syrup, providing 5 mg of elemental zinc, every 6 hours for 10 days reduces the duration of diarrhea by 6.5 hours and the duration of hospitalization by 24 hours when compared with zinc gluconate alone (108534).\nless\nDry mouth. It is unclear if oral honey is beneficial for dry mouth associated with intubation.\nPreliminary clinical research in a small group of intubated adults in an intensive care unit shows that applying Indonesian honey 20 mL to all areas of the mouth with a brush and gauze swab twice daily for 3 days, in addition to standard oral care with 20 mL chlorhexidine gluconate 0.2%, improves overall oral health scores on a modified Beck Oral Assessment Scale when compared with chlorhexidine alone (110002).\nless\nDysmenorrhea. It is unclear if oral honey is beneficial for dysmenorrhea.\nPreliminary clinical research shows that taking honey 1.2 mg/kg daily, starting on the 15th day of the menstrual cycle and continuing until the onset of menstruation, is comparable to mefenamic acid 250 mg every 6 hours for reducing pain associated with dysmenorrhea (97702).\nless\nGenital herpes. It is unclear if topical honey is beneficial for genital herpes.\nPreliminary clinical research shows that applying a gauze soaked with honey four times daily to the lesion until healing does not improves symptoms or healing time (55095).\nless\nGingivitis. It is unclear if chewing \"leather\" made from manuka honey is beneficial for gingivitis.\nPreliminary clinical research shows that chewing \"leather\" made from manuka honey after meals for 21 days reduces plaque severity and the number of bleeding sites when compared to baseline in patients with gingivitis and plaque (55091).\nless\nHemorrhoids. Topical honey has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that applying a spoonful of a mixture containing equal volumes of honey, olive oil, and beeswax to the skin twice daily for up to 4 weeks reduces bleeding and itching when compared to baseline in patients with hemorrhoids (34100). It is not clear if these effects are due to honey, the other ingredients, or the combination.\nless\nImpaired glucose tolerance (prediabetes). It is unclear if oral honey is beneficial for prediabetes.\nPreliminary clinical research shows that taking honey does not improve glycemic control or lipid levels in patients with prediabetes. In one study, taking honey (Dutch Gold Honey) providing 50 grams of carbohydrates daily for 2 weeks does not improve these measures when compared with sucrose or corn syrup providing similar amounts of carbohydrates (105238). In another study, taking Malaysian Kelulut honey (Bayu Kelulut) 30 grams daily for 30 days was not beneficial (105237). The validity of these studies is limited by the lack of an appropriate control group.\nless\nLeishmania lesions. It is unclear if topical honey is beneficial for leishmania lesions.\nSome research shows that honey might prevent the healing of leishmania lesions. One preliminary clinical study shows that applying honey-soaked gauze onto leishmania lesions twice daily for 6 weeks in addition to receiving a glucantime injection reduces the proportion of patients with healed wounds by about 28% when compared with glucantime injection alone (55118).\nless\nMale infertility. Intravaginal honey has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that applying 10 mL of a combination mixture containing various bee products intravaginally immediately before or after each coital act, beginning one day after the last menstruation and continuing for three menstrual cycles or until pregnancy, increases pregnancy rate from 3% to 8% when compared to standard intrauterine insemination in couples having difficulty getting pregnant due to male asthenozoospermia. However, since all unsuccessful couples were crossed over to the alternative treatment after 2 months, the causality of successful pregnancy is unclear. The mixture consisted of Egyptian bee honey 100 grams, royal jelly 3 grams, and bee bread 1 teaspoon, which was diluted in saline in a 1:1 ratio prior to application (55131).\nless\nMalnutrition. It is unclear if oral honey is beneficial for malnutrition in children.\nPreliminary clinical research in infants and children with a mean age of 11-13 months with protein-energy malnutrition (PEM) shows that honey improves weight and other biomarkers when compared to control. Honey 2 mL/kg diluted in water was used daily for 2 weeks in combination with conventional nutritional rehabilitation (55196, 55210).\nless\nMenopausal symptoms. It is unclear if oral honey is beneficial for metabolic control in postmenopausal individuals.\nIn postmenopausal individuals, preliminary clinical research shows that taking Tualang honey 20 grams daily for 4 months results in a slight increase in low-density lipoprotein (LDL) cholesterol and fasting blood sugar when compared with baseline. However, there were no statistically significant differences in lipid profile, glycemic control, or bone density when compared with low-dose hormone replacement therapy (105241). The validity of this study is limited by its short duration and lack of blinding.\nless\nNecrotizing fasciitis. It is unclear if topical honey is beneficial for necrotizing fasciitis.\nPreliminary clinical research has shown conflicting results with the use of honey, applied directly and covered with a dressing or applied as a honey-soaked gauze, given as an adjunct to antibiotics, for the treatment of Fournier's gangrene, a type of necrotizing fasciitis (55106, 55293, 55295, 55315, 91363).\nless\nObesity. It is unclear if oral honey is beneficial for metabolic control in adolescents with obesity.\nPreliminary clinical research in obese prepubertal females on a calorie-reduced diet shows that consuming a wild flower and thyme honey product (Attiki) 15 grams daily for 6 months does not improve levels of glucose, insulin, or blood lipids when compared with a marmalade control (101037).\nless\nOsteoarthritis. Oral honey has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in adults 40-85 years of age with knee osteoarthritis shows that taking a specific product (G-rup syrup, Yas Daru Pharmaceutical Co.) containing honey 150 mg/mL and ginger extract 100 mg/mL in a dose of 30 mL twice daily for 12 weeks reduces pain scores on a visual analog scale and improves scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) when compared with baseline. Total WOMAC scores decreased by about 7 in the active group and by 4 in the placebo group (110000). The validity of this finding is limited by the lack of statistical comparison to the placebo group. Additionally, it is unclear whether these changes would be considered clinically significant.\nless\nPeptic ulcers. Although there is interest in using oral honey for peptic ulcers, there is insufficient reliable information about the clinical effects of honey for this condition.\nPostoperative pain. Several small clinical studies suggest that topical honey may reduce pain after tonsillectomy in children and adults.\nA meta-analysis of low-quality clinical research in children 3 years and older immediately post-tonsillectomy shows that honey might reduce pain, analgesic use, and night-time awakening by a small to moderate amount in the week after surgery when compared with placebo or control. In these studies, honey was used in doses ranging from 4-15 mL every hour or once daily for 1-7 days (97703). A small observational cohort in adults post-tonsillectomy has found that applying honey 20 grams to the oral cavity for 5 minutes, 8 times daily for the first 5 days after surgery, is associated with reduced pain and bleeding when compared with usual treatment (103963). Another small clinical trial in adults post-tonsillectomy shows that gargling and then swallowing a solution containing 15 mL of honey mixed with 5 mL of water for two minutes every 6 hours for 10 days reduces pain and analgesic use when compared with placebo or no treatment (108530).\nless\nPressure ulcers. It is unclear if topical honey is beneficial for pressure ulcers in children.\nPreliminary clinical research in critically ill children aged 2 months to 17 years shows that use of a manuka honey dressing reduces the median time to complete healing of pressure ulcers by approximately 2 days when compared with standard wound care. In addition, complete healing was about 1.9 times more likely in children given the honey dressing. However, there were no differences in the proportion of children with complete healing or treatment failure, or in the duration of stay in the ICU or hospital (105229).\nless\nPruritus. It is unclear if topical honey is beneficial for pruritus due to intertrigo.\nPreliminary clinical research shows in adults with intertrigo that applying a honey cream (Medihoney Barrier Cream, Derma Sciences, Inc.) topically twice daily for 21 days reduces pruritus complaints when compared with zinc oxide ointment (55258).\nless\nRadiation dermatitis. It is unclear if topical honey is beneficial for treating radiation dermatitis.\nClinical research shows that applying honey gauze (HoneySoft) once daily to radiation-induced skin wounds does not increase the speed of wound healing when compared with paraffin gauze in patients with severe radiation-induced dermatitis (55105).\nless\nRadiation-induced esophagitis. It is unclear if topical honey is beneficial for radiation-induced esophagitis.\nIn patients with radiation esophagitis, preliminary clinical research shows that taking liquid manuka honey 10 mL or honey lozenges providing 10 mL of dehydrated manuka honey four times daily for 4 weeks does not improve pain on swallowing when compared with standard supportive care. However, only 14% of patients using liquid honey reported opioid use, compared with 37% of those given only supportive care (97698).\nless\nSinonasal polyposis. It is unclear if intranasal honey is beneficial in patients recovering from surgery for sinonasal polyposis.\nA small clinical study in patients recovering from sinus surgery for nasal polyposis shows that intranasal irrigation with a diluted processed honey spray four times daily starting the day after surgery does not improve healing or reduce polyp recurrence when compared with normal saline irrigation (108528).\nless\nSunburn. Although there is interest in using topical honey for sunburn, there is insufficient reliable information about the clinical effects of honey for this purpose.\nTooth extraction. It is unclear if topical honey is beneficial for wound healing after tooth extraction.\nA small clinical study in children that had a tooth extraction shows that applying a thin layer of Iranian Kurdistan Mountains honey with a cotton swab and keeping the swab in place for 45 minutes seems to reduce wound size more rapidly when compared with using normal saline (103966). The validity of this finding is limited because a large percentage of study participants were excluded from the final analysis.\nless\nVaginal candidiasis. It is unclear if intravaginal honey is beneficial for vaginal candidiasis.\nIn patients with vulvovaginal candidiasis, preliminary clinical research shows that applying 5 grams of a vaginal gel containing honey 50% nightly for 8 days is as effective as the same amount of clotrimazole 1% cream for reducing burning and sensitivity and improving culture results. Honey also reduces vaginal discharge in almost twice as many patients as those using clotrimazole (105227).\nless\nMore evidence is needed to rate honey for these uses.",
            "Dosing & Administration": "Adult\nOral:\nHoney has most often been used as 35-75 grams daily in one or more divided doses for 1-4 weeks. See Effectiveness section for condition-specific information.\nTopical:\nHoney has been used in various topical formulations, including as pure honey, in a cream, under dressings, or impregnated in gauze. It has also been used as an eye cream, gel, or drop. Honey has also been used as a mouth rinse that is slowly swallowed. See Effectiveness section for condition-specific information.\n\nEye drops containing manuka honey 16% and eye gel containing manuka honey 98% (Optimel Manuka Plus Eye Drops and Optimel Antibacterial Manuka Eye Gel, Melcare Biomedical Pty Ltd) have been used in clinical research (97694, 97695)\nIntravaginal:\nResearch is limited; typical dosing is unavailable.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nHoney has been used in various topical formulations, including as pure honey, under dressings, or impregnated in gauze. It has also been used as a mouth rinse that is slowly swallowed. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nIn clinical trials, honey has been used orally, topically, intranasally, and intravaginally. Honey used in clinical trials may be unprocessed or medical-grade. Honey may come from a single plant or may be multi-floral in origin.\n\nMedical-grade honey (e.g., Medihoney) is gamma irradiated to inactivate bacterial spores such as Clostridium botulinum (16356, 16357, 16362, 16370, 91362). It is also standardized to have consistent antibacterial activity (16356, 16370, 16371, 16373). Some authors also state that medical-grade honey should be collected from hives that are free from pathogens and not treated with antibiotics, and that the nectar should be from plants that have not been treated with pesticides (7847).\n\nEye drops and eye gels containing honey have been studied in clinical trials. Evaluated products include eye drops containing manuka honey 16% and eye gel containing manuka honey 98% (Optimel Manuka Plus Eye Drops and Optimel Antibacterial Manuka Eye Gel, Melcare Biomedical Pty Ltd). These products are standardized and approved as medical devices for eye treatment in Australia, New Zealand, and Europe. The gel contains acacia gum 2%. The drops contain water, sodium chloride, and benzoic acid 0.2% (97694, 97695).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, honey may increase the risk of bleeding when used with anticoagulant or antiplatelet drugs.\nIn vitro, honey inhibits platelet aggregation and increases the time to clotting (55222). Furthermore, animal research suggests that feeding mice large doses of honey for 12 days increases bleeding time when compared with no intervention (103964). However, these effects have not been reported in humans.\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Lower quality RCT)\nTheoretically, honey might decrease levels of drugs metabolized by CYP3A4, but research is conflicting.\nSome clinical research shows that honey induces CYP3A4 (55116). However, other clinical studies found no effect on CYP3A4 activity (55208). Different honey preparations may have different effects on CYP3A4.\nless\nPHENYTOIN (Dilantin)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, honey might increase levels of phenytoin.\nIn an animal model, the rate and extent of absorption of phenytoin was increased by honey (20352). This effect has not been reported in humans.\nless",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, honey may have antiplatelet effects.\nHoney might inhibit platelet aggregation and increase bleeding time (55222, 103964). Theoretically, honey might increase the risk of bleeding when used concomitantly with other herbs and supplements that have anticoagulant or antiplatelet effects. See products with antiplatelet activity here. See products with anticoagulant activity here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nDIABETES\nTheoretically, oral honey may interfere with blood glucose control; use with caution. In some clinical research in patients with type 2 diabetes, honey increased glycated hemoglobin (HbA1c) and fasting blood glucose, although this effect appears to be dose-dependent (55182, 105230). As with all sources of carbohydrates, honey should be used in moderation.\nless\nPOLLEN ALLERGIES\nHoney may cause allergic reactions in people with pollen allergies (6, 108532); use with caution.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nHoney from the Black Sea coast of Turkey, which is derived from the nectar of rhododendrons, has been linked with a unique form of poisoning. Honey from this region sometimes contains excessive concentrations of grayanotoxins, which can cause bradycardia, atrioventricular (AV) block, cardiac arrhythmias, myocardial infarction, hypotension, increased salivation, nausea, vomiting, dizziness, sweating, weakness, and respiratory depression within a few minutes to several hours after consumption (12220, 55110, 55119, 55126, 55129, 55190, 55238, 55269, 55270, 55280)(55294, 55296). Fatalities have not been reported.\nTreatment\nPoisoning related to honey containing grayanotoxins typically responds to fluids and the reversal of cardiac conduction abnormalities with atropine (12220, 55110, 55126, 55129, 55238, 55269, 55270, 55280).",
            "Pharmacokinetics": "Absorption\nClinical research shows that consuming honey 1.5 grams/kg body weight results in the absorption of flavonoids, although less than one-third of flavonoids available in honey appear to be absorbed (93072).",
            "Mechanism of Action": "General\nHoney is produced by honeybees of the Apis genus from the nectar of several varieties of plants. It is a supersaturated solution of sugars, of which 38% is fructose and 31% glucose (16363, 16365). Some disaccharides are also present (16363). Honey also contains fatty acids, proteins, and amino acids (16359). Protein content varies from about 160 mg to 550 mg per 100 grams of honey (16365). Enzymes present include saccharase, amylase, and glucose oxidase (16363). A peptide in honey can inhibit polyphenol oxidase and prevent enzymatic browning of fruits and vegetables (16365). Organic acids, such as glucuronic acid, account for about 0.57% of honey, and minerals account for 0.17%. Potassium is the most abundant mineral present, with smaller amounts of calcium, copper, iron, manganese, and phosphorus (16363). Vitamins present include ascorbic acid, thiamine, riboflavin, nicotinic acid, and pyridoxine (16359, 16363). Honey contains polyphenols, such as caffeic acid, quercetin, galangin, and apigenin (55158, 55174, 55223), as well as pyrrolizidine alkaloids (55187). The pharmacological activity of honey can vary depending on the type of plant from which the nectar is obtained. For example, honey produced from poisonous plants can be poisonous.\n\nHoney can be contaminated with microorganisms from plants, bees, and dust during production, and also during collection and processing (16359, 16363). The antibacterial characteristics of honey ensure that most contaminating organisms cannot survive or reproduce (16359, 16363). However, spore-forming organisms such as Clostridium and Bacillus species may remain, and botulism has been reported in infants given honey orally (16359, 16363). Gamma irradiation can be used to inactivate bacterial spores without affecting the antibacterial properties of honey (16355, 16356, 16362, 16370).\nAnti-inflammatory effects\nSome of the benefits of honey in wound healing may be related to its anti-inflammatory effects. There is histological evidence of reduced numbers of inflammatory cells present in wounds dressed with honey (55078). Although some research disagrees (105238), honey appears to reduce elevated levels of inflammatory proteins such as C-reactive protein (CRP), interleukin (IL)-6, and tumor necrosis factor (TNF)-alpha in humans (55136, 105230). The antioxidant effects of honey may also play a role in its anti-inflammatory effects as shown in laboratory research (55138).\nAntimicrobial effects\nHoney has antibacterial and antifungal activity. These effects might help prevent and treat wound infections. Applying 0.5 mL of standardized medical-grade honey (Revamil, Bfactory; available in the Netherlands) to healthy skin under an occlusive dressing for 48 hours reduces skin colonization to very low levels, whereas colonization increases under an occlusive dressing without honey (16373). The antimicrobial potency of different honeys can vary by as much as 100-fold (16360, 16361, 16373). Potency depends upon the geographical and botanical source; the season; and the conditions of harvesting, processing, and storage (16369). Properties of honey which are thought to contribute to these antibacterial effects include osmotic effects of the high sugar content, the low pH, and the presence of glucose oxidase and antibacterial phytochemicals (396, 1261, 1428, 7850, 16356, 16358, 16362, 16363, 16370). The high osmolarity dehydrates bacteria, and the mean pH of 4.4 (range: 3.2 to 5.5) inhibits growth and discourages colonization (16356, 16370). Antibacterial phytochemicals present in some honeys, including manuka honey, have not been fully identified (16362, 16370). In laboratory research, honey appears to impact nitric oxide and prostaglandin levels, which may play an antimicrobial role (55227). Honey is also a prebiotic, with a role in the promotion of Bifidobacterium species in vitro (55072).\n\nIn vitro studies of various honeys have reported inhibition and killing of many organisms including aerobic, anaerobic, gram positive, and gram negative bacteria, and also some fungi and yeasts (16363, 16370, 16373, 55071, 55077, 55242, 55287). The honeys were active against Staphylococcus aureus (including methicillin-resistant strains, MRSA), Escherichia coli (including extended spectrum beta-lactamase producing strains), Porphyromonas gingivalis, Pseudomonas aeruginosa, Pseudomonas pyocyanea, Proteus mirabilis, coliform species, Klebsiella species, Enterococci (including vancomycin resistant strains, VRE), Enterobacter cloacae, Escherichia coli, Acinetobacter baumannii, Streptococcus faecalis, and Streptococcus pyogenes (1261, 7847, 7849, 16352, 16362, 16363, 16369, 16370, 16373, 55120, 55259, 110002).\n\nThe antibacterial effects of honey may also be beneficial for management of Helicobacter pylori (H. pylori) infection in peptic ulcer disease. Honey and solutions with similar sugar content demonstrate similar effectiveness at inhibiting H. pylori (1428).\nAntioxidant properties\nHoney varieties have antioxidant effects, although potency can vary 20-fold between different floral sources (16364, 16365, 16366, 16367). Antioxidant content seems to be higher in darker honeys (16366, 16367). Antioxidants in honey have been demonstrated to be bioavailable, increasing plasma total phenolics, and plasma antioxidant and reducing capacities (16366, 16367, 55087). Also, antioxidant effects of honey have been shown in various laboratory models (55069, 55078, 55138). Constituents of honey responsible for the antioxidant effects include phenolic compounds, flavonoids, ascorbic acid, carotenoid-like substances, peptides, enzymes, and organic acids (16365, 16366, 16367). The phenolic compounds vary between different types of honey, but include 4-hydroxybenzoic and 4-hydroxycinnamic acids, coumaric acid, and abscisic acid (16365, 16366, 16367). Flavonoids identified in honey include pinobanksin, pinocembrin, chrysin, and galangin (16365, 16367). The ascorbic acid content is generally low (around 5 mg per 100 grams of honey) and may be lost during processing (16365).\nAntitumor activity\nIn surgery for some types of malignant cancer, cells from the tumor can become seeded in the wound margins during excision, resulting in growth of the cancer in the wound. Preliminary evidence from animal models suggests that honey can reduce the growth of these tumors, by impeding the seeding or inhibiting the growth of these cancer cells (7852). Also, animal research shows that honey may help reduce tumor volume (55082). Mechanisms of action may involve the promotion of apoptosis, or cancer cell death (55082).\nAntitussive effects\nIt is suggested that the beneficial effect of honey on coughs is due to its pleasant taste, which causes reflex salivation and promotes secretion of airway mucus to increase lubrication. The sweet taste may also promote production of endogenous opioids (16351).\nDermatologic effects\nTopical honey is of interest for atopic dermatitis. In vitro, manuka honey inhibits mast cell histamine release, as well as the induced secretion of a protein (CCL26) which plays a key role in the pathogenesis of the disease from keratinocytes (105239).\nGlycemic effects\nSome clinical research suggests that consuming honey modestly decreases fasting and postprandial blood glucose and/or glycated hemoglobin (HbA1C) when compared to other sources of sugar in patients with or without diabetes (55087, 55090, 55136, 55150, 55263, 55268, 101037). However, there is also some evidence that honey can increase HbA1c in patients with type 2 diabetes (55182). Laboratory research suggests that the fructose and oligosaccharide constituents of honey can help stimulate insulin release and/or uptake of glucose (55240, 55243). It is unclear as to whether the effects of honey on the glycemic index are dependent on the type of honey used or the fructose to glucose ratios (55104, 55179, 101040). In humans, the glycemic index of different types of Greek honey was negatively correlated to the ratios of sucrose to oligosaccharides or fructose to glucose, as well as the actual content of sucrose or fructose (101040).\nHormonal effects\nHoney may help reduce symptoms of menopause, possibly due to hormonal effects. In animal research, a type of honey called Tualang honey improved the health of the uterus, vaginal cells, and tibia bones in the legs. The honey also reduced body weight. It is possible that these benefits were due to effects of the honey on hormone levels; estradiol and progesterone levels were lower, and testosterone levels were higher than animals of this model not treated with honey (91371).\nMetabolic effects\nThere is interest in using honey for beneficial metabolic effects. Eating honey instead of sugar might increase satiety and reduce overconsumption of calories and unhealthy fats. A small clinical study in healthy patients shows that eating clover honey increases satiety and reduces calorie, carbohydrate, and saturated fat consumption, when compared with consuming an isocaloric amount of sucrose (103960).\nPrebiotic effects\nIn premature infants, adding a medical-grade honey to formula increased levels of probiotic bacteria in the gut, including bifidobacteria and lactobacilli. It is not clear if this probiotic effect produced a clinical benefit (97697).\nWound healing effects\nHoney is thought to help in wound healing by several mechanisms. It provides a protective barrier due to its viscosity, and prevents adhesion of dressings to wounds (16354, 16355). It maintains a moist healing environment, encouraging epithelialization and reducing scarring, and may provide nutrients for the wound healing process (16354, 16355). Increased rates of angiogenesis, granulation, and epithelialization have been reported (16356, 16360). Enzymes and hydrogen peroxide in honey can aid in debridement (395, 396, 399, 7849, 16355, 16356). It also draws lymph into the wound by osmosis, which helps to flush bacteria and debris out of the wound (16355, 16356).\n\nThe low pH of honey, with a mean of 4.4, reduces the activity of proteases, which destroy growth factors and protein fibers produced during the wound healing process (16356). Glucose oxidase, a compound in honey, produces gluconic acid and hydrogen peroxide in the wound (16364, 16356). This hydrogen peroxide is released continuously in very low concentrations which are sufficient to produce antibacterial effects, but do not seem to cause the tissue damage associated with topical application of hydrogen peroxide solutions (16355). Since glucose oxidase is destroyed by heat and light, the ability of honey to generate hydrogen peroxide can be lost during processing or aging (16368). Honeys from different botanical sources also vary in hydrogen peroxide production; for example, manuka honey generates very little hydrogen peroxide (16364, 16369).\n\nHoney can prevent and remove odors associated with wounds, probably because bacteria use its sugars for energy, producing lactic acid instead of the ammonia, amines, and sulfur compounds produced when proteins from dead cells and serum are metabolized for energy (16354, 16355). Also, applying honey has been shown to improve bacterial clearance from the wound (101032).\n\nIn vitro studies indicate that honey has anti-inflammatory activity, increases the activity of phagocytes, causes B- and T-lymphocyte proliferation, and can stimulate monocytes and macrophages to produce cytokines, including tumor necrosis factor alpha and interleukins 1 and 6, which play a role in wound healing (16359, 16360, 16362, 16363, 55078, 55084). A non-protein component has been isolated from manuka honey (produced with nectar from Leptospermum scoparium), which binds to TLR4 receptors on monocytes, but it has not been fully identified (16359)."
        }
    },
    "Honeysuckle": {
        "sections": {
            "Overview": "Honeysuckle is a group of flowering shrubs or twining vines. Traditionally, it has been used as medicine, especially in parts of Asia, for various purposes, including treating pain, fever, bacterial and viral infections, gastrointestinal disorders, and metabolic conditions (12606, 12607, 106515, 112867, 112868).",
            "Safety": "POSSIBLY SAFE when honeysuckle flower extract is used orally and appropriately, short-term. Honeysuckle flower extract has been used with apparent safety at doses up to 125 mg twice daily for up to 8 weeks (103877).\nThere is insufficient reliable information available about the safety of honeysuckle when used topically or intravenously.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, honeysuckle seems to be well tolerated. No adverse effects have been reported. There is insufficient reliable information available about the safety of honeysuckle when used topically. However, a thorough evaluation of safety outcomes has not been conducted.\nImmunologic\nTopically, applying honeysuckle to the skin has been associated with contact dermatitis in a case report (12611). Orally, a case of biopsy-confirmed allergic drug eruption is reported in a young adult male after taking honeysuckle granules 30 grams over a 24-hour period. Symptoms resolved with discontinuation of honeysuckle and 2-weeks of antihistamine and glucocorticoid therapy (112866).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAge-related cognitive decline. It is unclear if oral honeysuckle extract is beneficial in patients with age-related cognitive decline.\nA small clinical study in elderly adults shows that taking honeysuckle (Lonicera caerulea) berry extract 200-400 mg, 90 minutes prior to a cognitive test, improves episodic memory, but not working memory or executive function tasks, when compared with placebo (103876). The long-term effects of honeysuckle on cognitive decline are unclear.\nless\nAtopic dermatitis (eczema). Although there has been interest in using topical honeysuckle for atopic dermatitis, there is insufficient reliable information about the clinical effects of honeysuckle for this purpose.\nBronchiolitis. Intravenous honeysuckle has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in children with respiratory syncytial virus (RSV) infection shows that intravenous administration of a combination of honeysuckle, Baikal skullcap, and forsythia might decrease the duration of symptoms of bronchiolitis when compared with a control group (12613). It is unclear if these findings are due to honeysuckle, other ingredients, or the combination.\nless\nDiabetes. Although there has been interest in using oral honeysuckle for diabetes, there is insufficient reliable information about the clinical effects of honeysuckle for this purpose.\nDyspepsia. It is unclear if oral honeysuckle flower bud extract is beneficial in patients with dyspepsia.\nA small clinical study in patients with functional dyspepsia shows that taking honeysuckle (Lonicera japonica) flower bud extract 125 mg twice daily for 8 weeks improves gastrointestinal symptom scores when compared with placebo (103877).\nless\nPostoperative infection. Topical honeysuckle has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA large open-label trial in adults with obstructive sleep apnea recovering from uvulopalatopharyngoplasty shows that gargling with honeysuckle in combination with numerous other herbs 25 mL for 5 minutes 4 times daily for 2 weeks does not reduce post-operative wound infection when compared with saline placebo (112867). The interpretation of this study is limited by the unclear dose of honeysuckle.\nless\nPostoperative pain. Topical honeysuckle has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA large open-label trial in adults with obstructive sleep apnea recovering from uvulopalatopharyngoplasty shows that gargling with honeysuckle in combination with numerous other herbs 25 mL for 5 minutes 4 times daily for 2 weeks improves post-operative resting, swallowing throat pain, and patient comfort when compared with saline placebo (112867). It is unclear if this effect is due to honeysuckle, other ingredients, or the combination. The interpretation of this study is also limited by the unclear dose of honeysuckle.\nless\nPruritus. Although there has been interest in using topical honeysuckle for pruritus, there is insufficient reliable information about the clinical effects of honeysuckle for this purpose.\nRespiratory tract infections. Although there has been interest in using oral honeysuckle for various respiratory tract infections, including bronchitis, the common cold, influenza, and pneumonia, there is insufficient reliable information about the clinical effects of honeysuckle for these conditions.\nRheumatoid arthritis (RA). Although there has been interest in using oral honeysuckle for RA, there is insufficient reliable information about the clinical effects of honeysuckle for this purpose.\nUrinary tract infections (UTIs). Although there has been interest in using oral honeysuckle for UTIs, there is insufficient reliable information about the clinical effects of honeysuckle for this purpose.\nWound healing. Although there has been interest in using topical honeysuckle for wound healing, there is insufficient reliable information about the clinical effects of honeysuckle for this purpose.\nMore evidence is needed to rate honeysuckle for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of honeysuckle.",
            "Interactions with Drugs": "ANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, honeysuckle might increase the risk of bleeding when taken with anticoagulant or antiplatelet drugs.\nIn vitro research shows that polyphenols extracted from honeysuckle can inhibit platelet aggregation (12610).\nless",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, honeysuckle might have antiplatelet effects.\nTaking honeysuckle with other products that increase the risk of bleeding might have additive effects. In vitro research shows that polyphenols extracted from honeysuckle can inhibit platelet aggregation (12610). See products with anticoagulant activity here. See products with antiplatelet activity here.\nless",
            "Interactions with Conditions": "PERIOPERATIVE\nHoneysuckle has antiplatelet effects (12610), which might cause excessive bleeding if used perioperatively. Tell patients to discontinue honeysuckle at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with honeysuckle.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of honeysuckle.",
            "Mechanism of Action": "General\nThe applicable parts of honeysuckle are the flower, seed, berry, and leaf. Honeysuckle contains essential oils, saponins, terpenoids, flavonoids, phenolics, and other compounds including daidzen, beta-sitosterol, luteolin, loganin, linalool, d-limonene, quercetin, kaempferol, chlorogenic acid and macranthoidin B (12604, 12608, 106515, 112868, 112869, 112871). The most abundant polyphenolic constituents in honeysuckle berry extract include chlorogenic acid, cyanidin-3-glucoside, and quercetin (106515).\nAnalgesic effects\nHoneysuckle is traditionally used for pain. Animal research shows honeysuckle flower essential oil decreases the pain response to painful stimuli such as heat and acids at least as well as analgesic medications (112869).\nAnti-bacterial effects\nHoneysuckle is traditionally used for treating bacterial infections. In vitro research shows honeysuckle dried powder extract, as well as constituents luteolin, quercetin, and kaempferol, inhibit Bacillus cereus and appear to do so by destroying the bacterial cell wall and membrane (112871).\nAnti-inflammatory effects\nHoneysuckle is traditionally used orally and topically for inflammatory illnesses. In vitro, the honeysuckle flavonoid, luteolin, inhibits tumor necrosis factor (TNF)-alpha and interleukin (IL)-8 production in intestinal cells, suggesting it might be useful for intestinal inflammatory disorders (12605). An aqueous extract of honeysuckle also seems to have anti-inflammatory effects in animal models of inflammation (12606). The loniceroside saponins of honeysuckle appear to have anti-inflammatory activity (12607).\nAnti-oxidant effects\nSome of the potential beneficial effects of honeysuckle may be attributed to anti-oxidant and free radical scavenging effects. In vitro research shows honeysuckle flower essential oil to exhibit anti-oxidant activity; particularly free radical scavenging activity (112869). Other research in mice with atopic dermatitis found oral honeysuckle extract to reduce reactive oxygen species (112870).\nAntiviral effects\nHoneysuckle is traditionally used for viral illnesses such as influenza, swine flu, and pneumonia. In vitro research suggests that tannins from honeysuckle might inhibit reverse transcriptase activity of human immunodeficiency virus (HIV) (12609). Additional animal and in vitro studies show that honeysuckle extracts can inhibit the replication of influenza viruses, including H1N1, H3N2, and oseltamivir-resistant H1N1 strains, through inhibition of viral neuraminidase, thereby suppressing the release of influenza virus from host cells (106514).\nContraceptive effects\nTraditionally, honeysuckle is used as a contraceptive. Honeysuckle might have contraceptive activity by inhibiting implantation, similar to oral contraceptives (12612).\nDermatologic effects\nAnimal research shows that honeysuckle extract improves atopic dermatitis. In mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis, oral honeysuckle extract reduced skin lesions, inhibited skin hyperplasia, and reduced mast cell number, reactive oxygen species, levels of immunoglobulin E, interleukin-17, thymic stromal lymphoprotein, and NLRP3 inflammasome activation (112870).\nHepatoprotective effects\nThere is interest in using honeysuckle to prevent liver disease, including nonalcoholic fatty liver disease (NAFLD). Animal research shows that honeysuckle (Lonicera caerulea) berry extract has hepatoprotective effects, possibly through antioxidant effects and by increasing hepatic glucose enzyme activity and upregulating genes involved in lipid metabolism (103878).\nLipid effects\nIn vitro research shows that polyphenols extracted from honeysuckle reduce the expression of fatty acid synthase and increase phosphorylation of acetyl-CoA carboxylase, important enzymes in the biosynthesis of fatty acids. This might lead to an inhibition of lipid accumulation in adipocytes (106515).\nWound healing effects\nAnimal research shows an ointment with honeysuckle flower essential oil 1% and 2% concentration to improve lacerated skin wound healing better than standard treatment (112869). Analysis indicates this may be due to the essential oil-induced increase in hydroxyproline levels, collagen deposition, and re-epithelialization in the healing skin."
        }
    },
    "Hoodia": {
        "sections": {
            "Overview": "Hoodia is a succulent that grows in the Kalahari Desert (91610). It is claimed that the San bushmen eat hoodia to stave off hunger during long hunts (91607, 91611).",
            "Safety": "There is insufficient reliable information available about the safety of hoodia.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, hoodia has been reported to cause minor adverse effects including disturbances of skin sensation, headache, dizziness, giddiness, and nausea (18052). There is also concern that hoodia may increase blood pressure and heart rate (18052).\nCardiovascular\nOrally, hoodia might increase blood pressure and heart rate. Clinical research in healthy women shows that intake of purified hoodia extract containing steroid glycosides increases systolic blood pressure by 5.9 to 15.9 mmHg, diastolic blood pressure by 4.6 to 11.5 mmHg, and heart rate by 4.8 to 12.4 beats per minute (18052).\nless\nDermatologic\nOrally, hoodia extract has been reported to cause disturbances of skin sensation (18052).\nless\nGastrointestinal\nOrally, hoodia extract has been reported to cause nausea (18052).\nless\nNeurologic/CNS\nOrally, hoodia extract has been reported to cause headache, dizziness, and giddiness (18052).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nObesity. Clinical evidence shows that drinking a raspberry-flavored yogurt drink containing hoodia purified extract 1110 mg twice daily for 15 days does not reduce energy intake or body weight compared to placebo in overweight women (18052).\nMore evidence is needed to rate hoodia for this use.",
            "Dosing & Administration": "Adult\nThere is insufficient information available about the dosing of hoodia.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hoodia. Additionally, some reports suggest that some samples of hoodia products sold on the Internet show no evidence of containing actual hoodia (12002).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nAnimal research shows that a steroid glycoside of hoodia, gordonoside F, increases glucose-stimulated insulin secretion by activating GPR119. This effect enhances glucose disposal (91614). Theoretically, concomitant use of hoodia with antidiabetes medications may enhance blood glucose-lowering effects and increase the risk of hypoglycemia. Some antidiabetes medications include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), chlorpropamide (Diabinese), glipizide (Glucotrol), tolbutamide (Orinase), and others.\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nClinical research shows that hoodia can increase blood pressure (18052). Theoretically, concomitant use of hoodia with antihypertensive drugs might decrease the effectiveness of the antihypertensive drugs and increase the risk of hypertension. Some antihypertensive drugs include captopril (Capoten), enalapril (Vasotec), losartan (Cozaar), valsartan (Diovan), diltiazem (Cardizem), Amlodipine (Norvasc), hydrochlorothiazide (HydroDiuril), furosemide (Lasix), and many others.\nBETA-BLOCKERS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nEvidence from in vitro research shows that hoodia may stimulate beta-adrenergic receptors (91607). Also, clinical research shows that hoodia can increase blood pressure and heart rate (18052). Theoretically, using hoodia with beta-blockers might decrease the effects of these medications. Some beta-blocker drugs include atenolol (Tenormin), metoprolol (Lopressor, Toprol XL), nadolol (Corgard), and propranolol (Inderal).\nINSULIN\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nAnimal research shows that a steroid glycoside of hoodia, gordonoside F, increases glucose-stimulated insulin secretion by activating GPR119 (91614). Theoretically, concomitant use of hoodia with insulin may enhance the blood glucose-lowering effects of insulin. Blood glucose levels should be monitored.",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nEvidence from animal research shows that a steroid glycoside of hoodia, gordonoside F, increases glucose-stimulated insulin secretion and glucose disposal (91614). Theoretically, it might have additive effects when used with other herbs and supplements that also lower glucose levels. This might increase the risk of hypoglycemia in some patients. Some herbs and supplements with hypoglycemic effects include alpha-lipoic acid, bitter melon, chromium, devil's claw, fenugreek, garlic, guar gum, horse chestnut, Panax ginseng, psyllium, Siberian ginseng, and others.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nDIABETES\nHoodia might affect blood glucose control in some patients with diabetes by enhancing glucose-stimulated insulin secretion (91614). Blood glucose levels should be monitored closely.\nless\nHYPERTENSION\nHoodia may increase blood pressure (18052). Theoretically, hoodia may worsen hypertension.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxic effects of hoodia in humans.\n\nAnimal research shows that the no-observable-adverse-effects level for hoodia extract is 3-5 mg/kg daily in pregnant mice and rabbits (91608, 91609). In pregnant rabbits, higher doses (up to 12 mg/kg daily) do not seem to affect fetal development, although maternal feed consumption is reduced (91609). However, in pregnant mice, higher doses of hoodia extract (up to 50 mg/kg daily) appear to delay fetal development by reducing maternal feed consumption (91608). It is unclear if this type of delayed fetal development would occur in humans.\n\nIn vitro and animal research suggests that hoodia extract is not mutagenic or genotoxic (91610).",
            "Pharmacokinetics": "Absorption\nFollowing ingestion of hoodia purified extract, the time to peak plasma concentration of a hoodia steroid glycoside constituent is 45-50 minutes (18052).\nExcretion\nThe elimination half-life of a steroid glycoside constituent of hoodia is 50 minutes (18052).",
            "Mechanism of Action": "General\nThe applicable parts of hoodia are the stems and roots.\nAntidepressant effects\nAnimal research suggests that hoodia extract may have antidepressant effects. In mice, acute administration of hoodia extract increases serotonin levels in a part of the brain called the striatum, while chronic administration increases serotonin, norepinephrine, and dopamine levels (91606).\nSympathomimetic effects\nClinical research shows that a purified hoodia extract containing steroid glycosides can increase blood pressure and heart rate in healthy women, suggesting possible sympathomimetic effects (18052). In rats, a specific hoodia spray (Fytofontana Dietceutical Hoodia spray, Herb-Pharma Hu Ltd.) causes a dose-dependent relaxation of spontaneous and stimulated contractions of uterine rings. This relaxing effect is more pronounced in non-pregnant rather than late-pregnant rats. The sympathomimetic activity is attributed to the stimulation of beta-adrenergic receptors (91607).\nWeight loss effects\nSome research suggests that a specific component of hoodia extract, P57, is responsible for the proposed appetite suppressant properties of hoodia. P57 is an oxypregnane glycoside (12002, 91606), and is thought to act centrally to stimulate sensations of satiety (55322). The precise mechanism is not known. Preliminary unpublished evidence suggests that overweight men who consume P57 have significantly lower calorie intake than those on placebo (12004). Other preliminary research suggests that another constituent of hoodia, gordonoside F, is responsible for the anorexant effects of hoodia. Evidence from animal research shows that gordonoside F, a steroid glycoside, activates GPR119, a receptor expressed in pancreatic beta cells and intestinal L cells. In mice, this activation suppresses appetite by increasing insulin secretion (91614). P57 does not appear to activate GPR119, suggesting that if it is also an active constituent, it works via a different mechanism (91614)."
        }
    },
    "Hops": {
        "sections": {
            "Overview": "Hops are cone-like structures, or flowers, of Humulus lupulus, a twining vine that is native to Eurasia and temperate regions of North America. The term \"hops\" originates from the Anglo-Saxon term \"hoppan\", meaning \"to climb\" (91967). Hops have been used as food flavoring and for brewing beer (55417). Hops extract is used in skin creams and lotions.",
            "Safety": "LIKELY SAFE when consumed in amounts commonly found in foods. Hops extract and hops oil have Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when hops extract and hops-derived bitter acids are used orally and appropriately for medicinal purposes, short-term. Hops extract has been used with apparent safety in doses of up to 300 mg daily for 2-3 months. Hops-derived bitter acids have been used with apparent safety at a dose of 35 mg daily for 3 months (12, 55338, 55370, 102899, 105953, 107813).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, hops extract and oil are generally well tolerated when used in food amounts. Hops extract also seems to be well tolerated when used in supplemental amounts.\nMost Common Adverse Effects\nOrally: Drowsiness, sedation.\nDermatologic\nTopically, allergic reactions have been reported after contact with the fresh hops plant and plant dust. Contact dermatitis is attributed to the pollen (4, 12, 105930).\nless\nGenitourinary\nOrally, supplements containing hops and soy have been associated with 4 cases of postmenopausal bleeding (55404). It is unclear if this effect is due to hops, soy, or the combination. Also, menstrual disturbances have been reported in female workers harvesting hops (10684, 55405).\nless\nNeurologic/CNS\nOrally, hops might cause drowsiness and sedation. Historically, hops are thought to have sedative effects, since workers harvesting hops were observed to tire easily after oral contact with hop resin. The European Medicines Agency states that hops may have sedative effects; however, there is a lack of clinical research confirming that hops extract causes drowsiness and sedation (105930).\nless\nPulmonary/Respiratory\nOccupational exposure to dust from hops, usually in combination with dust from other products, is associated with chronic respiratory symptoms such as dry cough, dyspnea, chronic bronchitis, and other occupational respiratory diseases (55333, 55414).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAge-related cognitive decline. It is unclear if oral hops-derived bitter acids are beneficial for memory and attention in patients with age-related cognitive decline.\nA small exploratory clinical study in older adults aged 45-64 years, with self-awareness of cognitive decline, shows that taking matured hops bitter acids (Kirin Holdings Co. Ltd) 35 mg daily for 12 weeks does not improve memory, attention, or performance on most cognitive tests when compared with placebo (102899). A follow-up clinical study in patients aged 45-69 years with subjective cognitive decline shows that taking the same dose of the same product for 12 weeks also does not improve memory, learning, or selective attention, but might improve divided attention as measured on the Symbol Digit Modalities Test (SDMT), when compared with placebo (105953). Both studies were funded by the supplement manufacturer and conducted in Japan; it is unclear if these findings are generalizable to other geographic locations.\nless\nAnxiety. Although there is interest in using oral hops for anxiety, there is insufficient reliable information about the clinical effects of hops for this condition.\nAttention deficit-hyperactivity disorder (ADHD). Although there is interest in using oral hops for ADHD, there is insufficient reliable information about the clinical effects of hops for this condition.\nBody odor. Although there is interest in using topical hops to reduce body odor, there is insufficient reliable information about the clinical effects of hops for this purpose.\nDyspepsia. Although there is interest in using oral hops-derived bitter acids for dyspepsia, there is insufficient reliable information about the clinical effects of hops for this condition.\nInsomnia. Taking oral hops extract in combination with valerian root extract seems to be modestly beneficial in patients with insomnia. However, the effect of hops extract when used alone is unclear.\nIn patients with diagnosed sleep disorders, taking hops extract in combination with valerian root for at least 28 days seems to be beneficial. One clinical study in adults with mild insomnia shows that taking two tablets of a combination product containing a total of 83.8 mg hops extract and 374 mg valerian root extract nightly seems to modestly improve subjective sleep measures, including sleep latency, when compared with placebo, after 28 days. However, there was no difference in efficacy between treatment groups after only 14 days (15018). Additionally, a small clinical study in patients with non-organic sleep disorders shows that taking a specific fixed combination product (Ze91019) containing hops extract 120 mg and valerian root extract 500 mg daily for 28 days improves sleep latency when compared with placebo (19413).\n\nIt is unclear if taking hops and valerian root as a single dose is beneficial in healthy patients. One small clinical study in healthy volunteers with poor sleep shows that taking a specific preparation (Dormeasan, Bioforce AG) containing hops extract 460 mg and valerian root extract 460 mg dissolved in 50 mL of honey water once at night increases total sleep time and time spent in deep sleep when compared with placebo (19418). However, another preliminary clinical study in healthy adults shows that taking a single dose of a specific product (Hova, Zyma S.A.) containing hops extract 200 mg and valerian root extract 400 mg does not improve sleep latency when compared with placebo (6248).\n\nResearch also shows that taking certain combination products containing hops and at least two other ingredients can improve sleep quality. These combination products have combined hops with lemon balm and valerian (Valerina Natt) (19417); or passionflower and valerian (NSF-3, M/s Tablets India) (88193, 89406). However, other combination products have not been beneficial. These have combined hops with soya oil, soya lecithin, and cannabis (Cyclamax, Persee Medica) (55382); or with vitamin B6, zizyphus extract, hydrolyzed milk protein (Lactium), and magnesium oxide (LZ Complex3, Sanofi) (95971).\nless\nLactation. Although there is interest in using oral hops for increasing lactation, there is insufficient reliable information about the clinical effects of hops for this purpose.\nMenopausal symptoms. It is unclear if oral hops extract is beneficial in patients with menopausal symptoms.\nSmall clinical studies in patients with menopausal symptoms show that taking a specific hops extract (MenoHop, Biodynamics) 75.1-300 mg standardized to contain 100-200 mcg of 8-prenylnaringenin daily does not improve menopausal symptoms, including hot flashes, after 8-12 weeks of treatment when compared with placebo (55338, 55370).\nless\nObesity. It is unclear if administering bitter hops extract intraduodenally or intragastrically is beneficial in patients with obesity.\nA very small clinical study in healthy young adult males shows that intraduodenal or intragastric administration of bitter hops extract 100-250 mg once does not affect appetite perception, gastrointestinal symptoms, or subsequent energy intake when compared with control (112233). It is unclear if these results are generalizable to individuals with overweight or obesity.\nless\nOveractive bladder. Oral hops extract has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nAn observational study in females with overactive bladder suggests that taking a specific combination product (Granu Fink femina, Omega Pharma) containing hops extract 18 mg, sweet sumac bark extract 56 mg, and pumpkin seed oil 227 mg three times daily for 12 weeks decreases the frequency of urination from an average of 0.9 to 0.4 episodes daily and the frequency of leakage when compared with baseline. The study also shows this specific combination product (Granu Fink femina, Omega Pharma) improves quality of life when compared with baseline (103253). The validity of these findings is limited by the lack of a control group. Also, it is unclear if these findings are due to hops extract, other ingredients, or the combination.\nless\nPsychological well-being. It is unclear if drinking non-alcoholic beer containing matured hops bitter acids is beneficial in healthy adults.\nA clinical study in healthy adults shows that consuming 350 mL of non-alcoholic beer containing matured hops bitter acids 35 mg (Kirin Holdings Co. Ltd) daily for 3 weeks improves mood scores on the Profile of Mood States 2 (POMS2) and Two-dimensional Mood Scale (TDMS) when compared with baseline (107813). The validity of these findings is limited by the lack of a control group.\nless\nSexual dysfunction. It is unclear if topical hops gel is beneficial in patients with postmenopausal vaginal atrophy.\nA small clinical study in adults with postmenopausal vaginal atrophy shows that applying intravaginal topical gel containing hops extract (Barij Essence) daily for 7 days and then twice weekly thereafter for 2 months does not improve sexual desire, sexual arousal, vaginal lubrication, satisfaction, orgasm, sexual pain, or overall measures of sexual dysfunction when compared with intravaginal estradiol (112125). The validity of these effects is limited by baseline differences between groups.\nless\nShift work disorder. It is unclear if drinking non-alcoholic beer containing hops is beneficial in patients with shift work disorder.\nA small open-label clinical study in healthy female nurses working rotating or night shifts shows that drinking 333 mL of non-alcoholic beer containing hops (San Miguel 0% alcohol) at dinner for 2 weeks reduces sleep latency by about 8 minutes, total activity during the night, andanxiety when compared with baseline. However, it does not appear to increase the duration of sleep (55403). The validity of these findings is limited by the lack of a control group and unconfirmed hops content in the beer.\nless\nVaginal atrophy. Topical hops extract has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nAn open-label, multicenter clinical study in postmenopausal patients with vaginal atrophy shows that inserting 2.5 grams of a vaginal gel containing hops extract 1%, hyaluronic acid, liposomes, and vitamin E (Gynomunal Vaginal gel or Esvegyne, Polichem SA) into the vagina daily for one week followed by twice weekly for 11 weeks reduces vaginal dryness, burning, itching, and rash when compared with baseline (55339). The validity of these findings is limited by the lack of a control group. Also, it is unclear if these effects are due to hops, other ingredients, or the combination.\nless\nVenous leg ulcers. Although there is interest in using topical hops for venous leg ulcers, there is insufficient reliable information about the clinical effects of hops for this condition.\nMore evidence is needed to rate hops for these uses.",
            "Dosing & Administration": "Adult\nOral and topical:Research is limited; typical dosing is unavailable.\nStandardization & Formulation\nTablets (15018) and capsules (55338, 55370) containing hops extracts have been used in clinical research. A specific hops extract (MenoHop, Biodynamics) is standardized to contain 250 mcg of 8-prenylnaringenin per 300-mg dose (55338). Another specific hops extract (Amarasate, Plant & Food Research Ltd.), a supercritical carbon dioxide extract of hops cones, is comprised of 51.5% total alpha-acids (cohumulone, humulone, adhumulone) and 28.3% total beta-acids (colupulone, lupulone, adlupulone) (107812). Vaginal gels, topical creams, and oral tablets and capsules containing hops in combination with other ingredients also have been used in clinical research (15018, 55339, 89406).\n\nHops-derived bitter acids, which are primarily comprised of iso-alpha-acids, have also been used in clinical research. Matured hops bitter acids, which are generated by oxidizing the alpha- and beta-acids found in hops, have also been used. One specific product manufactured by Kirin Holdings Co. Ltd contains the following matured hops bitter acids: 4'-hydroxyallohumulinones,4'-hydroxyalloisohumulones, tricyclooxyisohumulones A, hulupones, and humulinones (102899, 105953).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nCNS DEPRESSANTS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use of hops with sedative drugs might cause additive sedation.\nSome animal research shows that hops has sedative effects (55415, 55340, 105930).\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMODERATE\nOccurrence\nUNLIKELY\nLevel of Evidence\nD (In vitro or animal study)\nHops extract does not seem to affect the metabolism of CYP1A2 substrates.\nIn vitro research suggests that flavonoid constituents of hops inhibit CYP1A2 enzyme activity (10686). However, a pharmacokinetic study in healthy postmenopausal patients shows that taking a standardized extract of spent hops containing prenylated phenols, as 59.5 mg twice daily for 2 weeks, does not affect levels of caffeine, a CYP1A2 probe substrate (105954).\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hops extract might alter metabolism of CYP3A4 substrates; however, this effect may not be clinically significant.\nAnimal research suggests that specific constituents of hops, called lupulones, can induce hepatic CYP3A4 enzyme activity (55325). However, a pharmacokinetic study in healthy postmenopausal patients with normal metabolism shows that taking a standardized extract of spent hops containing prenylated phenols, as 59.5 mg twice daily for 2 weeks, decreases the concentration of alprazolam, a CYP3A4 probe substrate, by 7.6%. This reduction is unlikely to be clinically relevant (105954).\nless\nESTROGENS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concomitant use of large amounts of hops might interfere with hormone replacement therapy due to competition for estrogen receptors.\nIn vitro research suggests that certain hops constituents can competitively bind to estrogen receptors (3701, 10684, 10685). However, most hops extracts contain very small amounts of these constituents (105930).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS AND SUPPLEMENTS WITH SEDATIVE PROPERTIES\nHops might have sedative effects.\nSome animal research shows that hops has sedative effects (55415, 55340). Theoretically, concomitant use of hops with herbs that have sedative properties might increase therapeutic and adverse effects. See other products with sedative effects here.\nless\nHERBS WITH ESTROGENIC ACTIVITY\nHops extract might have estrogenic activity.\nIn vitro research suggests that certain hops constituents can competitively bind to estrogen receptors (3701, 10684, 10685). However, most hops extracts contain very small amounts of these constituents (105930). Theoretically, hops could have additive effects with other products that have estrogenic activity.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nHORMONE SENSITIVE CANCERS/CONDITIONS\nTheoretically, hops might have adverse effects in patients with hormone-sensitive conditions. Some constituents of hops have estrogenic activity; however, most hops extracts contain very small amounts of these constituents (3701, 10684, 10685, 105930). Patients with hormone sensitive conditions should use hops with caution. Some of these conditions include breast, uterine, and ovarian cancer; endometriosis; and uterine fibroids.\nless\nPERIOPERATIVE\nTheoretically, hops might cause additive sedation when combined with anesthesia and other medications used during and after surgical procedures. Some animal research shows that hops has sedative effects (55415, 55340, 105930). Tell patients to discontinue hops at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hops.",
            "Pharmacokinetics": "Absorption\nA small clinical study in healthy females shows that taking a hops extract containing xanthohumol 2 mg, isoxanthohumol 1.2 mg, and 8-prenylnaringenin (8-PN) 0.1 mg three times daily for 5 days results in the following mean serum concentrations: xanthohumol, 5 nmol/L; isoxanthohumol, 14.9 nmol; and 8-PN, 2.2 nmol (55380). Absorption of hops constituents is described as \"slow\" and is affected by the demethylation of isoxanthohumol into 8-PN by intestinal microbiota in the distal colon (55380, 105954).\nDistribution\nWhen taken orally, the hops constituents xanthohumol, isoxanthohumol, and 8-PN appear to be distributed to glandular tissue, adipose/glandular tissue, and adipose breast tissue in healthy females (55380).\nMetabolism\nThe hops constituents xanthohumol, isoxanthohumol, and 8-PN appear to primarily undergo phase II metabolism and partially undergo phase I metabolism. Phase I metabolism includes demethylation of isoxanthuhumol to 8-PN. Phase II conjugation results in monoglucuronides, monosulfates, diglucuronides, and sulfate-glucuronic acid diconjugates (55380, 105954).\nExcretion\nThe prenylated phenols in hops, xanthohumol, isoxanthohumol, 6-prenylnaringenin, and 8-PN, are reported to have half-lives of more than 20 hours (55380, 105954).",
            "Mechanism of Action": "General\nThe applicable part of hops is the dried, female flowering part (strobile), also known as the cone. Hops contain several flavonoids including the isoprenylated chalcone xanthohumol, the isoprenylated flavanone isoxanthohumol, and others flavonoids such as 6-prenylnaringenin (6-PN), 8-prenylnaringenin (8-PN), quercetin, rutin, and astragalin (10683, 97014). Xanthohumol occurs at levels of 0.1% to 1% in the lupulin, also known as the hops resin. Hops also contain bitter acids, or iso-alpha acids (IAAs), which contribute to its bitter flavor. When oxidized, the alpha- and beta-acids found in hops convert to matured hops bitter acids, which have similar chemical structures to IAAs and include 4'-hydroxyallohumulinones, 4'-hydroxyalloisohumulones, tricyclooxyisohumulones A, hulupones, and humulinones (102899, 105953).\nAnti-inflammatory effects\nAnimal research suggests that xanthohumol in hops has anti-inflammatory activity (14384). Xanthohumol appears to inhibit lipopolysaccharide (LPS)-induced production of the inflammatory cytokines monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and interleukin-1 (IL-1) in a human monocytic cell line and mouse macrophages (55355, 55372). Xanthohumol also appears to inhibit LPS-induced production of nitric oxide (NO) and the cytokines IL-1beta and tumor necrosis factor (TNF)-alpha in a mouse-derived brain (microglial) cells (55390).\n\nHumulon, another constituent of hops, has also shown anti-inflammatory activity in animal research. Humulon can inhibit ear inflammation caused by arachidonic acid in mice (55409).\n\nHops bitter acids, including alpha-acids, beta-acids, and iso-alpha acids, have also shown anti-inflammatory activity. Hops bitter acids blocked TNF-alpha-induced production of IL-6 and inhibited the transactivation of the proinflammatory transcription factors NF-kappaB, activator protein-1 (AP-1), and cAMP-response element-binding protein in fibroblast cells. This anti-inflammatory effect was independent of glucocorticoid receptor-alpha and peroxisome proliferators-activated receptor-alpha or -gamma (55356). Other in vitro research suggests that rho-iso-alpha acids from hops can inhibit LPS-induced production of nitric oxide in macrophage cells, as well as reduce collagen-induced arthritis in an animal model (55357).\n\nIn humans, hops extract decreases complement C3 fraction, C-reactive protein levels, and IL-6 levels (55418).\nAntiangiogenic effects\nIn vitro and ex vivo studies suggests that the hops constituent xanthohumol and its metabolite isoxanthohumol reduce blood vessel formation, while the xanthohumol metabolite 8-prenylnaringenin stimulates angiogenesis (55385).\nAnticancer effects\nXanthohumol is thought to have several pharmacological effects, including potential anticancer activity (34008). Preliminary research suggests that xanthohumol inhibits metabolic activation of food-borne carcinogens and induces phase II enzymes involved metabolizing or detoxifying potentially harmful xenobiotics (14384, 55324). Xanthohumol and xanthohumol D have also been identified as ligands of quinone reductase-2, which is a target for chemopreventive drugs (55394).\n\nIn addition to its chemopreventive effects, there is interest in hops and the xanthohumol constituent for prostate cancer. In vitro research suggests that xanthohumol and a derivative can induce apoptosis in benign prostate hyperplasia and malignant prostate cancer cells (14386, 55374). These constituents seem to activate pro-apoptotic proteins Bax and p53. The constituents also seem to decrease activation of NF-kappaB (14386, 55387). Similarly, xanthohumol appears to inhibit the proliferation of liver cancer cells by inhibiting NF-kappaB activity (55367).\n\nSome preliminary evidence suggests that hops might possess antiproliferative properties, indicating potential chemoprevention against breast cancer, ovarian cancer, and colorectal cancer (10683, 55345). One mechanism suggested includes the inhibition of the P450 enzymes that activate carcinogens (9990, 10686, 97014). Additional laboratory research shows that the hops constituent 6-prenylnaringenin induces the estrogen 2-hydroxylation pathway. This pathway has been associated with a reduction in breast cancer risk, possibly through a detoxification effect (97014).\nAntidiabetic effects\nIn animal models of diabetes and obesity, xanthohumol activates the nuclear receptor farnesoid X receptor (FXR) and improves lipid and glucose metabolism (14384). Isohumulones, which are bitter acids derived from hops, have been shown to activate peroxisome proliferator-activated receptors (PPAR)-alpha and PPAR-gamma in vitro and reduce insulin resistance in diabetic mice (55330). However, other animal research shows that hops does not affect glucose homeostasis in diabetic mice (37425). Other animal research suggests that colupulone, another hops constituent, can actually elevate serum glucose levels in diabetic mice (55410, 55412).\nAntimicrobial effects\nEssential oils and extracts of hops have shown antimicrobial activity against Gram-positive bacteria, Gram-negative bacteria, five strains of acne-causing bacteria, and one species of fungi in vitro (55328, 55342, 55427, 55428). Some research attributes the antibacterial effects of hops to its weak acid derivatives, including trans-isohumulone, humulone, colupulone, and trans-humulinic acid (55329). Tetrahydroiso-alpha acids have also shown antibacterial effects against Gram-positive and Gram-negative bacteria in vitro (55358).\n\nSome research has investigated the antiviral potential of the hops constituent xanthohumol. In vitro research shows that xanthohumol can enhance the antiviral effect of interferon-alpha-2b against bovine viral diarrhea virus, a surrogate of the hepatitis C virus, suggesting its potential benefit when used along with anti-hepatitis C regimens (55360).\nAntioxidant effects\nPreliminary research suggests that xanthohumol in hops has antioxidant effects (14384, 55342). Hops chalcones with alpha,beta-unsaturated ketone functionality have been shown to inhibit the oxidation of low-density lipoproteins (LDL) (55326). Also, extract from hops cones has been shown to reduce oxidative stress in blood platelets, similar to that of resveratrol (55396).\nCytochrome P450 (CYP) effects\nIn vitro research suggests that flavonoid constituents of hops can significantly inhibit CYP1A1, 1A2, and 1B1 enzyme activity (10686), while other in vitro research suggests that a specific constituent of hops, 6-PN, can induce CYP1A1 and CYP1B1 enzyme activity (97014). However, research in humans suggests that hops extract does not have a clinically relevant effect on CYP enzymes. A pharmacokinetic study in healthy postmenopausal patients with normal metabolism shows that taking an extract of spent hops 59.5 mg (containing 8-PN 0.25 mg, 6-PN 1.30 mg, isoxanthohumol 0.80 mg, and xanthohumol 21.3 mg) twice daily for 2 weeks does not alter the metabolism of CYP1A2, 2C9, or 2D6 substrates. The exposure to the probe substrates tolbutamide, caffeine, and dextromethorphan was not affected by hops extract. Also, the area under the curve for alprazolam, a probe substrate of CYP3A4, decreased by 7.6%, suggesting a clinically insignificant induction of CYP3A4 (105954).\nDermatologic effects\nIn vitro, hops extracts, xanthohumol, and the lupulones have shown strong inhibitory activities against five strains of acne-causing bacteria (55342). The hops constituents xanthohumol, humulones, and lupulones also appear to inhibit collagenase activity, suggesting that these constituents reduce collagen degradation (55342). The hops constituent xanthohumol also appears to inhibit elastase and matrix metalloproteinases, enzymes which contribute to the deterioration of collagen and elastin associated with skin aging. This constituent also increases the production of collagen, elastin, and fibrillin in the skin, which may improve skin structure and firmness (55378).\nGastrointestinal effects\nA very small clinical study in healthy young adult males shows that intraduodenal administration of bitter hop extract 250 mg modestly stimulates peptide YY but does not affect antropyloroduodenal pressures, cholecystokinin, appetite, gastrointestinal symptoms, or energy intake when compared with control. Additionally, no effects were seen when bitter hops extract was administered intraduodenally at a lower dose of 100 mg or when administered intragastrically (112233).\nHematologic effects\nLaboratory and animal research suggests that spent hops extract, as well as the hops constituent xanthohumol, inhibits whole blood platelet aggregation induced by adenosine diphosphate (ADP). The mechanism of action appears to be related to the reduced expression of both P-selectin and activated GPIIB/IIIa (97015).\nHepatic effects\nEvidence from animal research suggests that the hops constituent xanthohumol reduces liver inflammation and fibrosis in mice with nonalcoholic steatohepatitis (55368). However, xanthohumol does not appear to protect liver tissue from ischemia/reperfusion injury in rat liver (55361).\nHormonal effects\nThe hops flavonoids 8-PN and isoxanthohumol are thought to have weak estrogenic activity (10684, 10685, 34032, 55336). The 8-PN flavonoid is reported to have a similar or even greater estrogen-binding capacity as the isoflavone genistein, which is found in soy (11093, 105954). The 8-PN flavonoid binds to both alpha- and beta-estrogen receptors, but with a higher affinity for the beta-estrogen receptor. Hops extract also appears to competitively bind to estrogen receptor (ER)-alpha and ER-beta (9998). Furthermore, an extract of hops has been reported to competitively inhibit estradiol binding to estrogen receptors and induce transcription in estrogen-responsive cells (6180).\n\nHops also seem to decrease luteinizing hormone levels in female rats that have had their ovaries removed (6180).\n\nSome hops flavonoids inhibit aromatase in vitro. The most potent aromatase inhibitor is 8-PN, followed by xanthohumol and isoxanthohumol respectively (14385). This suggests that these compounds might have some antiestrogenic activity as well as estrogenic activity.\n\nLaboratory research shows that the hops constituent 6-PN induces the estrogen 2-hydroxylation pathway, which has been associated with a reduction in breast cancer risk, possibly through a detoxification effect. 6-PN also upregulates cytochrome P450 (CYP) 1A1 and 1B1 in breast cells, two enzymes involved in estrogen metabolism (97014).\nImmune effects\nIn vitro, xanthohumol from hops appears to inhibit T cell proliferation, the development of IL-2 activated killer (LAK) cells and cytotoxic T lymphocytes (CTLs), and the production of various Th1 cytokines, including interleukin (IL)-2, interferon (IFN)-gamma, and tumor necrosis factor (TNF)-alpha. This effect appears to be mediated through the suppression of NF-kappaB (55351). This suggests a potential immunosuppressive effect.\nLibido effects\nHops extract appears to have gender-specific libido effects. In hormone-primed female rats, hops extract has been shown to increase the preference for the stimulus male in a partner preference test and the number of proceptive behaviors in a receptivity test, without affecting the lordosis (swayback) response (55395). In nave male rats, however, hops extract exerted an aphrodisiac effect by inhibiting mounting and ejaculating behavior (55352).\nSedative effects\nMouse models have found hops to have sedative and hypnotic properties (55415). In mice, hops extracts showed a dose-dependent reduction of locomotor activity and an increase in narcotic-induced sleep duration (55340). The sedative effect was attributed to alpha-bitter acids and, to a lesser extent, beta-bitter acids and hops oil. Other animal models have found the hops alpha-acid 2-methyl-3-buten-2-ol diminishes animal motility by 50% when given intraperitoneally (55406, 55407, 55408). The effects of this hops constituent were found to be similar to the sedative drug methylpentynol. In fresh hops, there are only traces of this constituent, but the concentration of 2-methyl-3-butene-2-ol has been shown by other studies to continuously increase after drying, reaching maximum levels (approximately 0.15%) within two years of storage at room temperature. Pharmacologically relevant concentrations of this compound may be acquired in both tea and bath preparations (55429).\nThyroid effects\nIn rats, xanthohumol, a hops constituent, modulated hepatic expression of genes involved in thyroid hormone distribution and metabolism (55379).\nWeight loss effects\nA small clinical crossover study in 19 males with a healthy weight shows that taking a supercritical carbon dioxide hops cone extract (Amarasate, Plant & Food Research Ltd.) 500 mg, either in delayed-release capsules intended for duodenal delivery or in quick-release capsules intended for gastric delivery, prior to lunch reduces ad libitum energy intake in total and when snacking, but not at lunch, when compared with placebo (107812)."
        }
    },
    "Hordenine": {
        "sections": {
            "Overview": "Hordenine is a naturally occurring alkaloid structurally similar to tyramine, N-methyltyramine, and synephrine (29888). It is also structurally related to epinephrine and ephedrine (29021). It was first isolated from the cactus species Ariocarpus fissuratus in 1894 and later isolated from germinating barley in 1906 (19513, 89632). Hordenine gets its name from barley (Hordeum vulgare); it is formed in the roots during germination of barley grains (19513, 29814, 90338, 103276, 103277, 110674). It can also be found in a variety of algae, cacti, and grass species and is a minor constituent of bitter orange (27936, 29888). Hordenine is included as an ingredient in a variety of dietary supplements used for athletic performance and obesity (90346).",
            "Safety": "POSSIBLY UNSAFE when used orally. Hordenine is structurally similar to the stimulants N-methyltyramine and synephrine, constituents in bitter orange (29888). Theoretically, hordenine may exhibit stimulant properties similar to these compounds. However, animal research suggests that hordenine has low oral bioavailability and therefore stimulant effects may only be seen with high oral doses or with intravenous use (29021).\nPREGNANCY AND LACTATION: Insufficient reliable information is available; avoid using.",
            "Adverse Effects": "General\nNo clinical studies have evaluated the safety of hordenine in humans. However, hordenine is structurally similar to the stimulants N-methyltyramine and synephrine, which are found in bitter orange (29888). Theoretically, hordenine may cause stimulant-related side effects similar to these compounds, including tachycardia and hypertension.\nCardiovascular\nHordenine is structurally similar to the stimulants N-methyltyramine and synephrine, which are found in bitter orange (29888). Theoretically, hordenine may cause stimulant-related side effects similar to these compounds, including tachycardia and hypertension. However, this has not been assessed or reported in humans.\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of hordenine.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hordenine.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nCYTOCHROME P450 2D6 (CYP2D6) SUBSTRATES\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nHordenine weakly inhibits cytochrome P450 2D6 (CYP2D6) enzymes in vitro (91878). Theoretically, hordenine might increase the levels of CYP2D6 substrates.\nSome of drugs that are CYP2D6 substrates include amitriptyline (Elavil), clozapine (Clozaril), codeine, desipramine (Norpramin), donepezil (Aricept), fentanyl (Duragesic), flecainide (Tambocor), fluoxetine (Prozac), meperidine (Demerol), methadone (Dolophine), metoprolol (Lopressor, Toprol XL), olanzapine (Zyprexa), ondansetron (Zofran), tramadol (Ultram), trazodone (Desyrel), and others.\nless\nMONOAMINE OXIDASE INHIBITORS (MAOIs)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nHordenine is structurally similar to tyramine (29888) In vitro research shows that hordenine is a selective substrate for monoamine oxidase-B in the liver (27943). Theoretically, concomitant use of hordenine with MAOIs might increase blood pressure, potentially leading to a hypertensive crisis.\nSome MAOIs include isocarboxazid (Marplan), phenelzine (Nardil), selegiline (Eldepryl, Emsam, Zelapar), and tranylcypromine (Parnate).\nless\nSTIMULANT DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nHordenine is structurally similar to N-methyltyramine and synephrine, constituents in bitter orange known to have stimulant properties (29888). Theoretically, taking hordenine with drugs with stimulant properties might increase the risk of hypertension and other adverse cardiovascular effects.\nSome of these drugs include amphetamine, caffeine, methylphenidate, pseudoephedrine, and many others.\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH STIMULANT PROPERTIES\nHordenine is structurally similar to N-methyltyramine and synephrine, constituents in bitter orange known to have stimulant properties (29888). Theoretically, taking hordenine with other herbs and supplements with stimulant properties might increase the risk of adverse cardiovascular effects. Some herbs and supplements with stimulant properties include ephedra, bitter orange, caffeine, and caffeine-containing supplements such as coffee, cola nut, guarana, and mate.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nHYPERTENSION\nHordenine is structurally similar to N-methyltyramine and synephrine, constituents in bitter orange known to have stimulant properties (29888). Theoretically, taking hordenine might exacerbate high blood pressure.\nless\nKIDNEY STONES\nAnimal research suggests that consumption of hordenine as a small portion of the diet (< 1%) for 21 days might increase the risk for kidney stones (90340). Theoretically, hordenine might increase the risk of recurrence in patients with a history of kidney stones.\nless\nPERIOPERATIVE\nHordenine is structurally similar to N-methyltyramine and synephrine, constituents in bitter orange known to have stimulant properties (29888). Theoretically, taking hordenine might interfere with surgery by increasing blood pressure and heart rate. Tell patients to discontinue using hordenine at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "EXPAND ALL\n|\nCOLLAPSE ALL\nAMPHETAMINE URINE DRUG SCREENING\nSome research shows that hordenine cross-reacts with amphetamine-enzyme linked immunosorbent assays (ELISA) (1302). These results suggest that use of hordenine might result in false-positive results on urine drug screens for amphetamines.\nless\nOPIOID URINE DRUG SCREENING\nSome research shows that hordenine cross-reacts with morphine-, oxymorphone-, and hydromorphone-enzyme linked immunosorbent assay (ELISA) kits, opiate-radioimmunoassay (RIA) kits, and thin layer chromatography of oxymorphone, hydromorphone, and apomorphine (1302). This suggests that hordenine may cause false-positive results on urine drug screens for opioids.\nless",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hordenine.",
            "Pharmacokinetics": "Absorption\nIn vitro research shows that hordenine is a selective substrate for monoamine oxidase-B in the liver, but it is not deaminated by monoamine oxidase A (MAO-A). This suggests that hordenine is not likely to be deaminated in the gut, increasing the likelihood for absorption when compared with tyramine, a structurally similar compound that is deaminated by MAO-A in the intestine (27943). However, preliminary research shows that there is high variability in hordenine pharmacokinetics, with low oral bioavailability. In humans, after consuming beer providing hordenine 0.075 mg/kg, peak hordenine levels of around 15 nM occur at 30-90 minutes (103277). In young, healthy males, taking 100 mg of hordenine orally on an empty stomach results in a mean maximum plasma concentration of 16.4 mcg/L at 65 minutes (110674).\nDistribution\nHordenine crosses the blood-brain barrier in humans (110674).\nMetabolism\nHordenine undergoes rapid and extensive sulfation and glucuronidation, producing hordenine sulfate and hordenine glucuronide (103277, 110674).\nExcretion\nIn young, healthy males, the half-life of free hordenine averages 54 minutes (110674). The half-lives for hordenine sulfate and hordenine glucuronide are around 115 minutes and 135 minutes, respectively (103277).",
            "Mechanism of Action": "General\nHordenine gets its name from barley (Hordeum vulgare); it is formed in the roots during germination of barley grains (19513, 29814, 90338, 103276, 103277, 110674). It has also been identified as a constituent in a variety of algae, cacti, grasses, and other plants.\nAntimicrobial effects\nIn vitro research suggests that hordenine may have antimicrobial effects at high concentrations. Bacteria communicate and coordinate gene expression through \"quorum-sensing\" regulatory pathways. In vitro, hordenine has been shown to inhibit these pathways in Agrobacterium tumefacians and Pseudomonas aeruginosa (88316).\nCardiovascular effects\nVarious in vitro and animal studies have evaluated the effect of hordenine on the cardiovascular system. Some data show that hordenine inhibits norepinephrine reuptake and might also cause release of norepinephrine stores in some tissues ( 11136,91721). However, it may have less adrenergic activity in some tissues compared to the endogenous amines tyramine and N-methyltyramine (91721). In vitro and animal research shows that high dose hordenine can cause short-lived increases in heart rate and blood pressure when given intravenously (11136, 27943, 29021). The cardiovascular impact was not observed in animals when given orally (29021); however, the reason for this is unclear.\nDermatologic effects\nIn vitro research shows that hordenine may have depigmentation effects. It appears to do this by inhibiting a variety of proteins and pathways involved in melanogenesis (88342).\nGastrointestinal effects\nAnimal research shows that hordenine stimulates gastrin release, which can increase gastric acid secretion in the stomach (29841). Additional animal research shows that high-dose hordenine causes short-lived inhibition of gut motility (11136).\nRespiratory effects\nAnimal research in horses shows that IV hordenine 2 mg/kg increases respiratory rate by 250% whereas oral administration of hordenine 2 mg/kg does not increase respiratory rate (29021)."
        }
    },
    "Horny Goat Weed": {
        "sections": {
            "Overview": "Horny goat weed has been used for over 2000 years to treat impotence and infertility (91592). The name is used for several species of the Epimedium genus, although Epimedium grandiflorum and Epimedium sagittatum are most commonly found in supplement products (11, 91591). Epimedium species grow in Asia, Europe, the Middle East, and the Far East (91592).",
            "Safety": "POSSIBLY SAFE when horny goat weed extract is used orally and appropriately, short-term. A specific extract of horny goat weed containing 60 mg icariin, 15 mg daidzein, and 3 mg genistein (Xianling Gubao; Tong Ji Tang Pharmacal Company) has been used daily with apparent safety for up to 24 months (14900, 97268). Another aqueous extract of horny goat weed containing up to 25.36% icariin has been used in a dose of 300 mL daily with apparent safety for up to 6 months (55452). Another horny goat weed extract has been used with apparent safety at doses up to 1000 mg daily (providing 200 mg icariin) for up to 30 days (108311).\nPOSSIBLY UNSAFE when used orally long-term or in high doses. Long-term use, or taking high doses of some species of horny goat weed, has been linked to serious adverse effects including respiratory arrest (10346).\nPREGNANCY: POSSIBLY UNSAFE when used orally. Horny goat weed might have androgenic activity (10346). Theoretically, it might harm a developing fetus; avoid using.\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, horny goat weed seems to be well tolerated when used short-term.\nMost Common Adverse Effects\nOrally: Dizziness, dry mouth, nosebleed, thirst, and vomiting.\nSerious Adverse Effects (Rare)\nOrally: Respiratory arrest.\nCardiovascular\nA 66-year-old male with a history of cardiovascular disease developed tachyarrhythmia after taking horny goat weed for 2 weeks (13006). It is not clear if this product contained only horny goat weed or a combination of ingredients; therefore, assigning causality is not possible.\nless\nGastrointestinal\nOrally, long-term use of horny goat weed has been associated with reports of vomiting, dry mouth, thirst, and nosebleed (10346).\nless\nHepatic\nA case of hepatotoxicity characterized by abdominal pain, nausea, vomiting, and fever has been reported in a 40-year-old male patient with hepatitis C, after a month of taking one tablet daily of a combination product containing horny goat weed and multiple other ingredients (Enzyte, Vianda). Symptoms improved following cessation of the product, but it is not clear if they were due to horny goat weed, another ingredients, or hepatitis C (91590). An observational study over 24 years found 26 cases of drug-induced hepatoxicity associated with horny goat weed (112707).\nless\nMusculoskeletal\nOrally, large doses of horny goat weed may cause exaggeration of tendon reflexes to the point of spasm (10346).\nless\nNeurologic/CNS\nOrally, long-term use of horny goat weed has been associated with reports of dizziness (10346).\nless\nPsychiatric\nThere is a case report of hypomania in a 66-year-old male who took horny goat weed for 2 weeks (13006). It is not clear if this product contained only horny goat weed or a combination of ingredients; therefore, assigning causality is not possible.\nless\nPulmonary/Respiratory\nOrally, large doses of horny goat weed may cause respiratory arrest (10346).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nBronchitis. Although there is interest in using oral horny goat weed for bronchitis, there is insufficient reliable information about the clinical effects of horny goat weed for this condition.\nCoronary heart disease (CHD). Although there is interest in using oral horny goat weed for CHD, there is insufficient reliable information about the clinical effects of horny goat weed for this condition.\nErectile dysfunction (ED). Although there is interest in using oral horny goat weed for ED, there is insufficient reliable information about the clinical effects of horny goat weed for this condition.\nFatigue. Although there is interest in using oral horny goat weed for fatigue, there is insufficient reliable information about the clinical effects of horny goat weed for this condition.\nGulf war syndrome. It is unclear if oral horny goat weed is beneficial in patients with Gulf war syndrome.\nA small clinical study in males with Gulf war syndrome shows that taking horny goat weed extract 250 mg or 500 mg twice daily, standardized to contain 50 mg or 100 mg of icariin per dose, respectively, for 30 days does not improve symptoms of Gulf war syndrome when compared with placebo (108311).\nless\nHepatitis. Although there is interest in using oral horny goat weed for hepatitis, there is insufficient reliable information about the clinical effects of horny goat weed for this condition.\nHIV/AIDS. Although there is interest in using oral horny goat weed for HIV/AIDS, there is insufficient reliable information about the clinical effects of horny goat weed for this condition.\nHypertension. Although there is interest in using oral horny goat weed for hypertension, there is insufficient reliable information about the clinical effects of horny goat weed for this condition.\nMale infertility. Although there is interest in using oral horny goat weed for male infertility, there is insufficient reliable information about the clinical effects of horny goat weed for this condition.\nMemory. Although there is interest in using oral horny goat weed for memory, there is insufficient reliable information about the clinical effects of horny goat weed for this purpose.\nMyocarditis. Although there is interest in using oral horny goat weed for myocarditis, there is insufficient reliable information about the clinical effects of horny goat weed for this condition.\nOsteoarthritis. Although there is interest in using oral horny goat weed for osteoarthritis, there is insufficient reliable information about the clinical effects of horny goat weed for this condition.\nOsteoporosis. Several small, low-quality clinical studies suggest that horny goat weed may modestly improve bone mineral density (BMD) in patients with osteoporosis.\nA meta-analysis of 12 small, low-quality clinical studies in patients with osteoporosis shows that taking horny goat weed alone or in combination with conventional therapy improves BMD when compared with a control group. When added to conventional therapy, horny goat weed appears to have a large effect on BMD, while its effect is more modest when used alone. The most common formulations and doses used include granules 1 gram twice daily for 6 months, an extract 600 mg taken in divided doses daily for 6 months, and a decoction 50 mL taken 2-3 times daily for 3-6 months. The pooled analysis suggests that horny goat weed decoctions are more effective than other formulations (109578). Additionally, a small clinical study in postmenopausal patients not included in the analysis above shows that taking a specific extract of horny goat weed containing 60 mg icariin, 15 mg daidzein, and 3 mg genistein (Xianling Gubao; Tong Ji Tang Pharmacal Company) daily, in addition to calcium 300 mg daily, for 24 months attenuates loss of BMD of the lumbar spine and femoral neck when compared with placebo plus calcium. BMD increased by 1.6% and 1.3% at each site, respectively, compared with decreases of 1.8% and 2.4%, respectively, with placebo (14900).\nless\nPostmenopausal conditions. It is unclear if oral horny goat weed is beneficial in patients with postmenopausal conditions.\nPreliminary clinical research in postmenopausal patients shows that taking horny goat weed water extract 300 mL daily for 6 months slightly decreases triglyceride and total cholesterol levels and can increase estradiol levels when compared with placebo (55452). The clinical significance of these effects is unclear.\nless\nSexual dysfunction. Although there is interest in using oral horny goat weed for sexual dysfunction, there is insufficient reliable information about the clinical effects of horny goat weed for this condition.\nMore evidence is needed to rate horny goat weed for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nProducts containing horny goat weed are most commonly standardized to icariin content (14900, 55452, 91591, 108311). A horny goat weed water extract used in one clinical trial has been standardized to contain 25.36% icariin (55452). Another horny goat weed extract used in clinical research has been standardized to contain 20% icariin (108311).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, horny goat weed might increase the risk of bleeding.\nIn vitro research and animal research shows that horny goat weed can inhibit platelet aggregation and thrombus formation (105832). This effect has not been reported in humans.\nless\nANTIHYPERTENSIVE DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, horny goat weed might increase the risk of hypotension.\nLaboratory research suggests that horny goat weed might have hypotensive effects (10346). This effect has not been reported in humans.\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, horny goat weed might increase the effects and side effects of CYP1A2 substrates.\nIn vitro, horny goat weed leaf extract inhibits CYP1A2 (97267). This effect has not been reported in humans.\nless\nCYTOCHROME P450 2B6 (CYP2B6) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, horny goat weed might increase the effects and side effects of CYP2B6 substrates.\nIn vitro, horny goat weed leaf extract inhibits CYP2B6 (97267). This effect has not been reported in humans.\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, horny goat weed might increase the effects and side effects of CYP3A4 substrates.\nIn vitro, horny goat weed extract inhibits CYP3A4 and suppresses CYP3A4 mRNA expression (112708). This effect has not been reported in humans.\nless\nESTROGENS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use of horny goat weed with estrogens might increase their therapeutic and adverse effects.\nIn vitro evidence suggests that horny goat weed has estrogenic activity. In clinical research, horny goat weed has been shown to increase blood levels of estrogen in some females (16061, 16063, 16060, 55452).\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, horny goat weed might increase the risk of bleeding.\nIn vitro and animal research shows that horny goat weed can reduce platelet aggregation and thrombus formation (105832). Theoretically, horny goat weed might increase the risk for bleeding when taken with other herbs and supplements with antiplatelet activity. See other products with antiplatelet activity here. See products with anticoagulant activity here\n\n.\nless\nCAFFEINE-CONTAINING HERBS AND SUPPLEMENTS\nTheoretically, horny goat weed might reduce the clearance of caffeine.\nHorny goat weed contains genistein. Taking genistein 1 gram daily for 14 days seems to inhibit caffeine clearance and metabolism in healthy females (23582). This effect has been attributed to inhibition of the cytochrome P450 1A2 (CYP1A2) enzyme, which is involved in caffeine metabolism. It is unclear if this effect occurs with the lower amounts of genistein found in horny goat weed.\n\nSee caffeine-containing natural ingredients here.\nless\nHERBS AND SUPPLEMENTS WITH HYPOTENSIVE EFFECTS\nTheoretically, horny goat weed might increase the risk of hypotension.\nHorny goat weed might have hypotensive effects (10346). Theoretically, concurrent use of horny goat weed with other herbs and supplements that decrease blood pressure might increase the risk of hypotension.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING DISORDERS\nHorny goat weed might decrease platelet aggregation and may increase the risk of bleeding (105832). Theoretically, taking horny goat weed may exacerbate bleeding disorders.\nless\nHORMONE SENSITIVE CANCERS/CONDITIONS\nIn vitro evidence shows that horny goat weed has estrogenic activity, and clinical evidence shows that horny goat weed can increase levels of estrogen in some females (16061, 16063, 16060, 55452). Theoretically, horny goat weed might exacerbate estrogen-sensitive conditions. Some of these conditions include breast cancer, uterine cancer, ovarian cancer, endometriosis, and uterine fibroids.\nless\nPERIOPERATIVE\nHorny goat weed may decrease platelet aggregation (105832). Theoretically, this might increase the risk of excessive bleeding perioperatively. Tell patients to discontinue horny goat weed at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with horny goat weed.",
            "Pharmacokinetics": "Absorption\nThe horny goat weed constituent icariin is absorbed in the duodenum and ileum. Epimedin C is primarily absorbed in the duodenum (55472). In rat research, peak plasma levels of icariin and other constituents of interest occur approximately 23-25 minutes after oral intake of horny goat weed (112706).\nMetabolism\nPeak plasma levels of the icariin metabolite, icariside II, occur about 4 hours after oral intake of horny goat weed. The accumulation of the desmethylicaritin metabolite is biphasic, with small and large peaks occurring after 5 and 24 hours, respectively. Peak levels last for up to 48 hours (100066).\nExcretion\nThe half-life of the icariin metabolite icariside II after oral intake of horny goat weed is 12-15 hours (100066).",
            "Mechanism of Action": "General\nThe applicable parts of horny goat weed are the leaves and stems (11, 12). Active constituents include the flavonoids apigenin, kaempferol, luteolin, quercetin, breviflavone, epimedokoreanin B, baohuoside I, hyperoside, and epimedin B and C (16064, 55449, 55455, 97268, 100067). Horny goat weed also contains the phytoestrogens icariin, genistein, daidzein, desmethylicaritin, and icaritin, as well as the lignan syringaresinol (14900, 16060, 16061, 16063, 16064, 55436, 55444, 100067). Other constituents include anhydroicaritin, icariside II, maohuoside A, saggittatoside A, salidroside, syringin, polysaccharides, sesquiterpenes, glycosides, ceryl alcohol, essential oils, and fatty acids (97268). The most abundant compound found in horny goat weed is icariin, a glycoside formed from the prenylflavonoid icaritin plus glucose and rhamnose. It constitutes up to 6.5% of the dry weight of an ethanolic extract of horny goat weed (97268).\nAnti-inflammatory effects\nHorny goat weed is traditionally used for many conditions that involve cellular inflammatory processes, including arthritis and hepatitis. In laboratory research, horny goat weed extract inhibited proinflammatory mediators, including cytokines, nitric oxide, and eicosanoids (100067).\nAntiaging effects\nIn vitro research shows that horny goat weed can accelerate the rate of DNA synthesis and prolong the lifespan of aging youth 2BS fusion cells, which are used as an aging model (52487).\nAnticancer effects\nIn vitro research shows that icariin, a constituent of horny goat weed, can induce differentiation and inhibit proliferation of tumor cells (55433, 55449). Other constituents of horny goat weed, including luteolin, epimedokoreanin B, and baohuoside I, have been shown to inhibit cancer cell proliferation (55449). Other in vitro research shows that horny goat weed extract can inhibit the proliferation of hepatoma and leukemia cell lines. However, icariin does not appear to inhibit the proliferation of these cells lines, suggesting that it may not be the active anticancer constituent (13647).\nAntioxidant effects\nIcariin, a constituent of horny goat weed, has been shown to have antioxidant activity (55438, 55447). Other constituents of horny goat weed, including luteolin, hyperoside, and epimedokoreanin B, have been shown to scavenge DPPH radicals (55449).\nAntiviral effects\nIn vitro research suggests that horny goat weed might have activity against HIV (1512, 52886).\nBone effects\nA number of compounds in horny goat weed are thought to target estrogen signaling and other bone formation pathways in osteoblasts. They also target mesenchymal stem cells, and osteoblast and osteoclast differentiation, proliferation, and functioning (97268). The icariin constituent of horny goat weed stimulates human osteoblasts by upregulating bone morphogenic protein-2 (16065, 16067, 55445). Clinical research also shows that taking horny goat weed extract increases levels of bone-specific alkaline phosphatase (BSAP), a marker associated with increased osteoblast function, and decreases levels of tumor necrosis factor receptor associated factor 6 (TRAF6), a marker associated with osteoclast activity (109579). In rodent studies, horny goat weed extract, icariin, and icaritin increase proliferation of osteoblasts. Icariin and icaritin also inhibit osteoclast differentiation in bone marrow cultures (97268).\nCardiovascular effects\nHorny goat weed causes vasodilation, possibly by blocking calcium channels. It also seems to have hypotensive effects, possibly by blocking catecholamines (10346). Laboratory research suggests horny goat weed increases coronary blood flow and decreases platelet aggregation (10346, 105832). Other laboratory research shows that horny goat weed extract reduces homocysteine levels by inhibiting S-adenosyl-L-homocysteine hydrolase in hepatic cells. Theoretically, this effect may offer cardioprotective benefit (16066).\nCytochrome P450 effects\nIn vitro, an ethanol extract of horny goat weed leaves inhibits cytochrome P450 (CYP) 1A2 and 2B6 in human liver microsomes but does not affect the activity of CYP2C9, 2C19, 2D6, 2E1, or 3A4 (97267). However, other in vitro research suggests that horny goat weed extract inhibits CYP3A4 and suppresses CYP3A4 mRNA expression (112708).\nGenitourinary effects\nThe icariin constituent of horny goat weed inhibits phosphodiesterase-5 (PDE5) and enhances cyclic guanosine monophosphate (cGMP) in cavernous smooth muscle cells (16062).\nHepatic effects\nTheoretically, icariin may have hepatoprotective effects (55465, 112705). Icariin, a constituent of horny goat weed, appears to attenuate increased levels of glutamic pyruvic transaminase and sorbitol dehydrogenase released from hepatocytes exposed to carbon tetrachloride (55465). Also, a study in rats induced with polycystic ovary syndrome and nonalcoholic fatty liver disease suggests that exposure to icariin daily for 28 days improves fatty acid oxidation and reduces accumulation of fat within the liver when compared with control (112705). Conversely, rat research of a specific species of horny goat weed, Epimedium koreanum Nakai, is associated with increases in liver weight, liver function tests, and fat within liver cells when compared with control after 28 days of daily exposure. These findings are associated with risk of liver toxicity through ferrous-driven cell death (112704).\nHormonal effects\nThe glycosides in horny goat weed might have hormonal effects. Animal research suggests that horny goat weed promotes semen secretion and stimulates growth of prostate, testes, and anus rector muscles. Some researchers think it might increase testosterone secretion (10346).\n\nHorny goat weed and its constituents icaritin, desmethylicaritin, breviflavone B, kaempferol, apigenin, quercetin, and luteolin have estrogenic activity in vitro (16060, 16061, 16063, 16064, 55444). It is a strong activator of estrogen receptors; however, it does not seem to affect androgen receptors (16064, 55444). Some data indicate that horny goat weed leaf extract increases estrogen activity at low doses, but inhibits it at higher doses (97268). Additionally, a study in rats induced with polycystic ovary syndrome and nonalcoholic fatty liver disease suggests that exposure to horny goat weed daily for 28 days reduces levels of testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone (112705).\nImmunomodulating effects\nIn patients undergoing hemodialysis, treatment with horny goat weed appears to normalize levels of both soluble IL-2 receptor and IL-6, as well as improving activity of IL-2, suggesting that it may help restore immune function in patients who are immunodeficient (55457, 55459). Also, animal research shows that horny goat weed dried leaf extract, as well as the horny goat weed constituents icariin and epimedin C, can activate phagocytic activity of Kupffer cells in the liver. This suggests horny goat weed may stimulate the innate immune system (55455).\n\nBaohuoside I, a flavonoid isolated from horny goat weed, appears to inhibit lymphocyte proliferation and suppress T cell activation in vitro. This suggests immunosuppressant activity (55443).\nNeurologic effects\nEvidence from in vitro research shows that syringaresinol, a constituent of horny goat weed, might increase the formation of neurites (55436)."
        }
    },
    "Horse Chestnut": {
        "sections": {
            "Overview": "Horse chestnut is a broad-leafed, deciduous tree that is native to parts of southeastern Europe, including Bulgaria, Macedonia, and Greece (55523, 91980). The fruits contain one to three seeds that resemble the sweet chestnut but have a bitter taste (55523). Traditionally, horse chestnut has been used for arthritis, concussion, pain and swelling, dysmenorrhea, hemorrhoids, enlarged prostate, diarrhea, lupus, malaria, fever and cough, and skin conditions.",
            "Safety": "LIKELY SAFE when standardized horse chestnut seed extracts are used orally and appropriately, short-term. These extracts, from which esculin, a toxic constituent, has been removed (9420), have been used with apparent safety for 2-12 weeks (281, 282, 283, 284, 285, 12113, 95429, 95430).\nUNSAFE when the raw seed, bark, flower, or leaf is used orally. Horse chestnut contains significant amounts of the toxin esculin, and can be lethal (17).\nThere is insufficient reliable information available about the safety of horse chestnut when used topically, intravenously, or intramuscularly.\nCHILDREN: UNSAFE when the raw seeds, bark, flower, or leaves are used orally. Poisoning has been reported from children drinking tea made with twigs and leaves (9, 55528).\nPREGNANCY AND LACTATION: UNSAFE when the raw seed, bark, flower, or leaf are used orally. Horse chestnut preparations can be lethal (17); avoid using. There is insufficient reliable information available about the safety of horse chestnut seed extract when used during pregnancy and lactation; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, horse chestnut seed extract, from which the toxic constituent esculin has been removed, seems to be well-tolerated. Topically, no adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.\nMost Common Adverse Effects\nOrally (extract): Dizziness, gastrointestinal upset, headache, and pruritus.\n\nOrally (seed or bark): Gastrointestinal irritation and toxic nephropathy.\nCardiovascular\nOrally, there is one case report of pericardial tamponade following exudative pericardial effusion in a previously healthy 32-year-old male who consumed three boxes of horse chestnut paste over 6 weeks. The patient was treated with steroid therapy for 2 months, as well as colchicine 0.5 mg twice daily and ibuprofen 600 mg twice daily for 3 months. These cardiovascular events were considered to be possibly related to the antiplatelet activity of horse chestnut or to an immunologic response to antigens present in horse chestnut paste (91972). A case of atrial fibrillation is also reported in a previously healthy 46-year-old male after accidental ingestion of a horse chestnut seed. The patient also presented with abdominal pain, nausea, sweating, and palpitations. The arrhythmia resolved within a few hours without medical intervention (110439).\nless\nDermatologic\nOrally, horse chestnut seed extract has been reported to cause pruritus (282, 12113, 55486).\nless\nGastrointestinal\nOrally, horse chestnut seed extract has been reported to cause nausea, vomiting, diarrhea, abdominal pain, constipation, dry mouth, gastrointestinal upset, and dyspepsia (282, 12113, 55477, 55486, 55493, 55520, 110439).\nless\nHepatic\nOrally, there is one case report of hepatotoxicity in a 69-year-old female who took 6-15 tablets of a specific product (Venencapsan) containing horse chestnut leaf, milfoil, celandine, sweet clover, milk thistle, and dandelion root daily for 6 weeks. The patient's symptoms disappeared 6 weeks after discontinuing the product and reappeared following re-initiation (55518). Another case report describes a 70-year-old male presenting with acholia, choluria, and jaundice after 3 weeks of self-treatment with an unspecified dose of a specific combination product (Venenkraft) containing horse chestnut. The patient presented with elevated liver transaminase and bilirubin levels, and was diagnosed with drug-induced liver injury. Following discontinuation, laboratory values and symptoms progressively resolved (107702). In both of these case reports, it is unclear if hepatotoxicity was due to horse chestnut, another ingredient, or the combination.\n\nIntravenously and intramuscularly, isolated cases of liver toxicity have occurred after administration of horse chestnut extract containing aescin (2, 512, 552).\nless\nImmunologic\nPollen from the horse chestnut flower can cause allergic reactions in children (7775). Horse chestnut can also cause hypersensitivity reactions, which occur more commonly in people who are allergic to latex (7853, 8418).\n\nRectally, the horse chestnut constituent esculin has caused severe allergic contact dermatitis and proctitis in a 38-year old man (10383).\n\nIntravenously, administration of aescin can cause anaphylaxis (18, 553).\nless\nMusculoskeletal\nOrally, calf spasms have been reported in patients with CVI who took horse chestnut seed extract (282).\nless\nNeurologic/CNS\nOrally, horse chestnut seed extract has been reported to cause headache or dizziness (55486, 55520).\nless\nRenal\nOrally, high doses of aescin have been reported to cause kidney toxicity (55525). Horse chestnut seed and bark can cause toxic nephropathy (4). A case of life-threatening kidney rupture occurred in a patient who was taking horse chestnut seed extract and had been diagnosed with angiomyolipoma, a condition characterized by increased risk of kidney rupture with hemorrhage. The rupture was attributed to the anticoagulant effects of horse chestnut seed extract, which may have increased the risk of hemorrhage (55496).\n\nIntravenously, isolated cases of kidney toxicity have occurred after administration of horse chestnut containing aescin (512).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nChronic venous insufficiency (CVI). Most clinical research suggests that oral horse chestnut extract reduces symptoms of CVI.\nClinical research shows that taking horse chestnut seed extract 300 mg twice daily or providing aescin, a constituent of horse chestnut, 50-75 mg twice daily for up to 12 weeks can reduce some symptoms of CVI, such as varicose veins, pain, tiredness, tension, itching, edema, and swelling in the legs (281, 282, 283, 284, 285, 12113, 55477, 55481, 55501, 55502)(55520, 55526, 55537). However, some preliminary clinical research suggests that horse chestnut seed extract (Venostasin, Klinge Pharma GmbH) may be less effective than maritime pine bark (Pygnoforton, Plantorgan) for reducing leg swelling, cramps, and a feeling of heaviness in patients with CVI (7693).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nHemorrhoids. Oral horse chestnut has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA moderate-sized clinical study in adults with acute bleeding from grade 1 or 2 internal hemorrhoids shows that taking aescin, a constituent of horse chestnut, 40 mg three times daily, combined with micronized purified flavonoid fraction (MPFF) 3 grams daily, for 7 days stops bleeding and reduces hemorrhoid swelling more quickly than MPFF alone, and is associated with lower rates of treatment failure (115331).\nless\nIrritable bowel syndrome (IBS). Oral horse chestnut has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small, preliminary clinical trial and retrospective case series show that taking a combination product containing horse chestnut extract 470 mg, quebracho colorado 150 mg, and peppermint oil 0.2 mL (Atrantil, KBS Research, LLC) daily for 2 weeks reduces abdominal pain, constipation, and bloating when compared with baseline in patients with constipation-predominant IBS (95429, 95430). The effects of horse chestnut alone are unclear.\nless\nKidney stones (nephrolithiasis). It is unclear if oral aescin, a constituent of horse chestnut, is beneficial for kidney stones.\nA large clinical study in outpatient adults in Iraq with a single kidney stone shows that taking aescin, a constituent of horse chestnut, 120 mg daily for 10 days increases the rate of stone expulsion when compared with placebo, but not when compared with prednisolone 25 mg daily. Aescin also decreases the time to stone expulsion and increases the percent of patients experiencing complete pain relief when compared with prednisolone or placebo (110440). The validity of these findings is limited by the lack of blinding.\nless\nMale infertility. It is unclear if oral horse chestnut is beneficial for male infertility.\nPreliminary clinical research shows that taking horse chestnut seed extract 150 mg (Aescuven Forte), containing aescin 30 mg, twice daily for 2 months increases sperm density, but does not improve sperm motility, in men with varicocele-associated infertility (55493).\nless\nPostoperative pain. Oral horse chestnut has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA moderate-sized open-label clinical trial in adults undergoing facial trauma surgery shows that taking horse chestnut 185 mg (20% coumarin) with bromelain and sweet clover (Brovas, Agave Group) twice daily for 15 days postoperatively modestly reduces pain scores when compared with control. However, a significant reduction is only observed at post-operative day 15, not earlier time points (115304). Additionally, the clinical significance of the reduction is uncertain, and it is unclear if the effect is due to horse chestnut, other ingredients, or the combination.\nless\nPostoperative swelling. Oral horse chestnut has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA moderate-sized open-label clinical trial in adults undergoing facial trauma surgery shows that taking horse chestnut 185 mg (20% coumarin) combined with bromelain and sweet clover (Brovas, Agave Group) twice daily for 15 days postoperatively reduces facial edema and increases the rate of complete edema resolution when compared with control (115304). However, clinical significance of this benefit is uncertain. Additionally, it is unclear if the effect is due to horse chestnut, other ingredients, or the combination.\nless\nMore evidence is needed to rate horse chestnut for these uses.",
            "Dosing & Administration": "Adult\nOral:\nHorse chestnut has been used in doses of 300-600 mg daily for 8-12 weeks. See Effectiveness section for condition-specific information.\n\nHorse chestnut extract is often standardized to contain 16% to 20% triterpene glycosides (saponins), which is referred to as aescin content (55477, 55493).\nTopical:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nA specific product (Venostasin retard, Klinge Pharma GmbH) containing horse chestnut seed extract 300 mg is standardized to contain aescin 50 mg per capsule (55477).\n\nAnother specific product (Aescuven Forte) containing horse chestnut seed extract 150 mg is standardized to contain aescin 30 mg (55493). The horse chestnut extract in a combination product containing horse chestnut extract 470 mg, quebracho 150 mg, and peppermint oil 0.2 mL (Atrantil, KBS Research, LLC) is standardized to 20% saponin content (95429, 95430).",
            "Interactions with Drugs": "ANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nHorse chestnut may have antiplatelet effects and may increase the risk of bleeding if used with anticoagulant or antiplatelet drugs.\nHorse chestnut contains the constituent esculin which has been shown to have antithrombotic effects. Therefore, horse chestnut might have antiplatelet effects (19). This has not been shown in humans.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nTheoretically, horse chestnut may have antiplatelet effects.\nHorse chestnut contains the constituent esculin which has been shown to have antithrombotic effects. Therefore, horse chestnut might have antiplatelet effects (19). Theoretically, concomitant use of herbs that might affect platelet aggregation could increase the risk of bleeding in some people. See other products with anticoagulant activity here. See products with antiplatelet activity here.\nless\nGINKO\nTheoretically, taking horse chestnut with ginkgo may increase the risk of adverse effects of horse chestnut.\nGinkgo might compete with the hepatic metabolism of sodium aescinate, a purified form of the horse chestnut constituent, aescin. Both agents are metabolized by hepatic cytochrome P450 (CYP) 2C9 and CYP3A4 isoenzymes. One case of acute kidney failure requiring continuous hemodialysis has been reported in a 58-year-old male given a sodium aescinate 10 mg injection daily and ginkgo extract injection daily for 16 days following fracture repair surgery (95671). It is hypothesized that ginkgo might interfere with the hepatic metabolism of the sodium aescinate, which is a known, dose-dependent nephrotoxic agent.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBLEEDING DISORDERS\nTheoretically, taking horse chestnut might increase the risk of bruising and bleeding in patients with bleeding disorders. Horse chestnut might have antiplatelet effects (19).\nless\nGI IRRITATION\nAvoid use in individuals with infectious or inflammatory gastrointestinal conditions. Horse chestnut seeds and bark can irritate the gastrointestinal tract (19).\nless\nHEPATIC IMPAIRMENT\nAvoid using in patients with hepatic impairment. There is one report of liver injury associated with horse chestnut (4).\nless\nLATEX ALLERGY\nUse cautiously in patients with latex allergy. Cross reactivity has been reported with horse chestnut exposure in people that are allergic to latex (7853, 8418).\nless\nPERIOPERATIVE\nTheoretically, horse chestnut might increase the risk of excessive bleeding if used prior to surgery. Tell patients to discontinue horse chestnut at least 2 weeks before elective surgical procedures. Horse chestnut might have antiplatelet effects (19).\nless\nRENAL IMPAIRMENT\nAvoid using in patients with renal impairment. Toxic nephropathy has been reported with horse chestnut (4).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nUnprocessed horse chestnut seeds, leaves, bark, and flowers contain esculin, which has been associated with significant toxicity and death. Poisoning from unprocessed horse chestnut may cause vomiting, diarrhea, headache, stupor, coma, weakness, muscle fasciculation, and paralysis (55507). Horse chestnut seed standardized by aescin content should not contain clinically relevant levels of esculin, and thus lacks toxicity.\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with horse chestnut.",
            "Pharmacokinetics": "Absorption\nOrally, the horse chestnut constituent, aescin, is not well absorbed and undergoes substantial first-pass metabolism. Of the aescin that is absorbed, peak plasma levels occur 2-3 hours after ingestion (55511).\nExcretion\nThe half-life of aescin is approximately 10-20 hours (55511).",
            "Mechanism of Action": "General\nThe applicable parts of horse chestnut are the seed, bark, flower, and leaf. An extract of horse chestnut seed is most commonly used. Horse chestnut contains triterpene saponins referred to as aescin (escin), as well as the toxic glycoside esculin (aesculin) (11, 55476). Esculin is a hydroxycoumarin (19).\nAnti-inflammatory effects\nPurified aescin has been shown to decrease chemically-induced inflammation in rats (55513, 55521, 55530).\nAntioxidant effects\nHorse chestnut extract has been reported to have antioxidant effects (55512).\nAntithrombin effects\nHorse chestnut contains the hydroxycoumarin esculin, which may have antithrombin activity and produce toxicity in humans (6048, 20322, 20323). Esculin is found in the bark, buds, and other parts of the fruits, but it should not be present in properly extracted horse chestnut seed extract.\nCardiovascular effects\nEsculin is a hydroxycoumarin, which may increase bleeding time due to antithrombin activity (19). Aescin, a constituent of horse chestnut, decreases the permeability of venous capillaries (55513, 55521). Aescin also increases blood vessel contraction, possibly by increasing the secretion of prostaglandin F2-alpha (PGF2alpha) from vascular endothelial cells (55476, 55506, 55513). PGF2alpha is involved in promoting blood vessel contraction and facilitating venous return. This may benefit patients with chronic venous insufficiency.\nDermatologic effects\nIn vitro, aescin constricts veins and reduces the capillary permeability induced by histamine or serotonin (7162). These properties of the saponin components are the basis for the cosmetic applications of horse chestnut seed extract (4).\nIntestinal effects\nIn vitro and animal studies show that saponins, which are found in horse chestnut extract, can promote intestinal motility via antimicrobial effects, and reduce methane production. These may be beneficial in the management of irritable bowel syndrome (95429)."
        }
    },
    "Horsemint": {
        "sections": {
            "Overview": "Horsemint is a flowering herb with a pungent, bitter taste that has a scent reminiscent of thyme. It has traditionally been used as medicine for digestive disorders and for its purported stimulant and emmenagogic effects (18).",
            "Safety": "There is insufficient reliable information available about the safety of horsemint.\nPREGNANCY: POSSIBLY UNSAFE when used orally due to its purported menstruation promoting and uterine stimulant effects (12).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNone reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDysmenorrhea. Although there has been interest in using oral horsemint for dysmenorrhea, there is insufficient reliable information about the clinical effects of horsemint for this purpose.\nMore evidence is needed to rate horsemint for this use.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of horsemint.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with horsemint.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of horsemint.",
            "Mechanism of Action": "There is insufficient reliable information available about the possible mechanism of action and active ingredients of horsemint."
        }
    },
    "Horseradish": {
        "sections": {
            "Overview": "Horseradish is a cold-hardy, perennial plant (39801). It is a common condiment used with beef, sausages, and fish. In Poland, horseradish roots and leaves have been used since the 1700s for seasoning and food preservation (6, 6002, 39801). Horseradish has also traditionally been used orally as an antitussive and for genitourinary and gallbladder conditions, as well as topically as a counterirritant.",
            "Safety": "LIKELY SAFE when the root is used orally in amounts commonly found in foods. Horseradish has Generally Recognized as Safe (GRAS) status in the US (4912).\nLIKELY SAFE when the root is used orally in amounts commonly found in foods. Horseradish has Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY SAFE when used orally and appropriately in medicinal amounts (2, 4, 6, 12, 18). Horseradish has been used with apparent safety at a dose of 480 mg daily for 12 weeks (96309). ...when topical preparations containing no more than 2% mustard oil, a constituent of horseradish, are used (2).\nLIKELY UNSAFE when the tincture is used regularly and in large amounts, as it is considered an abortifacient (19).\nPREGNANCY AND:\nCHILDREN: LIKELY UNSAFE when used orally in children less than 4 years of age because it can cause gastrointestinal problems (2, 12, 19).\nLACTATION: LIKELY SAFE when the root is used orally in amounts commonly found in foods. Horseradish has Generally Recognized as Safe (GRAS) status in the US (4912).\nLACTATION: LIKELY UNSAFE when used orally in large amounts. The mustard oils produced by glucosinolates from horseradish are considered toxins that can be excreted through breast milk (33031).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, horseradish is generally well tolerated when consumed in amounts commonly used with foods. But consuming large amounts of horseradish can cause various adverse effects.\nMost Common Adverse Effects\nOrally: When consumed in large amounts, bloody vomiting, diarrhea, gastrointestinal upset.\n\nTopically: Fresh horseradish can cause irritation or allergic reaction.\nSerious Adverse Effects (Rare)\nOrally: Transient vasovagal syncope.\nDermatologic\nTopically, skin contact with fresh horseradish can cause irritation (4, 19) or allergic reaction (4).\nless\nEndocrine\nOrally, horseradish and other members of the cabbage and mustard family are associated with depressed thyroid function (4).\nless\nGastrointestinal\nOrally, consuming large amounts of horseradish can cause gastrointestinal upset, bloody vomiting and diarrhea (2, 6), and irritation of mucous membranes (2, 4).\nless\nGenitourinary\nOrally, consuming large amounts of horseradish can cause irritation of the urinary tract (19).\nless\nNeurologic/CNS\nOrally, consuming large amounts of horseradish can cause vasovagal syncope in rare cases. At least two cases of vasovagal syncope associated with horseradish consumption have been reported. In one case, a 56-year-old male experienced a sharp burning sensation in his stomach followed by tachycardia, weakness, and excessive perspiration after consuming an oyster topped with an olive-sized dollop of fresh horseradish. He experienced vasovagal syncope within 5 minutes of horseradish ingestion but regained consciousness moments later, with few residual symptoms and no medical intervention required. Researchers theorize that the vapors from horseradish can irritate the gastric or respiratory tract mucosa triggering the vaso-vagal response. Horseradish-induced vasovagal syncope has also been referred to as Seder syncope due to the tradition of consuming bitter herbs, including horseradish, during the Jewish Passover holiday dinner. To reduce the potential for this reaction, researchers suggest that freshly prepared horseradish rest before consumption, allowing some of the active vapor ingredient, thought to be isothiocyanate, to evaporate before ingestion (111724).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nColic. Although there has been interest in using oral horseradish for colic, there is insufficient reliable information about the clinical effects of horseradish for this condition.\nGout. Although there has been interest in using oral horseradish for gout, there is insufficient reliable information about the clinical effects of horseradish for this condition.\nIntestinal parasite infection. Although there has been interest in using oral horseradish for intestinal parasite infection, there is insufficient reliable information about the clinical effects of horseradish for this condition.\nRespiratory tract infections. Oral horseradish root has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in patients with a history of recurrent respiratory tract infections (RTIs) shows that taking a specific combination product (Angocin Anti-Infekt N, Repha GmbH) containing a total of 320-400 mg horseradish root and 800-1000 mg nasturtium daily for 12 weeks modestly decreases the rate of new RTIs when compared with placebo. However, there were no differences between groups in time to infection, intensity or duration of infection, or rates of specific infections, including acute rhinopharyngitis, sinusitis, laryngitis, or tracheitis (96309).\nless\nUrinary tract infections (UTIs). Oral horseradish root has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA small clinical study in patients with recurrent UTIs shows that taking a specific product (Angocin Anti-Infekt N, Repha GmbH) containing a total of 320 mg horseradish root and 800 mg nasturtium daily for 90 days modestly reduces the recurrence of UTIs when compared with placebo at 3 months after treatment completion, but not at the time of treatment completion (96310). However, this analysis excluded patients that were not cured from their initial active UTI. Additionally, the small size, short duration, and high dropout rate in this study limits the validity of these findings.\nless\nMore evidence is needed to rate horseradish for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of horseradish.",
            "Interactions with Drugs": "THYROID HORMONE\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, horseradish might interfere with the effects of thyroid hormone.\nHorseradish and other members of the cabbage and mustard family are associated with depressed thyroid function (4).\nless",
            "Interactions with Supplements": "HERBS WITH THYROID ACTIVITY\nTheoretically, horseradish may alter thyroid function.\nHorseradish and other members of the cabbage and mustard family are associated with depressed thyroid function (4). Theoretically, concomitant use of horseradish with other herbs with thyroid activity might alter the effects of these products.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nGASTROINTESTINAL (GI) CONDITIONS\nHorseradish can irritate the GI tract (19). Avoid or use with caution in individuals with infectious or inflammatory GI conditions, or stomach or intestinal ulcers.\nless\nTHYROID DISORDERS\nTheoretically, horseradish and other members of the cabbage and mustard family are associated with depressed thyroid function (4).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with horseradish.",
            "Pharmacokinetics": "Excretion\nMustard oils in horseradish are excreted via the kidneys. Most are eliminated unchanged, but some are metabolized (96310).",
            "Mechanism of Action": "General\nThe applicable part of horseradish is the root (96309, 96310).\nAntibacterial effects\nResearchers state horseradish has antimicrobial efficacy against Gram-negative and Gram-positive bacteria (2, 18). The antimicrobial effects of horseradish have been attributed to isothiocyanates and mustard oil constituents (96309, 96310).\nAnticancer effects\nResearchers state that horseradish might be carcinostatic (2, 18). The potential anticancer effects of horseradish have been attributed to isothiocyanate constituents (55547).\nAntispasmodic effects\nHorseradish has antispasmodic properties (2, 18).\nCardiovascular effects\nHorseradish shows evidence that it can stimulate local blood flow (2, 18).\nIrritant effects\nThe toxic mustard oil constituents of horseradish are irritating to mucous membranes (2, 4) and the urinary tract (19)."
        }
    },
    "Horsetail": {
        "sections": {
            "Overview": "Horsetail is a plant that reproduces using spores. Species of horsetail inhabit the wetlands of the Northern and Southern hemispheres (92288, 92289, 92293). The German Commission E expert panel has approved a specific species of horsetail (Equisetum arvense) as an oral diuretic for the treatment of edema (92288, 92290). Horsetail is also traditionally used for kidney, bladder, and liver health, and for diabetes, menorrhagia, tuberculosis, various types of arthritis, and wound healing.",
            "Warnings": "Crude horsetail contains thiaminase, which can cause thiamine deficiency with prolonged consumption. Equisetum arvense products sold in Canada are required to be certified as free from thiaminase-like activity (55579, 105301).\n\nEquisetum palustre (marsh horsetail) contains the toxic alkaloid palustrine. Palustrine has caused poisonings in cattle and sheep, but toxicity in humans has not yet been established. Historical adulteration of horsetail products with Equisetum palustre has been reported (13567).",
            "Safety": "POSSIBLY UNSAFE when horsetail products containing thiaminase are used orally, long-term. Thiaminase is an enzyme that destroys thiamine, which could theoretically lead to thiamine deficiency. In Canada, horsetail products are required to be thiaminase-free (105301).\nThere is insufficient reliable information available about the safety of thiaminase-free horsetail products when used orally or topically.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nThere is limited clinical research evaluating the safety of horsetail.\nMost Common Adverse Effects\nOrally: Abdominal distension, increased bowel movements, and nausea.\nDermatologic\nIn one case report, a patient developed seborrheic dermatitis after topical application of horsetail, requiring treatment with local epinephrine and oral antihistamines. The nicotine component of horsetail was determined to be the likely cause of this reaction (13563).\nless\nGastrointestinal\nOrally, horsetail has been associated with mild gastrointestinal side effects including abdominal distension, increased frequency of bowel movements, and nausea (55576). Orally, chronic consumption of horsetail infusion has been associated with acute pancreatitis. In a case report, a 56-year-old female presenting with recurrent mild acute pancreatitis every 6-7 months, previously thought to be drug-induced, discontinued ingesting horsetail infusions. The patient had a history of bilateral adrenal gland removal and was being treated for hypertension, dyslipidemia, and hormone replacement, and then self-medicated with horsetail infusions. After discontinuing horsetail infusions, there were no further recurrences of pancreatitis during a 14-month follow-up (97574).\nless\nHepatic\nIn one case report, a patient with asymptomatic hepatitis B developed symptomatic liver failure following consumption of boiled horsetail juice 500 mL daily for 2 weeks. Liver enzymes returned to normal following discontinuation of the juice (92291). It is not known if the horsetail juice was contaminated or mixed with other ingredients.\nless\nImmunologic\nHorsetail has been associated with cross-allergenicity with carrots (13577).\nless\nRenal\nThere are at least 4 case reports of hyponatremia thought to be at least partially associated with horsetail consumption. In one case report, an elderly patient who had taken oral horsetail 15 mg daily for 10 years presented with hyponatremia and syndrome of inappropriate secretion of antidiuretic hormone (SIADH) secondary to reduced oral intake and nausea for the previous 2 days. Horsetail was thought to be a contributing factor. The patient's symptoms resolved after 5 days of treatment with oral sodium chloride and fluid restriction (108851).\nless\nOther\nCrude horsetail contains thiaminase, which can cause thiamine deficiency with prolonged consumption. Canadian Equisetum arvense products are required to be certified as free from thiaminase-like activity (55579, 105301). In one case report, the development of autism in a child exposed to both horsetail and alcohol during pregnancy was thought to be caused by thiamine deficiency attributed to this combination (92292). However, it is not known if other genetic or environmental factors were involved in the development of this condition in utero.\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAndrogenic alopecia. Although there is interest in using oral horsetail for alopecia, there is insufficient reliable information about the clinical effects of horsetail for this condition.\nHypertension. Oral horsetail seems to reduce blood pressure in patients with hypertension.\nA clinical trial in patients with stage 1 systemic arterial hypertension shows that taking horsetail extract 900 mg daily for 3 months decreases systolic and diastolic blood pressure by 13 mmHg and 8 mmHg, respectively, and is similarly effective to hydrochlorothiazide 25 mg daily (108849). The validity of this finding is limited due to high withdrawal rates and low adherence to treatment protocols.\nless\nKidney stones (nephrolithiasis). Although there is interest in using oral horsetail for kidney stones, there is insufficient reliable information about the clinical effects of horsetail for this condition.\nObesity. Although there is interest in using oral horsetail for weight loss, there is insufficient reliable information about the clinical effects of horsetail for this purpose.\nOsteoporosis. It is unclear if oral horsetail is beneficial for osteoporosis.\nPreliminary clinical research shows that taking two tablets of either dried horsetail extract or a specific combination of horsetail extract with calcium (Osteosil Calcium) daily for 2-month intervals separated by 2 weeks of no treatment for up to one year can increase bone density when compared with no treatment in postmenopausal patients with osteoporosis. The effect of horsetail extract plus calcium (Osteosil Calcium) seems to be greater than the effect of dried horsetail extract alone (55578).\nless\nTonsillitis. Oral horsetail has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research in children with acute non-bacterial tonsillitis shows that taking a specific combination product (Imupret) for 10 days in addition to standard symptomatic therapy accelerates recovery by a small amount when compared with symptomatic therapy alone. Overall treatment response after 10 days occurred in 82% of patients taking the combination product compared with 65% of patients receiving symptomatic therapy alone. Withdrawal from antipyretic drugs occurred approximately one day earlier in children using the horsetail product. Per 100 grams, Imupret provides 29 grams of an alcoholic extract produced from horsetail 0.5 grams, marshmallow root 0.4 grams, chamomile flowers 0.3 grams, walnut leaves 0.4 grams, English walnut leaves 0.4 grams, yarrow 0.4 grams, oak bark 0.2 grams, and dandelion 0.4 grams. In children aged 6-11 years, 15 drops 6 times daily for 5 days and then 15 drops 3 times daily for 5 days was used. In children aged 12-18 years, 25 drops 6 times daily for 10 days was used. (100347). Due to the small difference between the two groups and the open-label design, the clinical relevance of this study is unclear. Also, it is unclear if these benefits are due to horsetail, the other ingredients, or the combination.\nless\nUrinary incontinence. Oral horsetail has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPreliminary clinical research shows that taking a specific supplement (Urox, Seipel Group) 840 mg, containing a combination of horsetail stem, three-leaf caper, and lindera root daily with food for 8 weeks modestly decreases urinary frequency, stress incontinence, and urgency incontinence when compared with placebo in patients with urinary incontinence and/or overactive bladder (97575). It is unclear if these effects are due to horsetail, the other ingredients, or the combination.\nless\nUrinary tract infections (UTIs). Although there is interest in using oral horsetail for UTIs, there is insufficient reliable information about the clinical effects of horsetail for this condition.\nMore evidence is needed to rate horsetail for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of horsetail.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking horsetail with antidiabetes drugs might increase the risk of hypoglycemia.\nEquisetum myriochaetum has demonstrated hypoglycemic activity in clinical research (13576). In an animal diabetic model, Equisetum giganteum had hypoglycemic effects (105300). It is unclear whether other horsetail species have hypoglycemic effects.\nless\nDIURETIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, taking horsetail with diuretic drugs might increase potassium loss and the risk of hypokalemia.\nLaboratory research shows that various species of horsetail have diuretic properties (13574, 13575). Due to its diuretic effects, there has been concern that taking horsetail along with potassium-depleting diuretics might increase the risk for hypokalemia. However, pharmacokinetic research in humans shows that taking horsetail 900 mg daily for 4 days does not affect urinary excretion of electrolytes, including potassium and sodium, despite having a diuretic effect similar to taking hydrochlorothiazide 25 mg daily (92288). It is unclear if taking horsetail for a longer duration would affect electrolyte levels. Until more is known, use with caution.\nless\nEFAVIRENZ (SUSTIVA)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, horsetail might decrease the levels and clinical effects of efavirenz.\nIn two case reports, patients were found to have detectable viral loads when taking horsetail-containing supplements along with an antiretroviral regimen that included efavirenz. In one case, the antiretroviral regimen included zidovudine, lamivudine, and efavirenz; in the other case, the regimen consisted of emtricitabine, tenofovir disoproxil fumarate, and efavirenz. One month after discontinuing horsetail, the viral loads became undetectable in both cases. The exact mechanism of this interaction is unknown (97573). It is also unclear if this interaction is specific to efavirenz or if it is related to various components of antiretroviral therapy.\nless\nLITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, horsetail might increase the levels and adverse effects of lithium.\nAnimal research suggests that horsetail has diuretic properties (13574). Theoretically, due to these potential diuretic effects, horsetail might reduce excretion and increase levels of lithium. The dose of lithium might need to be decreased.\nless\nNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Anecdotal evidence)\nTheoretically, horsetail might decrease the levels and clinical effects of NRTIs.\nIn two case reports, patients were found to have detectable viral loads when taking horsetail-containing supplements along with an antiretroviral therapy. In one case, the antiretroviral regimen included zidovudine, lamivudine, and efavirenz; in the other case, the regimen consisted of emtricitabine, tenofovir disoproxil fumarate, and efavirenz. One month after discontinuing the supplement, the viral loads became undetectable in both cases. The exact mechanism of these interactions is unknown (97573). It is also unclear if these interactions are specific to NRTIs or if they are related to various components of antiretroviral therapy.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nBETEL NUT\nTaking horsetail with betel nut might increase the risk of thiamine deficiency.\nCrude horsetail contains thiaminase, which breaks down thiamine (13571, 13572, 13573). Betel nuts also reduce thiamine activity, probably by chemical inactivation (10538).\nless\nCHROMIUM-CONTAINING HERBS AND SUPPLEMENTS\nTaking horsetail with chromium-containing herbs and supplements might increase the risk of chromium toxicity.\nHorsetail contains chromium (0.0006%). In one case report, chromium-induced acute hepatitis was thought to be related to the use of chromium polynicotinate and chromium-containing herbs including horsetail for 5 months (9141).\nless\nHERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nTheoretically, horsetail might have hypoglycemic effects.\nEquisetum myriochaetum has demonstrated hypoglycemic activity in clinical research (13576). In an animal diabetic model, Equisetum giganteum had hypoglycemic effects (105300). It is unclear whether other species of horsetail have hypoglycemic effects. Theoretically, horsetail might have additive effects when used with other herbs and supplements that also lower glucose levels. See other products with hypoglycemic activity here.\nless\nSILICON\nTaking horsetail might increase silicon serum levels and increase the urinary excretion of silicon.\nHorsetail contains large amounts of silicon. An exploratory clinical study shows that ingestion of horsetail tea increases plasma silicon levels by approximately 11-fold from baseline within 30 minutes. Higher concentrations of horsetail did not result in higher plasma levels of silicon; additional silicon was excreted in the urine (108850).\nless\nTHIAMINE\nTheoretically, taking horsetail might reduce the bioavailability of thiamine.\nCrude horsetail contains thiaminase, which breaks down thiamine. Chronic ingestion in animals has been associated with thiamine deficiency (13571, 13572, 13573, 55579).\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nALCOHOL USE DISORDER\nTheoretically, horsetail might cause or exacerbate thiamine deficiency in patients with alcohol use disorder (13571, 13572, 13573). Crude horsetail contains thiaminase, which breaks down thiamine. Chronic ingestion in animals has been associated with thiamine deficiency (13571, 13572, 13573, 55579).\nless\nCROSS-ALLERGENICITY\nTheoretically, cross-reactivity to horsetail is possible in individuals allergic to carrots (13577).\nless\nHYPOKALEMIA\nTaking horsetail might increase potassium excretion; use with caution in patients who are at risk for potassium deficiency. Horsetail has been shown to have diuretic activity (13574, 13575, 92288). Some pharmacokinetic research in humans shows that taking horsetail does not increase potassium excretion despite having a diuretic effect. However, the duration of horsetail intake in this study was only 4 days (92288). It is unclear if horsetail increases potassium excretion if used for longer durations.\nless\nNICOTINE ALLERGY\nHorsetail contains small quantities of nicotine, which may cause allergic reactions in people with nicotine allergy (13563).\nless\nTHIAMINE DEFICIENCY\nTheoretically, horsetail might cause or exacerbate thiamine deficiency. Crude horsetail contains thiaminase, which breaks down thiamine (13571, 13572, 13573).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with horsetail.",
            "Pharmacokinetics": "Excretion\nIn human research, horsetail intake resulted in the excretion of metabolites from caffeic acid, kaempferol, and quercetin, including ferulic acid, dihydrocaffeic acid, and hippuric acid (55572).",
            "Mechanism of Action": "General\nThe applicable parts of horsetail are the above ground parts. Horsetail constituents include petrosins, caffeic acid, hydroxycinnamic acid derivatives, triterpenoids, sterols, tannins, and saponins (13564, 13565, 13567, 92290, 92293). Horsetail also contains various flavonoids, including equisetumpyrone, genkwanin, protogenkwanin, apigenin, luteolin, and kaempferol and quercetin compounds. Horsetail also contains trace amounts of nicotine (13563, 105300), as well as significant amounts of silicon as silicic acid and silicates (13562, 92290, 108850). In one study, tea prepared from horsetail 25 grams/L was found to contain silicon 200 mg/L; tea prepared from horsetail 250 grams/L was found to contain silicon 750 mg/L (108850).\nAnalgesic effects\nAnimal research suggests that horsetail extracts might have analgesic effects. These effects do not appear to be related to the opioid system (13569, 92289).\nAnti-inflammatory effects\nLaboratory and animal research shows that the aqueous and hydroalcoholic extracts of horsetail have both antioxidant and anti-inflammatory effects. Flavonoid constituents and other phenolic compounds are thought to play a role. Anti-inflammatory effects appear to be related to a reduction in the function of immune cells (13566, 13568, 13569, 92289, 92290).\nAnticonvulsant effects\nAnimal research suggests that horsetail extracts might have anticonvulsant effects, which decrease the severity and frequency of induced seizures (13566).\nAntimicrobial effects\nLaboratory research shows that certain horsetail extracts exhibit antimicrobial effects. Specific extracts appeared to have differential effects against various species of bacteria and fungi (92293).\nAntioxidant effects\nLaboratory research shows that the aqueous and hydroalcoholic extracts of horsetail have both antioxidant and anti-inflammatory effects. Flavonoid constituents and other phenolic compounds are thought to play a role (13566, 13568, 13569, 92290, 92293).\nAntiviral effects\nLaboratory research suggests that horsetail might have antiviral effects (13570).\nDiuretic effects\nAnimal and human research show that various horsetail species demonstrate diuretic properties (13574, 13575, 92288). In clinical research, taking horsetail for four days produced a diuretic effect equivalent to hydrochlorothiazide 25 mg. However, electrolyte excretion was not affected (92288). The mechanism of this diuretic effect is not entirely clear, but has been attributed to flavonoid, phenolic compounds, and mineral salt constituents of horsetail.\nHepatic effects\nPreliminary research suggests that the flavonoid and petrosin constituents of horsetail might have hepatoprotective properties (13564).\nHypoglycemic effects\nIn human or animal research, Equisetum myriochaetum and Equisetum giganteum have demonstrated hypoglycemic activity (13576, 105300). The mechanism of action is unclear. However, in animal research, Equisetum giganteum did not affect the number or size of pancreatic islets (105300). It is unknown if other species of horsetail have hypoglycemic activity.\nSedative effects\nAnimal research suggests that horsetail extracts might have sedative effects. These effects resulted in increased sleeping time and increased fall rate (13566).\nThiaminase effects\nCrude horsetail contains thiaminase, an enzyme that destroys thiamine (vitamin B1). Thiaminase-containing plants have been associated with neurological toxicity in animals due to thiamine deficiency (13571, 13572, 13573).\nVasorelaxant effects\nLaboratory research suggests that horsetail constituents might have vasorelaxant effects (13565)."
        }
    },
    "Hound's Tongue": {
        "sections": {
            "Overview": "Hound's tongue is a flowering plant that is native to Germany and Switzerland. It has traditionally been used for wound healing and for its purported analgesic, antidiarrheal, antimicrobial, and expectorant effects (18).",
            "Warnings": "All parts of the hound's tongue plant contain pyrrolizidine alkaloids (PAs), which are considered toxic (18). Dietary supplements sold in the US are not required to include the amount of PAs they contain (3484); therefore, all oral preparations containing hound's tongue should be considered potentially unsafe.",
            "Safety": "LIKELY UNSAFE when products containing hepatotoxic pyrrolizidine alkaloid (PA) constituents are used orally. Repeated exposure to low concentrations of hepatotoxic PAs can cause severe veno-occlusive disease. Hepatotoxic PAs might also be carcinogenic and mutagenic (12841, 12842). ...when products containing hepatotoxic PAs are used topically on abraded or broken skin. Absorption of hepatotoxic PAs through broken skin can lead to systemic toxicity (12841).\nThere is insufficient reliable information available about the safety of PA-free hound's tongue when used orally or topically.\nPREGNANCY: LIKELY UNSAFE when used orally. Hound's tongue preparations containing pyrrolizidine alkaloid (PA) constituents might be teratogenic and hepatotoxic (12841, 12842). There is insufficient reliable information available about the safety of using PA-free hound's tongue products during pregnancy.\nLACTATION: LIKELY UNSAFE when used orally. Hepatotoxic pyrrolizidine alkaloid (PA) constituents in hound's tongue are excreted in milk (12841, 12842). There is insufficient reliable information available about the safety of using PA-free hound's tongue products during lactation.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, all parts of the plant are considered toxic due to the presence of pyrrolizidine alkaloids (PAs), which can be hepatotoxic, pneumotoxic, carcinogenic, and mutagenic.\nHepatic\nThe pyrrolizidine alkaloid (PA) constituents of hound's tongue are hepatotoxic (12841, 12842). Chronic exposure to other plants containing hepatotoxic PA constituents is associated with veno-occlusive disease (VOD) (4021). Subacute VOD causes vague symptoms with persistent liver enlargement (4021). Symptoms of acute VOD include epigastric pain, vomiting and diarrhea, and ascites formation within several days. Enlargement and induration of the liver occurs within a few weeks (12842).\nless\nOncologic\nThe pyrrolizidine alkaloid (PA) constituents of hound's tongue are considered carcinogenic and mutagenic (12841, 12842).\nless\nPulmonary/Respiratory\nThe pyrrolizidine alkaloid (PA) constituents of hound's tongue are considered pneumotoxic (12841, 12842).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of hound's tongue.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hound's tongue.",
            "Interactions with Drugs": "CYTOCHROME P450 3A4 (CYP3A4) INDUCERS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, CYP3A4 inducers can increase the toxicity of the pyrrolizidine alkaloid (PA) constituents of hound's tongue.\nHepatotoxic PAs are substrates of cytochrome P450 3A4 (CYP3A4) (12841, 12860). Drugs that induce CYP3A4 might increase the conversion of PAs to toxic metabolites.\nless",
            "Interactions with Supplements": "EXPAND ALL\n|\nCOLLAPSE ALL\nHERBS THAT INDUCE CYTOCHROME P450 3A4 (CYP3A4)\nHound's tongue contains hepatotoxic PAs, which are substrates of CYP3A4.\nTheoretically, herbs that induce CYP3A4 might increase the conversion of hepatotoxic PAs to toxic metabolites, enhancing toxicity (12841, 12860). See herbs that induce CYP3A4 here.\nless\nPYRROLIZIDINE ALKALOID (PA)-CONTAINING HERBS AND SUPPLEMENTS\nHound's tongue contains hepatotoxic PAs.\nConcomitant use is contraindicated due to the risk of additive toxicity (12841). See other herbs that contain hepatotoxic PAs here.\nless",
            "Interactions with Conditions": "LIVER DISEASE\nHound's tongue contains hepatotoxic pyrrolizidine alkaloids (PAs). Theoretically, PAs might exacerbate liver disease (12841, 12842).\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hound's tongue.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of hound's tongue.",
            "Mechanism of Action": "General\nThe applicable parts of the plant are the leaf and root. Hound's tongue contains various pyrrolizidine alkaloids (PA), some of which are toxic. PAs are most concentrated in the plant roots, but may be found in all plant parts. PAs, particularly unsaturated PAs, can cause hepatotoxicity and pneumotoxicity (12841, 12860).\nHepatotoxic effects\nThe cyclic diesters, such as retrorsine and senecionine, found in hound's tongue are the most hepatotoxic pyrrolizidine alkaloids (PAs). PAs are metabolized by cytochrome P450 3A4 (CYP3A4) to toxic dehydroalkaloids and pyrroles. Enzyme inducers such as phenobarbital seem to enhance toxicity (12841, 12860). Metabolism is also affected by pregnane X receptor induction of CYP3A4. Genetic or drug-induced variation in CYP3A4 or pregnane X receptor activity can affect the degree of PA toxicity by increasing or decreasing its metabolism (12841, 12842).\nPneumotoxic effects\nThe pyrrolizidine alkaloid (PA) constituents of hound's tongue are toxic to the lungs. In animals, pneumotoxicity occurs as pulmonary hypertension and right ventricular hypertrophy (12841, 12842)."
        }
    },
    "Houseleek": {
        "sections": {
            "Overview": "Houseleek is a succulent evergreen plant with fleshy, juicy leaves growing directly from the root. It is native to Europe (18, 100621).",
            "Safety": "There is insufficient reliable information available about safety of houseleek.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of houseleek.",
            "Dosing & Administration": "Adult\nOral:\nTraditionally, 1 cup of tea prepared from houseleek leaves is taken every 3 hours (18).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of houseleek.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of houseleek.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of houseleek.",
            "Mechanism of Action": "General\nThe applicable parts of houseleek are the fresh leaves before flowering, and their juice (18). The juice contains glycosides of flavonols including kaempferol and quercetin. It also contains organic acids, primarily malic acid, with smaller amounts of citric, succinic, oxalic, ascorbic, and fumaric acids (100621).\nAntimicrobial effects\nThe juice from houseleek leaves has antimicrobial effects in vitro against Proteus mirabilis, Pseudomonas aeruginosa, and Staphylococcus aureus (100621)."
        }
    },
    "Hu Zhang": {
        "sections": {
            "Overview": "Hu zhang is a perennial plant originating from Asia. It also grows in North America. The root is commonly used as part of traditional medicine in various countries in Asia (93969).",
            "Safety": "There is insufficient reliable information available about the safety of hu zhang.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nThere is currently a limited amount of information on the adverse effects of hu zhang.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAllergic rhinitis (hay fever). Although there has been interest in using oral hu zhang for allergic rhinitis, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.\nBiliary disorders. Although there has been interest in using oral hu zhang for biliary disorders, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.\nConstipation. Although there has been interest in using oral hu zhang for constipation, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.\nDiabetes. Although there has been interest in using oral hu zhang for diabetes, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.\nGout. Although there has been interest in using oral hu zhang for gout, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.\nHepatitis. Although there has been interest in using oral hu zhang for hepatitis, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.\nMenopausal symptoms. Although there has been interest in using oral hu zhang for menopausal symptoms, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.\nOsteoarthritis. Although there has been interest in using oral hu zhang for osteoarthritis, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.\nRheumatoid arthritis (RA). Although there has been interest in using oral hu zhang for RA, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.\nUnstable angina. Oral hu zhang has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nOne clinical study in patients hospitalized with unstable angina shows that taking hu zhang granules 7.5 grams and hawthorn granules 5 grams twice daily for 4 weeks, along with conventional therapy, improves quality of life and angina symptom scores, but does not reduce the frequency of angina attacks, when compared with conventional therapy alone (109610).\nless\nWound healing. Although there has been interest in using topical hu zhang for wound healing, there is insufficient reliable information about the clinical effects of hu zhang for this purpose.\nMore evidence is needed to rate hu zhang for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nIn one clinical trial a hu zhang extract standardized to 20% trans-resveratrol (Pure Encapsulations Inc.) was used (93967).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICOAGULANT/ANTIPLATELET DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, hu zhang might increase the risk of bleeding when taken with anticoagulant or antiplatelet drugs.\nHu zhang contains the constituent resveratrol. Resveratrol seems to have antiplatelet effects (2949, 2950, 2951, 2952, 2961, 70813, 70828, 70831, 70892, 70968, 71106).\nless\nCARBAMAZEPINE (Tegretol)\nInteraction Rating\nMINOR Be watchful with this combination.\nSeverity\nMILD\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hu zhang might increase the effects and adverse effects of carbamazepine.\nIn animals, blood and tissue levels of carbamazepine were increased when given in combination with hu zhang. It is thought that increased levels of carbamazepine are due to cytochrome P450 3A4 (CYP3A4) inhibition (101418). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 1A1 (CYP1A1) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, hu zhang might increase levels of drugs metabolized by CYP1A1.\nHu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP1A1 enzyme (70862, 70811). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 1A2 (CYP1A2) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, hu zhang might increase levels of drugs metabolized by CYP1A2.\nHu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP1A2 enzyme (21733). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 1B1 (CYP1B1) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, hu zhang might increase levels of drugs metabolized by CYP1B1.\nHu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP1B1 enzyme (70834). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 2C19 (CYP2C19) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, hu zhang might increase levels of drugs metabolized by CYP2C19.\nHu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP2C19 enzyme (70896). This interaction has not been reported in humans.\nless\nCYTOCHROME P450 2E1 (CYP2E1) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, hu zhang might increase levels of drugs metabolized by CYP2E1.\nHu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP2E1 enzyme (7864, 70896). Also, a pharmacokinetic study shows that taking resveratrol 500 mg daily for 10 days prior to taking a single dose of chlorzoxazone 250 mg increases the maximum concentration of chlorzoxazone by about 54%, the area under the curve of chlorzoxazone by about 72%, and the half-life of chlorzoxazone by about 35% (95824). Chlorzoxazone is used as a probe drug for CYP2E1.\nless\nCYTOCHROME P450 3A4 (CYP3A4) SUBSTRATES\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, hu zhang might increase levels of drugs metabolized by CYP3A4.\nHu zhang contains the constituent resveratrol. In vitro research shows that resveratrol might inhibit the CYP3A4 enzyme (7864, 70896). However, a clinical study in adults with NAFLD found that adding resveratrol 3000 mg daily for 8 weeks did not necessitate dose adjustments to any established medications metabolized by CYP3A4 (91327).\nless\nESTROGENS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, hu zhang might competitively inhibit the effects of estrogen replacement therapy.\nIn vitro research shows that hu zhang might have estrogenic activity (13124, 16061).\nless",
            "Interactions with Supplements": "ANTICOAGULANT/ANTIPLATELET HERBS AND SUPPLEMENTS\nThe hu zhang constituent resveratrol might have antiplatelet effects.\nTaking hu zhang with other products that increase the risk of bleeding might have additive effects. Hu zhang contains the constituent resveratrol. Resveratrol seems to have antiplatelet effects (2949, 2950, 2951, 2952, 2961, 56939). See products with anticoagulant activity here. See products with antiplatelet activity here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nHORMONE-SENSITIVE CANCERS/CONDITIONS\nTheoretically, hu zhang might worsen hormone sensitive conditions. Until more is known, patients with hormone-sensitive conditions should avoid hu zhang. Some of these conditions include breast cancer, uterine cancer, ovarian cancer, endometriosis, and uterine fibroids. In vitro research suggests that hu zhang has estrogenic activity (13124, 16061).\nless\nPERIOPERATIVE\nHu zhang contains the constituent resveratrol, and resveratrol has antiplatelet effects (2949, 2950, 2951, 2952, 2961, 70813, 70828, 70831, 70892, 70968, 71106). Taking hu zhang might cause excessive bleeding if used perioperatively. Tell patients to discontinue hu zhang at least 2 weeks before elective surgical procedures.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hu zhang.",
            "Pharmacokinetics": "Absorption\nIn animal research, hu zhang given as a single oral dose resulted in increases of both resveratrol and emodin metabolites in the blood, suggesting that hu zhang is absorbed when taken orally (93960).\nDistribution\nIn animal research, a single oral dose of hu zhang extract resulted in resveratrol or its glucuronide/sulfate metabolites in the duodenum, liver, kidney, lung, heart, and stomach (56938, 93960). Emodin metabolites were found in the kidney and lung with free emodin in the liver (93960).\nMetabolism\nFrom animal research it appears that the hu zhang constituents emodin and resveratrol are glucuronidated or sulfated following intake in hu zhang (56938, 93960).\nExcretion\nIn animals, plasma levels of emodin and resveratrol, constituents of hu zhang, were back to normal within approximately 500 minutes and 1000-1500 minutes, respectively, after oral intake of hu zhang (93960). Animal research also suggests that the majority of resveratrol from hu zhang is eliminated in the urine as metabolites within 24 hours. More than 99% of excreted resveratrol is in a metabolized form (56938).",
            "Mechanism of Action": "General\nThe applicable part of hu zhang is the root. Hu zhang has several active constituents including emodin, resveratrol, emodin-8-O-D-glucoside, physcion, piceid or polydatin, the anthraquinone malonylglucosides polygonins A and B, flavonoids, and others. Hu zhang is considered to be one of the richest sources of trans-resveratrol (2030, 15154, 93959, 93968, 93969). The hu zhang constituent, emodin, is an anthraquinone, which seems to be responsible for many of hu zhang's potential pharmacological activity.\nAnti-diabetes effects\nHu zhang is traditionally used for diabetes in China. In animal models of diabetes, hu zhang protected against renal cell injury and retinopathy (93962, 93963). It is possible that the constituent emodin helped to protect against the formation of advanced glycation end-products to protect against renal injury (93962). Hu zhang also inhibited the pathway leading to retinal vascular permeability (93963).\nAnti-inflammatory effects\nHu zhang is traditionally used as an anti-inflammatory agent for arthritis and gout. Animal models have shown that hu zhang extract reduces inflammation in various inflammatory models, including arthritis (93969). In humans, hu zhang reduced levels of the inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha (93967). Laboratory research suggests that hu zhang constituents might inhibit the formation of some inflammatory 5-lipoxygenase end-products (56943). Hu zhang extract and constituents might inhibit inflammatory pathways involving the inducible nitric oxide synthetase and cyclooxygenase-2 enzymes (56931, 93969). In an animal model, hu zhang reduced the migration of white blood cells, resulting in reduced inflammation (56936). Thus, it appears that hu zhang and at least some of its constituents have anti-inflammatory effects. There may be more than one mechanism (93969).\nAntiallergic effects\nHu zhang is traditionally used to reduce symptoms of allergies. Laboratory research suggests that hu zhang extract inhibits histamine release and cytokine production from mast cells (56935).\nAntibacterial effects\nLaboratory research suggests that hu zhang extract has antibacterial effects against various bacteria, including drug-resistant organisms. The extract appears to disrupt the cell wall and cytoplasmic membrane (56928, 93964). The constituent emodin also has antibacterial effects (56942). A traditional use of hu zhang is for oral health. This is likely based on the antibacterial effects of hu zhang extract on common oral bacterial (93969).\nAnticancer effects\nHu zhang appears to have several potential anticancer effects. The emodin constituent and other polyphenols such as resveratrol contained in hu zhang seem to have antimutagenic effects. In vitro, hu zhang extracts and emodin decrease the mutagenicity of benzo[a]pyrene and other mutagens in a dose-dependent manner (13122). Several constituents of hu zhang seem to have a cytotoxic effect on HL-60 cells. Emodin appears to be the most cytotoxic (13125). The emodin constituent of hu zhang is also a strong inhibitor of protein tyrosine kinase (13126, 13128). Tyrosine kinases have a role in regulation of cell growth. Tyrosine kinases are therefore a target for potential anticancer agents (13126). Preliminary evidence also suggests that a hu zhang root extract has antiangiogenesis activity (13129).\n\nIn vitro evidence suggests that a hu zhang extract can increase proliferation of estrogen-sensitive breast tissue cells, MCF-7. The emodin constituent binds both estrogen receptor-alpha and estrogen receptor-beta and is thought to be a potent phytoestrogen (13124).\nAntilipemic effects\nHu zhang extract decreases serum levels of very low density lipoprotein (VLDL) cholesterol in animal models. Hu zhang seems inhibit acyl-coenzyme A-cholesterol acyltransferase (ACAT), which is involved in determining cholesterol levels. The resveratrol constituent of hu zhang is thought to be the constituent primarily responsible for inhibiting ACAT (13123). However, the constituent polydatin has also been shown to reduce levels of cholesterol in an animal model (56941).\nAntioxidant effects\nThe antioxidant effects of hu zhang might play a role in its potential clinical effects including reduced swelling and inflammation. The antioxidant effects of hu zhang have been shown in various animal and in vitro models (56919, 56932, 93969).\nAntiviral effects\nLaboratory research shows that some constituents of hu zhang, including piceid, emodin, and catechin, have antiviral activity against the HIV virus (93959). Another constituent, a procyanidin-tri-O-gallate, has the potential to reverse HIV viral latency. This suggests the potential for hu zhang to be used in combination with highly active antiretroviral therapy to eliminate latent viral reservoirs (93965). Laboratory research also suggests that hu zhang and its constituents such as resveratrol and emodin might inhibit replication of various strains of the influenza virus, including H1N1. Inhibition of interferon-beta appears to play a role in the mechanism of action (93961). Hu zhang extract has also been shown to inhibit the replication of other viruses, such as hepatitis B virus (HBV) (56915).\nCardioprotective effects\nAlthough hu zhang has not been investigated for its cardioprotective properties in animals or humans, there is evidence to suggest that two hu zhang constituents, polydatin and resveratrol, have the potential to improve outcomes associated with cardiac perfusion injury. Polydatin reduces free radical injury in laboratory models. It also inhibits the activation of the renin-angiotensin-aldosterone system and prevents ventricular remodeling. Resveratrol also appears to protect the heart from ischemia/reperfusion injury and is possibly protective against hypertensive-induced cardiac hypertrophy and atherosclerosis.\nDental effects\nHu zhang has traditionally been used to improve oral hygiene. In vitro research shows that hu zhang rhizome extracts improve measures of human gingival fibroblast viability, proliferation, and migration, suggesting that hu zhang extract might be beneficial for the treatment of gingival wounds (109609).\nEstrogenic effects\nHu zhang extract shows estrogenic activity in laboratory models (16061). This may be related to the constituent emodin, which binds to estrogen receptors and blocks the binding of 17-beta-estradiol to human estrogen receptors (13124, 93969).\nImmune effects\nIn an animal model, hu zhang stimulated an immune response. Hu zhang increased the proliferation of white blood cells and enhanced the activity of both macrophages and natural killer cells (93958).\nLaxative effects\nEmodin, like other anthraquinones, is thought to have a laxative effect (13122).\nNeuroprotective effects\nClinical benefits related to the neuroprotective effects of hu zhang are not clear. In animal models, hu zhang and constituents such as 2-methoxy-6-acetyl-7-methyljuglone, emodin, polydatin, and resveratrol reduced the infarction volume and prevent neurological and cognitive deficits. Furthermore, based on the mechanism of action involving the inhibition of cell adhesion molecule production, hu zhang extract might prevent injury due to stroke. The antioxidant properties of hu zhang constituents appear to play a role in these effects (93969).\nWound healing effects\nHu zhang is used traditionally for wound healing. In animal research, topical hu zhang extract improved wound healing, possibly by reducing inflammation and improving the rate of collagen production (93966).\nXanthine oxidase inhibition\nPreliminary evidence shows that a hu zhang root extract can inhibit xanthine oxidase, suggesting that hu zhang might have a role in gout. However, the degree of xanthine oxidase inhibition is about 38 times less with hu zhang compared to allopurinol (13127)."
        }
    },
    "Humic Acid": {
        "sections": {
            "Overview": "Humic acid is a constituent of humic substance, which is found in water, soil, coal, and other sources. Humic substance also contains fulvic acid and humin (13670). Humic acid and humic substance are high-molecular weight polymers that result from the degradation of organic matter, particularly dead plants (13674). Humic acid has traditionally been used as an antiviral and immunostimulant.",
            "Safety": "There is insufficient reliable information available about the safety of humic acid.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNone reported; however, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of humic acid.",
            "Dosing & Administration": "Adult\nResearch is limited; typical dosing unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of humic acid.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "AUTOIMMUNE DISEASES\nLaboratory research suggests that the oxihumate derivative of humic acid might stimulate immune function (13679). Theoretically, humic acid might exacerbate autoimmune diseases by stimulating disease activity. Advise patients with autoimmune diseases such as multiple sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or others to avoid or use humic acid with caution.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with humic acid.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of humic acid.",
            "Mechanism of Action": "General\nHumic acid is a constituent of humic substance, which is found in water, soil, coal, and other sources. Humic substance also contains fulvic acid and humin (13670). Humic acid and humic substance are high-molecular weight polymers that result from the degradation of organic matter, particularly dead plants (13674).\nAntiviral effects\nLaboratory research suggests that derivatives of humic acid might have activity against influenza viruses and HIV (13676, 13677, 13678). However, there are no clinical studies on the use of humic acid or its derivatives for influenza or HIV.\nHematologic effects\nLaboratory research suggests that humic acid inhibits plasmin, which dissolves the fibrin in blood clots, and adversely affects neutrophil function (13672, 13673).\nImmunostimulatory effects\nLaboratory research suggests that the oxihumate derivative of humic acid might have immunostimulant activity (13679).\nPro-oxidant effects\nAlthough it is promoted as an antioxidant, laboratory research suggests that humic acid might actually induce oxidative DNA damage and induce apoptosis (cell death) in endothelial cells and fibroblasts (13674, 13675)."
        }
    },
    "Huperzine A": {
        "sections": {
            "Overview": "Huperzine A is an alkaloid isolated from certain species in the Lycopodium family, including Chinese club moss (Huperzia serrata) and fir club moss (Huperzia selago) (55671). Huperzine A was identified, purified, and formulated for medicinal use by scientists at the Chinese Academy of Sciences in the 1980s. It was determined to be an inhibitor of acetylcholinesterase (AChE) and was approved for the treatment of Alzheimer disease in China in 1994 (55629, 93480, 93482, 93483).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately, short-term. Huperzine A 200-800 mcg daily has been used with apparent safety in clinical trials lasting up to 6 months (3171, 3561, 4626, 93478, 93479, 93480, 93481, 93482, 93483, 93485).\nCHILDREN: POSSIBLY SAFE when used orally and appropriately, short-term. Huperzine A has been used with apparent safety in clinical research lasting for 1 month (4626).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, huperzine A seems to be well tolerated. There is currently a limited amount of information about the tolerability of intramuscular huperzine A.\nMost Common Adverse Effects\nAll ROAs: Huperzine A can cause dose-dependent cholinergic side effects such as blurred vision, constipation, diarrhea, dizziness, dry mouth, insomnia, nausea, sweating, and vomiting.\nCardiovascular\nOrally, huperzine A might cause decreased heart rate (3138, 93482). There are two cases reported where consumption of a tea mistakenly brewed from Lycopodium selago, a source of huperzine A, has resulted in significant cholinergic toxicity, including hypertension (13193).\nless\nGastrointestinal\nOrally, huperzine A can cause cholinergic side effects such as nausea, vomiting, diarrhea, and anorexia (93480, 93481, 93482, 93483). Constipation and thirst have also been reported (93482, 93483). In two case reports, consumption of a tea mistakenly brewed from Lycopodium selago, a source of huperzine A, has resulted in significant cholinergic toxicity, including vomiting and diarrhea (13193).\nless\nMusculoskeletal\nIn two case reports, consumption of a tea mistakenly brewed from Lycopodium selago, a source of huperzine A, has resulted in significant cholinergic toxicity, including leg cramps (13193).\nless\nNeurologic/CNS\nOrally, huperzine A can cause cholinergic side effects such as dizziness (3140, 55613, 93481, 93482) and sweating (93482). Huperzine A can also cause hyperactivity and insomnia (3138, 3140, 55613, 93482). Fainting has also been reported (4624). In two case reports, consumption of a tea mistakenly brewed from Lycopodium selago, a source of huperzine A, has resulted in significant cholinergic toxicity, including sweating and slurred speech (13193).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nAlzheimer disease. Oral huperzine A seems to improve memory, cognitive function, and behavior in patients with this condition.\nMeta-analyses of small clinical studies in patients with Alzheimer disease show that, overall, huperzine A 200-800 mcg in 2-3 divided doses daily for 8-36 weeks improves cognitive function as measured on some scales, but not others, when compared with placebo (55674, 93482). Improvement in cognitive function was observed consistently when measured using the Mini-Mental State Examination (MMSE) (55674, 93482, 93483, 101469). However, results are inconsistent with other scales, such as the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), the Hasegawa Dementia Scale (HDS), and the Wechsler Memory Scale (WMS) (55674, 93482). Meta-analyses also show that huperzine A improves overall behavior and performance of daily living activities when compared with placebo (55674, 93482).\n\nMost research has been conducted in China, where huperzine A is an approved drug for this condition. Only one clinical trial has been conducted in the United States. This study was conducted in patients with probable mild to moderate Alzheimer disease and shows that taking huperzine A 200 mcg twice daily for at least 16 weeks does not improve cognition based on the ADAS-Cog when compared with placebo. However, this dose results in modest benefit when cognition is measured using the MMSE, and a higher dose of 400 mcg twice daily shows modest benefit when measured on both the ADAS-Cog and MMSE (93479). Long-term, large-scale clinical trials in diverse geographic locations are necessary to confirm these findings and determine which dose of huperzine A, if any, is beneficial.\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. It is unclear if oral huperzine A is beneficial for improving athletic performance.\nOne very small, double-blind randomized crossover study in physically active adults shows that taking huperzine A 200 mcg as a single dose 30-45 minutes prior to exercise does not affect athletic performance, neuromuscular performance, or cognitive function when compared with placebo (107470). Due to the single-dose nature of this study, the effects of continued administration of huperzine A on athletic performance are unclear.\nless\nCocaine dependence. It is unclear if oral huperzine A is beneficial in patients with cocaine use disorder.\nA very small clinical study in adults with cocaine use disorder shows that taking huperzine A in gradually increasing doses over 9 days, up to a dose of 200 or 400 mcg twice daily, might attenuate the stimulation and anxiety effects of an intravenous cocaine infusion when compared with placebo (93484). It is unclear if huperzine A can attenuate cravings and cocaine use in these individuals.\nless\nCognitive impairment. Although there is interest in using oral huperzine A for mild cognitive impairment, there is insufficient reliable information about the clinical effects of huperzine A for this condition.\nDepression. It is unclear if oral huperzine A is beneficial in patients with major depressive disorder.\nA meta-analysis of three small, low-quality clinical studies in patients with major depressive disorder shows that taking huperzine A 100-300 mg daily in combination with antidepressants for 6-8 weeks does not further improve depressive symptoms when compared with antidepressants alone. However, huperzine A might improve cognitive functioning, based on the Wisconsin Card Sorting Test and the Wechsler Memory Scale-Revised (WMS-R) (93485). All available research has been conducted in China, so it is unclear if these findings are generalizable to other geographic locations.\nless\nMemory. It is unclear if oral huperzine A is beneficial for improving memory in healthy adolescents.\nA small clinical trial in Chinese adolescents around 15 years of age who complain of poor memory shows that taking huperzine A 100 mcg daily for 4 weeks improves memory quotient scores when compared with placebo (4626).\nless\nMyasthenia gravis. It is unclear if intramuscular huperzine A is beneficial in patients with myasthenia gravis.\nA small, open-label clinical trial in stabilized patients with myasthenia gravis shows that giving huperzine A 400 mcg intramuscularly for 10 days maintains muscle strength similarly to patients treated with intramuscular neostigmine alternating with intramuscular huperzine A. Huperzine A was reported to have a 7-hour duration of effect, compared to only 4 hours with neostigmine (3561).\nless\nSchizophrenia. Small clinical studies suggest that oral huperzine A may modestly improve symptoms of schizophrenia in adults.\nA meta-analysis of small, low-quality clinical trials in hospitalized patients with schizophrenia shows that taking huperzine A 150-400 mcg daily for 8-24 weeks as an adjunct to antipsychotic medications improves memory, intelligence, and positive, but not negative, psychiatric symptoms when compared with antipsychotic medications alone (93478). Limited research also suggests that huperzine A might improve outcomes in patients with resistant schizophrenia and cognitive impairment. A small, open-label clinical study in patients with treatment-resistant schizophrenia and cognitive impairment shows that adding huperzine A 300 mcg daily for 12 weeks to treatment with antipsychotics improves negative symptoms of schizophrenia by 32% and memory by 15% when compared to baseline (55665). The validity of this finding is limited by the lack of a comparator group. Furthermore, all available research has been conducted in China, so it is unclear if these findings are generalizable to other geographic locations.\nless\nVascular dementia. Small clinical studies suggest that oral huperzine A may modestly improve symptoms of vascular dementia in adults.\nA meta-analysis of two small clinical trials in patients with vascular dementia shows that taking huperzine A 200-300 mcg daily for 12-24 weeks modestly improves cognitive function and activities of daily living when compared with control (93483). The validity of this meta-analysis is limited by small study size and publication bias.\nless\nMore evidence is needed to rate huperzine A for these uses.",
            "Dosing & Administration": "Adult\nOral:\nHuperzine A is most commonly used in doses of 200-500 mcg daily for up to 6 months. This total daily dose is typically divided into 2-3 doses (93478, 93482, 93483).\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nHuperzine A for medicinal use is a laboratory-purified, single molecule drug (93484).",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTICHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, huperzine A might decrease the effects of anticholinergic drugs.\nHuperzine A has acetylcholinesterase (AChE) inhibiting effects. In animal models, huperzine A reversed cognitive deficits induced by scopolamine, an anticholinergic drug (3134, 3135, 55692).\nless\nCHOLINERGIC DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, concurrent use of huperzine A with cholinergic drugs might increase the effects and side effects of these medications.\nHuperzine A can inhibit acetylcholinesterase (AChE) and might cause cumulative effects if used with cholinergic drugs (3131).\nless",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nBRADYCARDIA/CARDIOVASCULAR DISEASE\nHuperzine A might decrease heart rate and exacerbate bradycardia and other related cardiac conditions. Huperzine A inhibits acetylcholinesterase (AChE) and might cause cholinergic adverse effects such as decreased heart rate (3561); use with caution.\nless\nEPILEPSY\nTheoretically, huperzine A might exacerbate seizure disorders. Huperzine A inhibits acetylcholinesterase (AChE) and might cause cholinergic effects which are thought to increase the risk of seizures (3561); use with caution.\nless\nGASTROINTESTINAL TRACT OBSTRUCTION\nTheoretically, huperzine A might exacerbate gastrointestinal obstruction due to its pro-secretory effects. Huperzine A inhibits acetylcholinesterase (AChE) and might cause cholinergic adverse effects due to increased gastric secretions (3561); use with caution.\nless\nPEPTIC ULCERS\nTheoretically, huperzine A might exacerbate peptic ulcer disease due to its pro-secretory effects. Huperzine A inhibits acetylcholinesterase (AChE) and might cause cholinergic adverse effects due to increased gastric acid secretions (3561); use with caution.\nless\nPULMONARY CONDITIONS\nTheoretically, huperzine A might exacerbate pulmonary conditions such as asthma and chronic obstructive pulmonary disease (COPD) due to its pro-secretory effects Huperzine A inhibits acetylcholinesterase (AChE) and might cause adverse cholinergic adverse effects due to increased bronchial secretions (3561); use with caution.\nless\nUROGENITAL TRACT OBSTRUCTION\nTheoretically, huperzine A might worsen urogenital tract obstruction in patients prone to obstruction. Huperzine A inhibits acetylcholinesterase (AChE) and might cause cholinergic adverse effects due to increased secretions (3561); use with caution.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "Presentation\nTaking too much huperzine A might cause cholinergic toxicity, with symptoms of sweating, vomiting, diarrhea, hypertension, leg cramps, and slurred speech (13193).\nTreatment\nThere is insufficient reliable information available about the treatment of overdose with huperzine A. Theoretically, an anticholinergic agent might reverse the cholinergic toxicity caused by large doses of huperzine A.",
            "Pharmacokinetics": "Absorption\nAfter oral administration, huperzine A is absorbed rapidly by the body (55673, 93480) and reaches peak concentrations in 60-80 minutes (55691, 93477). Researchers disagree as to whether absorption is explained by a one- or two-compartment model (55691, 55702, 93477). In animal research, overall bioavailability is estimated at 96.9%, which is greater than that for other acetylcholinesterase inhibitors used for Alzheimer disease such as donepezil, rivastigmine, and tacrine (55702, 101468). Huperzine A is also absorbed when given by the intranasal route (55662, 55664) or by transdermal patch (55672).\nDistribution\nHuperzine A is distributed widely in the body (93480). It readily crosses the blood-brain barrier, possibly to a greater extent than other acetylcholinesterase inhibitors used for Alzheimer disease, such as donepezil, rivastigmine, and tacrine (3561, 55664, 93480, 101468).\nExcretion\nThe elimination half-life of huperzine A has been estimated at 4 hours (55691, 93484) or 11 hours (55673, 93477). In an animal model, huperzine A is excreted in the urine within 24 hours after intravenous administration; only 2.4% is recovered from the feces (55702).",
            "Mechanism of Action": "General\nHuperzine A is a sesquiterpene alkaloid isolated from Chinese club moss (Huperzia serrata) and fir club moss (Huperzia selago) (3561, 101468). It is an optically active molecule, but only the levorotatory isomer has pharmacological effects (3561).\nCholinergic effects\nHuperzine A is thought to be beneficial in dementia, memory impairment, and myasthenia gravis due to its effects on acetylcholine levels (3133, 3134, 3135, 3136, 3172). It reversibly inhibits acetylcholinesterase (AChE) for up to three hours and crosses the blood-brain barrier (3137). It raises acetylcholine levels in various areas of the brain to different degrees. The largest increases occur in the frontal and parietal cortexes with 125% and 105% increases respectively, while other brain regions have 22% to 65% increases (3141). Huperzine A might be more specific for AChE and have a longer duration of action than the drugs tacrine (Cognex) or donepezil (Aricept), which are marketed as prescription drugs for Alzheimer disease (3131, 3132). In animal studies, huperzine A was found to be 64 times more potent than tacrine (3561).\nHepatic effects\nIn vitro studies with rat liver show that huperzine A increases hepatocyte loss of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), but not lactate dehydrogenase (LDH). The effect on ALT and AST can be completely blocked by atropine, suggesting that it is due to AChE inhibition rather than direct hepatotoxicity (55618).\nN-methyl-D-aspartate (NMDA) receptor antagonist effects\nHuperzine A is a weak antagonist at cerebral cortex NMDA receptors (3129, 3137).\nNeurological effects\nHuperzine A may have neuroprotective effects related to antioxidant and anti-apoptotic activity. The anti-apoptotic effects may be due to down-regulation of anti-apoptosis genes (55583, 55601, 55614, 55619). Laboratory research shows that huperzine A can upregulate nerve growth factor and its receptors (55642). Huperzine A can also protect against beta-amyloid peptide induced oxidative stress, and it may shift metabolism of beta-amyloid to a non-amyloidogenic pathway (55583, 55589, 55590, 55603, 93479). Huperzine A also protects neurons against toxic levels of glutamate by blocking glutamate-induced neuronal calcium influx and cell death (3131, 3561).\n\nHuperzine A might protect against seizures and neuropathological changes caused by exposure to organophosphate nerve agents such as soman by maintaining peripheral and central stores of acetylcholine (3137, 3139).\n\nHuperzine A has also been evaluated for cocaine use disorder. A very small clinical study shows that taking huperzine A might attenuate the stimulation and anxiety effects of an intravenous cocaine infusion. Huperzine A does not influence the metabolism of cocaine, so this effect is thought to be due to dopaminergic activity (93484)."
        }
    },
    "Hyacinth Bean": {
        "sections": {
            "Overview": "Hyacinth bean is a climbing plant. The leaves, flowers, pods, and seeds are edible and grown as a food crop. Hyacinth bean is also used in medicine (90475, 90476, 90478).",
            "Safety": "POSSIBLY UNSAFE when consumed raw and in large quantities. Raw, mature hyacinth beans contain relatively high amounts of cyanogenic glycosides, which might cause poisoning (26194).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nOrally, raw hyacinth bean can be toxic due to its cyanogenic glycoside content.\n\nHyacinth beans contain cyanogenic glycosides, which might cause poisoning when taken orally (26194).",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nDiarrhea. Although there has been interest in using oral hyacinth bean for diarrhea, there is insufficient reliable information about the clinical effects of hyacinth bean for this condition.\nInsomnia. Although there has been interest in using oral hyacinth bean for insomnia, there is insufficient reliable information about the clinical effects of hyacinth bean for this condition.\nMore evidence is needed to rate hyacinth bean for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hyacinth bean.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hyacinth bean.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of hyacinth bean.",
            "Mechanism of Action": "General\nConstituents of hyacinth bean include proteins such as arcelin and dolicholin (26818, 26827), saponins, such as lablab saponin 1 (26819, 26837), lablabosides (26837), phytosterols (26839), and lectins (26812, 26822, 26835, 26836, 26844, 26849). Cooking hyacinth beans increases the digestibility of its proteins and starches, but decreases the content of protein, calcium, phosphorus, and thiamine (26823).\nAntidiabetic effects\nHyacinth bean and related beans are of interest for diabetes. In an animal model of type 2 diabetes, hyacinth bean polysaccharide reduces fasting blood glucose, insulin resistance, and pancreatic inflammation and oxidative stress. The mechanism of action is thought to be related to an increase in glucagon-like peptide-1 levels in the gut and pancreas, promoting insulin secretion, reducing inflammatory markers including nitric oxide, interleukin (IL)-1-beta, and IL-6, and increasing the activity of antioxidant enzymes (115752).\nHepatoprotective effects\nIn an animal model, hyacinth bean extract protects against high fat diet-induced non-alcoholic fatty liver disease. The extract improves liver function tests and serum lipid levels, increases adiponectin levels, and decreases expression of hepatic genes involved in liver fat uptake and accumulation (98624, 98625)."
        }
    },
    "Hyaluronic Acid": {
        "sections": {
            "Overview": "Hyaluronic acid is a polysaccharide chain of repeating disaccharide units. It is found throughout the body where it serves as part of the supporting structure in the extracellular space. It is found most abundantly in cartilage, synovial fluid, skin, and the aqueous humor in the eye (9139). Some hyaluronic acid products are available as US Food and Drug Administration (FDA)-approved medical devices for various routes of administration, including intra-articular, deep subcutaneous, and ophthalmic.\n\nThis monograph does not include information on the use of approved medical devices or injectable products.",
            "Warnings": "The FDA has warned consumers and healthcare professionals against the use of unapproved needle-free devices for the injection of lip and facial fillers, including those containing hyaluronic acid. The use of these needle-free devices has resulted in serious injury, and in some cases permanent harm, to the skin, lips, and eyes (108613).",
            "Safety": "LIKELY SAFE when used orally and appropriately. Supplements standardized to contain hyaluronic acid 70%, in an 80 mg daily dose, have been used daily for up to 3 months with no reports of adverse effects (55742, 91779). ...when used topically and appropriately. Hyaluronic acid, in a gel or impregnated gauze, has been safely applied to the skin in clinical trials (7889, 7892, 104389, 108627, 108640). ...when eye drop preparations containing up to 0.3% hyaluronic acid are used multiple times per day for up to 3 months (97885, 97894, 97895, 110555).\nPREGNANCY: There is insufficient reliable information available about the safety of hyaluronic acid; avoid using.\nLACTATION: There is insufficient reliable information available about the safety of hyaluronic acid. It is not known if hyaluronic acid is excreted in breast milk (7890); avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally and topically, hyaluronic acid appears to be well tolerated.\nMost Common Adverse Effects\nTopically: Eczema, erythema, itching, wound hemorrhage, wound infection (e.g., erysipelas).\nDermatologic\nThe use of needle-free devices to inject hyaluronic acid for cosmetic purposes has been reported to cause serious injury, and in some cases permanent harm, to the skin, lips, and eyes (108613).\n\nTopically, hyaluronic acid application has been reported to cause eczema, erythema, itching, wound hemorrhage, and wound infection (e.g., erysipelas) (108628, 108640).\nless\nOcular/Otic\nOcular pain has been reported rarely in patients using eye drops containing up to 0.3% hyaluronic acid (97885).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nDry eye. Applying eye drops containing hyaluronic acid alone or in combination with other ingredients, seems to improve symptoms of dry eye.\nA large meta-analysis of clinical studies in patients with dry eye disease shows that using eye drops containing hyaluronic acid 0.1% to 0.4% for at least 14 days modestly improves tear production when compared with artificial tears or saline control, with a more significant improvement when compared with saline control. Tear stability is also modestly improved when compared with saline control (108622). Several individual clinical studies using specific hyaluronic acid eye drops have also demonstrated improvement. One clinical study in patients with dry eye disease shows that applying eye drops containing hyaluronic acid 0.1% to 0.3% 5-6 times daily for 12 weeks might improve symptoms to a similar degree as cyclosporine 0.05% eye drops. The products used in this study included Hyalein ophthalmic solution 0.1%, New Hyaluni ophthalmic solution 0.15%, and Hyaluni ophthalmic solution 0.3% (97885). Another clinical study shows similar efficacy between hyaluronic acid 0.15% eye drops (New Hyaluni), applied 6 times daily for 12 weeks, and eye drops containing cyclosporine 0.05% and carboxymethylcellulose 0.5%, applied twice daily (110555). A smaller clinical study in patients with dry eye disease shows that applying specific eye drops containing hyaluronic acid 0.2% (Hyalistil) seems to have similar efficacy as using tamarind seed polysaccharide eye drops (16301). Furthermore, adding hyaluronic acid to conventional treatment seems to offer additional benefit. A large multicenter clinical trial in patients with dry eye disease shows that applying 1-2 drops of artificial tears containing carboxymethylcellulose 0.5% and hyaluronic acid 0.1% (Optive Fusion, Allergan) at least 2 times daily for 3 months seems to further improve pain and discomfort when compared with using artificial tears containing carboxymethylcellulose alone (104384). One small clinical study also shows that hyaluronic acid 0.3% ocular gel and hyaluronic acid 0.18% eye drops, applied 4-6 times daily for 12 weeks, are equally effective for improving dry eye symptoms (110556).\n\nHyaluronic acid has also been studied in combination with other ingredients. Several small clinical studies in patients with dry eye syndrome ranging from mild to severe shows that applying eye drops containing hyaluronic acid 0.2% or 0.3%, polyvinylpyrrolidone, and glycerin (Visaid 0.2% or 0.3%, Avizor S.A.), administered as one drop 3-8 times daily for one month, improves some signs and symptoms of dry eye when compared with sodium chloride 0.9% (97894, 97895). Conversely, a large clinical study in patients with mild to moderate dry eye disease shows that applying preservative-free eye drops containing sodium hyaluronate with chondroitin sulfate (Humylub Ofteno PF, Laboratorios Sophia), one drop into each eye four times daily for 90 days, seems to be no different for improving dry eye severity when compared with using polyethylene/propylene glycol eye drops (104443).\nless\nVenous leg ulcers. Topical application of hyaluronic acid-impregnated gauze reduces wound size and promotes wound healing.\nClinical studies in patients with at least one leg ulcer of venous or mixed arterial/venous origin show that once daily application of a specific hyaluronic acid-impregnated gauze (Ialuset, Laboratoires Genvrier) reduces wound size at 45 days by 73% and produces complete wound healing at or before 20 weeks in 40% of patients. In those receiving a neutral vehicle gauze, these improvements occurred in 46% and 19% of patients, respectively (108627, 108640).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAging skin. Oral hyaluronic acid has only been evaluated in combination with other ingredients; its effect when used alone is unclear. It is also unclear if topical hyaluronic acid is beneficial for aging skin.\nA very small study shows that taking a specific combination product (GliSODin Skin Nutrients Advanced Anti-Aging Formula, Isocell North America Inc.) containing hyaluronic acid, krill oil, sea buckthorn berry oil, and cacao bean extract orally three times daily for 90 days, along with applying tazarotene 0.1% cream, moderately decreases wrinkling and photodamage and improves skin moisture and elasticity when compared with tazarotene cream alone (91778). Another small clinical study in females with aging skin shows that taking a specific combination product (BioCell Collagen, BioCell Technology, LLC) containing hyaluronic acid 100 mg, chondroitin sulfate 200 mg, and collagen peptides 600 mg daily for 12 weeks reduces lines and wrinkles by about 13% when compared with baseline (28681). The validity of this finding is limited by the lack of a comparator group. Furthermore, it should be noted that both studies were funded by the product manufacturer.\n\nA small open-label clinical study in females with mild to moderate lip dryness and mild to severe lip condition shows that three daily applications of a two-step lip treatment containing hyaluronic acid for 4 weeks improves the overall condition of lips, as well as texture/visual roughness, plumpness, color/rosiness, definition/contour, and lines/wrinkles when compared with baseline (108634). The validity of these findings is limited by the lack of a comparator group.\nless\nAllergic rhinitis (hay fever). It is unclear if nasal irrigation with sodium hyaluronate is beneficial in patients with mild, persistent seasonal allergic rhinitis.\nA small clinical study in patients with mild, persistent seasonal allergic rhinitis receiving an oral antihistamine and an intranasal corticosteroid shows that nasal irrigation with sodium hyaluronate twice daily for 1 month improves mucociliary clearance time by 3 minutes, compared with 1 minute with the use of isotonic saline and 5 minutes with the use of surfactant (108630). It is unclear if this change is associated with clinically relevant symptom improvement.\nless\nBurns. It is unclear if topical hyaluronic acid is beneficial in patients with burns.\nA meta-analysis of small clinical trials suggests that topical hyaluronic acid and hyaluronic acid derivatives might improve the healing of wounds, including burns, when compared with control (104389). A small nonrandomized clinical study in patients with partial- to full-thickness burns shows that hyaluronic acid 0.2% gel daily for 12 weeks during the re-epithelialization phase reduces erythema, tension, pruritus, burning, and neoangiogenesis when compared with baseline (108636). The lack of statistical comparison to the ozonated oil group and the single-blinded nature of the study limit the validity of these findings.\nless\nCanker sores. It is unclear if topical hyaluronic acid is beneficial for canker sores.\nA clinical study in adults with recurrent canker sores shows that applying a gel containing hyaluronic acid 0.2% two to three times daily for 7 days reduces soreness immediately and for up to 30 minutes after application when compared with baseline. However, these improvements are numerically similar to those seen with placebo (108637). The lack of statistical comparison to placebo limits the validity of this finding. A small observational study in children with recurrent canker sores has found that applying a gel containing hyaluronic acid 0.2% twice daily for 7 days is similarly effective to dexamethasone topical ointment applied three times daily for 5 days for reducing pain and ulcer size (104388).\nless\nCorneal abrasion. It is unclear if eye drops containing hyaluronic acid are beneficial in preventing recurrence in patients with a history of traumatic corneal abrasion.\nA small clinical study in patients with fully healed traumatic corneal abrasion at risk for recurrence shows that administration of eye drops containing hyaluronic acid 0.3% five times daily for 3 months does not reduce the incidence rate of major symptomatic episodes at 12 months when compared with observation alone (108623).\nless\nDiabetic foot ulcers. Oral hyaluronic acid has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA meta-analysis of results from 4 clinical studies shows that applying hyaluronic acid combination gels or hyaluronic acid-based biomaterials to diabetic foot ulcers increases the odds of complete healing at 12 weeks by about 1.7-fold when compared to control treatment. Forms of hyaluronic acid assessed in the evaluated studies included zinc hyaluronate, hyaluronic acid-based biomaterial (Hyalograft 3D autograft), and a gel containing hyaluronic acid and amino acids (Vulnamin Gel, Errekappa) (91776). It is not clear if the beneficial effects were due to hyaluronic acid or other components of the treatments.\nless\nExercise-induced muscle soreness. Oral hyaluronic acid has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nA very small clinical study in healthy, recreationally active adults shows that a specific product (BioCell Collagen, BioCell Technology, LLC) containing hyaluronic acid 150 mg, chondroitin sulfate 300 mg, and collagen peptides 900 mg, taken twice daily for 6 weeks prior to two bouts of resistance exercise, attenuates muscle damage and decreases delayed-onset muscle soreness when compared with placebo (96301). It is unclear if these effects are due to hyaluronic acid, the other ingredients, or the combination. Furthermore, it should be noted that both studies were funded by the product manufacturer.\nless\nGastroesophageal reflux disease (GERD). Oral hyaluronic acid has only been evaluated in combination with other ingredients; its effect when used alone is unclear.\nPatients with non-erosive GERD are thought to be less responsive to conventional acid suppression with proton pump inhibiters (PPIs) and H-2 blockers. A small preliminary clinical study shows that taking a syrup containing hyaluronic acid and chondroitin sulfate along with PPIs, H2-receptor antagonists, and/or antacids, reduces the intensity of symptoms associated with non-erosive GERD by about 3.5-fold when compared with placebo (89592). A larger clinical study in patients with non-erosive GERD shows that taking a different formulation of the same combination of chondroitin sulfate and hyaluronic acid (Esoxx, Alfa Wassermann) 4 times daily for 14 days, in conjunction with a PPI, improves GERD symptom severity by 21%, heartburn by 15%, and regurgitation by 10% when compared with using a PPI and placebo (101271). Hyaluronic acid has also been evaluated in combination with chondroitin sulfate in patients with extraesophageal symptoms of GERD. A small, open-label study shows that taking a specific combination product (Gerdoff, SOFAR S.p.A.) containing hyaluronic acid and chondroitin sulfate three times daily with omeprazole 40 mg daily for 6 weeks increases the rate of treatment response, defined as a 50% or greater improvement in reflux symptoms index scores, by around 40% when compared with omeprazole alone. While average symptom scores were not significantly improved with the combination product over omeprazole, the need for omeprazole as rescue therapy for breakthrough symptoms was reduced in the treatment group (109648). It is unclear if the findings described above are due to hyaluronic acid, chondroitin sulfate, or the combination.\nless\nGingivitis. It is unclear if hyaluronic acid used in a mouthwash reduces gingivitis severity.\nA small clinical study in patients with biofilm-induced gingivitis shows that rinsing with 10 mL of hyaluronic acid 0.025% mouth wash (Gengigel, RICERFARMA SRL) for 1 minute twice daily reduces probing index and bleeding when compared with rinsing with a placebo solution, but is less effective when compared with chlorhexidine 0.12% solution (104383). Another small clinical study in patients with plaque-induced gingivitis shows that rinsing with 10 mL of a mouthwash containing hyaluronic acid 0.1% and hydrogen peroxide 1.8% for 30 seconds twice daily for 21 days reduces gingival index scores but not plaque index scores when compared with placebo (110554). It is unclear if these findings are due to hyaluronic acid, hydrogen peroxide, or the combination.\nless\nIntranasal surgery. It is unclear if topical hyaluronic acid irrigation improves recovery in patients after nasal surgery.\nA small clinical study in patients that underwent nasal surgery for chronic rhinosinusitis shows that performing nasal irrigation with high molecular weight sodium hyaluronate 9 mg twice daily for 6 weeks improves sinus scarring, crusting, and headache when compared with nasal irrigation with saline. However, the sodium hyaluronate irrigation did not improve sinus inflammation or secretions, nasal obstruction, or facial pain (101288).\nless\nIntrauterine adhesions. Several small studies suggest that intrauterine administration of hyaluronic acid gel seems to prevent intrauterine adhesions after uterine surgery.\nMeta-analyses of 11-12 small clinical studies in patients undergoing uterine surgery shows that intrauterine application of 1-10 mL of hyaluronic acid gel after surgery reduces the risk of intrauterine adhesions by around 50% and increases pregnancy rates when compared with no treatment (110551, 110552). One analysis suggests that hyaluronic acid is most effective for prevention of intrauterine adhesions when at least 5 mL of gel is applied (110551).\nless\nLichen planus. It is unclear if topical hyaluronic acid is beneficial in patients with oral lichen planus.\nA clinical study in patients with oral lichen planus shows that application of a gel containing hyaluronic acid 0.2% four to five times daily for 28 days reduces soreness in as little as 5 minutes for up to 4 hours when compared with baseline. These findings are numerically similar to those seen with placebo; however, the lack of statistical comparison to placebo limits the validity of this finding (108635). A small clinical study in patients with symptomatic oral lichen planus (including mixed forms) shows that application of a gel containing hyaluronic acid 0.2% three times daily for 4 weeks is similarly effective to triamcinolone for improving pain, erythema, and lesion size (108633). It is unclear if the improvement from baseline differed between groups.\nless\nMelasma. It is unclear if topical hyaluronic acid is beneficial in patients with moderate to severe facial melasma.\nA small clinical study in patients with mostly mixed-type, moderate to severe facial melasma shows that twice daily application of hyaluronic acid along with isobutylamido thiazolyl resorcinol reduces melasma severity similarly to isobutylamido thiazolyl resorcinol alone (108628). The single-blinded nature of the study limits the validity of these findings.\nless\nOral mucositis. Topical hyaluronic acid has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nA small clinical study in children aged 5 years or older with chemotherapy-induced oral mucositis shows that using a solution containing sodium hyaluronate, verbascoside, and polyvinylpyrrolidone (Mucosyte; Biopharm) three times daily is more effective than placebo for improving pain and other symptoms (97890). Another small clinical study in adults in recovery from hematopoietic stem cell transplantation shows that using a spray product containing sodium hyaluronate with synthetic amino acid precursors of collagen (Mucosamin) attenuates the development of severe oral mucositis when compared with chlorhexidine 0.2% (97889).\nless\nOsteoarthritis. It is unclear if oral hyaluronic acid is beneficial in patients with osteoarthritis of the knee.\nA small study in patients with knee osteoarthritis shows that taking chicken comb extract (Hyal-Joint, Bioibrica) 80 mg, standardized to contain hyaluronic acid 60% to 70%, once daily for 8 weeks does not reduce pain when compared with placebo (55742). This study was limited by small size and a significant placebo effect. Another small study in patients with knee osteoarthritis shows that taking a different supplement (Oralvisc, Bioibrica) 80 mg standardized to contain hyaluronic acid 70% and glycosaminoglycans once daily for 3 months modestly reduces pain when compared with placebo (91779). Reasons for these differing findings may relate to hyaluronic acid formulation, study funding sources, or the magnitude of placebo effect. Hyaluronic acid has also been studied in combination with chondroitin and collagen peptides (BioCell Collagen, BioCell Technology, LLC) with some evidence of benefit (28680).\nless\nOtitis media. It is unclear if using intranasal hyaluronic acid solution is beneficial for otitis media in children.\nPreliminary clinical research in children 3-12 years of age who have recurrent or chronic middle ear inflammation and adenoiditis shows that using a compound (Yabro, IBSA Farmaceutici Italia S.r.l.) containing hyaluronic acid in saline intranasally 15 days per month for 3 months modestly reduces the number of patients with impaired otoscopy or middle ear function when compared to baseline (97888). It is unclear if this effect is due to the hyaluronic acid product or to the natural resolution of inflammation over time.\nless\nRadiation dermatitis. It is unclear if topical hyaluronic acid is beneficial for the prevention of radiation dermatitis.\nA small clinical study in patients with breast cancer undergoing adjuvant radiation therapy following lumpectomy shows that three daily applications of a specific hyaluronic acid gel (RadiaPlex, MPM Medical) to one side of the breast results in a grade 2 or greater dermatitis occurrence rate of 62%, compared with a rate of 48% on the side receiving petrolatum-based gel. A review of a planned interim analysis led to early trial discontinuation (108638).\nless\nRhinosinusitis. It is unclear if hyaluronic acid solution is beneficial for acute or chronic rhinosinusitis when used in an intranasal saline rinse.\nA small clinical study in adults with acute rhinosinusitis who are being treated with levofloxacin and prednisone shows that using a 3% hyaluronic acid in saline nasal douche twice daily improves smell, obstruction, and discharge within 14 days when compared with saline alone (97886). A very small clinical study in patients with chronic rhinosinusitis without nasal polyps shows that receiving micronized nasal hyaluronic acid douches twice daily for 30 days improves nasal symptoms, nasal obstruction, and ability to smell to a similar degree as normal saline (104387).\nless\nSexual dysfunction. It is unclear if vaginal hyaluronic acid is beneficial for improving sexual function in adults with dyspareunia.\nA small nonrandomized clinical study in females with dyspareunia while taking oral hormonal contraceptives shows that once daily vaginal application of a hyaluronic acid gel for 12 weeks reduces pain and improves sexual function at 12 weeks when compared baseline. Though patients treated with twice weekly vaginal estrogen therapy had better 12-week scores than patients treated with hyaluronic acid, it is unclear if the improvements from baseline differed between groups (108639).\nless\nTooth extraction. It is unclear if topical hyaluronic acid is beneficial for wound healing after tooth extraction.\nA small clinical study in patients undergoing tooth extraction shows that application of hyaluronic acid 0.2% gel or hyaluronic acid 0.1% spray to the extraction socket twice daily for 7 days increases the rate of wound closure when compared with no treatment (110553). The validity of these findings is limited by a lack of placebo control group.\nless\nUrinary tract infections (UTIs). Oral and intravesical hyaluronic acid have been evaluated for the prevention of UTI in combination with other ingredients; its effect when used alone is unclear.\nA meta-analysis of prospective and retrospective studies shows that intravesical administration of 50 mL of specific solutions containing chondroitin sulfate 2% and hyaluronic acid 1.6% (iAluRil, IBSA Farmaceutici; Cystistat, Bioniche), once weekly to once monthly for up to 6 months, reduces the rate of UTI recurrence by about 2-3 incidents per year and delays the time to the first UTI recurrence when compared with placebo or prophylaxis with sulfamethoxazole-trimethoprim (99688). However, the validity of these findings is limited by the low quality and high heterogeneity of the included studies, as well as concerns for publication bias. Also, the effect of hyaluronic acid alone is unclear.\n\nOral hyaluronic acid has also been evaluated in combination with other ingredients for the prevention of recurrent UTI. A small prospective observational study shows that taking 1-2 capsules of a combination of hyaluronic acid, chondroitin sulfate, curcumin, and quercetin daily for 15 days each month, in conjunction with the use of local topical estrogen therapy for up to 12 months, reduces the number of women with recurrent UTIs when compared with taking the oral combination product or the vaginal estrogen product alone (96781). It is unclear if this effect is due to hyaluronic acid, other ingredients, or the combination.\nless\nVaginal atrophy. It is unclear if topical hyaluronic acid is beneficial for improving symptoms of vaginal atrophy.\nA small, open-label clinical trial in patients going through menopause with symptoms of vaginal atrophy shows that applying 3 grams of a topical vaginal preparation of hyaluronic acid (Hyalo Gyn, Fidia Farmaceutici) every 3 days for 30 days improves vaginal health scores and reduces vaginal itching, vaginal burning, and pain during intercourse when compared to baseline. However, it does not appear to be any more effective than a polycarbophil vaginal gel (110549). Also, a small observational study in postmenopausal patients with vulvovaginal atrophy has found that applying a topical vaginal preparation containing hyaluronic acid (Justgin, JustPharma) three times weekly for 8 weeks is associated with improved symptoms of vaginal dryness, burning, and itching, as well as pain during intercourse, when compared to baseline (97887). The validity of these findings is limited by the lack of a comparator group and retrospective nature of the study.\n\nSome research has evaluated combination products containing hyaluronic acid for vaginal atrophy. A clinical trial in patients with cervical cancer shows that intravaginal administration of a specific suppository (Santes, Lo.Li. Pharma) containing hyaluronic acid, vitamin E, and vitamin A, once daily for the 5 week duration of radiotherapy reduces vaginal dryness, inflammation, and dyspareunia when compared with no additional treatment (101283). Also, a small, open-label clinical study in patients with vaginal atrophy after treatment for breast cancer shows that intravaginal application of a suppository containing hyaluronic acid and extract of aloe, marigold, tiger grass, and tea tree daily for 10 days then every 3 days for 80 days improves vaginal health scores and reduces vaginal dryness and pain during intercourse when compared to baseline, with no difference between the hyaluronic acid-containing suppository and vaginal laser therapy (110550). It is unclear if these findings are due to hyaluronic acid, other ingredients, or the combination.\nless\nWound healing. Small clinical studies show that topical hyaluronic acid and hyaluronic acid derivatives may improve the healing of various types of wounds.\nA meta-analysis of small clinical trials suggest that topical hyaluronic acid and hyaluronic acid derivatives might improve the healing of burns, wounds, and skin ulcers when compared with control (104389).\nless\nMore evidence is needed to rate hyaluronic acid for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nTopical:\nHyaluronic acid has been used in various topical formulations, including as a mouthwash, gel, eye drop, and nasal douche. See Effectiveness section for condition-specific information.\nChildren\nOral & topical:Research is limited; typical dosing is unavailable.\nStandardization & Formulation\nHyaluronic acid is available as capsules, oral syrup, topical gels, eye drops, nasal rinses, and solutions intended intravesical use (7892, 16301, 89590, 89592, 89594, 91778, 91779, 97885)(97886, 97887, 97888, 97889, 97890, 97894, 97895).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nRADIOTHERAPY\nThere is some concern that application of hyaluronic acid to the skin might increase the risk for radiotherapy-related complications. One clinical study found an increased rate of grade 2 or greater dermatitis in patients with breast cancer who were applying a gel containing hyaluronic acid to the breast while undergoing radiotherapy (108638). Until more is known, advise patients undergoing radiotherapy to avoid application of hyaluronic acid to irradiated tissue.\nless\nSCLERODERMA\nTopical hyaluronic acid might worsen scleroderma symptoms. A retrospective review found that topical application of hyaluronic acid-based products caused deterioration and worsening of skin ulcers in patients with scleroderma. It is hypothesized that hyaluronic acid produced a pro-inflammatory effect in these patients (101284). Until more is known, do not use topical hyaluronic acid in patients with scleroderma.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hyaluronic acid.",
            "Pharmacokinetics": "Absorption\nNo information is available about the behavior of hyaluronic acid after oral administration. However, because of its pharmacokinetic characteristics, it would not be expected to achieve significant blood concentrations after oral administration (9139).\nExcretion\nThe half-life of hyaluronic acid in serum is 2.5 to 5.5 minutes. It is eliminated from circulation through uptake and biotransformation in the liver and spleen (9139, 55746).",
            "Mechanism of Action": "General\nHyaluronic acid is a polysaccharide chain of repeating disaccharide units. It is found throughout the body where it serves as part of the supporting structure in the extracellular space. It is found most abundantly in cartilage, synovial fluid, skin, and the aqueous humor in the eye (9139). The disaccharide moiety consists of sodium acetyl glucosamine and sodium glucuronate (8498). Hyaluronic acid is obtained from rooster combs and from bacterial fermentation. The source and preparation method determine the molecular weight, which varies between 90,000 and 5,000,000 daltons. The primary therapeutic effects of hyaluronic acid are physical lubricating and cushioning. The viscosity of hyaluronic acid increases as the concentration, molecular weight, and polysaccharide chain length increase (9139).\nAnti-bacterial effects\nIn vitro, hyaluronic acid interferes with bacterial adhesion. Early clinical research suggests that hyaluronic acid might prevent ear infections and urinary tract infections, and help to treat sinus infections (97888).\nAnti-inflammatory effects\nHyaluronic acid may decrease osteoarthritis pain by decreasing inflammation. Oral hyaluronic acid seems to modestly decrease levels of inflammatory cytokines (91779).\nJoint effects\nHyaluronic acid has been used for numerous joint disorders. Some research suggests it might prevent the breakdown of natural cushioning barriers in joint (9134, 9139, 55747). Hyaluronic acid seems to bind to cellular receptors on located on the surface membrane of cartilage and other cell types, possibly modulating immune response and improving wound healing (7883, 9126).\n\nIn osteoarthritis, hyaluronic acid might inhibit the release of enzymes that contribute to the breakdown of cartilage. It seems to inhibit chemotactic factors and phagocytosis by mononuclear leukocytes (7883, 7884).\nWound healing effects\nHyaluronic acid might promote wound healing by improving blood flow, regulating inflammatory processes, and promoting the formation of granulation tissue (9126). In addition, hyaluronic acid improves hydration of the wound margins (8497). Preliminary evidence indicates that hyaluronic acid can decrease adhesions to devices implanted during surgical procedures (7882). It does not improve healing in experimental models of tympanostomy tube (ear tube) placement (8493)."
        }
    },
    "Hydrangea": {
        "sections": {
            "Overview": "Hydrangea is a shrub that is native to eastern and north-central parts of the United States. The rhizome and root are used in traditional medicine (4).",
            "Safety": "POSSIBLY UNSAFE when used orally in excessive amounts. Doses of dried hydrangea rhizome/root greater than 2 grams have been associated with reports of dizziness and a feeling of tightness in the chest (4, 12).\nThere is insufficient reliable information available about the safety of hydrangea when used in lower amounts.\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, hydrangea may cause gastroenteritis, dizziness, and a feeling of tightness in the chest (4).\nCardiovascular\nOrally, hydrangea may cause a feeling of tightness in the chest (4).\nless\nGastrointestinal\nOrally, hydrangea may cause gastroenteritis (4).\nless\nNeurologic/CNS\nOrally, hydrangea may cause dizziness (4).\nless",
            "Effectiveness": "There is insufficient reliable information available about the effectiveness of hydrangea.",
            "Dosing & Administration": "Adult\nNo typical dosage.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hydrangea.",
            "Interactions with Drugs": "LITHIUM\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPROBABLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nHydrangea is thought to have diuretic properties. Theoretically, due to these potential diuretic effects, hydrangea might reduce excretion and increase levels of lithium. The dose of lithium might need to be decreased.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of hydrangea.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of hydrangea.",
            "Mechanism of Action": "General\nThe applicable parts of hydrangea are the rhizome and root (4).\nToxic effects\nHydrangea contains the cyanogenic glycoside constituent, hydrangin. Toxic symptoms caused by hydrangea leaf and flower have been attributed to this constituent. This constituent is also found in the root and may be responsible for some of the adverse effects caused by the root and rhizome (12).\nUrinary tract effects\nHydrangea is traditionally used for diseases of the urinary tract. Hydrangea possesses mild diuretic activity and properties that prevent the formation of stones or calculus (4)."
        }
    },
    "Hydrazine Sulfate": {
        "sections": {
            "Overview": "Hydrazine sulfate is an inorganic, solid salt produced from the combination of hydrazine and sulfuric acid. Hydrazine is a hazardous, colorless liquid with an ammonia-like odor, which has a number of industrial and commercial applications (8005). Although it has been historically used as an adjunctive treatment for cancer via Investigational New Drug (IND) programs, the FDA no longer regularly approves use of hydrazine sulfate as an IND (8005).",
            "Safety": "POSSIBLY UNSAFE when used orally. Hydrazine sulfate has been linked to cases of significant adverse effects including hepatotoxicity, encephalopathy, and death (8005, 10384, 10385, 12780, 55766, 55785).\nPREGNANCY AND LACTATION: POSSIBLY UNSAFE when used orally. Hydrazine sulfate has been linked to cases of significant adverse effects including hepatotoxicity, encephalopathy, and death (8005, 10384, 10385, 12780, 55766, 55785).",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nHydrazine sulfate is generally considered unsafe for use. Any benefits of therapy may not outweigh the risk of toxicity.\nMost Common Adverse Effects\nOrally: Blurred vision, confusion, dizziness, nausea, vomiting.\nSerious Adverse Effects (Rare)\nOrally: Encephalopathy, hepatorenal failure.\nDermatologic\nOrally, hydrazine sulfate has been reported to cause dry skin and transient pruritus (55770).\nless\nEndocrine\nOrally, hydrazine sulfate has been associated with one case of hypoglycemia in a patient with alveolar cell carcinoma of the lung (55780).\nless\nGastrointestinal\nOrally, hydrazine sulfate has been reported to cause nausea and vomiting in numerous clinical studies (55796, 8004, 8005, 55764, 10385, 11767). It has also been reported to cause anorexia, pyrosis, diarrhea, constipation, distorted taste, and hunger (11767).\nless\nHepatic\nIn one case report, a 55-year-old male with sinus carcinoma developed hepatorenal failure after self-treating with hydrazine sulfate 180 mg daily for approximately four months. Two weeks after discontinuing hydrazine sulfate, the patient presented to the emergency room with rash, pruritus, progressive malaise, and jaundice. The patient developed hepatic encephalopathy, renal failure, and profound coagulopathy, and died after severe gastrointestinal hemorrhage. Autopsy showed autolysis of the kidneys and necrosis of the liver (10384).\nless\nNeurologic/CNS\nOrally, hydrazine sulfate has been reported to cause paresthesia in the upper and lower extremities, tremors, lethargy/somnolence, confusion, convulsions, depression, headache, palpebral tic, slurred speech, hiccup, and vertigo (11767, 55782, 55785, 55769). It has also been reported to cause dizziness, excitement, and polyneuritis (55796, 55764, 10385, 55780).\n\nIn one case report, a 71-year-old male developed severe encephalopathy after taking oral hydrazine sulfate 180 mg daily for two weeks followed by 360 mg daily (55766). In another case report, a 40-year-old male who accidentally consumed about 2-3 mL of 80% hydrazine sulfate solution, which he immediately spit out, experienced drowsiness the next day, followed by flapping tremors, bilateral extensor plantar reflex, and encephalopathy (55795).\nless\nOcular/Otic\nOrally, hydrazine sulfate has been reported to cause blurred vision in 2 of 29 patients in a clinical trial (11767).\nless\nPsychiatric\nOrally, hydrazine sulfate has been reported to cause visual and auditory hallucinations in one patient in a clinical trial (55764).\nless\nRenal\nIn one case report, a 55-year-old male with sinus carcinoma developed hepatorenal failure after self-treating with hydrazine sulfate 180 mg daily for approximately four months. Two weeks after discontinuing hydrazine sulfate, the patient presented to the emergency room with rash, pruritus, progressive malaise, and jaundice. The patient developed hepatic encephalopathy, renal failure, and profound coagulopathy, and died after severe gastrointestinal hemorrhage. Autopsy showed autolysis of the kidneys and necrosis of the liver (10384).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY INEFFECTIVE\nCancer. Clinical research shows that oral hydrazine sulfate does not improve overall survival in patients with various forms of cancer.\nHigh-quality research shows that taking hydrazine sulfate orally 120-180 mg daily for up to 24 months does not improve tumor response, quality of life, or overall survival in patients with non-small cell lung cancer or colorectal cancer (8001, 8002, 8003, 55774). Also, one study has suggested that taking hydrazine sulfate may actually decrease overall survival in patients with colorectal cancer when compared with placebo (8002). Some very small, low-quality studies have suggested that hydrazine sulfate might delay tumor progression or cause minimal tumor responses in some patients. However, the validity of these results is limited by the lack of a comparator group and inclusion of multiple cancer types (10385, 11767, 55764, 55765, 55770, 55780, 55796).\nless\nLIKELY INEFFECTIVE\nLung cancer. Taking hydrazine sulfate as an adjunct to chemotherapy is not beneficial for treating non-small cell lung cancer (NSCLC) in most patients.\nSeveral randomized controlled trials in patients with NSCLC show that taking hydrazine sulfate orally 120-240 mg daily for 6-24 months does not improve quality of life, tumor response, weight gain, or survival when compared with placebo (8001, 8003, 11368, 55774). However, one subgroup analysis suggests that taking hydrazine may increase overall survival by an average of 17 weeks in patients with nonresectable NSCLC who are considered to have favorable performance status (55774).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nBrain tumor. Although there has been interest in using oral hydrazine sulfate for brain tumors, there is insufficient reliable information about the clinical effects of hydrazine sulfate for this purpose.\nCachexia. There is limited evidence on the oral use of hydrazine sulfate in patients with cancer- related cachexia.\nPreliminary clinical research in patients with cancer and a weight loss of at least 10% from baseline shows that taking hydrazine sulfate orally 60 mg three times daily for 30 days increases the proportion of those maintaining weight by 57% when compared with placebo (8004). Low-quality observational research in patients with cancer has found that taking hydrazine sulfate at an undefined dose orally for 3 weeks increases weight by an average of up to 3.6 kg when compared with baseline (55792).\nless\nColorectal cancer. It is unclear if oral hydrazine sulfate is beneficial in patients with colorectal cancer.\nPreliminary clinical research in adults with metastatic colorectal cancer shows that taking hydrazine sulfate orally, for a median of 7 months, as a single agent does not improve overall survival or quality of life when compared with placebo. Secondary analyses with adjustment for covariates also suggest that hydrazine sulfate may worsen overall survival and quality of life when compared with placebo. Hydrazine sulfate was initiated at 60 mg daily for 4 days, then 120 mg daily. Patients weighing more than 50 kg were further titrated to 180 mg daily on day 9 (8002).\nless\nHodgkin lymphoma. Although there has been interest in using oral hydrazine sulfate for Hodgkin lymphoma, there is insufficient reliable information about the clinical effects of hydrazine sulfate for this purpose.\nNeuroblastoma. Although there has been interest in using oral hydrazine sulfate for neuroblastoma, there is insufficient reliable information about the clinical effects of hydrazine sulfate for this purpose.\nMore evidence is needed to rate hydrazine sulfate for these uses.",
            "Dosing & Administration": "Adult\nOral:\nHydrazine sulfate has commonly been used in doses of up to 180 mg daily for 1-4 months, either alone or in combination with chemotherapy. However, taking hydrazine sulfate may be unsafe. See Effectiveness section for condition-specific information.\n\nTheoretically, hydrazine sulfate acts as a monoamine oxidase inhibitor (MAOI) and can increase blood levels of tyramine (55784). Avoid concomitant use with tyramine-containing foods, such as avocado, brewer's yeast, caviar, aged cheese, fermented beverages, herring, liver, pickled meats, soy sauce, and tofu.\nChildren\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hydrazine sulfate.",
            "Interactions with Drugs": "EXPAND ALL\n|\nCOLLAPSE ALL\nANTIDIABETES DRUGS\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nMODERATE\nOccurrence\nPOSSIBLE\nLevel of Evidence\nB (Nonrandomized clinical trial)\nTheoretically, taking hydrazine sulfate concomitantly with antidiabetes drugs could increase the risk for hypoglycemia.\nAnimal research shows that hydrazine sulfate lowers blood glucose (55800). Hypoglycemia has also been reported in some patients taking hydrazine sulfate during clinical studies (11767). Monitor blood glucose levels closely.\nless\nISONIAZID\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (In vitro or animal study)\nTheoretically, concurrent use of isoniazid and hydrazine sulfate might increase the risk for liver damage.\nHydrazine sulfate is a metabolite of isoniazid. Animal research shows that hydrazine sulfate might be responsible for isoniazid-induced hepatotoxicity (12779).\nless\nMONOAMINE OXIDASE INHIBITORS (MAOIs)\nInteraction Rating\nMODERATE Be cautious with this combination.\nSeverity\nHIGH\nOccurrence\nPOSSIBLE\nLevel of Evidence\nD (Theoretical based on pharmacology)\nTheoretically, concomitant use with other MAOIs might increase the effects and adverse effects associated with MAOIs.\nMedications with hydrazine chemical moieties (e.g., phenelzine) are known to inhibit monoamine oxidase. Theoretically, hydrazine sulfate acts as an MAOI (55784).\nless",
            "Interactions with Supplements": "HERBS AND SUPPLEMENTS WITH HYPOGLYCEMIC POTENTIAL\nHydrazine sulfate may lower blood glucose levels in some patients.\nAnimal research shows that hydrazine sulfate lowers blood glucose (55800). Hypoglycemia has also been reported in some patients taking hydrazine sulfate during clinical studies (11767). Theoretically, taking hydrazine sulfate with other herbs and supplements with hypoglycemic potential could increase the risk for hypoglycemia. See other products with hypoglycemic potential here.\nless",
            "Interactions with Conditions": "EXPAND ALL\n|\nCOLLAPSE ALL\nLIVER DISEASE\nHydrazine sulfate may worsen preexisting liver disease. Hydrazine can cause hepatotoxicity in humans (10384, 12779, 12780, 55804). Avoid using hydrazine sulfate in patients with liver disease.\nless\nPERIOPERATIVE\nTheoretically, hydrazine sulfate might interfere with blood glucose control during and after surgical procedures (11767, 55800). Tell patients to discontinue hydrazine sulfate at least 2 weeks before elective surgical procedures.\nless",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hydrazine sulfate.",
            "Pharmacokinetics": "Absorption\nHydrazine sulfate is rapidly absorbed in humans after oral administration (55781). A peak concentration of 12 ng/mL occurs at approximately 160 minutes after administration (55781).\nMetabolism\nThe proposed metabolic pathway for hydrazine sulfate is hepatic transformation to acetyl hydrazine, diacetyl hydrazine, and pyruvate hydrazine through binding with ketoacids (55817, 55816).",
            "Mechanism of Action": "General\nHydrazine sulfate is a solid, inorganic salt produced from the combination of hydrazine and sulfuric acid (8000).\nAntidiabetes effects\nAnimal research shows that hydrazine sulfate 40 mg/kg as a single dose decreases plasma glucose levels (55800). In one clinical study conducted in cancer patients, hydrazine sulfate was associated with an improvement in glucose tolerance, suggesting that hydrazine sulfate may produce increased insulin sensitivity in cancer patients (55790)\nAntineoplastic effects\nHydrazine sulfate has been touted as an anti-cancer drug based on its ability to inhibit phosphoenolpyruvate carboxykinase (PEP-CK), an enzyme critical to gluconeogenesis (55783). It was theorized that the dependence of cancer cells on glycolysis would translate to an increased reliance on gluconeogenesis, the disruption of which would lead to the starvation and regression of tumors. However, this hypothesis has not been supported by clinical research (8001, 8002, 8003, 11767, 55764, 55765, 55770, 55780, 55796). Furthermore, hydrazine sulfate has demonstrated carcinogenic activity in animal research (55787, 55778, 55777, 55805, 55808, 55804)."
        }
    },
    "Hydroxymethylbutyrate (HMB)": {
        "sections": {
            "Overview": "Hydroxymethylbutyrate (HMB) is a metabolite of the amino acid leucine and its ketoacid, alpha-ketoisocaproate. It can be found naturally in small quantities in grapefruit, alfalfa, and catfish. HMB is also naturally synthesized in the human body. Endogenous production of HMB occurs in the muscle and liver, and it is believed to be involved in muscle protein synthesis (2168, 3374).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. Doses up to 3 grams or 76 mg/kg daily for up to one year have been used with apparent safety (1909, 2167, 2168, 3374, 46606, 55820, 55822, 96637, 96645, 99248)(99249, 102872). The International Society of Sports Nutrition states that chronic use of HMB is safe for young and old patients (96644).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, HMB seems to be well tolerated.\nCardiovascular\nOrally, high blood pressure has been reported in one person taking HMB in a clinical trial (108770).\nless\nDermatologic\nOrally, itching has been reported in two people taking HMB in clinical trials (99245, 102872).\nless\nGastrointestinal\nOrally, abdominal pain, constipation, dyspepsia, flatulence, heartburn, and nausea have been reported rarely in people taking HMB in clinical trials (99245, 102872, 108770).\nless\nGenitourinary\nOrally, increased urinary frequency has been reported in two people taking HMB in a clinical trial (108770).\nless",
            "Effectiveness": "EXPAND ALL\n|\nCOLLAPSE ALL\nPOSSIBLY EFFECTIVE\nSarcopenia. Oral HMB seems to increase muscle mass and may attenuate muscle loss in older adults. However, it may not offer additional benefit when used in conjunction with exercise.\nMeta-analyses of clinical research as well as individual clinical studies in healthy older adults, including those at risk for sarcopenia, show that HMB supplementation increases muscle mass or fat-free mass when compared with placebo or other control (96645, 106027, 108771). Furthermore, some clinical research in elderly people with a recent hip fracture who are undergoing rehabilitation shows that a specific liquid nutritional supplement (Ensure Plus Advance, Abbott) providing the calcium salt of HMB (Ca-HMB) 1.5 grams, calcium 500 mg, and calcidiol 500 IU, taken twice daily in addition to standard therapy, attenuates muscle loss, but does not affect function, when compared with standard therapy alone (96640).\n\nHMB has also been evaluated in combination with exercise. In a meta-analysis subgroup of healthy, older adults, HMB supplementation combined with exercise did not result in additional increases in fat-free mass when compared with supplementation alone (106027). Similarly, in an individual clinical study in older females at risk for sarcopenia, HMB supplementation did not enhance the effects of exercise on fat-free mass when compared with exercise alone (108770).\nless\nPOSSIBLY INEFFECTIVE\nPhysical performance. Oral HMB, when taken in conjunction with participation in an exercise regimen, does not seem to improve physical performance in older adults.\nMost clinical research in elderly patients shows that HMB is not beneficial for improving overall physical performance (99245, 99249, 102869). A meta-analysis of 10 clinical studies in patients 50-80 years of age shows that taking HMB along with physical exercise does not improve muscle strength, physical performance measures, or body composition when compared with physical exercise alone (102869). Conversely, a small clinical study in older adults shows that taking the calcium salt of HMB (Ca-HMB) along with vitamin D for 12 months improves a composite functional index of physical performance at 6 and 12 months, but not at 3 and 9 months, when compared with control. The addition of moderate resistance exercise training 3 times weekly did not further improve the composite functional index among those receiving supplementation (106026).\nless\nINSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. It is unclear if oral HMB, alone or in combination with other ingredients, is beneficial for improving performance in athletes at various levels.\nA small clinical study in elite male rowers shows that taking HMB 1 gram three times daily for 12 weeks increases aerobic capacity and peak anaerobic power when compared with placebo. It also increases the maximum volume of oxygen consumed, compared with a small decrease following intake of placebo. However, anaerobic adaptation does not seem to be improved (99246).\n\nHMB has also been evaluated in combination with other ingredients. A small clinical study in adolescent, middle-distance runners aged 14-17 years shows that supplementation with a specific calcium salt of HMB (Ca-HMB) (HMB 1250 Mega Caps, Olimp Laboratories) 2.5 grams along with L-arginine alpha-ketoglutarate (AAKG 1250 Extreme Mega Caps, Olimp Laboratories) 2.5-3.75 grams, taken 3 times daily, attenuates reductions in countermeasure jump height during a 12-day intensive training camp when compared with placebo (106032). Conversely, a very small clinical study in male collegiate rugby players shows that supplementation with HMB along with creatine monophosphate for 6 weeks does not improve maintenance of performance and body composition when compared with creatine monophosphate alone (106031). Changes in markers of muscle damage and stress were similar between groups in both studies (106031, 106032).\nless\nCachexia. Oral HMB has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nA small clinical study in patients with cancer-related cachexia shows that taking HMB 3 grams daily in combination with arginine 14 grams and glutamine 14 grams daily in two divided doses for up to 24 weeks increases body weight and lean body mass by about 1 kg, compared with reduced body weight and lean body mass in those taking placebo (52280). Conversely, a small clinical study in patients with cachexia due to rheumatoid arthritis (RA) shows that taking this combination for 12 weeks does not improve body weight or lean body mass when compared with placebo (52340).\nless\nCirrhosis. It is unclear if oral HMB is beneficial in patients with liver cirrhosis.\nA small clinical study in patients with liver cirrhosis shows that taking HMB 3 grams daily for 12 weeks improves muscle mass and some measures of muscle function when compared with baseline (108768). The lack of statistical comparison to placebo limits the validity of these findings. Additionally, it should be noted that the groups were unmatched at baseline in terms of cirrhosis etiology and liver frailty index.\nless\nCritical illness (trauma). It is unclear if a calcium salt of HMB (Ca-HMB) can reduce muscle wasting in critically ill adults.\nA small clinical study in patients with severe critical illness receiving mechanical ventilation shows that taking Ca-HMB 1.5 grams twice daily, beginning on day 4 of admission and continuing for 10-30 days, does not reduce muscle wasting when compared with placebo (108769).\nless\nDiabetic foot ulcers. Oral HMB has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nA clinical study in patients with diabetic foot ulcers shows that drinking a specific beverage (Juven/Abound, Abbott Nutrition) containing HMB 1.2 grams, L-arginine 7 grams, and L-glutamine 7 grams twice daily for 16 weeks does not improve wound healing when compared with placebo (96637).\nless\nExercise-induced muscle damage. It is unclear if oral HMB is beneficial for reducing exercise-induced muscle damage.\nA small clinical study in resistance trained males shows that taking a free acid form of HMB (HMB-FA) 1 gram prior to a high-volume resistance training session, and then 2 grams in divided doses later that day, attenuates an increase in creatine kinase levels when compared with placebo. Also, perceived recovery 48 hours after exercise was approximately 38% higher than placebo (99250). Conversely, a very small clinical study in elite male rowers shows that taking HMB 3 grams within 30 minutes after each training session and 30 minutes before bed on non-training days for 10 weeks does not reduce markers of exercise-induced muscle damage, including aspartate aminotransferase, lactate dehydrogenase, and creatine kinase, when compared with placebo (102871).\nless\nExercise-induced muscle soreness. Small clinical studies suggest that oral HMB does not improve exercise-induced muscle soreness in trained and untrained males.\nOne small clinical study in resistance-trained males shows that taking a specific free acid form of HMB (HMB-FA) (Clear Muscle, Muscle Tech) or a specific calcium salt of HMB (Ca-HMB) (HMB, Millennium Sport Technologies, Inc.) 1 gram three times daily for 12 weeks does not improve participant ratings of delayed onset muscle soreness when compared with placebo (102872). Another small clinical study in untrained males participating in a resistance training program shows that taking HMB 3 grams daily for 2-4 weeks prior to resistance training does not reduce muscle soreness when compared with placebo (102873).\nless\nHIV/AIDS-related wasting. Oral HMB has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nA small clinical study in patients with AIDS-related wasting shows that taking HMB 3 grams in combination with arginine 14 grams and glutamine 14 grams daily in two divided doses for 8 weeks seems to increase body weight and lean body mass and possibly improve immune function when compared with placebo (1909).\nless\nKidney failure. It is unclear if oral HMB reduces the incidence of complications in patients with kidney failure receiving maintenance hemodialysis.\nA small clinical study in patients on maintenance hemodialysis shows that taking HMB 3 grams daily for 6 months does not affect body composition, bone density, muscle strength, or physical function, when compared with placebo (99255). The validity of this study is limited by its small size and low rate of adherence.\nless\nMalnutrition. It is unclear if an oral calcium salt of HMB (Ca-HMA) is beneficial in patients with, or at risk of, malnutrition.\nA large clinical trial in older, community-dwelling adults at medium to high risk for malnutrition who are receiving dietary counseling shows that taking an oral nutrition supplement containing Ca-HMB 0.74 grams twice daily results in achievement of the goal outcome in 33% of patients, compared with 9% of those receiving placebo. The goal outcome was a composite of survival without hospital admission or readmission and at least 5% weight gain at 6 months. Ca-HMB supplementation also resulted in significant improvements in various nutritional and functional outcomes (106028). A retrospective study in patients with or at risk of malnutrition receiving dietary and exercise counseling shows that supplementation with an oral nutrition supplement(Ensure Plus Advance, Abbott Nutrition) containing Ca-HMB 1.5 grams twice daily for 3-6 months seems to improve anthropometrics and body composition when compared with baseline (108772). The validity of this finding is limited by the lack of statistical comparison to those taking a standard oral nutrition supplement.\nless\nMuscle fatigue. It is unclear if oral HMB is beneficial for reducing muscle fatigue in trained males.\nA small clinical study in trained males shows that taking a free acid form of HMB, 3 grams as a single dose, prior to a muscle damage protocol returns work capacity to pre-exercise levels within 24 hours, compared with more than 72 hours with placebo. However, there was no effect on other measures of muscle recovery (99253).\nless\nMuscle strength. The benefits of HMB for improving muscle strength seem to depend on the physical fitness of the individual. Although small clinical studies suggest HMB may be modestly beneficial in untrained adults, most research has shown no benefit in trained adults.\nA meta-analysis of 11 studies in a mixed population of both trained and untrained healthy adults shows that HMB does not increase muscular strength outcomes or improve body composition when compared with placebo (106030). However, research in specific populations suggests that benefits may differ depending on baseline training level.Most research in previously untrained individuals seems to show that HMB offers a modest benefit on muscle strength (11003, 96642, 96643). Some preliminary clinical research shows that HMB might increase strength and body composition and reduce muscle damage when used during resistance training or intense endurance exercises (1929, 2168, 10062, 55821, 102873). A meta-analysis of clinical studies in mostly untrained males shows that taking HMB 3 grams daily can modestly increase lean body mass by 0.3% and strength by 1.4% weekly (21446). Another meta-analysis assessing untrained weightlifters shows that taking HMB results in small increases in upper body strength, but not lower body strength, when compared with control (96642). Another small clinical study in untrained males participating in a 12-week training program not included in the above meta-analyses shows that taking calcium HMB 1 gram three times daily does not increase muscle strength or reduce fat mass, but might increase fat-free mass in the legs, when compared with placebo (102870).\n\nConversely, most research in trained athletes shows that salt formulations of HMB do not increase muscle strength, improve body composition, or reduce muscle damage (2167, 55820, 55825, 55826, 55831, 96638, 96641, 96643, 102872, 102874). A small clinical study in resistance trained males shows that taking HMB 1 gram three times daily for 9 weeks does not increase muscle strength or lean mass overall, but does increase lower body strength by approximately 9%, when compared with placebo (99251). However, this finding has not been supported in other research in previously trained athletes (96642). Research using the free acid form of HMB (HMB-FA) has shown some benefit in previously trained males. A small clinical study in this population shows that taking HMB-FA 1 gram three times daily for 12 weeks increases muscle strength approximately three-fold when compared with placebo. There is also an approximate 90% prevention of muscle strength loss during a two-week overtraining phase when compared with placebo, as well as improvements in lean body mass and muscle power (99248).\nless\nObesity. It is unclear if oral HMB is beneficial for reducing abdominal adiposity.\nA small clinical study in elderly males shows that taking HMB 1.5 grams twice daily for 12 weeks while undergoing a resistance training program reduces abdominal adiposity by approximately 9.5% when compared with either the resistance exercise program alone, HMB alone, or placebo (99247). Another small clinical study in postmenopausal adults with overweight or obesity shows that taking a specific product (Abound, Abbott) containing a calcium salt of HMB (Ca-HMB), L-arginine, and L-glutamine twice daily for 4 weeks reduces visceral adipose tissue by 94 grams, compared with an increase of 60 grams in those taking placebo (108773). It is unclear if this effect is due to HMB, the other ingredients, or the combination.\nless\nOral mucositis. Oral HMB has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nA small clinical study in patients with head and neck cancer undergoing chemoradiotherapy shows that taking a specific product (Abound, Abbott) containing HMB 1.2 grams, arginine 7 grams, and glutamine 7 grams in water twice daily during treatment does not reduce the incidence of moderate to severe functional changes from oral mucositis when compared with baseline (99243). The validity of this finding is also limited by the lack of a comparator group and the use of subjective measures.\nless\nPostoperative recovery. Oral HMB has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nA small clinical study in patients with abdominal malignancies shows that taking a specific product (Abound, Abbott) containing HMB 1.2 grams, arginine 7 grams, and glutamine 7 grams in water once daily for ten days, starting three days prior to surgery, does not reduce the incidence of wound complications or length of hospitalization when compared with placebo (99413).\nless\nRadiation dermatitis. Oral HMB has only been evaluated in combination with other ingredients; its effects when used alone is unclear.\nA small clinical study in patients with head and neck cancer undergoing chemoradiotherapy shows that taking a specific product (Abound, Abbott) containing HMB 1.2 grams, L-arginine 7 grams, and L-glutamine 7 grams in water twice daily, starting on the first day of chemoradiotherapy and continuing for up to 1 week after completing therapy, does not reduce the incidence of grade 3 dermatitis when compared with control (96639).\nless\nMore evidence is needed to rate HMB for these uses.",
            "Dosing & Administration": "Adult\nOral:\nHMB and a calcium salt of HMB (Ca-HMB) have most often been used in doses of 2.4-3 grams daily, in 1-3 divided doses. See Effectiveness section for condition-specific information.\nStandardization & Formulation\nCalcium HMB (Ca-HMB) and a free acid form of HMB (HMB-FA) are two forms of HMB that have been studied; however, Ca-HMB is more commonly used in research. It's not yet known if one form is superior (96644). There is conflicting research with respect to which form has greater bioavailability (99252, 106029).",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with HMB.",
            "Pharmacokinetics": "Absorption\nPlasma HMB levels have been shown to be elevated approximately 30 minutes following consumption of 1 gram of HMB. Following a single-dose administration of 3 grams of HMB to healthy volunteers, peak plasma levels of about 480 nM/L occurred in 1-2 hours (55824). In human research, HMB absorption is slightly lower when consumed with glucose (55824). Free acid forms of HMB (HMB-FA) have previously been thought to be more bioavailable than the more common calcium salt of HMB (Ca-HMB), producing increased peak plasma levels and plasma clearance rates and no effect on urinary loss. However, more recent research has not confirmed these findings (99252, 106029).\nExcretion\nThe half-life of HMB has been estimated at approximately 2.5 hours, with less than 15% to 30% of the unchanged compound excreted in the urine. Plasma HMB peaked at about 1 hour when administered with glucose, and at about 2 hours when administered alone (55824).",
            "Mechanism of Action": "General\nHMB is a byproduct of metabolism of the amino acid leucine and its ketoacid, alpha-ketoisocaproate. It can be found naturally in small quantities in grapefruit, alfalfa, and catfish (2168, 55827). HMB is also a precursor to cholesterol. HMB found in the cytosol of liver and muscle cells is converted to beta-hydroxy-beta-methylglutarate-Co-A (HMG-CoA) (2168, 3374).\nAntidiabetic effects\nA very small clinical study in young males performing an oral glucose tolerance test shows that taking a free acid form of HMB (HMB-FA) reduces insulin exposure, but not glucose exposure or several insulin sensitivity indices, when compared with not taking HMB-FA. The effects on insulin exposure were not observed in older males (106029).\nImmunomodulation effects\nIn human research, HMB supplementation increased basophils (55822), lymphocytes, and eosinophils (55828). In human research, a combination of HMB, arginine, and glutamine seemed to increase the number of CD3 and CD8 cells (1909). Preliminary in vitro research shows that HMB enhances nitrogen-stimulated DNA synthesis in lymphocytes, but only in the presence of leucine (55838).\nMuscular effects\nHMB inhibits proteolysis and increases protein synthesis (96644). HMB found in the cytosol of liver and muscle cells is converted to beta-hydroxy-beta-methylglutarate-Co-A (HMG-CoA). HMG-CoA is used for the cellular synthesis of cholesterol, and might also promote muscle growth by reducing the catabolism of muscle protein (2168, 3374, 99254). There is also some evidence that HMB lowers levels of creatine phosphokinase (CK) and lactate dehydrogenase (LDH) and decreases the excretion of 3-methylhistidine (3-MH). This suggests that HMB might also prevent or decrease muscle membrane inflammation or injury, and prevent increased proteolysis that is often associated with intense exercise (1929, 2168, 3374, 55821, 99248). HMB prevents muscle protein degradation in cancer-induced weight loss through attenuation of the ubiquitin-proteasome proteolytic pathway of protein degradation (55832, 55833, 55834, 55837). Research in murine myotubes as a surrogate model of skeletal muscle has indicated that HMB may increase proteasome expression by the tumor factor proteolysis-inducing factor (PIF) (55834). The specific mechanism related to the anticatabolic effects of HMB in skeletal muscle is still not clear. Multiple other signaling pathways, including p38/MAPK-and PI3K/Akt-dependent mechanisms, have been suggested as potentially being involved (99254).\nRenal effects\nIn human research, HMB supplementation seems to decrease urine urea nitrogen and plasma urea, suggesting a nitrogen-sparing effect (10062).\nWound-healing effects\nHMB in combination with arginine and glutamine has been shown to enhance collagen synthesis (52286)."
        }
    },
    "Hyperimmune Egg": {
        "sections": {
            "Overview": "Hyperimmune eggs contain increased levels of immunoglobulins (IgY). They are produced by immunizing hens against various bacteria or viruses (13215). The amount of immunoglobulin obtained from the eggs of immunized hens is approximately 18 times higher than the amount obtained from the serum of immunized rabbits, and is easier to harvest (13206).\n\nKEY HIGHLIGHTS\nSometimes used for athletic performance, cystic fibrosis, Helicobacter pylori, periodontitis, and rotaviral diarrhea, but there is no strong evidence to support its use for any condition.\nPossibly safe when taken by mouth in appropriate doses.\nNo known interactions.\nContains high levels of immunoglobulins that may provide passive immunity.\nA branded hyperimmune egg product, Immune26 (Legacy for Life), contains the proprietary ingredient Egcel, which is a specific hyperimmune egg extract obtained by immunizing hens against numerous enteric pathogenic bacteria (13207, 13213, 102905). Other hyperimmune egg products have been prepared by immunizing hens with other organisms, including rotavirus (13206), Porphyromonas gingivalis (102902), Pseudomonas aeruginosa (102908, 102909), and Helicobacter pylori (102910, 102911).",
            "Safety": "POSSIBLY SAFE when used orally and appropriately. A specific commercial hyperimmune egg product (Immune26, Legacy for Life) has been used with apparent safety in studies lasting up to 26 weeks (13207, 13213). A hyperimmune egg product containing antibodies against Helicobacter pylori has been used with apparent safety for 4 weeks (102910, 102911). A hyperimmune egg product containing antibodies against Pseudomonas aeruginosa has been used with apparent safety in a limited number of adult patients with cystic fibrosis for up to 12 years (102908, 102909).\nCHILDREN: POSSIBLY SAFE when used orally and appropriately. A hyperimmune egg extract containing antibodies against rotavirus has been used with apparent safety in children aged 2-24 months for 4 days (13206). A hyperimmune egg product containing antibodies against Pseudomonas aeruginosa has been used with apparent safety in children aged 1-18 years with cystic fibrosis for up to 12 years (102908, 102909).\nPREGNANCY AND LACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "EXPAND ALL\n|\nCOLLAPSE ALL\nGeneral\nOrally, hyperimmune egg seems to be well tolerated when used short-term. Side effects reported in clinical trials include gastrointestinal effects and skin rash (13213, 102904).\nDermatologic\nOrally, skin rash has been reported in one clinical trial, but did not require treatment (102904).\nless\nGastrointestinal\nOrally, hyperimmune egg products have been reported to cause diarrhea, gas, stomach ache, and bloating (13213, 102904).\nless",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nAthletic performance. Preliminary clinical research in recreationally active young men shows that taking hyperimmune egg (Immune26, Legacy for Life) orally in a dose of 4.5 grams daily for 2 days, then 9 grams daily for 2 days, then 13.5 grams daily for 6 days, reduces the maximum heart rate and increases peak power during three 5-minute submaximal exercise bouts on a treadmill when compared with placebo (102905). Poor study design limits the reliability of this research.\nCystic fibrosis. Preliminary clinical research in cystic fibrosis patients aged 2-32 years who have had a prior infection with Pseudomonas aeruginosa shows that using a hyperimmune egg yolk extract containing 50 mg of IgY antibodies to two strains of P. aeruginosa as a gargle once daily at bedtime, and then swallowing the liquid, prolongs the time to the second infection when compared with patients who do not receive the gargle (102908). During follow-up of 36-92 months (mean 57 months), patients using the gargle had 2.5 positive sputum cultures for P. aeruginosa per 100 months of observation, compared with 13.7 per 100 months in the untreated control group. In the treated group, no patients became chronically colonized with the organism, compared with 24% of patients in the control group (102908). In further follow-up lasting up to 12 years, the treated patients were switched to an egg extract containing 50 mg of IgY antibodies against six strains of P. Aeruginosa, which was used as a gargle for 2 minutes once daily and swallowed. There were 2.3 positive sputum cultures per 100 months of observation, and 2 patients developed chronic colonization with P. aeruginosa. In the untreated control group, there were 7 positive sputum cultures per 100 months, and 7 patients became chronically colonized (102909). The reliability of this research is reduced by lack of randomization, since treated patients from Sweden were compared with untreated patients from Denmark. Additionally, some, but not all, of the evaluated patients were receiving chronic treatment with azithromycin.\nHelicobacter pylori. Preliminary clinical research shows that taking a specific defatted egg powder product prepared from eggs of hens immunized with Helicobacter pylori urease (Ovlagen, GHEN Corp., Japan), 900 mg three times daily after meals for 4 weeks, is associated with a reduction in urea breath test values, but not complete eradication of H. pylori, in asymptomatic volunteers with H. pylori-positive urea breath tests (102910). Other clinical research shows that taking a yogurt drink containing H. pylori urease-specific IgY 15 mg, Lactobacillus acidophilus, and Bifidobacterium species, 150 mL three times daily for 4 weeks, is associated with a 40% reduction in urea breath test values when compared with baseline in volunteers positive for H. pylori by urea breath test. Taking the same yogurt drink without IgY is associated with a 15% reduction in urea breath test values when compared with baseline (102911). The validity of this finding is limited by the lack of a direct comparison to the control group.\nHyperlipidemia. Preliminary clinical research shows that taking a specific hyperimmune egg powder formulation (Immune26, Legacy for Life) for 26 weeks does not significantly lower cholesterol when compared with baseline (13213). The validity of this finding is limited by the lack of a comparator group.\nOsteoarthritis. Preliminary clinical research shows that some patients with osteoarthritis might have reduced subjective measures of joint pain or swelling after taking a specific hyperimmune egg powder formulation (Immune26, Legacy for Life) for 2 months when compared with baseline (13207). Poor study design limits the reliability of this research.\nPeriodontitis. Preliminary clinical research shows that using lozenges containing hyperimmune egg yolk immunoglobulin (IgY) from hens immunized with Porphyromonas gingivalis proteinases (gingipains) reduces gingival bleeding index and oral P. gingivalis counts more than placebo in people with periodontitis. Two lozenges, each containing 12 mg powdered IgY, were dissolved in the mouth 3 times daily after meals for 8 weeks (102902).\nRheumatoid arthritis (RA). Preliminary clinical research shows that taking a specific hyperimmune egg powder formulation (Immune26, Legacy for Life) for 2 months does not significantly improve subjective measures of RA symptoms when compared with baseline (13207). Poor study design limits the reliability of this research.\nRotaviral diarrhea. Preliminary clinical research shows that taking a preparation of purified egg yolk immunoglobin (IgY) from hens immunized against strains of rotavirus, 10 grams daily in 4 divided doses for 4 days, can modestly decrease rotaviral diarrhea in children aged 2-24 months. The IgY preparation seems to significantly reduce stool output and oral rehydration solution intake on day 1 of treatment. But it does not seem to significantly reduce stool on subsequent days. Children treated with the IgY also seem to clear rotavirus from the stool more quickly when compared with children receiving placebo (13206).\nMore evidence is needed to rate hyperimmune egg for these uses.",
            "Dosing & Administration": "Adult\nOral:\nAthletic performance: A specific powdered hyperimmune egg product (Immune26, Legacy for Life), 4.5 grams daily for 2 days, then 9 grams daily for 2 days, then 13.5 grams daily for 6 days, has been used (102905).\n\nCystic fibrosis: A hyperimmune egg yolk extract, containing 50 mg of IgY antibodies to 2 or 6 strains of Pseudomonas aeruginosa, gargled and then swallowed once daily, has been used for up to 12 years (102908, 102909).\n\nHelicobacter pylori: A defatted egg powder product containing IgY antibodies to Helicobacter pylori urease (Ovlagen, GHEN Corp., Japan) 900 mg three times daily after meals for 4 weeks has been used (102910). A yogurt drink containing H. pylori urease-specific IgY antibodies 15 mg, in combination with Lactobacillus acidophilus and Bifidobacterium species, 150 mL three times daily for 4 weeks has been used (102911).\n\nOsteoarthritis: A specific powdered hyperimmune egg product (Immune26, Legacy for Life), 4.5 grams mixed in a drink and taken daily for 8 weeks has been used (13207).\n\nPeriodontitis: A hyperimmune egg product prepared by immunizing hens against Porphyromonas gingivalis proteinases (gingipains), containing 24 mg IgY in 2 lozenges, dissolved in the mouth 3 times daily after meals for 8 weeks, has been used (102902).\n\nRheumatoid arthritis (RA): A specific powdered hyperimmune egg product (Immune26, Legacy for Life), 4.5 grams mixed in a drink and taken daily for 8 weeks has been used (13207).\nChildren\nOral:\nCystic fibrosis: A hyperimmune egg yolk extract, containing 50 mg of IgY antibodies to 2 or 6 strains of Pseudomonas aeruginosa, gargled and then swallowed once daily, has been used for up to 12 years (102908, 102909).\n\nRotaviral diarrhea: In infants and children aged 2-24 months, 10 grams of IgY-containing powder, prepared from hyperimmune egg yolk of hens immunized against rotavirus, given in four equally divided doses daily for 4 days, has been used (13206).\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hyperimmune egg.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "EGG ALLERGY\nHyperimmune egg is derived from chicken eggs. Theoretically, patients who are sensitive to chicken eggs might also be sensitive to hyperimmune egg products.\nless",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the toxicology of hyperimmune egg.",
            "Pharmacokinetics": "Absorption\nImmunoglobulin Y from hyperimmune egg is broken down in the gut. Significant intact absorption is unlikely (102906).\nMetabolism\nImmunoglobulin Y from hyperimmune egg is hydrolyzed in the gut. Less than 0.01% of orally ingested IgY is recovered intact from stool (102906).",
            "Mechanism of Action": "General\nThe applicable part of hyperimmune egg is the yolk immunoglobulin (IgY). Hyperimmune eggs are created by immunizing hens against specific pathogens. Thus, different hyperimmune egg products contain different types of IgY. OneA specific commercial form of hyperimmune eggthis extract, Egcel (Immune26, Legacy for Life), is produced by immunizing hens with numerous inactivated enteric pathogens including Shigella dysenteriae, Staphylococcus epidermidis and simulans, Escherichia coli (E. coli), Salmonella enteritidis and typhimurium, Pseudomonas aeruginosa, Klebsiella pneumoniae, Haemophilus influenzae, and at least 6 species of Streptococcus (13215). IgY can also be produced by immunizing hens against other organisms and molecules including rotavirus, Helicobacter pylori urease, Pseudomonas aeruginosa, and Porphyromonas gingivalis proteinases (13206, 102902, 102903, 102908, 102909, 102910, 102911).\nGastrointestinal effects\nIn mice, hyperimmune egg immunoglobulin (IgY) from hens immunized with VacA, a toxin produced by Helicobacter pylori which causes epithelial cell damage, reduces H. pylori colonization of the stomach and histological changes in gastric tissues when given orally (102903). In clinical research, hyperimmune egg IgY from hens immunized with H. pylori urease appears to reduce, but not eliminate, H. pylori colonization, as measured by urea breath test (102910, 102911). Urease is produced by H. pylori to enable it to survive in the stomach (102911).\nImmunological effects\nTheoretically, egg yolk immunoglobulin Y (IgY) from hens immunized against specific diseases could provide passive immunity to humans (13215). It is most likely to be effective for local conditions in the gastrointestinal (GI) tract, such as Helicobacter pylori-induced ulcers and rotaviral diarrhea. IgY is hydrolyzed in the GI tract, and in healthy volunteers less than 0.01% of the amount ingested is detected in the stool. In infants and in the presence of diarrhea, GI transit times may be shorter and more IgY may reach the colon intact (102906).\n\nHyperimmune egg yolk immunoglobulin (IgY) does not interact with mammalian IgG and does not activate mammalian complement. Therefore, it does not cause inflammatory responses in the GI tract (102903)."
        }
    },
    "Hyssop": {
        "sections": {
            "Overview": "Hyssop is a flowering plant that is native to southern Europe and the Middle East. It has a long history of use in traditional medicine (4, 6, 11, 110425). It is also used as a flavoring in foods and as a fragrance in soaps and cosmetics (2, 18).",
            "Safety": "LIKELY SAFE when used orally in amounts commonly found in foods. Hyssop, hyssop oil, and hyssop extract have Generally Recognized as Safe (GRAS) status in the US (4912).\nPOSSIBLY UNSAFE when hyssop oil is used in medicinal amounts. Hyssop oil in medicinal quantities has been reported to cause tonic-clonic convulsions (2, 18).\nThere is insufficient reliable information available about the safety of hyssop or hyssop extract when used in medicinal amounts.\nPREGNANCY: LIKELY UNSAFE when used orally. Hyssop may produce uterine stimulant and menstrual stimulant effects (12).\nLACTATION: Insufficient reliable information available; avoid using.",
            "Adverse Effects": "General\nNo adverse effects have been reported. However, a thorough evaluation of safety outcomes has not been conducted.",
            "Effectiveness": "INSUFFICIENT RELIABLE EVIDENCE TO RATE\nBruises. Although there has been interest in using topical hyssop for bruises, there is insufficient reliable information about the clinical effects of hyssop for this purpose.\nCough. Although there has been interest in using oral hyssop for cough, there is insufficient reliable information about the clinical effects of hyssop for this purpose.\nDysmenorrhea. Although there has been interest in using oral hyssop for dysmenorrhea, there is insufficient reliable information about the clinical effects of hyssop for this purpose.\nRespiratory tract infections. Although there has been interest in using oral hyssop for respiratory tract infections, there is insufficient reliable information about the clinical effects of hyssop for this purpose.\nUrinary tract infections (UTIs). Although there has been interest in using oral hyssop for UTIs, there is insufficient reliable information about the clinical effects of hyssop for this purpose.\nSore throat. Although there has been interest in using oral hyssop for sore throat, there is insufficient reliable information about the clinical effects of hyssop for this purpose.\nMore evidence is needed to rate hyssop for these uses.",
            "Dosing & Administration": "Adult\nOral:\nResearch is limited; typical dosing is unavailable.\nStandardization & Formulation\nThere is insufficient reliable information available about the standardization of hyssop.",
            "Interactions with Drugs": "None known.",
            "Interactions with Supplements": "None known.",
            "Interactions with Conditions": "None known.",
            "Interactions with Lab Tests": "None known.",
            "Overdose": "There is insufficient reliable information available about the presentation or treatment of overdose with hyssop.",
            "Pharmacokinetics": "There is insufficient reliable information available about the pharmacokinetics of hyssop.",
            "Mechanism of Action": "General\nThe applicable parts of hyssop are the above ground parts. Constituents include flavonoids such as apigenin, diosmin, luteolin, and quercetin; phenolic acids such as caffeic acid, chlorogenic acid, rosmarinic acid, and ferulic acid; the diterpenoid lactone marrubiin; the monoterpenoids linalool and 1,8-cineole; quinone, and tannins (6, 11, 55841, 103243, 113575). The plant also contains pinocamphone, isopinocamphone, and pinene (6, 110426).\nAnti-inflammatory effects\nResearch in animals shows that methanol extracts of hyssop decrease rat paw edema induced by carrageenan, and inhibit the cyclo-oxygenase enzymes, COX-1 and COX-2. Chlorogenic acid, a constituent of hyssop, inhibits pro-inflammatory cytokines including interleukin (IL)-1-beta, IL-6, and tumor necrosis factor alpha. Another constituent, rosmarinic acid, inhibits activation of the complement pathway at the site of inflammation (110425).\nAntiviral effects\nIn vitro, hyssop extracts show antiviral activity against herpes simplex virus and HIV. Potential active constituents include caffeic acid and tannins, as well as a polysaccharide (MAR-10) (55841, 55842).\nCentral nervous system effects\nIn an animal model of seizures, a hydroalcoholic extract of the above-ground parts of hyssop given daily for 14 days increases tonic seizure threshold, reduces hippocampal neuronal damage and mortality, and improves memory, learning, and brain antioxidant capacity, including reducing malondialdehyde and nitric oxide levels. Hyssop extracts increase gamma-aminobutyric acid (GABA) receptor gene expression. The GABA receptor antagonist flumazenil reduces the antiseizure activity of hyssop extracts (113575).\nCytotoxic effects\nResearch in rats implanted with C6 glioblastoma cells, and in cultures of these cells, shows that hyssop extracts have cytotoxic activity, reducing tumor volume via an increase in apoptosis, and a reduction in angiogenesis, inflammation, cell division, and cell proliferation. Animals treated with hyssop extract, 100 mg/kg for 7 days, have decreased tumor volume, decreased invasion of tumor cells into normal tissue, decreased inflammation, less weight loss, and prolonged survival, when compared with animals with implanted tumors who do not receive hyssop extract (110426).\nExpectorant effects\nThe hyssop constituent marrubiin stimulates bronchial secretions (4, 11).\nGastrointestinal effects\nSome laboratory research shows that an ethanolic extract of hyssop leaf possesses gastroprotective activity, similar to that of ranitidine, in rats with indomethacin-induced gastric ulcers. This is thought to be due to the antioxidant activity of some constituents of hyssop (103243)."
        }
    }
}